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Abstract
With the advent of régulai* antimicrobial usage there has been recognition, world­
wide, that they aie overused and misused. The won'ies of inappropriate usage 
centre on increased antibiotic resistance with consequent loss of efficacy, 
unnecessaiy exposuie to toxic side effects and latterly, financial waste.
The two studies undertalcen for this thesis have attempted to demonstrate how the 
combination of the costs of treatment with clinical and process measures of 
outcome could be used to avoid resouice wastage.
The first study was an audit of aminoglycoside utilisation and the general 
antibiotic management of gram-negative bacteraemia. The aminoglycosides were 
found to be poorly managed and associated with several opportunity costs. Tlnee 
readily measui able indicators of adverse outcome of hospital antibiotic therapy 
associated with mai'ked increases in hospital tieatment costs were characterised. 
These were: -
• Change to an alternative iv drug regimen,
• Retreatment with antibiotics in hospital,
® Readmission with infection.
Another area of resource wastage was the excessive use of the intravenous route 
for antibiotic administration.
Detailed feedback of these findings to selected clinicians was used in an attempt to 
heighten awareness to the management problems and associated cost of the 
aminoglycosides and to persuade prescribers to reduce the overall use of 
intravenous antibiotics by talcing advantage of oral administration.
The second study examined the feasability of non-inpatient intravenous (NIPIV) 
antibiotic caie and compar ed the costs and benefits of this type of programme with 
traditional, hospital inpatient treatment. The study concluded that NIPIV care is 
feasible, appropriate criteria for patient selection were developed and provision of 
a quality service was shown to be practical. The issue of'safety' was raised; as a 
result, the notion of 'acceptable risk' deserves exploration in the furtlier 
development of NIPIV care. Sensitivity analysis was used to explore the bias 
introduced to the costings in this study by commercial sponsorship.
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Chapter 1
1. Introduction
In most countries, resoinces for healthcare are finite. Consequently, as the ability 
to treat and prevent diseases increases, the greater the pressure is to ensure these 
limited resources are used in the most efficient marmer. Healthcare is a complex 
interplay of many dimensions and it is necessary, therefore, in the pursuance of 
efficient resource allocation to be able to evaluate both the costs and benefits of 
each dimension.
An aspect of healthcare which has seen much technological advancement is drug 
treatment. With tlris advancement, both healthcar e benefits and costs have been 
accrued but because, primarily, cost-contairmient teclmiques have been used to 
control rising expenditure little is Icnown about the cost-effectiveness of individual 
dr*ug tlierapies. There is a need therefore, to value both existing and fiiture 
treatments, in terms which go beyond acquisition costs alone.
From an acute, secondary car e perspective, a therapeutic group of drugs which 
urgently require this form of evaluation, is the antimicrobials. Fhstly, because 
drug budget expenditure is proportionally greater for antimicrobial agents than for 
any other therapeutic group and ratiorralisation of use based on cost-effectiveness 
would assist in more efficient resource allocation. Secondly, inappropriate use of 
antimicrobials can induce bacterial resistance which in turn, severely limits the 
future usefulness not only of the inducing agent but of other antimicrobials also. 
This problem is not experienced with any other group of drugs. The burden of 
costs caused by this phenomenon is largely unlmown, however, Phelps (1989) 
estimated for 150 million amiual antibiotic prescriptions in the US, the 
rmr ecognised costs of bacterial resistance could realistically range fiorn $.1 billion 
to $30 billion.
This thesis aims to show how pragmatic application of basic economic principles 
to antimicrobial use, which involves assessing both costs and outcome of 
treatment, can be used to improve the efficiency of resource allocation for this 
group of drugs.
Chapter 2 describes the development of international interest in economic 
evaluation of healthcare with particular reference to drug budgets. The measures 
used by the UK government to exert downward pressine on NHS drug expenditure 
are discussed in detail. It is also shown how the UK govermnent is attempting to 
intr oduce and encour age the application of economic principles to dr ug 
expenditur e and highlights the difficulties associated with this initiative. 
Govermnental measures introduced to control NHS drug expenditure however, 
have been of principal relevance to the primary car e sector. Responsibility for 
controlling drug expenditur e in the secondary care sector has fallen to this sector 
itself, consequently hospitals have developed and used their* own cost-containment 
methods to limit drug expenditure. Chapter* 3 discusses the effectiveness and 
failings of these methods and suggests that the ability to allocate available funds in 
the most efficient marmer can only be fiuther progressed by including outcome 
assessment as well as cost data, in the decision malting process. Chapters 4 and 5 
specifically discuss the var ious economic issues of antimicrobial use and show 
why this therapeutic group should be subject to more intense evaluation than they 
have been. Chapters 6 and 7 describe and discuss the practical application of 
economic evaluation to antimicrobial use. Chapter 6 repor*ts a two phase 
observational study of antimicrobial utilisation. Phase I involved data collection 
and analysis, rneaningfiil outcome rneasiues were identified which in turn 
distinguished areas of resource wastage. The outcome measures identified were 
not institutional specific and could readily be applied to antimicrobial use in other 
secondary care institutions. Phase II endeavoiued to modify current clinical 
practice by an interactive educational programme which utilised the information 
gathered and analysed in Phase I. The impact of this study on local practice and its 
weaknesses are discussed as are the implications for futiue research. Chapter 7 
reports on a feasability study of non-inpatient intravenous (NIPIV) antibiotic care. 
The direct var iable costs and the benefits of NIPIV antibiotic treatment are 
compar ed and contrasted with traditional inpatient hospital treatment. The 
wealaiesses of the study ar e discussed as ar e the implications for futiue research. 
Chapter* 8 summarises the findings, critically appraises the two studies reported 
and suggests how their study design could be improved. Additionally a suggestion
10
is made for the way in which a national database for the economic evaluation of 
clinical practice could be readily constructed. The purpose of the database being to 
provide information to aid decision-makers in their quest to distribute funds in the 
most efficient marmer.
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Chapter 2
2. Governmental methods used to control drug expenditure and
the role economic evaluation can play.
Depending on the country and system of financing healthcare, the methods used to 
control the escalation of ding expendituie, at governmental level, varies. This 
chapter will briefly examine the development and use of the systems and control 
measures of several different countries but will lar gely focus on those in the UK.
2.1 The US approach
Prior to 1966, 80% of healthcare provision in the US was privately financed by 
either the patient or by personal medical insurance. It is now a mixed model of 
federal and private provision. In 1966 two programmes were introduced by the US 
govermnent to finance healthcar e services for particular* groups of people. These 
prograimiies were Medicare, which finances services for* the aged and Medicaid, 
which finances services for the imderprivileged. Medicare was extended in 1974 
to cover* all persons with cluonic renal disease. With the enactment of these two 
programmes, the aged and poor had increased access to medical care. Hospitals 
were paid according to their costs, and physicians received their usual fees. 
Coverage imder* Medicare is incomplete and the services covered are not 
comprehensive, in addition, a copayment is required for* both hospital and 
physician services, There are limited benefits for* post hospital care, such as skilled 
nm'sing and home care, and outpatient prescription drugs. All aged people, 
regardless of their income are presently covered by Medicare. Those aged with 
higher* incomes can afford to pmchase medical services and to buy supplementar*y 
coverage for those gaps not covered by Medicare. However, because Medicare 
benefits are not income-related, many aged find it difficult to pay the necessary 
out-of-pocket expenses. The result is that approximately 20% of the aged must 
rely on Medicaid (Feldstein, 1993).
Medicaid is financed through general tax revenues fiorn the states and from 
federal income taxes. It is administered by each state, which in turn sets the
12
eligibility criteria for persons in receipt of Medicaid. There are wide variations in 
eligibility requirements and in services covered. Medicaid expenditures have risen 
rapidly and states have foimd themselves mider pressure to reduce their share of 
the costs, tlrey have attempted to do this by limiting eligibility, reducing benefits 
and by paying medical providers less. This latter approach has reduced the poor's 
access to medical care; lower reimbiusement levels have limited the willingness of 
many providers to serve Medicaid patients (Feldstein, 1993).
Since the introduction of Medicaid and Medicare, uptake of private medical 
insiuance, primarily tlirough the workplace, has also increased. This increase in 
third party payers has led to an increased demand for healthcare which in turn has 
led to a rapid increase in overall healthcare expenditure. In 1965, 5% of the US 
gross national product (GNP) was being spent on personal medical services, by 
1990 tlris figure had reached 12% (Feldstein, 1993). Both private insurance and 
government payments lessened the financial burden on the patient. Direct patient 
payments for all medical services declined from 51.6% in 1965 to 23.2% in 1990. 
As more of the bill for medical services was paid for by govermnent and private 
insiuance, the importance of price on the patients use of the service and choice of 
a provider from whom to purchase that service diminished. As a result, there were 
few constraints remaining to hold down the use of services and prices charged by 
providers. The lack of incentive, i.e. financial responsibility by the decision 
rnalcers, patients and physicians, to substitute less costly care when medically 
possible, led to rapid increases in hospital costs, duplication of facilities and 
services and excess hospital capacity. It has been suggested (Feldstein, 1993) that 
hospitals avoided bankruptcy due to their excess capacity by exerting downward 
pressme on the admitting physicians to extend lengths of stay as well as admitting 
additional patients unnecessarily.
The US govermnent has sought controls for holding down hospital costs. There 
was an attempt to rationalise the expansion of healthcare systems by reducing 
capital investment by sti'onger plamiing regulations. Tliis culminated in the 
enactment of certificate-of-need (CON) laws in the mid 1970s (Feldstein, 1993). 
In essence tlris not only reduced competition for existing hospitals but also 
enlianced their market power by providing a bander to entry. CON legislation
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assumed that no changes were required in the method of hospital reimbursement 
and provided no new incentives to change patient or physician behaviom*. It is not 
smprising that CON turned out to be unsuccessflil in controlling hospital 
expenditines, which was the problem it was intended to redress. Other cost- 
containment measuies were sought.
Prior to 1983 Hospitals in the United States (US) were reimbursed for healthcare 
services by Government agencies, insuiance companies, and patients, either on the 
basis of charges or on the basis of costs. The Hospitals operated a practice called 
"cost-shifting" whereby the costs not met by certain insuiance policies e.g. 
Medicaie, Medicaid, Blue Cross, who paid what they considered basic hospital 
caie costs, were shifted to that segment of the patient population who paid what 
they were chaiged (Finkler, 1982). Hence by escalating chaiges for various 
services, the Hospitals recouped umeimbmsed costs. The clinical laboratory is an 
example of what was considered a convenient profit centre that could be used to 
support mnelated deficit-producing hospital operations (Conn, 1978). On October 
1, 1983, the Prospective Payment Scheme (PPS) was introduced into the US as a 
form of hospital rate regulation for hospitalised Medicaie patients. The PPS 
involves an average prospective payment made to the Hospital for treatment of a 
disease state which falls into a specific Diagnostic Related Grouping (DRG) rather 
than an individualised payment per patient treated. For example, the costs of 
managing a broken neck of lemur in an elderly patient can vary widely for lots of 
different valid reasons, however, imder the PPS a Hospital treating this indication 
now only receives a population averaged payment. For the obvious reason of 
profit maximisation the advent of the PPS necessitated that Hospitals rigidly 
control their costs such that every reimbuised dollar is used optimally. Cost- 
shifting was no longer an option, coiTections in distorted chai'ges had to be made 
and all cost components of diagnostic and therapeutic interventions had to be 
determined. Basically, the very last sticking plaster used in the care of a patient 
had to be accounted for. If the cost of treating a patient exceeds the DRG price, the 
hospital loses money. Hospitals therefore, have a financial incentive to produce 
caie at a cost below the fixed DRG price, since the difference can be kept.
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The DRG system is based on tlie assumption that patients with the same DRG 
would use similar hospital resources. DRG's aie developed according to patient 
chai'acteristics and the treatment received. DRG's are determined empirically; they 
were created according to whether the primaiy and secondary diagnosis, age and 
existence of a surgical procedure affected the patient's length of stay. Within each 
DRG there is assimied to be a certain resouice use associated with a patient's 
treatment, and the use of those resources is assumed to vary according to such 
factors as the patient's age, sex, primaiy and secondaiy diagnoses, and discharge 
status. There are approximately 480 Medicare DRG's. Under DRGs, a fixed 
amount is paid to a hospital for each patient within a DRG. However, there are a 
number of concerns with the DRG system. These concerns revolve aiound the 
classification of assigned DRG, patients frequently have multiple diagnoses, the 
fact that DRGs do not talce account of severity of illness and that the actual 
payment system is based on average costs over a large number of hospitals rather 
than the lowest production cost by the most efficient hospital for a given DRG. 
Facing a fixed price, a hospital has an incentive to minimise its costs of caring for 
the patient. It can do this by reducing a patient's length of stay, treating them as 
outpatients and restricting the amount of ancillary services used. In addition, it is 
also profitable and possible for a hospital to manipulate the DRG coding for 
patients with multiple pathology to select the higher price attracting DRG 
classification. This has been termed DRG creep' (Donaldson et al, 1991). 
Exclusion of more severely ill patients from the institution will increase net 
profits.
A study by Assaf et al (1993) carried out in 7 New England hospitals looked at the 
assignment of dischar ge diagnostic codes for patients with coronary hear t disease 
(CHD), both before and after the inception of the PPS. These workers found that 
the fr equency of assignment of codes for the acute forms of CHD, which entail 
higher reimbursement, had increased significantly. Conversely, the frequency of 
assignment of codes for the chronic forms of CHD, which entail lower 
reimbmsernent, had decreased reciprocally. These workers concluded that the PPS 
had influenced the assigrmient of hospital discharge codes in a way that would 
increase payment. It was not possible, however, to distinguish from the data
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whether hospitals began to assign more precise diagnoses with the advent of the 
DRG system, or whether they began to favour diagnoses of acute conditions solely 
for financial reasons.
It has been demonstrated by several groups (Jacobs et al, 1992, Falcone et al,
1992) that there is a definite financial disincentive to hospitals to treat severely 
injufed patients as the DRG-based reimbursement is substantially lower than the 
actual treatment costs. Jacobs et al (1992) examined the charges associated with 
treating trauma patients over a 5 month period and compared this with actual 
reimbursement. Only 65.5% of the total charges were reimbursed. Falcone et al,
(1992) showed that sur'gical review of trauma patient DRG assigrmient can 
improve reimbursement rates but even so there remains a short fall fiorn total 
calculated charges.
More effective ways of using drugs has been one mechanism by which hospitals 
have sought to reduce the costs of care. Several studies evaluating the impact of 
certain drugs on the cost of treatment began to appear* in the literature shortly after 
introduction of the PPS (Crist et al, 1987, Quintilliani et al, 1987, Dannenlioffer et 
al, 1989). It was at this point that pharmacoeconomic evaluation i.e. the 
application of economic evaluation to drug use, came to be of high profile within 
the American Health Care Institutions (Bloom, 1992). The necessity of cost 
control had to be reconciled with the maintenance of quality of care of the patient 
(Comi et al, 1985), pharmacoeconomic evaluation enables this fiorn the 
perspective of drug treatment however, it does not cover the entire culminated 
costs of care. Friedrich et al (1992) examined the hospital, pharmacy and 
antibiotic costs for 46 patients with penetrating abdominal trauma admitted over a 
4 year* period and compared them with reimbursement received. Less than 10% of 
patients were responsible for 43% of the hospital costs. The antibiotics represented 
only 0.5% of the DRG reimbursement received. For 4 patients costs exceeded 
DRG reimbursement by a median of $8210 leading to an average net loss of $295 
per* trauma patient. It was concluded that cost-containment practices for* this set of 
patients should be directed at other ancillary services and length of stay as any 
antibiotic cost-contairmient modification would have negligible impact on 
reimbursement monies.
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DRG reimbursement can be fmther maximised by 'unbundling' of services. 
Unbundling occurs when the hospital shifts part of the treatment to another setting 
while still receiving the full DRG payment. For example, patients may be 
discharged earlier and admitted to a nursing home or to their own home; the 
patients can then purchase, tlnough Medicare, additional services, such as home 
care or additional outpatient services. Unbimdling reduces costs in the regulated 
sector and shifts costs to the unregulated sector. Costs are shifted to the patient in 
the form of additional out-of-pocket expenses and to family members who have to 
care for tlie discharged patient. Unbimdling increases total Medicare expenditures, 
since hospitals receive the full DRG payment while Medicare incurs additional 
costs for nursing home and home health care for services previously provided in 
the hospital.
Another govermnental initiative during tlie 1970s, to contain healthcare costs was 
the inception of health maintenance organisations (HMO's) (Feldstein, 1993). 
FIMO's are capitation prepaid health plans. They are a heterogeneous mix of 
companies which are organised in a variety of ways (Luft, 1991). For an enrolled 
population, the contractual responsibility of an HMO is to assm*e the delivery of a 
range of medical services and to reimbinse patients incimed costs. HMOs can own 
their own hospitals and employ physicians on salary. Alternatively, an HMO can 
contract separately with hospitals and physicians for their services and reimburse 
them on a fee-for-service basis and have a profit sharing bonus. The economic 
incentive of HMO's is to retain the difference between the capitation payment and 
the costs of providing medical services. The organisation and its physicians have a 
financial incentive, therefore, to minimise the cost of medical care provided to its 
eni'ollees. A key aspect of the HMO concept is that providers conti'ol tlie whole 
range of benefits. HMO's attract emollees by a variety of methods, they generally 
cover a wider range of preventative services and prescription drugs than 
conventional insurance plans usually offer. They also have minimal copayments 
and lower premiums than conventional fee-for-service insuiance plans. The lack 
of financial baniers can be an attraction to consumers. The negatives that must be 
considered against the lower costs aie longer waits for an appointment and less 
continuity of care with the same physician.
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The one mechanism that the US government has put in place to directly control 
drug expenditme has been the federal Omnibus Budget Reconciliation Act of 
1990. This Act was designed to reduce and contiol federal and state outlays for 
prescription drug products provided to Medicaid outpatients (ASHP Govt. Affairs 
Div., 1991), From January 1, 1991, for the drug product line of a manufactuier to 
be eligible for any coverage imder Medicaid, tlie manufacturer must agree to 
provide rebates to all state Medicaid agencies i.e. a rebate is made to the state by 
the manufactiu'er towards the state's expendituies for the manufactui'er's drugs. 
The amount of rebate a manufactuier must give is a proportion of the drug price 
chaiged to the retail supplier. This Act does not relate to drugs prescribed in 
hospital, however the Act may have an hnpact on the hospital dmgs budget as the 
phaimaceutical industry may choose to maintain its profit margin by offsetting its 
rebates with price increases for new products.
In summary, prior to 1966 access to healthcare in the US was limited by an 
individuals ability to pay. Changes within the US system have to some extent 
increased access to healthcare although Iglehart (1986) reports that some 30 
million citizens still lack healthcaie insuiance. The changes in access have 
increased overall healthcaie expenditure. Vaiious mechanisms have been sought 
by the US government to contain this expenditine which in turn has forced 
Hospitals to improve their internal efficiency of resource utilisation such that 
profits can be maximised. From a governmental perspective the current DRG- 
based reimbiusement system is not entnely successfiil in controlling healthcare 
costs and would appear to be open to abuse as evidenced by DRG creep and 
imbimdling techniques. Eiuolment of Medicare patients with HMO organisations 
removes the problems associated with DRG reimbursement away fiom the 
government. However this shifts costs to the eiuollee as the range of healthcare 
services provided are limited to those set by the HMO.
Because of the way in which patient ti'eatment costs aie reimbursed the US 
govermnent has only been motivated to implement mechanisms which directly 
conti'ol outpatient drug expenditure. The control of inpatient drug expenditure has 
become the concern of the providers i.e. the Hospitals, HMO's etc. and it is these
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organisations who have become increasingly interested in the role 
phaimacoeconomics can play in assuring efficient drug use.
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2.2 The Canadian Approach
The evolution of Canada's scheme of hospital and physician insurance dates from 
1914, when the first Municipal Doctor Plan was introduced in Saskatchewan. 
Tlirough the intervening years public policy developed between federal and 
provincial governments culminating in 1965 in a publicly administered, universal 
program for medical services. All of Canada's 25.5 million citizens received care 
through its health scheme irrespective of their circumstances. The provinces were 
made responsible for administering the health insm'ance plans, the funds for 
which, come partly from the federal government and partly from taxation of 
provincial citizens. The ten provinces have broad constitutional authority to spend 
the revenues as they deem best, and to regulate health programmes. Citizens can 
still imdertake private health insurance plans for extended benefits, but under the 
provincial health plans, individuals have had virtually rmlimited access to care 
with the physician of their choice. It is understandable that Canadians report a 
high level of satisfaction with the municipal health care programme (Iglehart, 
1986, Wyman et al, 1995).
Problems have developed with the frmding of the health insur ance programme, not 
only because of increased health expenditure but also because the country's federal 
govermnent faces a massive budget deficit (Iglehart, 1986). The government has 
transferred the health care expenditure problem to the provincial govermnents to 
deal witlr. This has been done by capping the federal financial contribution to the 
health insurance plans and by implementing legislation that protects patients from 
paying for any part of their care (Iglehart, 1986). Provincial governments 
however, are transfening the responsibility for many services to third parties by 
de-listing services which were previously covered by the public health insiuance 
programmes (Carruthers, 1995). These third-party payers include employers, 
insurance companies, no-fault automobile insurance companies and the public, 
which now pays directly for services such as in vitro fertilisation (Carruthers, 
1995).
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Ontario is Canada's most populated province and its most influential region in 
terms of establishing trends. Early in 1992 Ontario's Health Minister outlined 
various health care reforms (Martm, 1992). Strategic priorities included major 
reviews of the hospital system, laboratory services and the drug-beneflts 
prograrmne. Goverimiental drug expenditure to date has been restricted to specific 
patient populations (Carruthers, 1995).
In Ontario, residents are eligible for drug benefits if they are over 65 or if they 
have low incomes. The provincial government plan pays for the entire cost of the 
prescription including the pharmacist's dispensing fee for this group of patients, so 
long as the drug is listed either as a benefit in the Ontario Drug Benefit Formulary 
or as a nonformulary benefit for specific indications, or special permission has 
been received from the Ontario Drug Programs Branch after written clinical 
justification by the attending physician. Recommendations about listing of 
pharmaceutical products in the Drug Benefit Formulary are given to the Minister 
of Health by the Dritg Quality and Therapeutics Committee (DQTC). The 
cormnittee, which considers issues of effectiveness, safety and cost, is made up of 
a group of experts representing academic and cornmimity-based physicians, 
pharmacists and biostatisticians (Detsky, 1993).
The provmcial drug prograimnes are the largest purchasers, on behalf of their 
beneficiaries, of drug products in Canada. The pharmaceutical industry has now 
come imder the spotlight for cost-containrnent measures. Pharmaceutical 
manufactur ers who submit an application for consideration of a drug to be added 
to a provincial Drug Benefit Formulary are now expected to provide economic 
information beyond simply listing the rmit price of the product. Not all 
submissions require economic analysis, but the submitting manufacturer is 
expected to justify its absence (Detsky, 1993). At the present tune each province 
performs a separate review of the submission information on effectiveness, safety 
and cost. An inter-provincial economic working group proposed that a smgle 
review committee be established for the purpose of reviewing economic 
components of pharmaceutical drug listing submissions (Detsky, 1993). Detsky
(1993), in recognition of the fact that experience and expertise in the use of 
economic analyses was still in its infancy, for both the pharmaceutical industry
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and government, published proposed guidelines for the economic analysis of 
pharmaceutical products. Deregulation of a larger number of dr'ugs from 
prescription status to over-the-cormter status has been proposed recently (Morgan 
et al, 1995) as a method to reduce costs to the Canadian government. It would 
appear however, that there is some initial resistance by the medical fraternity to 
this suggestion.
As in the US, govermnental initiatives to control drug expenditiue have largely 
focused on outpatient use rather than in the secondary healthcar e setting.
2.3 The Antipodean approach
Australia's public healthcare system is similar in many respects to the British 
National Health Service. It is funded by a special tax levy on income and provides 
imiversal access to doctors, hospitals and most ethical pharmaceuticals. Many 
sections of the community (low income, pensioner and other social welfare 
groups) receive healthcare at no cost to themselves.
As with other countries there has been concern in Australia about the level of 
public expenditiue on healthcare, in 1990-1991 this totalled A$21.7 billion (Parry 
1994). Although the pharmaceuticals budget accounts for less than 9% of 
recurrent healthcare expenditure (Pany, 1994) it has been the object of vigorous 
cost contaimnent by the Government. Bloom (1992) argues the reason for this is 
because it is a highly visible component of healthcare expenditure unlike other 
portions of the expenditur e and therefore becomes an easier target for academics 
and policy makers looking for ways to cut costs. Credence is given to this 
statement by Raftrse (1995) who reported on a project evaluating where major 
savings could be made in the Canadian Health Car'e System. The project suggested 
that the biggest saving would be made by a major reconfiguration of health care 
facilities such as reducing the number of acute care hospital beds, reducing the 
time spent in hospital and using alternatives such as residential and community 
care for the elderly. Logistically tliis is a more difficult area of expenditure to deal 
with than the pharmaceuticals budget.
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In Australia 70% of prescription phaiinaceuticals aie reimbursed by the 
Pharmaceutical Benefit Scheme (PBS) (Parry 1994). The PBS makes available to 
patients a wide range of prescription drugs at subsidised prices. Although there is 
a small capped co-payment by general users, certain categories of patient ar e not 
charged at all. Although the PBS was designed to provide low-cost access to a 
core range of drugs, the system has effectively replaced the free market with 
regard to prescription drugs. Products not covered by the PBS are in competition 
with drugs available on the PBS and have little chance of significant prescribing 
by practitioners.
The Commonwealtli of Australia exercises control over the ethical 
pharmaceuticals market by virtue of the fact it is the only purchaser under the 
PBS. A variety of mechanisms have been used to restrain expenditme on new 
pharmaceuticals (Parry 1994). These include:
1) Authority requirements' on drugs costing more than A$30 per prescription, 
whereby the more costly drugs can be prescribed only by the physician with 
explicit authority from the Department of Health. This is purely a budgetary 
device designed to suppress use of newer, more costly drugs, the cost of which is 
borne largely by the Government under the PBS.
2) Delayed listing of newer, more expensive drugs by the Australian Drug 
Evaluation Cormnittee. The needs of tight budgetary constraints are met by delays 
of up to 5 years in approval status.
3) The traditional pricing mechanism of the PBS. After general marketing 
approval, a drug will be listed on the PBS subject to negotiations with the 
Connnonwealth of Australia with respect to its value to the PBS and tire price that 
will be reimbursed by the Commonwealth.
4) Imposition of an economic analysis requirement for PBS listing. An 
application for a new drug to be added to the PBS must now demonstrate cost- 
effectiveness compared with existing medical treatrnent(s), including existing drug
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therapies. This control mechanism is recognition of the importance of economic 
evaluation in the allocation of resources by policy malcers. Australia is the first 
coimtry to issue mandatory guidelines of this natine.
Bloom (1992) in an analysis of the guidelines stated that although the 
requirements are seemingly appropriate several issues relating to them are raised. 
If studies of cost and benefit are to be done in tandem with controlled clinical 
trials of safety and efficacy, it is difficult to translate the artificial results of 
efficacy into effectiveness criteria so that ‘appropriate’ policy and other decisions 
can be made by political authorities. Clinical use of a drug and consequently the 
economic ramifications of that use can be far* different fr om the rigid, prescriptive 
use of the drug imder study conditions (Strom et al, 1985). A frnther issue is how 
the results of economic evaluation will be used. The criteria for registration and 
pricing piuposes must necessarily be complex because of the many different types 
of medications and the effects they have ranging from life-saving through to those 
that ameliorate symptoms alone.
Cost-effectiveiiess requirement for PBS listing
The new pharrnacoeconomic policy requirement for PBS listing infers that the 
federal Government considers various areas of expenditure within the context of 
the global healthcare budget. Parry (1994) suggests that this is not the case, he 
states that policy expenditure decisions on pharmaceuticals are taken in isolation 
from any implication for their effects on expenditure on medical or hospital 
services despite the new requirements. Although a new product may lead to 
significant savings elsewhere in the healthcare system, such as reductions in 
physician visits or reduced hospital stays, cormnitment to additional expenditure 
on that new drug is driven by PBS budgetary constraints only. Parry (1994) argues 
that tills is because federal govermnent budget ^/locations for each area are 
separate from each other and the inter linkages between categories of healthcare 
ar e almost completely ignored. If this is the case, it nialces a nonsense of the cost- 
effectiveness requirement for PBS listing and substantiates one of tire conclusions 
made by Drmnmond (1991) prior to the introduction of the guidelines. He 
concluded that inappropriate implementation would be nothing more than an
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expensive way of slowing down the entry of new medicines into Australia and of 
reducing pharmaceutical expenditme. In essence the guidelines achieve the 
objective of reducing the drug budget but the effect on overall healthcare 
expenditme remains miknown.
2.4 The UK Approach
The British National Health Service was introduced in 1948 to provide a 
comprehensive health service available to all, free at the point of delivery and 
financed mainly from taxation. Since its inception there has been a steady increase 
in tlie understanding of diseases, the development of healthcare teclmology and 
the ability to treat diseases. Consequently there has been an escalation in demand 
for public financial resourcing of healthcare. Responsibility for managing 
healthcare services is delegated by the Goverimients NHS Management Executive 
as far as possible to local health authorities. Until April 1, 1996, Family Health 
Service Authorities (FHSAs) were responsible for assessing the needs of their 
populations for primary medical and dental caie and for developing sei*vices to 
meet those needs, tlnough liaison with medical and dental practitioners. District 
Health Authorities (DHAs) were responsible for assessing the needs of their 
populations for all other commmiity and secondary care, and for pmchasing care 
from public and private providers to meet those needs. Since April 1, 1996, 
FHSAs and DHAs were structmally reorganised into unified Health Authorities 
(HA) with the previous remits being retained by the new HAs (Cmlis, 1996).
On a percentage basis the proportion of spending on drugs to total National Health 
Service (NHS) spend in the UK has remained relatively constant since the 
establislnnent of the NHS. It was 9.3% in 1949-50, 9.9% in 1959-70 and 11.1% in 
1989-90 (Health Committee, 1994). However, tliis disguises the fact that actual 
drug expenditme is on the increase. In England in 1992-3 gross NHS spend was 
£29.4 billion of which expenditme on drugs amoimted to £3.3 billion (see Table 
2 .1).
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The increase in the drugs bill is due to two factors, an increase in the number of 
drugs prescribed and an mcrease in the average price of medicines. The increase in 
the volume of drugs prescribed can be explained by an increase in the ageing 
population (Mulley, 1995), an increased rate of diagnosis and an increased use of 
drugs in preference to other treatments. The increase in the average price in 
medicines is due in the main to the introduction of new products, as the average 
price of existing di'ugs rises slowly. The average price of dmgs bought by the 
Hospital and Commimity Health Services (HCHS) sector (otherwise known as the 
secondary care sector) rose by 13.4% in 1992-93 and by an average 7% each yeai' 
over the preceding 11 years (Health Committee, 1994).
The largest proportion (80%) of the NHS drugs budget is accounted for by 
medicines prescribed by General Practitioners hi tlie Family Health Services 
(FHS) sector (otherwise laiown as the primary care sector). Such drugs cost £2.6 
billion in 1992-3. The figme for di'ugs purchased by the HCHS in the same yeai' 
was £634 million (Table 2.1).
Table 2.1 Cash spent (millions) on drugs bill in England
Cash spent (millions) on drugs bill in England
Year FHS 
(primary care)
HCHS 
(secondary care)
% increase on 
preceding year
80/1 766 185
81/2 876 214 15
82/3 1009 245 14.5
83/4 1130 267 10.9
84/5 1192 274 2.6
85/6 1275 297 8.4
86/7 1378 318 7.0
87/8 1536 352 10.7
88/9 1744 380 8.0
89/90 1942 414 8.9
90/1 2080 460 11.1
91/2 2317 591 2&5
92/3 2641 634 7.3
93/4 2951 696 9.8
HCHS - Hospital & community health services FHS -Family health services
Personal communication, Norman Taylor, DoH, London, 1995.
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2.4,1 Cost containment
The continuous real terms increase in the drugs bill has led the Government to 
explore ways in wliich Üiese costs might be contained. The two principal means at 
the Governments disposal for doing this are by influencing the price of drugs and 
by seeking to reduce the use of expensive drugs. Table 2.2 summarises the ways in 
which the Govermnent has endeavomed to influence the price and prescription of 
drugs in an attempt to limit the NHS drug bill.
Table 2.2 UK governmental methods for influencing the price and
prescription of drugs
Price modifying schemes Pharmaceutical Price Regulation Scheme (PPRS) 
Drug Tar iff
Prescription modifying schemes Selected List 
PACT Data
Indicative Prescribing Scheme
Deregulation of Prescription Only Medicines to
Pharmacy Medicines (POM to P)
Greater use of generic drugs
Patient Demand Limiter Fixed charge co-payment
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2.4.1.1 Price modifying schemes
Pharmaceutical Price Regulation Scheme (PPRS)
The Phai-maceutical Price Regulation Scheme (PPRS) is a voluntary aixangement 
between the Department of Health (DoH) and the pharmaceutical industry. It 
controls prices indirectly by controlling companies profits, however as it is 
primarily a profit control scheme, the price of an individual drug is entirely a 
matter for the company concerned (Wolfson et al, 1983).
The Drug Tariff
The Drug Tariff is a Government publication which amongst other information 
provides guidance on how pharmacists will be reimbmsed for dispensing NHS 
prescriptions received from GPs. The Drug Tariff sets generic drug prices for 
reimbm'sement of phaiinacists at levels that reflect those available in the market 
place. It follows rather than leads prices. In the view of the DoH it will exert some 
downwai'd pressure on prices especially for those drugs for which there is 
competition as suppliers will be aware of the level at which pharmacists will be 
reimbmsed and that they will be reluctant to buy alternative generic products at 
significantly liigher prices than those set in the Tariff.
2.4.1.2 Prescription modifying schemes
The Selected List Scheme
In 1986 regulations were introduced which limited the range of drugs available for 
prescription and supply on the NHS in several therapeutic categories, this included 
the benzodiazepines because it was felt there was a specific problem with this 
group of drugs. The rationale behind the selected list was that the Govermnent 
decided firstly, £120 million were mmecessarily spent each year* on a range of 
medicines which were used for minor or self limiting ailments which did not 
require medical intervention and could be bought over the counter, for example, 
tonics, cough and cold remedies. Secondly, £40 million a year were spent on 
benzodiazepines which included expensive proprietary brands of a similar nature 
to and no advantage over the small nmnber of generic benzodiazepines which
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were available. The principle of the Selected List is that drugs which are 
ineffective or which aie more expensive than other equally effective drugs should 
not be prescribed, these drugs essentially form a 'blacklist' i.e. the NHS will not 
pay for these dixigs. The proviso within the scheme is that a patient may request a 
branded drug that is not available on NHS prescription, to be prescribed privately. 
For this the patient incurs the full cost of the ding and dispensing charge. 
Introduction of the limited list was estimated to save the NHS approximately £100 
million each year (Deitch, 1984). In addition to the 'blacklist' of dmgs there aie 
drugs called 'borderline' substances which may not be prescribed on the NHS 
miless the drug is for a specific medical condition. The NHS prescription for the 
borderline dmg has to be aimotated indicating that it is for the treatment of an 
allowed medical condition, for example, the mucolytic acetylcysteine can be 
prescribed for the treatment of patients with cystic fibrosis but caimot be used for 
any other type of patient.
Indicative Prescribing Scheme
Family Health Services Authorities (FHSA's) were charged by the Government 
both with promoting rational prescribing and with keeping general practitioners 
(GPs) prescribing expenditure within budgetaiy allocations agreed with regions. 
Although a GP is limited to some extent by the selected list, GPs can decide how 
much and what they prescribe. The government sets an in-yeai* Reserve to cover 
overspends m tlie drugs budget but access to the Reserve cannot be regarded 
lightly. The Reserve is limited in size and is intended as a contingency to deal 
with unforeseen circumstances, for Treasury to permit access to it, it has to be 
demonstrated that any overspending which has occurred is despite best efforts to 
promote effective and economical prescribing (NHSME, EL(95)8, 1995).
From 1991 each GP practice has been asked to keep expenditme within its 
indicative (tai'get) drugs budget. This budget was set for all GPs by their FHSAs. 
The methodology deriving indicative prescribing amoimts, however, has been 
subject to criticism because imtil 1992/3 it was based on the historic expenditure 
of a given practice adjusted for price and volume changes and for local factors. 
This led to inequity between those prescribers who had historically attempted to 
rationalise their prescribing and those who hadn't. Little incentive was created for
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doctors who were over prescribing to review their habits (NHSME, EL(93)4,
1993). Since 1993 historic costs have been supplemented by weighted capitation 
benchmarks, taking into accoimt the age and gender structure of each GP's practice 
list (NHSME, EL(93)4, 1993). The purpose of weighted capitation benclmiaiics 
was to enable FHSA advisers to make more systematic and demonstrably fair 
reductions to the indicative (tar get) drugs budget of historic liigh prescribers.
GPs are only guided by the indicative prescribing amounts set annually and 
FHSAs have had virtually no power in the last resort to compel GPs to prescribe 
in a particular way imless it could be proved that their actions were harmfrrl to 
patients. However, for those GP's who joined the volimtary fimd-liolding scheme 
which was part of the Governmental healthcare reforms of 1989 there has been a 
powerful incentive to prescribe rationally. The GPs of a fluidliolding unit directly 
manage the practice budget for all aspects of healthcare. The fundholders 
themselves become piuchasers of care for then patients rather than this being done 
on their behalf by the local FHSA. The economic incentive to the fundholder is 
that savings made in one area, for example pharmaceuticals, can be redeployed 
elsewhere to improve the range of services offered by the practice. This incentive 
has been shown to have a definite impact. A study specifically designed to 
examine the effect of the fundholding scheme was carried out over a four year 
period. Six fundholding units were compared to non-frmdlrolding imits as controls. 
Amongst otlier findings it was demonstrated that the frmdholding units had a 
reduced volume of prescribing, were more cautious in the prescription of new and 
more expensive preparations yet maintained quality of prescribing as measured by 
their increased prescribing volume in 3 clinical areas recommended by consensus 
(Howie et al, 1995). These findings are supported by a review of primary care 
prescribing by Walley et a/ (1995). In summary, fundholders were found to make 
savings on their budget by either reducing prescribing costs or containing 
prescribing cost increases.
An incentive scheme for non-frmdholders was devised for the 1995-96 budgetary 
allocation following the perceived success of the incentive scheme for 
frmdholders. Under the new arrangements all non-fundliolding practices were 
given their prescribing allocation as a range of expenditure within which it was
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reasonable to expect the practice to meet the needs of their patients by rational, 
cost-effective prescribing. Practices which contained their prescribing expenditme 
within the range were eligible to receive an incentive payment subject to certain 
conditions (NHSME, EL(95)8, 1995). The type of condition that a FHSA could 
attach to the awar d of an incentive payment were, for example, the achievement of 
specific levels of generic prescribing/dispensing, audit of repeat prescribing 
systems, attendance at prescribing seminars etc. It was stated that these conditions 
were to be made known to the practices before the star t of the scheme (NHSME, 
EL(95)8, 1995). For the year* 1996/97, introduction of the unified HAs has 
essentially not changed the arrangements for* prescribing allocations and 
incentives to GPs (NHSME, EL(95)128, 1995).
PACT (Prescribing Analyses and Cost Tabulations) data 
Srmnnary PACT data has been supplied on a monthly basis smce 1988, by the 
Prescription Pricing Authority, to all FHSAs and most GPs. There are 3 levels of 
data, smnmary, detailed and full. The data provides GPs with information about 
their prescribing patterns and costs as well as information about FHSA and 
national averages. More detailed data are automatically sent to expensive 
prescribers, which might include, for example a breakdown of prescribing costs by 
therapeutic group. Any GP can request frill details.
PACT data can be used as a tool by GPs to monitor performance against their 
taiget budgets, it also enables them to compare their prescribing behaviour to that 
of their colleagues, both in their own area and nationally. In Scotland the 
equivalent to PACT data is SPA data which is disseminated on a quarterly basis. 
PACT data reveals only what GPs prescribe, in what quantities and at what cost. It 
does not reveal what conditions the drugs were prescribed for, in what dosage, or 
for how long, or how many patients have been treated, all of which aie central to 
any assessment of appropriateness, effectiveness and cost-effectiveness. Many 
prescribing errors would escape uimoticed in a scrutiny of PACT data alone. 
Deregulation of Prescription Only Medicines to Pharmacy Medicines 
Under the Medicines Act 1968, medicines are assigned one of tliree legal 
categories when they are licensed: prescription only (POM), pharmacy sale (P) or 
general sale (GSL). Medicines in the latter two categories may be supplied over
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the counter (OTC) without a prescription with the proviso that the P medicine is 
sold imder the supervision of a pharmacist. Many of these two categories may also 
be prescribed thi'ough the NHS. The government eventually realised that 
deregulation of medicines from POM to P provides a benefit both to the NHS and 
to the patient. The NHS benefits by shifting the costs of the medicine to the 
patient and the patient benefits by the convenience of being able to obtain the 
medicine without refeixal to a GP, in addition, for those patients who pay 
prescription charges, this may also be a less expensive way of acquiring the dmg 
(Bradley, 1995). A driving force for deregulation, therefore, was government 
policy to contain the NHS drugs bill. In the late 1980s the government made it 
easier to reclassify certain drugs from POM to P. Initially progress was slow with 
only 10 medicines being reclassified between 1988 and 1992. However, the 
criteria which govern whether a medicine should be POM or P became the subject 
of an EC directive (1992) which was incoiporated into UK law by way of 
amendment to the Medicines Act 1968 (Medicines Act 1968 Amendment, 1992), 
since this amendment a fruther 40 medicines have been reclassified (Blenldnsopp 
et al, 1996).
The likely NHS expenditure consequences of increased deregulation are imcleai*. 
In some instances, savings in the drugs budget have resulted:- for instance £1.8 
million per year when hydrocortisone and loperamide became available from 
phai'macies without prescription; in others prescription expenditme has continued 
to rise (Audit Commission, 1994). Another potential saving is in GPs time. A 
smvey by the Proprietary Association of Great Britain (PAGB) estimated that 
appropriate self medication with an OTC drug would reduce GP's workload by 
sixteen consultations a day. One estimate is that 100-150 million general-practice 
consultations per year are for conditions that are potentially self treatable (Anon, 
1994).
The deregulation of drugs has not been unopposed (Erwin et al, 1996), witli many 
GPs disagreeing that the supply of certain medicines should be allowed without a 
prescription. However, the level of opposition has decreased since the inception of 
frmdholding practices. The reason suggested to support this reduction in 
opposition is that fundholding practices have a greater concern for contaimnent of
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prescribing costs than non-fundholding practices and therefore support the 
proposal that a wider range of drugs be available for pmchase by a patient without 
a prescription (Erwin et al, 1996).
Fixed charge co-payment
Unless a patient is exempt, a fixed charge co-payment has to be paid towards each 
item prescribed for them by a GP. There are several categories of exemption, for 
example, old people, children, low income, certain medical conditions etc. At 
present the cost per item for a patient not exempt is £5.50. This flat-rate charge 
bear s no relationship to the amount of medicine prescribed or its actual cost to the 
NHS. For those patients who receive medication on a regular* basis but who are 
not exempt and have to pay the fixed charge there is a facility called a pre­
payment cer*tificate. This is rather like an insurance policy which limits the 
amoimt the patient co-pays over a given time period towards their* medication. 
Once a pre-payment cer*tifrcate is purchased no fruther* co-payment is required for* 
a prescription regardless of the niunber of items prescribed withm the twelve 
months covered by the certificate. At the present moment a pre-payment 
certificate costs £82.00 for* 12 months, provided the patient is prescribed more 
than 15 items within the year* then the pre-payment certificate is a cheaper* option 
than paying the fixed £5.50 charge per item.
The total revenue raised by prescription charges in 1992-93 was £242 million, 
which amounts to 7.3% of the NHS drugs budget, and 0.8% of the entire NHS 
budget (Health Committee, 1994). Information about the cost of collecting this 
revenue is not available. In 1992 over* 24 million people were estimated to be 
eligible for fr*ee prescriptions by reason of belonging to one or more categories. It 
is not known how many people were exempt from charges specifically on medical 
groimds. In 1992 80% of items were dispensed without charge (Health 
Cormnittee, 1994).
2.4.2 NHS Management Executive (NHSME) Letters
Another* method the Government uses to exert downward control over* the NHS 
health car*e budget is dissemination of NHS Management Executive (NHSME)
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Letters. The NHSME issues guidance directives in the form of 'executive letters' to 
the local health authorities concerning amongst other matters the management of 
the drugs budget. It is in this way that the call for action on national initiatives is 
disseminated. It is also tlnough these letters that the Management Executive 
informs the local health authorities of changes in the fiscal management of tlie 
amiual budgef a/locations. The success of tliese guidance directives appeal's to be 
dependent on the degree of coercion associated with these communications.
A recent executive letter (EL(93)115) stated that the NHSME wished to see better 
use made of reseai’ch-based evidence about clinical effectiveness. The letter 
provided a list of core information services concerning 'clinical effectiveness' 
which are available for consultation by piuchasers and providers to aid them with 
this initiative. However, the adage 'a horse can be led to water but cannot be 
forced to drink' is rather true in this instance Maynard (1993) suggested that most 
piu'chasers were not translating established performance guidelines into 
pmchasing practice as is evidenced by umiecessaiy insertion of gronmiets into 
children with glue eai* and mmecessaiy D&C's (Lewis, 1993). Maynard (1993) 
fui-ther suggested that there is a general failure to support the development of 
national initiatives to identify effective therapies that are also cost-effective. One 
reason for this maybe that research findings are difficult to interpret and apply. To 
highlight this, Scezepma (1994) used the example of the vaiious interventions 
which can be used after myocardial infarction. Coronary heart disease is the most 
common cause of death in Britain, consuming approximately 2.5% of NHS 
resom'ces and costing nearly £10 billion a yeai' in lost production and hospital care 
(Scezepma 1994). The literature contains few studies of the cost-effectiveness of 
the various interventions in myocaidial infarction, and those that have been 
reported show little consistency in methods, costs measured, discomiting of futm*e 
costs and benefits, or how costs at'e related to outcomes. Standai'disation of 
instruments to measme both clinical and economic factors is obviously a critically 
important next step in the evolution of useful research based information 
(Scezepm-a 1994).
It could also be said that there is a degree of resentment by healthcare 
professionals who are expected to implement tlie government initiatives. An
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editorial in a leading medical jomiial (Ham, 1995) following the publication of 
EL(93)115 on clinical effectiveness, suggested that it is not only the use of 
medical treatments which needs to be evidence based but also the policy making 
for health services as a whole at Govermnental level. It certainly does appear that 
the Government is capable of sending out mixed messages, an example of this is 
the NHS Executive Letter which directs Health Authorities to ensme that Beta- 
interferon, a drug used to treat multiple sclerosis, is available on the NHS despite 
the fact tliat many consultant nemologists consider this drug to be neither 
clinically proven nor cost-effective (Butler, 1995). There needs to be a mechanism 
for transferring the results of research into policy. Ham (1995) suggested that the 
only way in which the NHS could progress was for evidence-based policy making 
and evidence-based medicine to go hand in hand.
In contrast to EL(93)115 which was not associated with any direct form of 
coercion, the directive EL(95)5 about the purchase of high-tech health care for 
patients at home will most definitely be implemented because it includes 
mandatory financial guidelines. In fact EL(95)8 stated that resources available for 
allocation to GP practices had been reduced because of the initiatives in EL(95)5.
2.4.3 Other forms of control for restraining drug expenditure
2.4.3.1 Guidelines for Economic Analyses of Drug Treatment
The DoH in conjunction with the Association of British Pharmaceutical Industries 
(ABPI) have issued guidelines (DoH Press Release, 1994) for tlie conduct of 
economic analyses of drug treatment, but it would appeal* that this issue is little 
more than rhetoric. The guidelines are for the conduct of clinical trials but there is 
neither incentive or a mandatory requirement for their implementation 
(Freemantle et al, 1995). Without a facilitative or coercive approach it will be 
surprising if their use becomes widespread.
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2.4.3.2 Expert Body Evaluation of the Drugs Budget with their findings and 
recommendations for the future
2.4.3.2.1 Governmental Audit
The Audit Commission was set up by the Government in the eaiiy 1980s to audit 
and assess whether local authorities were delivering value for money. The 
Commission was to promote economy, efficiency and effectiveness. The 
Govermnents white paper on the NHS published in 1989 amiounced that the Audit 
Conmiission was to talce on the external audit of the health service. The 
responsibility began on 1st October, 1990 (Smith, 1990). The Audit Commission 
uses 3 criteria in deciding which issues to study, these are:-
1. The issue must cany substantial financial costs,
2. There is an opportunity to achieve improvements, and
3. There is the possibility of change, (Smith, 1990).
The NHS drugs budget fulfils all 3 criteria and as the laigest proportion of the 
NHS dmgs budget is accounted for by medicines prescribed by GPs it is not 
surprising that this became the focus of an Audit Commission evaluation.
A report of the GP study (Audit Commission, 1994) stated that more rational 
prescribing by GP's would lead to better quality caie for patients and to major 
economies in drug expenditme. It was suggested that a saving of £425 million 
would be made thioughout England and Wales if all doctors were to prescribe in a 
cost-effective manner similai* to those GP practices classed as 'good' prescribers in 
the evaluation. The report identified opportunities which could lead to better 
patient caie and more effective use of NHS resom'ces. One of the areas of patient 
care identified which required increased drug expenditme was that of the 
preventative treatment of astlima. It was estimated that if all GP's were to increase 
their prescribing of inlialed steroids for preventative treatment to 50% of the 
prescribed bronchodilator rate, then drug expenditme would increase by £75 
million. However, it was considered that it would be cheaper for the NHS as a 
whole as fewer patients would be admitted to hospital with severe astlima attacks 
or complications. Each year 2,000 people die in the UK as a result of an asthma
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attack, of which 80% aie avoidable. It was also felt that there was a general under 
diagnosis of clnonic conditions which if reversed would have additional 
prescribing resomce implications (Audit Commission, 1994). Table 2.3 
summaiises the opportunities for rationalising resources as identified by the Audit 
Commission.
Table 2.3 Opportunities for more rational prescribing with implications 
for resources (from Audit Commission, 1994)
Opportunity for modification Resource implication (compared 
to 'good' prescribers)
Over prescribed drugs £295 million saving
Less prescribing of drugs of limited therapeutic 
value
£45 million saving
Substitution of alternative drugs £25 million saving
More generic prescribing £50 million saving
More selective use of expensive formulations £30 million saving
More inlialed steroids for astlima £75 million spending increase
Additional prescribing resulting from a reduction 
in the under-diagnosis of cln onic
£ not estimated
Hospital/GP interface and cost-shifting
GP prescribing is influenced by medicines initiated in hospital or recommended 
when patients are referred to hospitals for an opinion. The frill expenditme 
implications are difficult to quantify (Audit Commission, 1994). There aie two 
reasons why hospital doctors prescribing behaviour should initiate more 
prescribing, and more expensive prescribing amongst GP's than is necessary. 
Firstly, drugs may be available at a lower price in hospitals tlian in the FHS 
(primaiy care) sector. The drug companies offer 'loss-leaders' to hospital 
pharmacies at an artificially low price so that the drug replaces others, which aie 
often cheaper in the primary caie sector, in the hospital formulary. Because 
hospitals aie cash limited there has been a strong incentive to persuade their 
doctors to prescribe the cheapest, clinically appropriate dmgs. Formulaiies are 
used to limit or guide their choice. By offering 'loss-leaders' the drug companies
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are attempting to get then products initiated by the hospital based doctors 
(Wolfson et al, 1983). When a patient goes to the GP for Huilier prescriptions it is 
very difficult for the GP to change the prescription even if there is a cheaper and 
equally effective alternative as the patient sees the consultant as the ultimate 
decision nialcer on therapy (Health Committee, 1994). Lower hospital drug prices 
may also result from hospitals using their position as bulk puichasers to negotiate 
lower prices. Wliichever way the hospital drug price is lowered, the drug company 
will attempt to recoup lost profit' by raising the price of their dmgs in the prhnary 
caie sector (Wolfson et al, 1983). Secondly, hospital drugs budgets aie cash 
limited whereas those of FHSAs aie not. Although fundholders have specific 
budgets, the majority of GP's (non-frmdholders) are subject to looser financial 
limits in their spending on medicines. They do have taiget budgets but as already 
explained there is a contingency budget for overspends This has provided an 
incentive to the hospitals to shift prescribing on to FHSA's in order to remain 
within their budgets. The lack of a unified system of funding between the primaiy 
caie sector and the secondary care sector has led to a cost-shifting approach. Many 
drugs initially prescribed for patients by hospital doctors ai'e continued for some 
yeai's after dischaige. The authors of one study (Jackson, 1993) estimated that 
between 15 to 20% of GP prescribing is hospital initiated; in total 40% may be 
strongly influenced by hospitals, since a GP's choices of drugs when prescribing 
for their own patients aie also likely to be guided by local consultants. In addition 
to the ubiquitous di'Ugs, GP's have been increasingly called upon to prescribe 
expensive specialist drugs to tieat more exotic conditions that until recently would 
have been treated by hospital doctors. These include treatments for infertility, 
growth deficiency, malignant disease and HIV; also drugs used as adjuncts to 
organ transplantation, cancer chemotherapy and home dialysis. Nationally, such 
'high-tech' drugs, normally prescribed only imder specialist supervision, now 
represent 4% of GP prescribing expenditure, although there are big local 
variations (Audit Commission, 1994). GP expenditure on these drugs rose by 
20.5% between 1991/92 and 1992/93. The Audit Commission (1994) 
recommended that the FHSA and DHA should jointly agree with the medical 
professions the circumstances in which such expensive drugs should be provided
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on tlie NHS and who should be responsible for tlie cost. It was considered that 
GP's should not be asked to malce political decisions on an ad-hoc basis. A flulher 
recommendation by the Audit Commission (1994) was for the prices at which 
drugs aie reimbursed in the commmiity to be talcen into consideration when 
agreeing regional purchasing contracts and when compiling and reviewing 
hospital formularies. Formulaiies should distinguish di'ugs considered suitable for 
routine prescribing by GP's from those intended primarily for specialist hospital 
use and that both sets of drug prices, hospital and commmiity, should be shown. 
The Audit Commission report frequently referred to the need for cost-effective
prescribing and considered that 'FHSAs should continue to foster the
realisation that prescribing decisions must be taken within the context o f the 
overall resources available to the NHS'.
The reconmiendations of the Audit Commission aie not mneasonable and can be 
practically put into operation. The inclusion of GP's and FHSA medical advisers 
on the drugs and therapeutics committees of major hospitals aie a useful way of 
ensming that commmiity interests are represented in hospital decisions about 
inclusion of new drugs in formulaiies or about prescribing responsibilities. Smrey 
is one FHSA that has promoted the formation of a joint co-ordinating committee 
on which all hospital miits in its area are represented and which talces the lead on 
issues of common interest to the commmiity (Jackson, 1993). However, joint 
general practice/liospital formularies are tliiii on tlie gromid, a survey of acute 
general hospitals in the UK found that although 90% had a formulary, less than 
4% operated a joint one (Joshi et al, 1994). The Grampian formulaiy, which was 
completed in 1992 (Ferrow et al, 1996), was one of the first reported joint general 
practice/liospital formularies and although compliance with the formulary by 
Grampian GPs is volimtary, it appeal's to be worldng quite well. A recent smvey 
(Ferrow et al, 1996) showed 84% of drugs being prescribed to patients admitted to 
local hospitals were joint formulary items. All Scottish Health Boaids were 
supposed to implement joint formulaiies by the end of 1995 but it is difficult to 
assess whether this has actually happened because the only published paper 
advertising this event is the one for Grampian region (Ferrow et al, 1996).
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2.4.3.2.2 Health Committee
The Health Committee was set up in 1992 by the Government to examine the 
expenditme, administration and policy of the DoH and associated public bodies. A 
major focus for the Committee's activities was the issue of priority setting in the 
NHS. It examined the ways in which decisions were being taken on the 
assessment of need and the level of Govermnent funding required to meet that 
need. The Committee specifically considered 'whether the measures introduced by 
the Government to control the NHS drugs budget are leading to more appropriate 
and cost-effective use o f drugs in terms o f current NHS resources and future 
patient needs'. Central to the inquiry was how the Government might best carry 
out its multiple responsibilities: those of simultaneously promoting welfaie, 
containing costs, encomaging rational and effective prescribing and supporting a 
vigorous UK phaiinaceutical industry. The conclusion and recommendations of 
the inquiry included the statement that an important constraint upon the 
Government's freedom to take action to reduce the drugs bill was that it is 
committed to the principle that patients have an 'entitlement to receive all the 
medicines they clinically require' (NHSME, EL(94)2, 1994). The 1994 Annual 
Report of the DoH states that it is 'policy that no patient be denied the medicines 
needed' (Health Conmiittee, 1994). The Health Connnittee (1994) restated this 
Governmental mission statement that in no circumstances should a patient be 
denied a medicine for which there is evidence of genuine need. The Committee 
fruther stated that insufficient research has been conducted to allow the cost- 
effectiveness of recent drug developments to be quantified but aclmowledged that 
the Selected List ('blacklist') was an attempt to introduce the criterion of cost- 
effectiveness into decision-making on the pui'chase of medicines in the NHS. It 
was suggested that a logical and desirable extension of the Selected List policy 
would be the development of a NHS Prescribing List ('whitelisf) covering all 
therapeutic categories. This would contain a wide spectrum of products which the 
NHS was prepared to buy. The list would automatically include all drugs at the 
time of their laimch and for five yeais thereafter. All new products would be 
prescribable on the NHS. After five years, a time sufficient to allow formal 
assessment of the therapeutic value of the product, each drug would be reviewed
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according to the criteria applied to dmgs in the current NHS Selected List. Those 
drugs which were foimd to be less effective, or more expensive with no 
therapeutic advantage, than competitor drugs would then be excluded from being 
prescribed on the NHS. In this way a 'national formulary' would be gradually built 
up in a predictable, rational way. The Committee considered that the introduction 
of cost-effectiveness criteria legislation at the point of licensing as flawed due to 
the fact that it is not always possible to assess the comparative efficacy of a drug 
until it has had a reasonable amount of time to establish its value. The interests of 
the pharmaceutical industry would also be protected by allowing a lengthy and 
predictable period for a new drug to prove its worth A further recommendation 
was that the DoH should allocate more resources for outcome studies and for the 
examination of cost-effectiveness and that these findings should be disseminated.
Have the recommendations had an effect?
Following the two expert reports (Audit Commission, 1994, Health Committee,
1994) the NHS Executive has issued two directives (EL(94)72 & EL(95)5) to the 
local health authorities which are a direct consequence of the expert 
recommendations. The directive, EL(94)72, maiics an important point in the way 
medicines should be handled in the NHS as the emphasis is on bringing primaiy 
and secondary care much closer together in the management of medicine use. The 
directive requests that piuchasers develop and agree strategies for improving the 
cost-effectiveness of prescribing across the primaiy/secondaiy care interface. It 
specifically asks that Health Authorities ensure the appropriateness of hospital-led 
prescribing and that an authority wide policy be developed for the managed entry 
of new drugs into the NHS. The directive states firstly, that piuchasers need to 
ensure hospitals, when establishing their policies on prescribing, take account of 
the total costs of drugs to the NHS. Secondly, the directive requires that 
purchasers malce use of evidence of the clinical and cost-effectiveness of new 
medicines when managing their entry into the NHS. The publication of EL(94)72 
appears to be malcmg an impact to some extent in that North West Health 
Authority (NWHA) has taken the lead in maldng explicit their intentions to 
change the way in which clinical trials are conducted across the region. NWHA
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intends to have input from GP's and professional advisers in primaiy care at the 
design stage of clinical trials and will make sine that everybody is awaie of 
current developments and have advance warning of any new products. The aim of 
changing the conduct of clinical trials is to get an early and effective assessment of 
where a drug fits into clinical practice and how cost-effective it is likely to be 
(Jackson, 1995).
The directive, EL(95)5, has instructed the local health authorities to re-organise 
the way in which 'packages of care' to patients at home are provided. These 
packages of care which normally involve the use of specialist drugs tend to be 
initiated at hospital level with the GP retaining responsibility for the care of the 
patient at home tlnough agreed shared caie aixangements. Until the 1st. April, 
1995, it could be either the GP's financial responsibility for the prescription of 
items in the package of caie (e.g. drugs, other products, equipment) or the 
hospitals responsibility. EL(95)5 changed these financial aixangements making it 
no longer permissible for the provision of these packages of care by GP 
prescription. District Health Authorities have been chaiged with this 
responsibility. The DHA has to make the appropriate logistic arrangements and 
contract negotiation with whoever they deem fit to provide the 'package of care' 
service to the 'at home' patients. The service can be provided by contract with a 
Trust or directly with an NHS or commercial supplier. The funding for these 
changes will be made by transferring monies fiom the FHSA (primaiy caie) drug 
budget to the hospital and community health service (HCHS) (secondaiy care) 
budget. The FHSAs will need to adjust downwards GP target budgets and GP 
fundholders budgef a/locations to reflect these changes.
2.5 Economic appraisal of healthcare: its use and lack of use
Economic evaluation is increasingly being aclmowledged by policy malcers as a 
potential aid to priority setting and resouice allocation but is it actually being 
taken into consideration when malcing a decision?
Davies et al (1994) reported on a survey which was designed to measme the 
impact that economic evaluations in EC countries have had on decision and policy
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maldng in health care since 1987. Health Semce researchers in 10 EC countries 
were asked to locate economic evaluations reported or undertalcen since 1987 in 
their comitry and to coimnent on whether the study was laiown to have had a 
visible impact on decision-making. Subject to exclusion criteria 66 studies were 
eligible for inclusion into the smvey. The main topic area covered by tlie 
evaluations was methods of prevention (n=35, 54%) followed by drug therapy 
(n=15, 23%) with vaiious other subjects making up tlie remainder. Just over a 
quai'ter of tlie drug studies were perceived to have had an impact on decision- 
nialdiig. This contiasts to those studies looking at the location or organisation of 
cai'e, of which 50% were perceived to have had an impact.
The somce of frmding of the studies was thought to be a strong determinant in 
whether the study influenced policy making. All of those looking at the location or 
organisation of care were frmded by government ministries whereas none of the 
drug studies were. Other important factors thought to have an influence on 
decision-nialdng were the dissemination of the research findings, the time talcen to 
conduct an analysis, and whether the topic addressed and the form the evaluation 
took, were relevant to the decision makers. Evaluations commissioned or fVuided 
by decision malcers were more likely to have an impact. It was concluded fr om the 
results of the survey that economic evaluation cmrently has a relatively low 
impact on health caie policy or decision making.
Ross (1995) caiiied out a novel piece of work in exploring Austi'alian key health 
care decision makers' perceptions of economic evaluations which reinforced the 
findings of Davies et al (1994). The decision malcers interviewed had 
responsibility for major healtli service expenditme decisions or for the provision 
of policy advice in which such expenditure decisions were made. It was found that 
although there was a high level of awareness of economic evaluation amongst the 
group only 38% had used or were in the process of using tliis type of analysis. 
Generally tlie evaluations used had been done as the result of regulatory 
requirement or under the auspices of a national health advisory body and had been 
specifically commissioned.
In the decision makers view major barriers to the use of economic evaluation 
included:
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i) Lack of time in the decision making process, political imperatives or no 
appropriate study or no time to commission one, Uiese reasons have also 
been expressed by decision makers in the UK (Watson et al, 1996).
ii) Lack of expertise and education, tliis was also voiced albeit from a 
different perspective by Salkeld et al (1995).
iii) Lack of credibility of teclmique.
Ross (1995) concluded that there was a conmiunication gap between the advocates 
of economic evaluation and decision malcers which could only be bridged by 
education and the use of demonstmtion studies.
The conclusions of Ross aie supported by Salkeld et al (1995) who reviewed all 
33 health related economic evaluations carried out in Australia since 1978 in terms 
of their rigor and usefulness. These authors found that a significant number of 
studies had an ambiguous analysis, results could not be generalised, sensitivity 
analysis was carried out in an ad hoc fashion and conclusions were irrelevant. 
There were also problems associated with the interpretation of league tables. 
However, it was concluded that the quality of studies had improved in the last few 
years in methodological terms and decision makers could be reasonably well 
informed by current studies. However there was still room for improvement in the 
application of methods and m reporting the results of economic evaluation. 
Henshall & Drmnmond (1994) in a discussion of economic appraisal in the British 
NHS claiifred some of the problems experienced by decision malcers in the UK 
when using this type of evaluation and offered suggestions to overcome the 
baniers. These authors feel that it is necessary for economists to resolve certain 
methodological issues in economic evaluation as the existing uncertainties both 
lessen the impact of economic appraisal results and cause confusion when 
economists liaise with clinical reseai’chers and NHS decision makers. The 
methodological aieas prioritised aie:-i) discounting of health benefits, ii) valuation 
of health states, iii) relevance of and measmement of indirect costs and benefits 
and iv) methodological issues in integrating economic appraisal with clinical 
reseai'ch. It was also thought that economists need to develop methods for dealing 
with micertainty in economic appraisal. Recognition was given to the fact that
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decision makers also need to laiow enough about economic appraisal methods so 
that they can interpret study results intelligently. The implication was that certain 
groups had training needs on the appreciation of economic appraisal rather than 
detailed methodological instruction.
A UK study carried out in mid 1995 to determine what mformation was used by 
senior health boar d managers maldng purchasing decisions supports the discussion 
of Henshall et al (1994) (Farmer et al, 1996). Purchasers were asked to consider 
from a given list the influence of various factors on their purchasmg decisions. 
Although finance resources were weighted as the third most important, health 
economic information was weighted as the least important being the lowest of all 
16 factors. Respondents in the study identified that there was a need for better 
data on costs and prices' and 'meaningful economic analysis tools'.
Should all the methodological issues become resolved, responsibility for maldng 
use of economic appraisal will still remain with the decision makers and to quote 
Sheldon (1996) 'The challenge for managers is to get into the habit o f 
using...information resources for their decision-making'.
What is the British Government doing to address the information gap?
In 1991 a new strategy for research and development (R&D) in the NHS was 
launched by the DoH. Inclusive in the objectives of the strategy is the purpose to 
improve the scope, relevance and quality of R&D to inform policy and practice in 
health and social care and to ensiue that the benefits of resear ch are systematically 
and effectively translated into practice (Peckliam, 1993). The launch of the NHS 
R&D strategy has marked a shift in emphasis away from the NHS as a passive 
recipient of new technologies to a Service which is going to develop a strong 
research infrastructure and competence capable of critically reviewing its own 
needs. The progranune is intended to correct existing deficiencies in knowledge 
and provide a basis for improvements in the approach taken to health care by 
managers, health care professionals and the users of health services. Intiinsic to 
the objectives of the R&D strategy must be the development and integration of 
economic appraisal of healthcare. In the report 'Research for Health' (Peckliam, 
1993) it is stated 'If patients are to benefit fi^om worthwhile new developments, it
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is essential that clinicians and managers Imow which interventions are cost- 
effective and which are not so that resources can be focused appropriately'. The 
report also noted that a vast array of interventions are undertaken each day which 
have not been systematically assessed for either effectiveness or cost. The 
evaluation of these procedures presents a major challenge.
Information systems are being set in place to support the R&D strategy. These 
include the National Register of Research, the Coclnane Centre, a facility for 
cormnissioning research reviews and a Dissemination and Enquiry Unit.
The National Register of Research will be compiled by a Projects Registers Co­
ordinating Unit which has been commissioned to assemble regional registers of all 
research projects that Regions fund or manage or which otherwise attract service 
support. A database of the regional registers can then be interfaced with databases 
of the MRC, the major charities and other health departments. This is supposedly 
to enable a complete picture of applied health reseai'ch to be assembled, however, 
this does not encompass that research undertaken Rinded by means other than 
through the NHS.
Since 1978 a team of researchers led by lain Chalmers in Oxford have 
systematically reviewed all research findings on pregnancy and childbirth. This 
team has been the single good example of research results being collated, 
rigorously-quality assessed, compared, synthesised, and then disseminated to 
health professionals and patients in formats Üiey can use. This body of experts 
provided the nucleus to the Coclirane Centre which was opened in 1992. The 
Centre has been established to assist specialists in a wide variety of fields to 
prepare, maintain and disseminate systematic, up-to-date reviews of randomised, 
controlled trials of healthcar*e information essential to decisions in healthcar e and 
research.
'Effective Health Care' bulletins sponsored by the NHS Management Executive 
has been found to be very useful in making Imown information relevant to clinical 
and managerial decisions. To frirther this initiative, a new facility for 
cormnissioning research reviews has been established. The purpose is to 
complement the work of the Cochrane Centre by cormnissioning reviews of
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available research beyond the area of controlled trials ensuring that the 
information is of good quality and of practical application
A Dissemination and Enquiry Unit was established in 1993 to focus on the 
systematic transfer of accessible and up-to-date oveiwiews of R&D information to 
NHS managers and clinicians. It also provides enquiry-based access to the results 
of R&D. This new facility is to conduct research on how to make research-based 
information more accessible to all those working in the NHS.
Despite the existence of these information sour ces there appear s to be a lack of 
clarity regarding the roles of the various agencies involved in producing 
effectiveness information. A recent National Association of Health Authorities 
and Trusts (NAHAT) report states 'Both the number o f information sources and 
the volume o f information on clinical and cost-effectiveness are gi^owing, and 
there are already some indications that this is resulting in duplication o f
effort. Ideally users should only have to deal with a single access point for
information on clinical e f f e c t i v e n e s s ' . et al, 1995).
2.6 Summary
The various methods used by different countries at governmental level to limit 
healthcare expenditure, which includes tire ciu'bing of drug expenditure, reflects 
how the healtlicar'e systems in operation are financed. Table 2.4 summarises these 
methods.
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Table 2.4 Governmental methods designed to exert downward pressure
on healthcare expenditure
Country and Governmental control measures Effect of control
United states Prospective payment 
inti’oduced in 1983 (DRGs etc.).
scheme Fixed price reimbursement per DRG has 
forced hospitals to improve their internal 
efficiency of resource utilisation such 
that profits can be maximised. As a result 
of this a major focus for hospitals has 
been to seek methods aimed at reducing 
pharmacy expenditure.
Canada Federal government has transferred 
responsibility for healthcare expenditure to the 
Provincial govermnents by capping the federal 
fmancial contiibution payable to the Provincial 
governments whilst in tandem hnplementing 
legislation which protects patients from paying for 
their care provided the healthcare service is a ‘listed’ 
service.
Provincial governments in turn have 
tiansferred responsibility for healthcare 
expenditure to third parties (employers, 
insurance companies, public etc.) by 
delisting services previously covered by 
them.
Pharmaceutical manufacturers are also 
expected to now provide economic 
information when submitting a drug to 
be added to a Provincial Drug Benefit 
formulary.
Commonwealth of Australia Mandatory 
economic analysis guidelines have been issued to 
specifically restrain expenditure on new 
pharmaceuticals.
Pharmaceutical companies have to 
demonshate cost-effectiveness of new 
drugs to gain Pharmaceutical Benefit 
Scheme (PBS) listing. Without this 
listing a product has little chance of 
significant prescribing by medical 
practitioners.
United KingdomDrug price modifying schemes, 
prescription modifying schemes, publication of NHS 
Executive Letters (which may or inaynot be coercive).
A degree of cost containment has been 
achieved but cost-shifting practices from 
the secondary care sector to the primary 
care sector has also occurred.
48
Although, the drugs budget represents only a small proportion (approximately 
10%) of total healthcare costs, it is a highly visible component and as such has 
become a defined target for control. Several methods have been used by the 
British Government to exert a downward pressiue on the NHS drug budget with 
varying degrees of success. It would appear' that the government does recognise 
the role that economic evaluation could have in controlling drug expenditure and 
indeed promotes its use to purchasers and providers of healthcare by refening to 
'cost-effectiveness' frequently in executive letters. However, as yet, there is a lack 
of a well developed formal framework and suppor*t mechanism to ensure these 
exliortations are applied. It is left to individual purchasers and providers of 
healthcare to use or not use economic information in their decision-making as they 
so desire. As already discussed there can be many reasons for the lack of use of 
economic appraisal in policy making. These can range ftom a complete lack of 
data in the therapeutic area being considered to a lack of expertise in interpreting 
appraisal data. The decision-makers may feel the information available is not valid 
for the decision imder discussion or there may be a lack of awareness of what 
economic appraisals have been midertalcen. Without a centralised structmed 
approach in the clarification of methodological issues, the cormnissioning of 
studies, the dissemination of research results and the training of decision making 
personnel in economic appraisal interpretation, the existing framework will remain 
ad hoc and piecemeal. It is to be hoped that the new R&D strategy will provide 
this much needed centr alised structure, initial indications are that a single point 
access is required for all the information being generated.
An important suggestion made by the House of Commons Health Committee 
(1994) was for all drugs to be allowed on formularies and be prescribable on the 
NHS ft'om the time of their laimch and for five years thereafter so that sufficient 
time is allowed to assess the therapeutic value of the product. Those drugs which 
were found to be less effective, or more expensive with no therapeutic advantage, 
than competitor drugs would then be excluded from being prescribed on the NHS. 
In this way a 'national formulary' would be gradually built up in a predictable, 
rational way. This would appear- to be suppor-ted to some extent by the medical 
commimity and was highlighted in a letter to the Lancet by chest physicians
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(Spencer et al, (1995) in response to tire suggestion by an anonymous review in an 
influential jomnal, that Dornase-alfa for cystic fibrosis should not be allowed onto 
formularies. The physicians felt that the opinion expressed in the review did not 
reflect the views of specialists car ing for patients with cystic flbrosis. Dornase-alfa 
is a novel agent in the treatment of cystic flbrosis for which there are no long term 
data. In the short term there ar e data to show a degr ee of improvement for some 
patients ti*eated with this drug. Spencer et al (1995) made the point that imless 
experience is gained long-term witlrin regional specialist centres for Dornase-alfa, 
it will not be possible to fully assess its impact on well-being and quality of life 
indices. It was felt that there could be an improvement in life expectancy of up to 
15 months for some patients. Only tluough experience would it be possible to 
target patient selection so that prescription of the dmg could be restricted to those 
patients who would benefit and to therefore maximise cost effectiveness. In 
Australia, this option does not exist for medical practitioners and experience 
camiot be gained with this dmg. Dornase-alfa has aheady been excluded from 
PBS listing brought about by the Australian Guidelines. The method suggested by 
the UK Health Committee is more flexible and allows for a more realistic 
assessment of a drug compaied to the rigid, mandatory guidelines recently 
introduced by the Austialian govermiient.
A related issue raised by Naylor et al (1993) which requires 'real-time' monitoring 
is 'technology creep'. Drugs aie flequently used for conditions other than those for 
which they were originally approved or for which clinical trial data were obtained. 
The costs and outcomes of using a drug assessed over a five yeai* time period 
would therefore take this into account and give a more realistic idea of its tiue 
cost-effectiveness tlian that projected flom artificially controlled conditions. A 
concern raised by Laupacis et al (1992) though, is that it is generally easier to 
witliliold fmiding for a new teclmology than it is to withdraw funding from an 
existing one.
In the UK there are medico-legal ramifications associated with the existing 
attempts to apply economics to resomce allocation. Society is having problems 
coming to terms with the concept that all healthcare will no longer be fully funded 
and that decisions will be taken on the grounds of the extent to which a patient can
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benefit from treatment. The initial reaction to overt rationed healthcare has been 
litigation. Eaiiy in 1995, a child with leukaemia was denied further NHS treatment 
by her local health authority. The decision was based on the medical grounds that 
her chance of survival with treatment would be around 2% and that the cost of 
treatment approximated to £75,000 (Hunter, 1995). The child's parent challenged 
the decision in court. The final judicial ruling was that the decision lay firmly with 
those responsible for allocating the resources, which in this instance was the local 
healtli authority. Under these circumstances it may well be that savings achieved 
tlrrough rationalisation will be lost tlirough litigation.
A national policy on healthcare resource allocation is needed in the UK, the 
criteria for which are accepted by society. Otherwise the decisions of local health 
authorities will continue to be challenged in court. Inefficiencies of the system 
will result as the costs of litigation will have to be borne not only by the pur suers 
bringing the action and the health authorities which the action is against, but also 
the Government, because some of the pur suers will be eligible for legal aid.
To summarise, the largest proportion of drug expenditure occur s in the primary 
health care setting in the UK, however, prescribing m the secondary care sector 
can have a substantial impact on primary care prescribing costs. Government 
recognition is given to the role economic evaluation could have in contributing to 
cost-effective healthcar'e resource allocation, however, governmental controls 
aimed at the national drug budget have principally been of a cost-contaimnent 
natiu'e directed at the primary care setting. The drug budget in the secondary care 
sector has not been subject to direct governmental control in the same way. Other 
forms of control, again of a cost-containrnent nature, have been used in the 
secondary care setting to restrain the drug budget, these controls are examined in 
the next chapter.
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Chapter 3
3. Methods For Controlling The Hospital Drug Budget - Cost
Containment
Prior to April 1, 1996, NHS governmental monies were devolved to District 
Health Authorities (DHAs) for the purchase of secondary healthcare. With these 
monies, DHAs then allocated an overall cash limited budget to each hospital imit 
in their area, assessed on the perceived secorrdary healthcare needs of the 
population in their catclmient area. How each hospital then used this monetary 
allocation to provide the piuchased healthcare became a matter for the hospital 
management structure. Essentially, the departmental head of each cost centre (e.g. 
radiology, pharmacy etc.) would be charged with ensming that the budgef 
a/located to their cost centre was adhered to.
The Hospital Drug Budget
The total cost of the hospital drug budget is a function of two variables, the 
quantity of drugs consumed and the price of those dr'ugs (see Equation 1).
Equation 1
Total cost of Drug budget = (Quantity Drug a X Price Drug a) +
(Quantity Drug b X Price Drug b) + (Quantity Drug c X Price Drug c) + etc.
The quantity of drugs consumed is determined by the number of drugs prescribed 
which includes dose used and dmation of treatment. An important factor affecting 
the prescription of drugs is the advent of new chemical entities. The availability 
and active promotion of new drugs obviously leads to an increase in prescribing 
which in turn increases tire size of the drug budget. The impact of a new drug on 
prescribing costs will vary depending on whether the drug is an alternative agent 
for a condition where a drug treatment already exists or whether it is an entirely 
novel therapeutic agent. The prescribing costs of an alternative tlrerapeutic agent 
will be partially offset by the decrease in prescribing cost of the agent it is 
replacing, conversely the introduction and use of a novel therapeutic agent wliich 
does not replace an existing dmg will not have a direct offset cost. However, it 
may have an indirect offset cost. A new drug, although not a replacement for an
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existing dmg may be a replacement for some other form of treatment, for example, 
the advent of the H2  antagonists replaced surgical intervention for gastric ulcer 
disease. Consequently a reduction in surgical intervention costs for this indication 
will have occurred. Tliis represents a cost-shifting between the surgical budget and 
the drug budget. In the pursuit of efficiency, savings accrued in the surgical 
budget tlnough the use of the H2  antagonists could be used to offset the cost of
these drugs. However, this does not occur".
As with other component cost centres within the hospital, the drug budget has 
been viewed in isolation fi’om other budgets, specific measures undertalcen to 
contr ol its rise have therefore been of a cost-containrnent nature. These measur es, 
to revert to equation 1, have primarily concentrated on reducing the quantity of 
drug prescribed by restricting access, attempts to reduce the price of drugs has also 
been made. Table 3.1 sununarises these measmes. Each of the strategies and how 
they interact witli each other will be considered m turn.
Table 3.1 Strategies used by Hospitals aimed at reducing both drug 
consumption and drug price
Schemes to reduce drug consumption Scheme used to reduce drug price
Formularies 
Consultant approval 
Automatic stop date 
Therapeutic substitution 
Policies
Drug utilisation review 
Behaviom* modification
Generic substitution
3.1 Consumption Reduction
3.1.1 Formulary Introduction
The concept of a hospital formulary can be traced back several centur'ies
for the UK and over two for the US (Pearce, 1992, Nash, 1993). The pur-pose of a 
formular-y has become more sophisticated over the years fiorn merely providing a 
list of available drugs tlnough to dynamic policies which provide guidance on
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selection from within a therapeutic group, dosage, adverse reactions, cost and 
other pharmaceutical ar eas of interest. Cost information has usually been limited 
to acquisition cost.
In tire UK a societal desire for the 'economical' use of drugs was made explicit as 
early as 1929 when the National Formulary for Health Insurance Purposes 
(NFHIP) was produced. The NFHIP was stimulated by the National Health 
Insurance Acts. Prior to the Acts, many prescribers had their own private 
arrangements with pharmacists in their irmnediate locality by which personal 
formulae abbreviations could be used and imderstood by doctor and pharmacist 
respectively. Wlien the Insurance Acts came into force, many of the prescriptions 
formerly made up by the doctor or pharmacist came to be written on National 
Health Insmance forms, and since there was ftee choice of pharmacist had to be 
comprehensible by all. This dictated that Insurance practitioners could no longer 
use tlieir own abbreviated formulae.
The new system caused a marked increase in prescription time writing wliich was 
felt to be mniecessary effort, because of this many Health Insmance Panel 
Committees compiled formularies which held valid for their respective areas. 
Before long a plethora of formularies existed which in turn caused difficulties 
because some doctors had to use several formularies. The same prescription had 
different titles in adjacent ar'eas and conversely the same title often covered 
different prescriptions. To overcome this problem a nimiber of adjacent Panel 
Committees combined to form a formulary for their group, 5 formularies were 
produced to cover 58 areas of England. It soon became the opinion of the Retail 
Pharmacists' Union, the Insurance Acts Committee of the British Medical 
Association and the Ministry of Health that this example of group action could be 
talcen fmlher by the compilation of a National Formulary to which all areas could 
conform. The 1927 Conference of representatives of Local Medical and Panel 
Cormnittees instructed the Insurance Acts Committee to expedite the production 
of a such a formulary.
The National Formulary for Health Insurance Purposes was published in 1929. A 
recurring theme tlirough the publication was that of economy. The publication was 
seen as a method of promulgating cost awar-eness amongst prescribers. Point 9f of
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the preface states 'That therapeutic efficiency be obtained with due regard to 
economy'. In Notes for the guidance of Medical Practitioners in Prescribing there 
is reference to therapeutic substitution and generic prescribing as an aid to cost 
containment, as is the avoidance of elaborate prescriptions and the prescribing of 
midue quantities. This section concludes 'it is hoped that practitioners will adopt 
the above suggestions, and thus assist in effecting a measure of economy which 
will relieve practitioners in general of any reproach on the subject of excess cost 
in prescribing'. As resources remain scai'ce tlie same exhortations have been made 
repeatedly tlnough the following 60 year's.
The NFHIP provided the roots for the present British National Formular'y (BNF). 
Due to teclmological advances in medicine the type of medicines and advice the 
BNF provides is vastly different from its forebears and is recormnended as a rapid 
pocket reference guide only, to be supplemented with other sources of information 
when necessary. Basic net costs are provided with the medicine listings in order to 
provide an indication of relative cost between agents. These costs are not actual 
but calculated ftom basic costs used in pricing NHS prescriptions and do not 
reflect the cost of drugs in the hospital setting as these tend to be purchased in 
bulk. These costs can therefore mislead the user when selecting between agents. 
Furthermore the preface in the BNF goes onto state that 'cost-effective' prescribing 
needs to take other factors into accomit that can also affect the total cost of 
treatment. The provision of basic net costs does not appear to serve any useftil 
purpose. The BNF although an excellent therapeutic reference guide is of little use 
for economic guidance.
In an attempt to rationalise drug use and therefore limit costs. Hospitals have 
resorted to the production of local formularies which list selected or preferred 
drugs available to prescribers. The range tends to be much more restricted 
compared to the BNF. Selection of drugs for inclusion in the formulary is 
normally made by a multidisciplinary Drug and Therapeutics committee. Crooks 
(1983) reported a 15% reduction in drug costs in medical wards following the 
introduction of a formulary at Ninewells hospital, Dmidee in 1981. This included 
an initial once and for all saving resulting ftom reduction of ward and phai'inacy 
stocks, savings in subsequent years were reported as less. A method used to
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encourage adherence to this formulaiy was the requisite of a separate prescription 
justifying the use of a non-formulary drug. Consequently mmecessary drug 
expenditure could be identified and restricted. This experience was repeated by 
Feely et al (1990) in Ireland. Wandswortli Health Authority also found a 
formulary useful in reducing dr’ug expenditure and improving the quality of 
prescribing (Collier et al, 1985). The Drug and Therapeutics Committee of this 
Health Authority imder certain circumstances not only consider the cost to the 
hospital when appraising a new dr ug for possible entry to the formulary but also 
consider whether the drug may have cost implications for general practitioner 
prescribing. The background to this is the financial inducement offered to 
hospitals by manufacturers, occasionally the market price may be reduced to 
l/80th. What the manufacturers lose to the hospitals they hope to gain in the 
primary healthcare market. This precise issue was highlighted in the Audit 
conmiission report on primary care prescribing (1994). Subsequently, a 
recommendation by tire Audit Conmiission (1994) was for the prices at which 
drugs are reimbursed in the cormnunity to be taken into consideration when 
agreeing regional purchasing contracts and when compiling and reviewing 
hospital formularies. Fmtliermore it was recommended that formularies should 
distinguish drugs considered suitable for routine prescribing by GP's from those 
intended primarily for specialist hospital use and that both sets of drug prices, 
hospital and commmiity, should be shown.
By 1986 an audit by Ridley (1986) showed a wide range of local formularies to be 
in use throughout the UK. Equally the formularies varied in their content from a 
limited list of one or two drugs in each major therapeutic group through to many 
drugs in each group. Reports of formularies to reduce drug expenditme continued. 
Trounce et al (1987) reported a reduction in their drug bill from $3.04m in 1982/3 
to $2.57m in 1986/7. Conversely others (Bateson, 1987) have reported an increase 
in drug expenditur e despite the presence of a formulary and have questioned their 
usefulness, what this author did not consider is that the increase could have been 
even greater but for the presence of the formulary.
A formulary requires to be adaptive to changing prescribing needs. In 1970 the 
Westminster Hospital formulary was compiled by a subcommittee of the medical
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executive and phaiinacy stocks were restricted to approved items (Baker et al, 
1988). If a non-formulary item was requested the prescriber would be contacted by 
a pharmacist and offered an approved alternative, if the clinician confirmed die 
request for the non-formulary item the drug would be supplied but a record of the 
request was kept. By 1978 because of the increased requests for non-formulary 
drugs and rising drug expendituie of 10-15% a yeai' it was felt that the formulary 
was not adaptive enough to cater for changing clinical needs. The strategic 
preparation and management of the formulaiy was changed such that 
representatives fiom all specialities had an input to the formulary thus creating one 
mechanism by wliich the need for change could be swiftly recognised. The 
formulary now covered both hospitals in the district. Regular* seminars and 
workshops were held with all levels of staff to educate them in die aims and 
workings of the system. Another mechanism for updatmg the formulaiy was 
regular monitoring, analysis of prescribing patterns could then identify potential 
aieas requiring change. Monthly compliance with die formulary was foimd to be 
consistently over 99%. In each successive year after the fundamental redesign, 
drug expenditure either fell or was held stable despite the release and approved use 
of several new drugs with high acquisition cost. Comparison with other London 
teaching districts showed the Westminster district pro rata drug expenditure to be 
consistently lower, no other district had a fully operational drug rationalisation 
policy.
Baker et al (1988) made explicit that the hiitial reason for fbrmidary introduction 
to the Westminster Hospital was a method to curtail rising drug expenditure. The 
purpose of containing costs by rationalising prescribing is to rnalce the most 
efficient use of a set resom*ce yet some physicians appear to be luicomfortable 
with the concept of making cost limitation explicit to suppor*t formulary usage. An 
editorial by Turner (1984) states that the purpose of a fbrmidary should be the 
improvement of patient care by increasing the level of rational prescribing and not 
economy, as if the two goals were separate. Mooney et al (1984) reporting on a 
workshop for senior NHS staff discuss the misconceptions that abomid about 
economics in the NHS and propose that it is the separation of professional and 
financial accountability which fails to foster the need for efficiency in health care.
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The previous comment by Turner (1984) lends additional credence to the Mooney 
et al (1984) proposal. Inefficient prescribing practices are perpetuated by the cry 
'freedom to prescribe'. Many doctors prescribe in ignorance, miaware of the 
constituents of combined preparations, of common side effects and of drug 
interactions, confusion from the vast range of alternatives available is one cause of 
the poor standard of prescribing (Anon. 1978). The use within a hospital of a 
restricted list of drugs solves several problems at once. In terms of cost- 
contaimnent, expensive drugs for which there are cheap, equally satisfactory 
alternatives can be excluded, so too, can drugs and drug combinations thought to 
have an unacceptably high risk of side effects or addiction.
The use of formularies is extensive in the US, witli over 80% of surveyed 
hospitals employing some type of formulary system (Nolte et al, 1991, Rascati, 
1992). A US sm'vey of multidisciplinary pharmacy and therapeutic committees 
reported that the two most important factors in decision making for formulary 
drug inclusion were effects on the quality of drug treatment followed by impact on 
hospital costs (Segal et al, 1988). As pointed out by Feely et al (1990) despite the 
primary objective of formularies being quoted as improving drug use, analysis has 
concentrated on the purported secondary aim, which is to reduce drug costs. A 
telephone survey of pharmacy directors fr om a random sample of 150 commimity 
hospitals reported the most frequently stated purposes of a formulary were to 
decrease costs (54.8%) and to ensure appropriate therapy (37.1%) in that order 
(Rascati, 1992). This is the opposite way around to the P&T conunittees priority 
(Segal et al, 1988) and obviously reflects the pharmacy directors primary 
responsibility for controlling the drug budget (Phmuidge et al, 1984).
Different cultmes can bring different arguments to the formulary concept. In the 
US, health care provision is primarily private, Martucci (1987) promotes the 
delimitation of certain drugs in a formulary as a method of marketing the hospital 
to the public. He suggests that although greater pharmacy operating and inventory 
costs may be increased by such a manoeuvre they would be offset by intangible 
benefits such as the patients comfori; factor and would encourage admitting 
physicians to use the hospital. Because of the widely differing health care system 
in Britain this argument would almost certainly never be used. In Norway the
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presence or absence of a hospital formulaiy appear s to have little impact on the 
drug budget (Baldce, 1984). Norway has strictly regulated the introduction and 
marketing of drugs for more than 50 year’s. The system is a state owned whole­
sale monopoly with nation-wide distribution. Because of such strict regulation , 
the total number of dr'ug products available is smaller than other Western 
European countries, yet, only a few therapeutic classes are not represented. Since 
the nmnber of chemical entities and drug products in the market are low compared 
to most other coimtries, the possibilities for further simplification and narrowing 
of the spectrum of available drugs at the hospital level ar e limited. The aim of the 
drug cormnittees has mainly been to identify a 'core' of products recormnended for 
routine use in most patients, without unduly obstructing the acquisition of other 
drugs when required for special purposes. Repeated ordering patterns are 
discussed by the committee before it is decided whether administrative action 
should be talcen to improve compliance or add medicines to tire formulary. 
Aldiough money can be saved by selecting appropriate and reasonably cheap 
established products instead of the most recently introduced and expensive 
medicines, the overall impact of the drug committees on expenditme has not been 
impressive. There has not been a discernible change in the rising trend in spending 
coinciding with the selection process, nor evidence of a lower per day or per 
patient drug bill in hospitals with committees as compared with those without 
(Baklce, 1984).
In those coimtries not subject to as strict regulations as Norway the impact of a 
formulary is dynamic. A survey of formulary presence in major Austialian acute- 
care hospitals by Pluim'idge et al (1984) led these authors to conclude that 
although two thirds of all these hospitals had a formulary 'effectiveness could be 
improved markedly'. The results of this survey cast serious doubt on whether 
formularies were being adequately prepared or introduced in an appropriate 
marmer. Evidence presented by others (Zilz, 1975) had already demonstrated that 
user acceptance is essential for successful formulary implementation and can be 
obtained only by continual consultation with physicians throughout the 
preparation phase. Although the task is complex and time consuming it is both 
essential and achievable. However, in the survey by Plumridge et al (1984) only
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50% of formularies had been prepared by a committee which incorporated 
specialist physicians. Furthermore only 35% of the formularies surveyed were 
regulariy revised to allow admission of new drugs and deletion of outdated ones. 
The method of introducing a formulary has also been shown to be important for its 
acceptance with personalised commimication achieving a far higher success rate 
when compared to mipersonal written armouncements (Check, 1980). Despite this, 
the two most frequently used methods of commimication for introduction of 
formularies in the survey undertaken by Phunridge et al (1984) were 
administrative memoranda (74%) and pharmacy bulletins (38%).
To reiterate, success of a formulary has been demonstrated to be dependent on its 
acceptance and active implementation by those prescribers who are intended to 
use it (Plumridge, 1984). A formulary alone is not capable of modifying 
prescribing behaviom* in a sustained way (Wyatt, 1992, Nash, 1993). Other 
educational techniques are required.
3.1.2 Strategies used to augment a formulary which further reduce 
consumption
Consultant Approval
The purpose of requiring a drug (usually high acquisition cost or high probability 
of toxicity) to have consultant approval prior to prescription is restrictive. The 
prescriber is required to justify and malce explicit the need for that particular drug 
to be used thus gaining specialist approval (Scher, 1990). By providing this barrier 
to free prescribing of selected drugs, inappropriate use is targeted.
Automatic stop orders
Automatic stop orders are primarily used in the US and are a power strategy to 
stop an indefinite prescription from continuing, the dmg categories subject to this 
form of control are usually antibiotics, narcotics, barbiturates, sedatives, 
anticoagulants, oxytocics and antineoplastics (Myers, 1988). The pmpose is to 
protect the patient from extended treatment in addition to preventing unnecessaiy 
waste of resources. The prescriber is notified prior to drug cancellation. Jewesson
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et al (1985) after a quality of use study suggested that an automatic stop of 
prescriptions for prophylaxis witlrin 24 to 48 hours after elective surgical 
procedures would reduce by 20-25% the use of all antimicrobial drugs in their 
hospital and would result 'in a savings o f several thousands o f dollars annually' 
An automatic stop order is used as part of a strategy to control prescribing rather 
than a means to an end by itself (Scher, 1990, Coleman, 1991).
Therapeutic substitution
Therapeutic substitution is the substitution of a drug with a different chemical 
identity from the one prescribed but is believed to have the same action. The 
purpose of substitution being to reduce costs by limiting the number of drugs used 
within a given therapeutic class. There is strong opposition to this form of 
substitution (Cormnittee on Drugs, 1987, Ballin, 1987, Nelson, 1989). Concerns 
devolve aromid the fact that the same drug may be used for multiple indications 
therefore the person who is making the substitution caimot necessarily identify the 
drugs immediate intended purpose without access to a patients case history. 
Nonetheless, a case may be made for substitution within certain therapeutic groups 
such as antibiotics.
Wright (1991) reported on a successful tlrerapeutic substitution program for the 
second generation cephalosporin, cefoxitin. A decision was made by a 
multidisciplinary Pharmacy and Therapeutics Committee to substitute all orders 
for cefoxitin with another second generation cephalosporin, cefotetan, which was 
considered equally efficacious. Cefotetan has a longer half-life than cefoxitin and 
need only be dosed twice daily compared to four* times daily for cefoxitin so 
although the acquisition costs are similar total daily costs are lower for cefotetan. 
Infection surveillance data were reviewed dming the substitution period, no 
change in infection rate or antibiotic faihne rate was found.
The prevalence to which therapeutic substitution is carried out is largely milaiown. 
In an attempt to quantify those hospitals carrying out this type of program Doering 
et al (1982) undertook a national questiomiaire survey of all short-term hospitals 
in the United States. Thirty nine percent returned usable questiormaires, of these 
31% reported that their formulary system allowed therapeutic substitution without
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contacting the physician for permission. Federally owned hospitals were twice as 
likely (62.5%) to engage in therapeutic substitution than those hospitals of other 
ownership types (23-32%). Two of tire major reasons given by non substituting 
hospitals for not engaging in therapeutic substitution were firstly, that it would not 
be accepted by the physicians and secondly that it interferes with the physician's 
right to select the drug which is best suited to the patient. Respondents were asked 
to estimate the dollar savings of their tlrerapeutic substitution programs, less than 
35% could give an answer and those that did answer did not necessarily base the 
response on actual accounting data. Doering et al (1982) concluded that two 
critical aspects of therapeutic substitution needed fmfher evaluation, these being 
cost savings and drug therapy outcomes. With the exception of some antibiotic 
programs (Guastella, 1988, Smith, 1989, Wright, 1991, Achusim, 1992a) and a 
few H2 antagonist therapeutic interchange programs (Rich, 1989, Oh, 1990, 
Berkowitz, 1992) this does not appear to have been imdertaken (Achusim, 1992b).
Policies
A policy is a refinement within a formulary which provides a systematic approach 
to the treatment of a specific indication. It suggests a defined coui'se of action to 
be talcen usually with the recommendation of a first, second and third line drug. 
The aim of a policy is to promote the safe, effective and rational use of drugs. 
Policies are quite widely used for the treatment of infection. In a national sui vey 
of 88 hospitals in the Netherlands, Janlcnegt et al (1994) found that 66% 
incorporated an antibiotic policy into their formulaiy. In the UK, 51% of 
responding hospitals to a national survey cairied out in 1990 had a wiitten policy 
for siu'gical prophylaxis (BSAC Working Paity Report, 1994).
3.1.3 Strategy used to augment a formulary which reduces Price
Generic substitution
The definition of generic substitution is the supply of a drug by its approved name 
rather than by its prescribed proprietary brand name, the drug has the same 
chemical entity as the proprietaiy brand but may be manufactured by an
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alternative drug company to the manufactmer who owns the proprietary patent. 
The acquisition cost of a generic pharmaceutical is usually much less than its 
proprietary equivalent (Hepburn, 1990). As a measure to contain costs, generic 
substitution within given limitations is now a widely accepted practice in the 
hospital setting, although it has been a contentious issue throughout the world 
(Retief, 1984, Pincus, 1983, Schwartz, 1985, Maddock,1986). The problems with 
generic substitution devolve around bioequivalence and bioavailability and 
concerns that a patient stabilised on a branded product may be subject to 
intoxication due to greater bioavailability of the generic product (Anon, 1972, 
Tyrer, 1970) or to therapeutic failure due to lesser bioavailability (MacDonald,
1987). However, exact bioequivalence is essential for relatively few drugs with a 
narrow therapeutic window (Walley, 1993). Despite tliis, generic substitution can 
be the cause of an intangible cost to the patient. For example, another problem 
which can be encountered with substitution relates to the excipient ingredients that 
can change from formulation to formulation. Excipients constitute a medication in 
addition to the active substance, such as colouring agents or propellants, and are 
considered to be inert. However, hypersensitivity reactions to various excipients 
have been reported (Anon, 1985, Anon, 1992). A patient stabilised on a branded 
drug and is changed to a generic drug which contains different excipients in its 
formulation has the potential to develop an adverse reaction. Generic substitution 
can also cause anxiety to the patient because the drug is a different colour, shape, 
or have a different taste fr om the branded medicine they ar e used to talcing.
As with automatic stop orders generic substitution is used as part of a strategy to 
control the costs of prescribing.
As part of a clear* national policy to ensure the optimal use of drugs within the 
country's resoirrces. South Africa, became the first in the world to legislate at a 
national level, that generic substitution by pharmacists will be allowed both in the 
public and private sectors. It will be incumbent on the pharmacist, prior* to 
dispensing a prescription, to inform the patient on the benefits of generic 
substitution (Edinbirrg, 1996).
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3.1.4 Strategies to reduce consumption by modification of behaviour
There have been many studies carried out to determine the most effective method 
for influencing the clinical practice of dmg prescribing. Kmiin et al (1973) 
reviewed the inappropriate use of antibiotics in the US and concluded that this was 
a major problem. These workers reported methods used in their hospital to counter 
this problem. Methods included 'a strong dmg formulary system' and 'continuous 
education of students, house staff and practising physicians in the use of drugs', 
however the authors did not expand on the operational details. The success of a 
restrictive drug formulary depends on the intervention strategy used to re-inforce 
it.
3.1.4.1 Written
Written information has been used to modify prescribing. In an American study to 
rationalise the use of iv ranitidine, an educational memo suggesting the use of oral 
ranitidine was placed in all patients charts who were receiving concmrent oral or 
nasogastric medications and iv ranitidine. Over an 8 month period a 61% change 
was induced by this method resulting in a cost saving of approximately $US3,100 
(Baciewicz, 1991). A study carried out previously reported similar* findings 
(Damienlioffer, 1989). The effectiveness of'therapeutic newsletters' in influencing 
hospital drug expenditme has been examined in the UK (Wilson, 1991). The 
newsletters considered gave a clear recommendation to use one particular* drug 
rather than another and emphasised situations m wliich the comparative drugs 
were and were not interchangeable. Analysis of defined daily doses of the drugs 
before and after circulation of the newsletters showed prescribing practice 
changes. Post circulation there was an increased usage of the recommended 
alternative drug with a corresponding decreased usage of the more expensive 
comparator. For the tlnee pairs of drugs examined amiual cost savings were 
estimated to be £26,000. Criticisms of this study can include that the changes were 
not shown to be sustainable, that there was no attempt to examine how rational the 
changes made were and whether there were any changes in the use of other drugs 
in the same therapeutic class as the pairs of drugs considered. Shenfield et al 
(1980) demonstrated that reduction in use of one di’ug in a therapeutic class
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tlnough a restriction policy can lead unexpectedly to an increased use of an 
alternative drug in the same therapeutic class. This has been described by others 
(West, 1977).
The timing in which wiitten information is presented appeal's to be important. An 
Israeli study (Rubinstein, 1988) demonstrated that monthly distribution of 
information to hospital prescribers concerning antibiotic costs and rates of usage 
had little effect on reducing overall antibiotic costs. However, when the average 
daily cost of each antibacterial agent was supplied on individual patient 
microbiological culture test result forms there was an overall reduction in montlily 
antibiotic costs. The timely presentation of the data obviously assisted the 
prescriber to malce an informed decision about which antibiotic to choose at 
individual patient level and at the time of treatment. The data presented previously 
on a monthly basis may not have had an impact for two reasons, firstly, because it 
did not relate to an individual situation, and secondly, the information was not 
provided at the point of delivery of care. In support of this aie findings of 
McDonald (1976), this worker studied the effect of prospective computer 
generated suggestions about the management of simple clinical events on the rate 
of clinical errors. It was found that physicians responded to 51% of 327 events 
when given the computer reminder and to only 22% of 385 events when not given 
the reminder. Mugford et al (1991) in a review of the effects of feedback of 
information on clinical practice also concluded that feedback is more likely to 
have a more direct effect on practice if presented close to the time of decision 
maldng.
3.1.4.2 Person to Person contact
Physician tutorials have been used with effect by Klein a/ (1981) to modify the 
prescribing of certain antibiotics in the treatment of urinary tract infection. Wliat 
these workers found important was to base educational intervention on those 
factors influencing current prescribing. Avorn and Soumerai (1983) found that in 
office practice, doctors who received face-to-face visits by 'academic detailers', 
together with attractively-presented printed material, significantly reduced their
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prescribing of target drugs when compaied with contiol subjects. No changes were 
seen in the prescribing of physicians who received printed material only. 
Schaffiier et al (1983) also foimd that doctors who were visited by a 'physician 
counsellor' showed a marked change in the targeted prescribing behaviom', 
whereas doctors who received mailed brochmes showed no significant difference 
in behaviour from that of control subjects. Conversely, in a study of tlnee 
approaches for marketing smoking cessation programmes to Australian general 
practitioners, which included an educational facilitator approach, a vohmteer 
cornier and a mailed approach, there was a failme to show a significant advantage 
between the vaiious approaches (Cockburn et al, 1992).
The professional standing of the individual providing the personal contact was 
thought to be important by Mailin et al (1980). These workers thought that one 
reason for tlie success of their weekly chart reviews in reducing the use of 
diagnostic tests was that the reviews were led by senior clinicians whose views 
were respected by jmiior staff. In support of this Eisenberg et al (1977) postulated 
that one of the reasons they failed to reduce the inappropriate use of tests for 
lactate dehydrogenase in a hospital was because feedback was provided by jimior 
and not senior staff in the hospital. They thought that house officers would be 
more likely to respond to figmes of authority. Pharmaceutical company 
sponsorship has been shown to wealcen the educational effect a program can have 
(Friis et al, 1991). Written material was disseminated between tlnee groups of 
physicians. In addition this material was followed up by 10 lectmes given by the 
same person to two of the tlnee groups. One group received lectures ananged by 
the local department of clinical microbiology, the other group received lectmes 
sponsored by a phaiinaceutical company. Overall prescribing habits changed 
significantly. However, the changes were significantly higher for the group who 
received the lectmes arranged by the microbiology depar'tment. The prescribing 
habits of the group who received the lectures sponsored by the pharmaceutical 
company did not change further when compared with those physicians who 
received written material only.
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3.1.4.3 Commercial style advertising
In one Austialian hospital, Hai'vey et al (1986) used a commercial advertising type 
campaign to both promote an Antibiotic Guidelines booklet and to change the 
prescribing of iv amoxycillin in primary pneumonia to iv benzylpenicilliii. A 
course of iv amoxycillin averaged 37 Australian dollars compared with 7.30 
Australian dollar's for a course of iv benzylpenicillin. The campaign used 
techniques of the pharmaceutical industry, such as posters, give-away pens and 
writing pads and was based on the findmgs of Avorn et al (1982) that non- 
scientific forces can be a powerful influence on clinicians prescribing behaviom'. 
The posters, using catchy slogans, clear' messages and powerful imagery, were 
placed where staff congregated such as dining rooms, nur sing stations, sm'geons 
lomiges, resident and student quai'ters, toilets and urinals. Campaign material 
provided a conversation piece for staff members and created a general awareness 
of the issues, not just by medical staff members but by students, nurses and other 
health professionals. The closed natme of the hospital enviromnent facilitated the 
campaign's impact and this institutional awareness may have provided extra 
pressme on prescribers. In addition, campaign material provided opportunities for 
microbiologists, clinical pharmacologists and pharmacists to reinforce the desired 
messages on a person-to-person basis. After the campaign 91% of patients were 
receiving benzylpenicillin as compared with 44% of patients before the campaign. 
However, the proportion had dropped to 68%, 18 months after completion of tlie 
campaign, however, this was still significantly higher than the proportion of 
benzylpenicillin recipients before the adver'tising campaign. Despite the drop off 
rate the campaign costs of $A10,000 were recouped within 12 months by savings 
on drug costs. A staff questiormaire aimed at identifying those areas of the 
campaign least and most effective was circulated to staff one month after the 
campaign. Representative responses for the most effective area included cost data, 
posters in the urinals rated high for the least effective.
This interventional campaign had been so successful it was decided to perform a 
controlled cross-over study in 12 Victorian public hospitals, to examine the power 
of the educational marketing tecliniques, and to promote specific 
recormnendations made in the Antibiotic Guidelines booklet (Landgren et al.
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1988). This study re-confirmed the findings of the first study (Harvey et al, 1986), 
that the campaigns used were associated with a significant improvement in the use 
of antibiotic agents. This type of campaigning has been so effective that a 
modified version has also been used to improve the timing of conversion fi*om 
intravenous to oral administration of antibiotics (Allen, 1992). A series of posters 
showing antibiotic costs and amiual expenditure, postcards mailed to all medical 
staff, medication chai't stickers and publication of campaign details in the 
phaiinacy bulletin were used. As a result, the potential annual wastage in the total 
hospital budget due to delayed conversion from the intmvenous to oral route of 
administration was estimated to have fallen from $130,435 Australian before the 
campaign to $60,596 after it. The campaign costs of $3,060 (which came from 
existing budgets) were minimal when compared with the potential annual savings.
3.1.4.4 Drug Utilisation Review (DUR)
DUR is the examination of prescribing patterns with subsequent feedback to 
prescribers. It is a quality assurance process designed to compare patterns of drug 
use in a given medical care delivery system against predetermined standards. 
Patterns of drug usage can be used to demonstrate the impact of formulaiy 
guidelines on drug usage or show the effect of the introduction of a new drug 
(Cooke, 1991). This type of data does not give information on the quality and 
appropriateness of prescribing but can provide useful information concerning the 
adherence of prescribers to formulary sections and guidelines and can be used as 
pai't of the audit process (West, 1977, Dobrzanski, 1991, Balcer, 1988, Klein, 
1981, Riley, 1991, Coleman, 1991, Adu, 1993). Unless a computerised system is 
used to collect data, even for the most basic of reviews, the process becomes 
prohibitive in terms of time (Fish, 1992).
Blackburn (1993) published a comprehensive review of DURs in institutions and 
in the ambulatory care setting. The consensus, internationally, was that DUR 
programmes are generally accepted as important components of the quality 
assessment processes but there is a general deficiency in quality evaluation 
components with few clearly defined clinical and economic outcomes. The
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primaiy aim of most DUR programmes has been to reduce the direct drug costs to 
a specific institution or drug programme and has ignored its relation to total 
healthcare costs and benefits.
Sacristan et al (1994) suggested that drug utilisation studies could be used to aid 
phaiinacoeconomic analysis, a rather glaring flaw in this suggestion is that the 
studies ar'e not conmionly used to study the benefits of drugs (Gross, 1984). An 
intrinsic component to any pharinacoeconomic evaluation is an assessment of 
outcome, so urrtil the time that drug utilisation databases record outcome 
information their contribution to any economic analysis would be limited.
3.1.4.5 Combined strategies
Check (1980) reported a combined strategy for influencing prescribing practice of 
antibiotics to be highly effective. Avorn et al (1988) also found a combined paper 
based strategy aimed at improving parenteral antibiotic usage to be cost efficient. 
Tliree commonly used parenteral antibiotics were selected as targets for dose 
interval recommendations. A new parenteral antibiotic order form was designed to 
bring the relevant educational message to the physicians attention each time a 
prescribing decision was made. Several months in advance of the implementation 
of the new order form, wiitten and poster materials containing appropriate 
information about the targeted antibiotics were placed in every patient chart in the 
hospital, mailed to all physicians and posted in new display cases in all patient 
care areas. This method produced a staggeringly high compliance with 
recoimnendations, inappropriate dosing of the targeted antibiotics which pre­
strategy ranged between 60-90% was reduced to less than 10% post-strategy. 
$US59,300 was realised amiually as a result of the changes in drug and excipient 
costs alone. Staff time and supply cost savings amounted to a frnther $US 17,000. 
In part, because of introduction of this approach, total antibiotic expendituies at 
this hospital declined by 4% in the yeai* after introduction of the form (Avorn,
1988).
A comprehensive program to change the type of intravenous nitrate used at a large 
English general hospital was caiiied out by Riley et aZ (1991). In the first instance 
the support of consultant caidiologists and the drug and appliances committee was
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sought. This was followed by oral presentations to nursing and junior medical 
staff which encouraged two way exchange. Written guidelines for the use of the 
new nitrate were circulated and a specific date set to implement the changeover to 
the nitrate of first choice. Clinical pharmacists visiting the wards where nitrates 
were used re-inforced the guidelines by one to one contact with prescribers. 
Compliance with the changeover was almost 100%. Savings of £24,000 and 
£21,000 for the fiscal years 1988-89 and 1989-90 were estimated by comparing 
actual intravenous nitrate expenditme with projected expenditui*e had the 
changeover not taken place.
Workers in Ireland (Feely et al, 1990) also formd that active intervention 
promoted formulary adherence. Specific forms of intervention used included 
feedback of prescribing habits to individual prescribers and consultants in char ge 
of miits. Additionally, peer comparisons and examples of specific savings were 
provided to prescribers and prescribing habits were discussed at monthly medical 
committee meetings. A drug information note was prepared in conjimction with 
the hospital's microbiologists on the use and abuse of tliird generation 
cephalosporins. Wlien a prescriber wished to obtain a drug not included in the 
formulary a separ ate requisition was required. Selected aspects of prescribing were 
subject to intervention with special attention given to generic prescribing and the 
use of third generation cephalosporins. Comparison of prescribing practice before 
and after formulary introduction, with and without active intervention showed that 
generic prescribing increased by 50% and without feedback fell to its previous 
level. Aspects of prescribing practice not subject to feedback did not change at all. 
Once prescribers became familiar with the formulary, non-formulary requests 
constituted 5% of all prescriptions however with feedback the percentage was 
reduced further but rose agam, firrther intensive feedback reduced the requests to 
2% but rose anew to 5% when the feedback stopped. Third generation 
cephalosporin use was reduced during active intervention as did the amiual cost, 
however without intervention the use increased as did the amiual usage cost 
despite a reduction in suppliers acquisition cost. These workers showed that 
change is related to the amomit of feedback prescribers receive and continuous
70
intervention is required if a formulaiy is to continue to achieve its objectives of 
improving drug use and reducing costs.
American hospitals appear to be more prepared to include a power strategy (i.e. a 
degree of coercion) within their combined approach to ensure prescribing 
conforms to a forimrlary/policy. Scher et al (1990) fomid that volimtary adherence 
to prophylactic antibiotic guidelines was poor in their hospital. In order to control 
rising costs of prophylactic antibiotics these workers implemented a four part 
program. The program consisted of limiting the number of cephalosporins on 
formulary, requhing consultant approval for any non-formulaiy cephalosporin, 
designating the use of a special order form to order any antibiotic on wliich its 
pmpose as prophylactic, empiric or therapeutic had to be included and lastly all 
prophylactic antibiotics were automatically discontinued 24 hours after the initial 
dose. Six months prior to initiation of this program direct antibiotic costs averaged 
$US 16.80 per case, in the twelve months following inception of the program 
direct antibiotic costs averaged $US 10.45 per case. Total savings during this 
twelve month period, which included preparation and supply cost avoidance, was 
estimated to be $US32,163. No detrimental effect was observed on woimd 
infection rates. The reverse of this type of program i.e. removal of a restriction 
policy for antimicrobials has been shown by Himmelberg gf a / (1991) to result in 
an increase in the inappropriate use of these agents and total expenditure to 
increase by 103%.
In the evaluation of savings brought about by reduction of wasteful practices it is 
important to consider the costs incuiTed by the campaign, without doing so it is 
not possible to know whether the intervention is cost-effective. Cockbmn et al 
(1992) studied tluee approaches for maiketing smoking cessation programmes to 
Austmlian general practitioners. The educational facilitator approach cost $A142 
per general practitioner with $14 for tlie volunteer courier and $A6 for the mailed 
approach. There was a failiue to show a significant advantage between the 
approaches and it was concluded that educational facilitators and volunteer 
comiers did not appear to he cost-effective. The added benefit in terms of smoking 
cessation in patients of general practitioners in the educational facilitator approach 
would need to be high to justify the expense.
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Coleman et al (1991) found that a limiting formulaiy within the framework of 
restricting the usage of new expensive antibiotics and promoting the use of 
selected antibiotics achieved only a limited success in controlling the costs of 
parenteral antibiotics in an American VA hospital. The perceived reasons for this 
failui’e were considered to be thi'eefold. Firstly, the policy allowed starting therapy 
with controlled antibiotics before infectious disease seiwice (IDS) review. Second, 
the IDS team did not continue to monitor control policy patients unless called to 
consult by the treating physician. Third, the IDS team was composed of a rotating 
staff who could not provide continuity of caie and had little incentive to strictly 
enforce medical centre antibiotic control policy. Based on these perceptions a 
change in enforcement protocol was initiated. IDS review prior to the prescription 
of restricted antibiotics was required, prospective and continuous review of 
antibiotic usage with authority to discontinue selected antibiotics on receipt of 
cultui'e results, evaluation of the clinical condition, or both, and the appointment 
of a permanent IDS team member to deal with antibiotic-related issues. The 
average monthly antibiotic costs during the 26-month post enforcement change 
period were $US7,600 less than during the 16-month pre-enforcement period, 
resulting in an average yeaiiy cost reduction of $US91,200. This new control 
procedure added 50 to 70 patients per month to the IDS workload. The medical 
centre's administration added a clinical pharmacist to the IDS team to help deal 
specifically with antibiotic issues when it was realised that the 23% reduction in 
drug acquisition costs during the first 4 months post enforcement was twice the 
salary expense of the position. Others have also fomid that cost savings accmed 
tlnough a combined strategy can be used to more than justify the persomiel costs 
associated with a combined strategy (Pillans et al, 1992). In the first yeai- of a 
rigorous strategy to contain drug expenditme, Pillans et al (1992) reported savings 
of 3.3 million Rand.
3.2 Summary
Both passive and active measures have been used by Hospitals to contain drug 
expenditme with vaiying degrees of success. Within these measm'es, five basic 
types of intervention have been used to influence and modify the prescribing
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behaviour of clinicians. The different types of intervention have been described by 
Plumridge (1984) as re-educative, persuasive, facilitative, power and combined 
strategies. Studies using these types of intervention have been reviewed by 
Grimshaw and Russell (1993). These workers identified and systematically 
reviewed 59 published evaluations of clinical guidelines that met defined criteria 
for scientific rigour. Their conclusion was that explicit guidelines do improve 
clinical practice hut the successful intioduction of guidelines is dependent on 
many factors including the clinical context and the methods of developing, 
disseminating and implementing those guidelines. Different methods being 
appropriate in different contexts. Grimshaw & Russell (1993) suggested a 
classification that highlights the more effective strategies. Within tliis 
classification those strategies with a high or above average probability of being 
effective had a dissemination strategy which was a specific educational 
intervention or was of a continuing educational nature.
The cost-containment methods found to be most successful in controlling the 
hospital drug budget substantiates the findings of Grmishaw & Russell (1993). 
That is, a formulaiy can be an effective tool for containing costs provided it is 
dynamic, reflects cmrent therapeutic needs, is augmented by measures such as 
consultant approval and generic substitution and is supported by continuing 
educational tecliniques aimed at stieamlining prescribing practice.
In the reports of effective formulaiy cost containment there have been few 
accounts of treatment outcome. One of the few was by Scher et al (1990), these 
workers examined the effect of restiicting the use of certain prophylactic 
cephalosporins on woimd infection rates. No change was found in the rate. In tliis 
instance therefore, the cost containment practice was also cost-effective.
Although it may he possible to achieve effective cost contahunent, without 
laiowing treatment outcome it is just not possible to determine whether the cost 
containment practice is cost effective. It could be argued that although a cost 
contahunent practice is effective in limiting drug expenditure, it could be having a 
negative impact on some other budget elsewhere in the hospital.
The next logical step within hospitals is to stop viewing drug expenditure in 
isolation and to take a wider view of the impact drug usage has witliin the
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framework of overall treatment cost. To do this the outcome of drug treatment has 
to be considered alongside both the obvious costs and the not so obvious costs of 
treatment. A recent report from one hospital (Delaney, 1996) demonstrates how 
undertaldng this exercise aided the decision to add what appealed to be an 
expensive acquisition cost diug (enoxaprin) to the drug formulaiy. Without the 
phai'inacoeconomic evaluation the drug would almost certainly have been 
excluded as it was estimated that raw drug cost alone per annum would have 
increased the drug budget by almost 5% (IR£21,500). However, because 
enoxaprin reduced the incidence of post-operative deep vein tluombosis fr'om 20% 
to 6%, amiual tieatment costs of IR£96,350 for this adverse event were averted, 
these savings more than offset tlie acquisition cost of the diug.
To sununarise, a major deficiency of cuirent formulaiies is that they have been 
compiled and operate without laiowledge of how tliey impact on the utilisation of 
other healthcaie resomces. A way forward in the selection of drugs for formulary 
inclusion would he to systematically apply economic evaluation to each 
therapeutic category of drug. With this decision a starting point needs to be 
identified. Almost without exception, tlie largest single group of drugs used in 
acute cai'e hospitals is the antibiotics and there are many reasons why this group of 
drugs should be subject to economic evaluation. These reasons are examined in 
the next chapter.
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4.
Chapter 4
The economic issues of antibiotic use: part I
Spending on prescription pharmaceuticals by the National Health Service (NHS) 
in England in 1996 was £3,780 million (Government Statistical Service, 1997), for 
the same period in Scotland the spend was £427 million (Prescription Pricing 
Authority, 1996).
Table 4.1 Prescription pharmaceutical costs by therapeutic classification 
(British National Formulary) in England (Government Statistical Service, 
1997) and Scotland, 1996 (Prescription Pricing Authority, 1996).
BNF Therapeutic Category
England 
Total cost (£ million) 
(% of total)
Scotland 
Total cost (£ million) 
(% of total)
G astro-intestinal system 578.9(15.3) 85.6 (20.0)
Cardiovascular system 740.1 (19.6) 75.3(17.6)
Respiratory system 485.8 (12.9) 52.3 (12.2)
Central Nervous system 527.6 ( 14.0) 60.5(14.2)
Infections 225.5 (6.0) 28.7 (6.7)
Endocrine system 337.5 (8.9) 33.6 (7.9)
Obstetrics 77.7(2.1) 9.2 (2.2)
Malignant disease and immunosuppression 118.1 (3.1) 10.9 (2.6)
Nutrition and blood 122.5 (3.2) 11.4 (2.7)
Musculoskeletal 200.8 (5.3) 24.0 (5.6)
Eye 50.3 (1.3) 4.3 (1.0)
Ear, Nose and oropharynx 44.3(1.2) 5.1 (1.2)
Skin 171.8(4.5) 20.0 (4.7)
Immunological/vaccines 88.8 (2.3) 5.7 (1.3)
Anaesthesia 1.8(0.05) 0.2 (0.05)
Other 9.0 (0.2) 0.3 (0.07)
Total 3780.5 427.1
It can be seen from Table 4.1 that the contribution made by anti-infectives to the 
spend is in the range of 6% to 7%. Despite this, a lot of effort has been directed at 
controlling the use of antibiotics particularly in the hospital setting where they are
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used in high frequency and have been reported to account for up to 34% of an 
acute hospitals dmg budget (Kunin, 1988, Kunin et al, 1973, Hess et al, 1990, 
Coleman ef a/, 1991).
As with any class of diug financial waste occiu's when antibiotics aie used 
inappropriately, that is when the costs exceed the benefits accmed. However, there 
are more complex economic issues involved in the use of antibiotics which are not 
experienced with other classes of drug. For example, the very way in which 
antibiotics are employed can have an impact on their future usefulness i.e. 
ecological changes can be brought about by the injudicious use of a particular 
agent, Üiese changes i.e. bacterial resistance, can nullify not only tlie firtme 
usefrilness of that particular' agent but the whole class to which the agent belongs. 
The ramifications of inappropriate use are therefore much frutlier reaching than 
the limited immediate resource wastage experienced with other drug classes. 
These economic issues are now discussed.
Antibacterial (antimicrobial) agents are derived either from bacteria or moulds 
(the antibiotics) or from total chemical synthesis. They are used to eradicate 
pathogens which cause infection. The first range of agents to be introduced into 
medicine were the syntlietic cupreines, these were produced by Morgenroth in the 
early 1900's (Sneader, 1985). Although these drugs were highly effective against 
pneumococci, streptococci and staphylococci they were associated with a high 
degree of toxicity which severely limited their use. Tluough the following year s a 
wider range of synthetic antibacterial drugs were developed which had lower 
toxicity therefore maldng them more suitable for generalised use. The first 
antibiotic to be introduced into regular* clinical practice was penicillin during the 
second world war. Soon after the introduction of penicillin many other antibiotics 
were discovered, for example, the cephalosporins, aminoglycosides, 
chloramphenicol; these rapidly became used on a regular* basis.
Widdison et al (1993) stated that antibiotics are the largest single group of drugs 
used in hospitals in the UK. A nation-wide survey through England and Wales 
showed 22% of all hospital inpatients to he the recipients of antimicrobial therapy 
(Anon., 1981). This figm*e seems to be a relatively acciuate assessment as a one 
day prevalence survey carried out in a single English hospital some two year s later
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reported 21% of all in-patients to be receiving an antibiotic (Cooke et al, 1983). 
Similar findings have been reported in the US (Kunin et al, 1973). A three month 
prevalence study in a teaching hospital showed 27% of patients admitted to the 
medical service to be treated with an antibiotic (Kunin et al, 1973). Elsewhere in 
the US the proportion of patients treated with an antimicrobial has been reported 
to be higher (Tamier & Nazaiian, 1984). A series of studies at Boston hospital 
showed that the percentage of patients receiving antibiotics increased from 26% in 
1964 to 42% in 1974 (Tamier & Nazarian, 1984).
With the advent of regular* antimicrobial use there was a recognition that they were 
being overused and misused and that this was a world-wide problem. In an 
evaluation of antibiotic use, Scheckler & Bennett (1970) showed 62% of patients 
receiving antibiotic treatment to have no evidence of infection at all. By 1974 
Lockwood (1974) had described the syndrome of compulsive antibiotic 
prescribing and advocated the formation of an organisation called Antibiotics 
Anonymous to deal with the issue. A former Commissioner of the American Food 
and Drug Administration reconmiended that a National Task Force on the Clinical 
Use of Antibiotics be set up (Kunin et a l , 1973). The problem was considered to 
be of such magnitude that this was subsequently done. It is not only first world 
countries which are experiencing antimicrobial misuse, an international network 
for the rational use of drugs (INRUD) in third world countries exists, one of the 
major problems this network is trying to address is that of antibiotic misuse 
(Quick et al, 1991).
The worries of inappropriate antibiotic usage have centred around increased 
antibiotic resistance with consequent loss of efficacy, unnecessaiy exposure to 
toxic side-effects and latterly, financial waste. No other group of drugs has such an 
effect on society by its legitimate misuse. There is thus, a societal perspective as 
well as individual patient implication from continued misuse (Price et al, 1970). 
Unlike other drug treatments the therapeutic outcome of antimicrobial treatment is 
soon laiown, a patient either gets better or they die. Contiary to this, for example, 
the cerebrovascular drugs, it can be many years before knowledge of their 
outcome is laiown. Because of the tangible outcome available for measmement 
and their ubiquitous use, antimicrobials are very amenable to phai'inacoeconomic
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evaluation. Tliis tool could be readily employed to assist in the rationalisation of 
their use and therefore limit resource wastage.
W hat are the fiscal implications of antibiotic use?
All facets of antibiotic use, for example, the puipose of use, ecological impact of 
use, adverse effects, the method of administration, the location of administration, 
all have economic implications. Each of these aspects will be discussed.
4.1 Prophylaxis and Treatment
With the discovery, development and introduction of an increasing nmnber of 
antibacterial agents the choice available for treatment of a particular pathogen 
continues to widen. Many agents exist which have similar spectra of activity and 
selection between the various agents can become ad hoc unless set criteria aie 
used to rationalise selection. Without rational criteria antihacterials can very easily 
he inappropriately employed. A crucial point which needs to he considered prior 
to choosing between the alternatives, however, is whether the patient actually 
needs to be in receipt of an antimicrobial.
Eradication of a pathogen can be achieved in one of two ways, prevention or 
active treatment. Prophylaxis is the use of an antimicrobial to prevent an infection 
occuning where there is a high probability that one might occur. Active tieatment 
is used when an infection already exists. Of all antibiotic use, prophylactic 
antibiotics account for 30-40% (Shapiro et al, 1979, Cooke et al, 1983, Widdison 
et al, 1993). The striking difference between the use of an agent for prophylaxis 
and its use for active treatment is the duration of time the agent is used for. A 
prophylactic agent is recommended for use no longer than 24 houis as little 
additional benefit is obtained from extending this duiation (Stone et al, 1979). An 
antibiotic used for treatment purposes ranges usually from 5 days upwards 
depending on the cultural backgroiuid of the physician and the infection it is 
intended to treat (Davey et al, 1992, Janknegt et al, 1993).
The economic ramifications of prophylactic antibiotic use centre aiomid the cost 
of employing these agents versus failme of prophylaxis, tlie incidence and cost of 
infection in the absence of prophylaxis, inappropriate selection of agent and the
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inappropriate use of prophylaxis. The economic ramifications of antibiotics used 
for treatment ai*e similar to those used for prophylaxis and centie on inappropriate 
use (lack of need, unsuitable agent selected or more efficacious agent available, 
incorrect dosage etc.) and failme of treatment.
4.1.1 Prophylaxis
Prophylactic antibiotics are used in several settings, for example, in the 
innmmocompromised host, in patients with cystic fibrosis etc., but mostly tliey aie 
used to give cover dming smgical procedmes. Although antimicrobial prophylaxis 
has a place in smgery its efficacy has only been scientifically demonstrated in 
certain procedmes and conditions (Kunin, 1979, Wilson, 1995). Wasteful resomce 
consmnption may occm* when prophylaxis is used without prior evaluation 
(Wilson, 1995).
It has been shown that time of diug administration, blood supply of tissue to be 
challenged and appropriateness of antimicrobial spectrmn are factors crucial to the 
success of surgical prophylaxis (Stone et al, 1979,). Classen et al (1992) 
determined the lowest risk of postoperative infection to be associated with 
administration of a prophylactic antibiotic in the time period two horns either side 
of smgery. The relative risk being increased sixfold (6.7, confidence interval 2.9- 
14.7) if the prophylactic antibiotics were administered 2-24 horns pre or post- 
operatively. An additional risk factor which can affect the success of prophylaxis 
is duration of operation (Garibaldi et al, 1991). As pai't of a ‘snapshot’ smvey of 
antibiotic use, Cooke et al (1983) reported that not only were 15% of smgical 
prophylactic antibiotic comses deemed inappropriate there was evidence that 
prophylaxis was started too late tliereby negating its usefulness. A study by 
Jogerst & Dippe (1981) cairied out in a comimmity hospital considered 64% of 
prophylactic antibiotic comses to be inappropriate, 28% by virtue of being staited 
too late.
Costs of prophylaxis in various surgical specialities
A study to determine the cost of prophylaxis was carried out for a cohort of 
patients undergoing both elective and emergency abdominal smgery (Stone et al.
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1979), this included costing the failuie of prophylaxis and the subsequent 
treatment of infection. These workers found that preventative antibiotic treatment 
was the most cost-effective option. It was fluther determined that almost two extra 
hospital days per patient were required hy those individuals denied preoperative 
antibiotic, the excess being entirely due to potentially avoidable surgical 
infections. The extra medical expenditines caused hy a single operation-related 
infection were calculated. The excess cost per patient incuired by prophylactic 
antibiotic and postoperative infection was $129 for those patients receiving a 
preoperative antibiotic and $429 for those patients not receiving a preoperative 
antibiotic, a difference of $300 in favom* of prophylaxis. It was noted that the 
indirect/intangihle costs to the patient of heing subject to infection had not been 
assessed but even so these existed in the form of losses of income due to 
prolonged incapacitation and a recognised increase in morbidity and mortality. 
These workers fiirtlier discussed that greater savings could be made if the dmation 
of prophylaxis was limited, financial waste occurred to the extent of $92 per 
patient when antibiotic was continued in the postoperative period in those patients 
who had received prophylaxis. It was found that antimicrohial therapy continued 
beyond the day of operation was neither a benefit nor a detriment to the 
subsequent hospital course, or to any risk for development of a postoperative 
infection within the wound and/or abdomen proper.
Mansfield et al (1992) clinically reviewed the consequences of infection 
developing after vascular graft smgery. The incidence of infection was reported as 
between 0.7% and 7%. Although the occmrence may not appear very high the 
consequences of infection in this setting are catastrophic. Management of the 
infection can range ftom extended antibiotic treatment in the hospital setting 
tlirough to major reconstructive smgery and intensive care support. Although not 
quantified in any form, the financial bmden alone, in terms of staff time, 
hospitalisation and drug costs must necessaiily be huge. The cost to the patient is 
also extensive. Mansfield et al (1992) reported a mortality rate of 24% and an 
amputation rate of 20% associated with late infection of vascular grafts at their 
hospital. Other workers have evaluated the direct cost of infection in clean 
vascular smgery. Kaiser et al (1983) compared the use of cefazolin prophylaxis vs
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placebo. The excess cost of hospitalisation due to preventable wound infections 
rose precipitously and was directly related to the severity of infection. The excess 
cost ranged from $3,600 per 100 operations for the mildest grade of infection 
tluough to $6,200 per 100 operations for the most severe grade. In this study the 
observed infection rate and subsequent cost of treatment exceeded the cost of 
prophylaxis for all classes of infection.
A trial which looked at the financial costs of failed prophylaxis was one which 
rather than compaiing prophylaxis with no prophylaxis compared the efficacy of 
different active agents (Roach et al, 1990). Cefazolin, which was cheaper to 
acquire and administer, was compared with cefamandole for prophylaxis in 
cai'diac surgery. It was found that although the acquisition cost and administration 
charges related to the use of cefamandole were in excess of those incurred with 
cefazolin, differences in the charges associated with treating the woimd infections 
that occurred despite prophylaxis with each regimen made cefamandole the more 
cost-effective prophylactic agent. There was a statistically significant difference in 
the perioperative woimd infection rate between the two antibiotics in favour of 
cefamandole. The average excess charge ahove the char ge of using cefamandole 
was $401 per patient receiving cefazolin. These excess charges were mainly 
attributable to réadmissions for sternal wound infection. In this study, costs and 
char'ges were reported, because of this it is not possible to determine the true fiscal 
difference between the two agents. The reasons for this are covered 
comprehensively in a paper by Finlder (1982) which explains the difference 
between costs and charges. Essentially in financial terms, costs refer to actual 
resources consumed in producing a product or service, for example, the cost of an 
iv administered drug will be the simi of the cost of the drug, the cost of 
consumahles required to administer the drug, a proportion of any fixed costs (such 
as any equipment employed) and the cost of the staff time involved in the 
preparation and administration of the drug. Chai'ges by compaiison are essentially 
list prices for a product or service which may or maynot beai* a direct relationship 
to the ‘true’ costs of producmg the product or service. Chai'ges will almost always 
exceed the ‘true’ costs. In addition to the ‘true’ costs of production, charges can 
include such tilings as equipment depreciation and other overhead costs such as
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laundry which may not beai’ any direct relationship to actual resources consumed. 
Although in any economic evaluation it would he ideal to use ‘true’ costs rather 
than charges, the amoimt of time and effort required to determine these may be 
prohibitive because of the difficulties encountered in the determination (Wliynes 
et al, 1995). For those situations where ‘ti'ue’ costs of resomce consumption 
cannot readily be determined, charges can be used as a proxy measme provided 
this is made explicit. As such an indication of cost difference between 
comparators can be achieved (as in the Roach et al (1990) although the precise 
magnitude of that difference can not be assessed.
Shapiro et al (1983) analysed the costs and benefits associated with antimicrobial 
prophylaxis in hoth vaginal and abdominal hysterectomy. These workers found 
that excess in-hospital infections occurred in 29% of women imdergoing vaginal 
hysterectomy who did not receive prophylaxis and in 18% of those undergoing 
abdominal hysterectomy. These results reflected the findings of others (Shapiro et 
al, 1983). The excess infectious morbidity costs were $1,777 for vaginal 
hysterectomy and $716 for abdominal hysterectomy. It was calculated that routine 
prophylaxis would translate to an average net benefit of $492 per vaginal 
hysterectomy patient and $102 per abdominal hysterectomy patient. These results 
would support the conclusion that prophylaxis in vaginal hysterectomy is more 
effective than prophylaxis in abdominal hysterectomy. Importantly, the benefit 
analysis was foimd to be sensitive to baseline infection rate, the efficacy of 
prophylaxis, the cost of antibiotic and the cost of treating the infections. An 
alternative conclusion was reached by Davey et al (1988). In this study the 
reduction in infection rate using cephradine prophylaxis in vaginal and abdominal 
hysterectomy followed a similai' pattern to that shown by Shapiro et al (1983) with 
a greater reduction heing seen in the vaginal group. However when the costs of 
treating infections, which occuiTed despite prophylaxis, both in hospital and after 
discharge to the coimnunity were considered, prophylaxis in vaginal hysterectomy 
was found to be more costly than placebo yet prophylaxis in abdominal 
hysterectomy was found to save hoth hospital and coimmmity resources. The 
conclusion in this case appears to he that prophylaxis in abdominal hysterectomy 
is to be favoured above that in vaginal hysterectomy. As stated by Davey et al
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(1992) the appaieiit conflict between the cost-effectiveness analysis and the 
traditional analysis in terms of cases of infection prevented illustrates two 
important points. The first is that there is no real basis for equating pelvic 
infections after vaginal hysterectomy with wound or pelvic infections after 
abdominal hysterectomy. The second is that use of continuous vaiiables for 
measmement of outcome e.g. financial costs of treating infection, ai'e preferable to 
using discontinuous vaiiables such as infection/no infection. The discontinuous 
variable does not take into accoimt the severity of infection or speed of recovery 
and as shown by the Davey et al (1988) study these aie factors cmcial in 
determining the use of resources. An important point discussed in the Davey et al 
(1988) prophylaxis study report was that only 5% of operations lasted more than 
1.5 horns and therefore the results may not be relevant to centres with longer 
operation times. In die Shapiro et al (1983) study 66% of operations lasted greater 
than 1.75 horns. This may be one source of discrepancy between the two studies, 
Gai'ibaldi et al (1991) demonstrated that duration of operation is important in 
terms of prophylactic success rate. Another som ce of discrepancy maybe the very 
different costs of management. It is obvious tliat the results of both studies 
(Shapiro et al, 1983, Davey et al, 1988) need to be considered within the context 
of other variables.
Until recently antibiotic prophylaxis in ftactme suigery was controversial, 
however a prospective, double-blind, multicentre study of over 2,000 patients has 
provided evidence that the costs of treatment for closed limb fr actures could be 
substantially reduced by employing single dose prophylaxis (Boxma et al, 1996). 
A single preoperative dose of ceftriaxone 2gm versus placebo was shown to be 
associated with significantly lower woimd infections and a lower incidence of 
nosocomial infection within 30 days of surgery. These workers estimated that if 
all patients in the study had received prophylactic antibiotic, total direct cost 
avoidance would have been US$535,550, which equated to savings of US$486 per 
patient.
It can be seen that the judicious use of prophylactic antimicrobial therapy assists 
in the efficient use of resources, their inappropriate use achieving the entire 
opposite. Oral antibiotics before and after prophylactic paienteral antibiotics have
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not been shown to be of additional benefit in reducing the infection-rate (Achong 
et al, 1977). Yet a study by Achong et al in 1976 (Achong et al, 1977) showed 
56% of patients in their sm gical wai'ds and 75% of patients in their gynaecological 
wards to be receiving oral antibiotics after receiving prophylactic parenteral 
antibiotic. It is accepted by many workers that prophylaxis extended beyond the 
24 horn" postoperative period is mmecessary (Stone et al, 1979, Crossley et al, 
1981, Cooke et al, 1983, Widdison et al, 1993). Crossley et al (1981) in a 
multihospital smvey of all smgical patients receiving prophylaxis reported that 
32% of 1,021 patients received prophylaxis for greater than 72 hours. The cost of 
this superfluous use can be estimated using the ftgme calculated by Stone et al 
(1979). Financial waste of $92 per patient was considered to occm' when antibiotic 
was continued in the postoperative period, a crude estimate of unnecessaiy 
monetai*y expenditure in the Crossley study is approximately $30,000.
Although the efficacy of a prophylactic agent and the process by which it is 
administered are important issues in cost-effective evaluations there is another 
dimension which in economic terms receives little attention, that is the occmi'ence 
of adverse events. If an antimicrobial is used routinely in a lai'ge nmnber of 
patients, there will eventually be side effects in some persons that have a 
measmable cost. To date these do not seem to have been considered (Elirenkianz, 
1989).
4.1.2 Treatment
Various studies have shown that patients receive medication umiecessarily, as 
mentioned earlier, Scheckler & Bennett (1970) showed 62% of patients receiving 
antibiotic treatment to have no evidence of infection whatsoever. The proportion 
of patients considered to have no indication yet, were in receipt of treatment was 
somewhat lower (16%) in a study by Jogerst & Dippe (1981). Resomce wastage 
occms when patients are treated both inappropriately and unnecessarily (Kunin et 
al, 1973, Achong et al, 1977, Jogerst & Dippe, 1981, Jewesson et al 1985, 
Dimagan et al, 1991, Shrimpton et al, 1993).
Several studies have documented the costs of hospital antibiotic tieatment, 
including hidden costs such as cost of prepaiation, frequency of administration.
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monitoring and toxicity (Tanner & Nazaiian, 1984, Eisenberg et al, 1987, 
Hoepelman et al, 1988, Wright, 1991, Davey et al, 1990, Pluimidge, 1990, 
Robson et al, 1992, Kerr et al, 1993, Malek et al, 1992, Smyth et al, 1995) and the 
information from this type of study has indeed been used at individual hospital 
level in an attempt to contain antibiotic prescribing costs (Abramowitz et al, 1982, 
Tanner & Nazaiian, 1984, Jewesson et al, 1985, Coleman et al, 1991). One study, 
a cost description of an adult cystic fibrosis unit, which included the antibiotic 
costings for patients requiring different levels of cai'e was used to secme funding 
and also facilitated the prediction of future requirements. Medication accounted 
for 57% of the total cost of caring for these patients, yet in the discussion of this 
study the authors state that tlie benefit of treatment used in this way is unproven 
(Robson et al, 1992). However, what is missing from the literature is information 
about total cost-effectiveness. Most clinical trials of tlierapeutic antimicrobials use 
outcome measm'es such as improvement or cure but very few provide any further 
information about the consequences of failed antibiotic treatment either for the 
patient or the health services. A prospective audit of costs and outcome of 
aminoglycoside treatment and of therapy for gram-negative bacteraemia by Davey 
et al (1995) does however demonstrate the rehound costs caused hy failed therapy. 
In this study a patient was treated for a womid infection in hospital for six days at 
a cost of £186 (drugs, consmnables, staff administration time) and was then 
discharged. Within two days the patient was readmitted with gross suppmation of 
the wound, total treatment cost for tlie second admission was £1,757 (drugs, 
consmnables, staff administration time) (Davey et al, 1995). In addition to this 
treatment cost, other costs which are more difficult to evaluate need to be taken 
into accomit, namely, the opportunity cost to other potential patients denied access 
to the hospital bed talcen up by the readniission and the intangihle cost to the 
patient who has been subject to failed therapy. It has been suggested by some 
(Copley-Merriman et al, 1992) that this sort of health resomce data should be 
collected prospectively at the time a drug is midergoing final clinical trials, the 
practicality of this suggestion however, is somewhat suspect.
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4.2 Adverse effects of antibiotic use
Antibiotic use, be it either prophylaxis or treatment, can be associated with various 
adverse effects. These can range from the change in bacterial resistance patterns 
seen with the overuse of antibiotics and the ecological impact this can have 
through to the idiosyncratic adverse effects experienced at individual patient level.
4.2.1 Resistance, Ecology & Infection Control measures
The ramifications of the injudicious use of antibiotics can be highlighted by a 
serious outbrealc of cross-infection due to Klebsiella aerogenes in a neuiosuigical 
unit in the late 1960s (Price et al, 1970). Large nimibers of patients within this imit 
regularly received prophylactic and therapeutic antibiotics both because of the 
severity of their medical condition and the fact that certain patients were at 
increased risk of infection. During 1968-69, of 228 patients on the unit almost 
30% became subject to serious infection with K. aerogenes, 8 patients died. 
Extensive measures were taken to control the cross-infection but all to no avail, to 
further compound the problem the infecting Klebsiella species were resistant to all 
chemotherapy. Drastic measures were sought and it was decided to withdraw the 
use of all prophylactic and therapeutic antibiotics. The rationale behind this was 
that K  aerogenes is an opportunist ready to colonise the respiratory tract of 
patients whose normal bacterial flora has been suppressed by broad spectrum 
antibiotics. Within foiu* weeks klebsiella ruinary tract infection fell from 20% to 
0% and klebsiella chest infection was reduced from 28% to 2%. Another 
imforseen benefit was that the total infection rate for other organisms was also 
drastically reduced. Price et al (1970) suggested that by withdrawing all 
antibiotics, the more antibiotic sensitive and less virulent bacteria were allowed to 
thrive. In tmii, the changed ecological situation resulted in a reduction in the 
munhers of infections due to the more resistant K  aerogenes. Although not 
considered in the report of tliis outbrealc, the costs of additional caie to the hospital 
and the costs of morbidity and mortality to the patients must by definition have 
been high. In a discussion of the prevention and control of nosocomial infections 
Dixon (1985) reported that almost 300 thousand patients acquire a nosocomial 
respiratory tract infection (RTI) each year in the US, with associated hospital care
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costs of approximately $10 billion. Similar additional hospital care cost estimates 
for nosocomial infections tliroughout the UK do not exist, hut the accoimt of an 
outbrealc of hospital acquired RTI in 8 debilitated elderly patients reported the 
mean monthly antibiotic bill for one ward to have more than doubled. Once the 
outbrealc was finished antimicrobial costs were more or less reduced to the former 
level (Millar et al, 1994). It can be seen therefore that costs of treatment alone 
rapidly escalate.
In 1972 Finland published an extensive review of bacterial susceptibility patterns 
to existing antibiotics at that time. His conclusion was 'that excessive use o f 
antibiotics; the use o f multiple, highly active, and broad spectrum agents; the use 
o f excessive dosages; and particularly their widespread use for prophylaxis are 
primarily responsible for the increased proportion o f the most resistant sti^ains o f 
many species and for the increasing prominence o f species with innate resistance 
to the antibiotics so widely used’.
The reports of bacterial resistance world-wide has continued (Jacobs et al, 1978, 
Moller, 1989, Couicol et al, 1989, Eady et al, 1993, Burke, 1995, Anon, 1996) 
with accompanying exhortations that processes be used to stem fiirther 
development. Eady et al (1993) reported that there are 23 ways of prescribing 
antibiotics for acne based on oral, topical, or combined use of available 
prepaiations. The relative risk of developing resistance with each regimen is 
unknown. These autliors proposed guidelines for antibiotic treatment of acne 
which firstline involved not prescribing antibiotics at all if a non-antibiotic topical 
treatment would suffice and that patients expectations for an endless supply of 
antibiotics needed to be changed, without following a policy it was felt that the 
bacterial resistance now seen in acne would only worsen.
Antibiotic formularies and policies have been introduced into institutions in an 
attempt to control antibiotic usage and limit bacterial resistance (Bendall MJ et al, 
1986, Coucol et al, 1989, Lamikanra et al, 1989, Moller JK, 1989, Sturm AW, 
1990, Neu HC, 1992, O'Brien TF, 1992, Eady et al, 1993). The success with 
which tliese work are dependent on more than just their existence, this is discussed 
in full later.
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Infection Control measures
Although bacterial resistance can be related to the use of antibiotics, nosocomial 
infection can be limited by other infection control practices such as good hand­
washing, bai'rier nui'sing, single patient use of mstruments and limiting the use of 
invasive procedmes (BSAC Working Party, 1995, Sanderson, 1995). Isaacs et al 
(1988) demonstrated how readily resistance can develop when infection control 
measmes are compromised. This study was prompted by two babies developing 
life-tlireatening systemic infections with gentamicin resistant Klebsiella oxytoca. 
Analysis of factors from prospectively collected surveillance data showed that the 
proportion of babies colonised with gentamicin resistant gram-negative organisms 
did not correlate with either the quantity or duration of aminoglycosides used but 
rather that the proportion of babies colonised coiTelated with two indicators of 
workload: the number of babies in the imit (expressed as haby days) and a score 
based on the level of nursing care required. As the workload score increased so did 
the nmnber of babies colonised. Isaacs et al (1988) suggested that the spread of 
resistant organisms between the babies was likely to be due to normal aseptic 
precautions becoming compromised when the workload was high. The cost of this 
resistance to the neonatal unit was not evaluated. O'Donoghue & Allen (1992) 
costed the outbrealc of 10 serious womid infections in an orthopaedic ward which 
were thought to be due to slack infection control measures. The wound infections 
had a high probability of being caused by 5 damaged and contaminated 
mattresses. The total cost of the outbrealc was £22,199 which only included the 
direct costs of prolonged inpatient stay, additional operative procedures, dressings 
and chemotherapeutic interventions. Personnel costs, consumables associated with 
the chemotherapy, the costs of investigation of the outbrealc such as environmental 
sampling and phage typing, and the intangible costs of pain and suffering to the 
patient and worry to the relatives were not included. The cost of replacing the 5 
damaged mattresses was £182. Although the evidence was circumstantial that the 
damaged mattresses were the source of the outbrealc no farther patients developed 
wound brealcdown after the mattresses had been discai'ded. An adequate infection 
control programme could have avoided this scenai'io and costs both to the hospital 
and patients would have been much reduced.
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A study by the Center for Disease Control (Haley, 1991) found that up to one- 
third of nosocomial infections can be prevented by effective infection control 
programs. However Sanderson (1995) discussed that there is a point at which 
nosocomial infections aie 'inévitable and irreducible’ and are a fimction of a 
hospitals procedmes rather than cross infection. For example, the rate at which 
patients aie catheterised and tlie expertise with which this procedme is executed 
will have an impact on tlie nosocomial level of UTI infection (Sanderson, 1995). 
From a societal perspective Stevenson et al (1988) discussed that a baseline 
surgical infection rate need not necessarily be the one which is the minimmn 
attainable because the avoidance of infection is a costly process. These authors 
suggested that the optiniimi infection rate is that which balances the costs of 
infection control against the benefits achievable i.e. it is only beneficial to 
continue to reduce infection rates whilst the social and medical costs of infection 
exceed or equal the costs of avoiding them. This rationale has been endorsed by
Davey et al (1995) in the discussion of which agent to select for smgical
prophylaxis.
Infection control processes, of which antibiotic policies are one, should be used to 
limit the development of antibiotic resistance provided the benefits accrued exceed 
tlie costs of implementation.
4.2.2 Idiosyncratic Adverse Effects
Untoward toxic effects of antibiotics vaiy, they range fi.*om death from
anaphylaxis or aplastic anaemia, with penicillin and chloramphenicol, to severe 
diaiThoea from lincomycin, rash from ampicillin, and nepluotoxicity and otoxicity 
from the aminoglycosides. It has been reported that approximately 5% of the 
hospitalised patients who are given an antibiotic will experience some adverse 
reaction to the drug, and ahout 20% of patients requiring medical care give a 
history of having a past adverse reaction to an antibiotic (Kunin et al, 1973). Up to 
10% of patients in whom protluombin time has been prolonged as a result of 
antibiotic therapy have been reported to manifest some form of bleeding
(Ehienkianz, 1989). Rarely has the cost of adverse reactions heen evaluated. 
However, Eisenberg et al (1987) measured tlie economic impact of
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aminoglycoside-associated nephrotoxicity at six Philadelphia area hospitals. These 
authors found that 7.3% of patients treated with an aminoglycoside developed 
aminoglycoside-associated nephrotoxicity. The additional cost of hospital 
ancillary services per case of nepluotoxicity was $446; the additional cost of 
hospital stay was $825 for additional routine days and $1152 for intensive care 
days. Additional consultations were $78 per patient. The mean total additional 
cost was calculated to be $2501 with the average additional cost per patient 
receiving aminoglycoside therapy being $183.
4.3 Non-compliance of prescribed antimicrobial therapy
Compliance is the degree to which a treatment plan is adhered to. It has been 
estimated that 30-50% of patients do not comply with their prescribed medication 
(Merck Manual, 15th edn). This is related to the fr equency with which a drug has 
to be talcen and the occurrence of side-effects (Davey et al, 1992, Nightingale et 
al, 1994). When compliance is discussed it is usually in reference to patient 
compliance with oral therapy (Merck Manual, 15th edn) but it has been shown that 
staff witliin hospitals can have problems complying with a given regimen (Davey 
et al, 1992). An audit of IV antibiotic administration by Davey et al (1990) 
showed that between 16-45% of administrations differed fr om the prescribed time 
by more than an hour'. Tliis phenomenon of inaccmate administration times for IV 
injections has been described elsewhere ( Clark et ah, 1986, Cousins et aL, 1989, 
Li et al, 1989). Inaccmate administration times can affect the therapeutic activity 
of antimicrobials in different ways. For the aminoglycosides inaccmate 
administration times may lead to inappropriate dosage adjustment. For the B- 
lactanis the time the drug concentration is maintained above the MIC of the 
infecting pathogen is important, if the concentration falls below the MIC then 
breaktlu'ough bacterial multiplication can occm' (Drusano 1988).
Non-compliance with prescribed antimicrobial therapy increases the probability of 
failme of treatment and failme of treatment is associated with var ious costs. These 
include additional drug treatment, the opportmiity cost of mmecessar y repeat visits 
to conimmiity or hospital practitioners, the costs of additional investigation and
90
the costs of long-term complications, such as ectopic pregnancy after untreated 
chlamydial infection in women (Washington et al, 1987).
4.4 Method of administration
Historical and cultmal factors can have an impact on how antibiotics ar*e utilised. 
Many of the original antimicrobials had very poor oral bioavailability, to ensur-e 
adequate sermn levels it was necessary for these agents to be administered 
parenterally. This has left an implicit legacy of belief that this is a superior way to 
administer an antibiotic, however, with many antimicrobials which have excellent 
oral bioavailability, this belief is misplaced. Similarly whereas it is the norm for 
patients in the UK to be admitted to hospital to receive intravenous medication, in 
the USA it is considered regular' practice for patients to receive intravenous (iv) 
care outside of the hospital setting.
The economic issues of hoth iv vs oral administration and non-inpatient vs 
inpatient care are now discussed.
4.4.1 IV vs Oral
Clinicians have long considered that tlie most effective route for the treatment of 
serious infections is the intravenous route, the problems of incomplete absorption 
that can occur' in oral therapy ar e avoided, and it is widely accepted that peripheral 
shutdown, as occurs in severe sepsis, causes non-distribution of an intramuscular ly 
administered antibiotic. However, this implicit assimiption tliat the intravenous 
route is optimal can be disputed.
Recently several new oral antibacterial dr'ugs have been developed which provide 
adequate cover to the whole range of Gram-negative and Gram-positive 
pathogens. Provided there are no manifestations of gut ischaemia and/or gross 
electrolyte disturbance there is no apparent reason why an appropriate oral 
antibiotic should not be employed. Wliere necessary dosage adjustments could be 
car ried out for those patients exhibiting varying degrees of renal impairment.
The use of oral antibiotics in serious infection has been hotly debated. Arguments 
against the use of oral antimicrobials have centred around the bioavailability of the 
antibiotic and the belief that the absorptive capability of a patient may be 
compromised. However there is a paucity of literature concerning the use of oral
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drugs in serious illness, this may be due in pait to a section in the American 
Federal Register which reads 'bioavailability studies may be conducted on suitable
non critically ill patients that studies on critically ill patients are
inappropriate and contrary to the best medical interest o f such individuals unless 
there is a potential benefit to the patient' (Federal Register 1977), it can be argued 
that the potential benefit of oral therapy to the patient over and above iv therapy is 
the additional comfort of not being the recipient of repeated venepuncture and the 
associated phlebitis that can so readily result (Falchuk et al 1985; Backliouse et al 
1987; Allcutt et al 1983).
4,4.1.1 Clinical studies comparing iv and oral therapy
Depending on the agent, the bioavailahility of an antibiotic can vary quite widely 
fi'om a low percentage tluough to a high percentage. Table 4.2 gives some 
examples (fiom Principles & Practice of Infectious Diseases, 3rd Edn).
Table 4.2 Some examples of antibiotics and their oral bioavailability
Antibiotic Group Antibiotic Oral Absorption %
Penicillins Amoxycillin 89
Ampicillin 50 (average)
Dicloxacillin 37-74
Nafcillin 10-20 (erratic)
Cephalosporins Cephalexin 80-100
Cephradine 90-100
Cefuroxime axetil 30-40
Cefixime 50
Aminoglycosides Gentamicin minimal
Netilmicin minimal
Tobramycin 0
Quinolones Ciprofloxacin 69-85
Ofloxacin 85-90
Temafioxacin 100
Tetracyclines Chlortetracycline 30
Minocycline 95-100
Others Metronidazole 95
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Recent studies have shown the usefulness of oral antimicrobials in groups of 
patients who would otherwise have heen candidates for iv therapy. In general, the 
quinolones have a high bioavailahility and the clinical studies carried out in 
seriously ill patients comparing the use of these drugs orally with the iv route of 
administration have been encouiaging. Pass (1987) used oral ciprofloxacin in a 
small group who had multiply resistant respiratory pathogens , the group showed 
'consistently favourable clinical responses appropriate for their infections and 
imderlying illness'. A study hy Strandvik et al (1989) compared the efficacy of 
oral ciprofloxacin with iv ciprofloxacin for the treatment of chest infections in 
patients with cystic fibrosis. It was concluded that the oral form was preferable for 
treatment giving a slightly better bacteriological outcome. There was a dose 
difference between the oral and iv regimens which may explain the difference in 
efficacy but the point made is that serious chest infections can be adequately 
treated via the oral route.
Hodson et al (1987) conducted a similar study in 40 adult patients with cystic 
fibrosis who had acute exacerbations of chest infection caused by the bacterium 
Pseudomonas aeruginosa. These authors compared oral ciprofloxacin with 
conventional iv therapy and found that the oral group, 20 patients in total, showed 
equivalent improvements to the iv treated group, however lung function 
improvements were statistically greater after ciprofloxacm.
This study also included a quality of life component in that the patients who 
received oral ciprofloxacin were asked whether they preferred oral treatment to iv 
treatment if they had received iv treatment in the past. Of the 20 patients, 17 said 
they prefeiTed oral treatment to previous iv therapy (1 had no preference, 1 had 
not had previously received iv treatment, and 1 patient did not answer).
One small study conducted by Johnson et al (1990) looked at the serum levels of 
oral ciprofloxacin in 6 neutropenic patients who had received chemotherapy for 
haematological malignancy. In 5 of the 6 patients, reduced serum levels of 
ciprofloxacin were found after cytotoxic chemotherapy treatment. This was 
thought to he due to reduced absorption of the ciprofloxacin which in tuin was due 
to damage of the gut mucosa induced by the cytotoxic agents. The authors 
concluded that levels achieved were probably adequate for tieatment of most
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infections but caution should he used when treating systemic infections with oral 
ciprofloxacin in this group of patients.
A serious infection as compared with a non serious infection can be defined as one 
that causes substantial morbidity and mortality if allowed to proceed michecked. 
Within the category of serious infection fall tuberculosis and pulmonary 
exacerbations of cystic fibrosis. Both of these conditions have been shown to 
respond successfully to appropriate oral antunicrobial therapy.
Another antibiotic with a high bioavailahility (95%) is metronidazole. An audit of 
iv metronidazole therapy by Jewesson et al (1985) found that 29% of the coui'ses 
were inappropriate in relation to the route of administration. The authors 
suggested that substitution of iv metronidazole with oral or rectal formulations in 
specific instances would result in substantial savmgs. Interestingly, Ridgway et al 
(1991) showed that cefuroxime axetil was suitable for treating lower respiratory 
and miliary tract infections in elderly patients despite the fact that this agent only 
has a bioavailahility of some 30-40%.
It would appeal* that these studies lend support to tlie use of oral drugs for 
treatment of serious bacterial infections. Wliat has not been fully investigated is 
the potentially higher bioavailahility tliat may exist in the infected state: the 
increase in plasma free fatty acid level decreases drug protein binding and 
therefore more unbound drug is available to exert a phaiinacological effect. 
Additionally, infection may inliibit diug metabolism so that it is inactivated at a 
lower rate (Smith, 1988). To ensme adequate sermn concentrations of 
antimicrobial agents and therefore promote successful outcome of therapy, sermn 
bactericidal titi'es at trough concentrations could be monitored (Davey et al, 1991, 
Drusano, 1988), the kinetic aim heing that the free drug remain above the 
minimum inliibitory concentration (MIC) for the infecting pathogen. Others 
(Klastersky et al, 1974) have also concluded that the eaiiy evaluation of sermn 
concentrations and antibacterial activity is very useful in leading to antibiotic 
dosage adjustment and therefore improving clinical outcome. More data are 
required compaiing the efficacy of oral and iv antimicrobial formulations (Neu, 
1989).
94
4.4.1.2 Management/administrative issues with iv administration of 
antibiotics
Quality of preparation
Several studies (Davey et al 1990; Clark et al 1986; Cousins et al 1989) have 
shown that the ward environment is not suitable for the routine prepar ation of iv 
drugs. Stability, sterility and compatibility are all compromised when iv additives 
are prepared on the ward by non-pharmacy staff. The recormnendations of the 
Breckemidge report (1976) on iv additives stated that 'the addition o f drugs to iv 
infusion fluids is an aseptic procedure, which should ideally be carried out in 
appropriate environmental conditions , under the direct control o f a pharmacist’. 
Due to these recommendations and the growing awar'eness of the poor quality of 
iv drug preparation at ward level, a centr'al iv additive service (CIVA) is now 
provided by a substantial nimrber of hospital pharmacy departments tlrroughout 
Britain. Wliere this service is provided there is a general acceptance of improved 
pharmaceutical quality, rate and time of administration and savings in medical and 
nursing time. All of these may lead to an improved quality of patient car e (Clark et 
al 1986; Cousins et al 1989; Clark 1988).
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Dosing intervals
The Breckemidge Report (1976) Airther stated 'where intramuscular or oral 
administration is feasible , the iv route should be avoided'. Wliere the iv route has 
to be used the precise method and rate of administi*ation is sometimes critically 
important in determining the efficacy or safety of therapy'. Tliis statement is 
pertinent to the use of antibacterial agents. As already discussed in the preceding 
section on compliance therapeutic efficacy for the B-lactam antibiotics depends 
mainly on the time that the bacteria aie exposed to effective concentrations, long 
intervals between doses therefore lengthens the time that the concentration of 
antibiotic in the sermn is below the minimiun inhibitoiy concentration (MIC) of 
the tai'get organism. A patient receiving B-lactam therapy under these conditions 
is put at risk of suboptimal treatment (Drusano 1988). The aminoglycosides and 
quinolones exhibit concentration-dependent bactericidal activity with a prolonged 
post-antibiotic effect. It is possible for these antibiotics to have an extended time 
interval between doses without compromising antibacterial efficacy (Baldcer- 
Woudenberg et al 1988). In a study carried out within Dimdee Hospitals to 
observe the utilisation of the aminoglycosides and the general antibiotic 
management of septicaemia, it was fomid that 44.5% of the study population 
experienced at least one missed/non recorded dose (Parker & Davey, 1992). The 
iv antibiotics were administered by house officers with the exception of the ICU 
where specially trained musing staff administered iv therapy. The reason that so 
many doses should be missed/non-recorded cmi be related to the house officers 
remit. Their duties are often at a maximum, attending consultant ward romids, 
clerking in patients, aiTanging x-rays and collecting blood samples or performing 
other tasks. Additionally, where several patients on the same ward aie on what can 
be quite complex antibiotic regimens, it is not possible for the iv antibiotic boluses 
to be prepared and administered to all of the patients at the prescribed time.
For 63.9% of the non-recorded doses it was not possible to ascertain whether the 
dose had in fact been administered. In some cases the antibiotic may have been 
administered and just not recorded. This in itself has ramifications in that a second 
person may notice the omission of recording and seek to rediess the situation by 
administering the dose, hence the patient receives two doses within a short period
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of time. Although in a lai'ge number of cases tliis may not be of clinical 
importance, it is when the antibiotic has a narrow therapeutic index such as an 
aminoglycoside or a glycopeptide. The situation then becomes clinically 
significant. Examples of this additional dosing due to non-recordmg of the first 
dose has occurred within Dundee Hospitals; a patient received 140mg gentamicin 
at ward level prior to surgery but the dose was not recorded on tire kai’dex, on 
receiving the patient in theatre the anaesthetist noticed the omission on the kai'dex 
and proceeded to administer a fiuther 140mg gentamicin, the patient had therefore 
received two doses of 140mg gentamicin within one hour”. It was not until later in 
the day when requesting the house officer involved to ensure that all patients 
received prescribed antibiotics prior to theatre that the incident of double dosing 
was imcovered. This type of incident was not an isolated occrmence.
Further implications of this non-recording/non administration of antibiotics 
include:-
1. The patient receiving inadequate treatment where the non recording reflects a 
non administered dose, therefore therapy may be fiuther prolonged. Where the non 
recording is just that i.e. a dose actually has been administered, then the potential 
for toxicity exists should a second dose be given.
2. All procedures to a patient must be documented and the docmnentation retained 
for a set period of time, therefore there are medico-legal implications.
3. It may be necessary for various reasons e.g. interpretation of aminoglycoside 
levels, to know the exact nmnber of doses a patient has received, incorrect 
recording can lead to incorrect dosage adjustments.
A publication by Denton et a l(\99 \)  highlights that these findings aie not peculiai* 
to Dundee Hospitals. These authors also fomid that the time intervals for multiple 
daily dosing regimens were highly variable. A practice was created whereby a 
long interval between successive doses overnight ensued and occuired on all imits 
where nursing staff did not give iv antibiotics. Inaccmate administiation times for 
iv injections has been described in other centres (Li et al 1989; Clai'k et al 1986; 
Cousins et al 1989).
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4.4.1.3 Cost factors in IV delivery 
Drug cost/price
Costing of drug therapy is made difficult by failure to distinguish clearly between 
costs to tlie hospital and charges to the patient. This inconsistency of utilising 
costs and charges is highlighted by McCue et al (1985). These authors surveyed 
hospital charges for iv antibiotics in 71 hospitals in 25 US cities. They found that 
the percentage of patient charges due to drug cost ranged fi'om only 6.9% to 
38.8% and that it was impossible to estimate the cost of the drug to the hospital 
fi'om the chaiges made to the patient.
The base price, the figiue on which hospitals calculated their mai'kups, was the 
actual drug acquisition cost in only 53.6% of the hospitals, the remaining 43.7% 
used one of the wholesale price guides to set their base price, even though none of 
them consistently paid the average wholesale price (AWP) for their drug 
purchases. 81.7% purchased at least one antibiotic tlii'ough competitive bidding or 
a collective buying anangement; of these hospitals ,67% passed savings onto 
patients, and tire remainder put the profit generated by the differences between the 
actual drug acquisition cost and the price that was based on AWP into hospital or 
pharmacy operating fimds.
In addition to the markup on the drug cost, 64% of the hospitals added a phar macy 
dispensing fee for each dose of iv drug administered. Wlien a pharmacy-prepar ed 
system e.g. minibag, the commonest method of antibiotic administration , was 
used, an additional charge of $9.09 per dose was levied. Examples of the average 
hospital drug-related and pharmacy-related charges for selected iv antibiotic 
regimens are shown in Table 4.3, taken from McCue et al (1985).
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Table 4.3 Average hospital drug-related and pharmacy related charges 
for selected iv antibiotic regimens.
Drug
Dose
Freqeiicy
Gentamicin Cefazolin Cefoperazone
80mg 
8 hourly
Drug cost ($) 3.25 
Amount
mai'kup ($) 11.87
Dispensing 
Charges ($) 32.20
Daily Charge 
to Patient ($)* 47.30
% of Patient 
Charges due 6.9 
to Drug cost
lOOOmg 
8 hourly
11.04
16.52
31.20
58.67
2000mg 
12 hour ly
38.03
36.36
23.63
97.93
18.8 38.8
Does not include dose preparation char-ge, $9.09, or any iv-line related charges. 
Equipment/Consumables
Intravenous administration of a drug involves not only the cost of the drug itself 
but the costs of the persomiel time involved in the preparation and administration 
of the drug and the costs of consumables used during the preparation and 
administration i.e. syringes, needles, giving sets, in-line filters etc. Because of the 
large annual costs involved with iv therapy, one American 530-bedded hospital set 
up an interdisciplinary committee to look at infrision control devices. By 
rationalisation of the infrision control devices used, this group was able to show a 
total savings attributable to decreased use of $142,223 for the fiscal year* 1986 
(Domielly <3/ 1988).
In 1989, Cousins et al produced an average total cost for a ward based antibiotic 
bolus of £5.17 per dose and for a Cl VA antibiotic bolus of £5.13. One year' later 
Davey et al (1990) reported an average cost for a ward based antibiotic bolus of 
£5.66.
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The overall costs of providing a CIV A service have been found to be of the same 
magnitude to the hospitals as the traditional bolus dose ward-based service, 
although the various elements which make up the overall cost varies markedly 
between the two operations (Cousins et al 19^9).
Table 4.4, data from Cousins et al (1989), shows that the two elements of 
operational cost that differ mostly are musing labour* and consmnables. The bolus 
musing labom* cost was based on the minimum theoretical time required for 
correct bolus dose preparation and administration of 10.5 minutes, compared with 
the average time of 5.25 minutes for muses to obtain and hang a Cl VA dose. The 
full administration time was not included for the Cl VA dose as a nurse was not 
involved in administration after comiecting the minibag and releasing the roller 
clamp. The variation in consumable costs is due to the cost of the minibag system, 
sterile gloves, alcohol wipes and bacteriological filters wliich are used in addition 
to the needles and syringes, during the preparation of a Cl VA dose. Some of these 
additional items (sterile gloves, alcohol wipes) should be used at ward level but 
rarely are (Davey et al 1990).
Table 4.4 Comparative costs (£) of ward-based iv bolus and central iv 
additive (CIVA) seiwice (from Cousins et aL 1989)
Bolus CIVA
Drug (£) 3.30 3.30
Consumables (£) 0.17 1.01
Waste (£) 0.26 0.18
Error (£) 0.43 0.05
Pharmacy labom* (£) 0.00 0.27
Nm’sing Laboiu (£) 1.01 0.32
Nursing Time (min) 10.50 5.25
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IV Wastage
Wastage occurs due to error and poor communication between medical and 
nursing staff. Depending on the system in use for iv preparation the report of iv 
wastage has ranged from 2,06% up to 19.98%.
Wastage is at a maximum when preparation is carried out at ward level, injections 
are frequently incorrectly prepared, badly labelled and incorrectly stored. Wastage 
at ward level has been reported to range between 6-19.98% (Davey et al 1990; 
Cousins et al 1989; Newhouse et al 1988). A consistent finding of utilising a 
CIVA seiwice is the large reduction in drug wastage, the subsequent savings made 
from this reduction can be used to offset the increased cost of consumables. By 
initiating a CIVA service Cousins et al (1989) demonstrated a 50% decrease in 
drug wastage from 7.9% to 4%. Newhouse et al (1988) reduced iv wastage to 
under 2.25% using a similar system.
Staff time
Most manufacturers recommeird iv drug boluses to be administered over tlrree to 
five minutes. It has long been recognised tliat clinicians and muses working under 
pressure on busy wards have difficulty in complying with these recormnendations. 
Clark et al (1986) fomid that 78% of drugs given by iv bolus were administered in 
less than one minute. These findings were similar to those of Davey et al (1990). 
Additional to the administration time of the drug is the preparation time. Clark 
foimd an average time of 13.7 minutes for a nm*se prepared/administered iv drug 
and an average time of 7.6 minutes for a doctor prepared/administered iv drug. It 
was calculated that the amiual labom* cost to the District Health Authority was 
£267,368.
Davey et al (1990) found that the average preparation time per* injection at ward 
level was less for* batches than for a single injection, the batch preparation mean 
being 2.1 minutes and the single injection mean being 4.8 minutes. The estimated 
amiual musing time was 54 horns on general medical wards and 91 horns on 
general smgical wards; house officer time was 163 hours and 159 homs 
respectively.
Cousins et al (1989) showed that the labom* costs involved in the preparation and 
administration of a CIVA dose was almost half that of a ward prepared dose i.e.
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59p per dose compaied with 10Ip per dose. A CIVA service provides for batch 
preparation of injections thus allowing for a lower average preparation time per 
injection (Newhouse et al 1988).
Additional costs
Certain drugs because of their potential for toxicity require serum monitoring 
regardless of their route of administration e.g. digoxin, theophylline, phenytoin. 
This involves the personnel time and consumables used for sample taking and 
assaying. However, there are drugs that are given only by the iv route which also 
require serum monitoring e.g. aminoglycosides. The alternative oral drugs which 
can be used in place of the aminoglycosides do not require serum monitoring. 
Malek et al (1991) in a paper comparing two types of antimicrobial therapy 
showed that assay laboratory costs for patients receiving aminoglycoside therapy 
averaged £36.59 per patient.
Another additional cost is the element of patient discomfort experienced due to the 
additional venepuncture.
Cost of treating adverse effects
In addition to these operational costs a value has to be placed on the probability of 
the occuiTcnce of an adverse event. Infusion-related phlebitis is a prevalent 
disorder and has been stated to affect over half of all patients receiving an infusion 
without an m-line filter. An in-line filter has been shown to reduce the incidence 
by 50-60%, this still means that approximately 25% of patients receiving iv 
therapy experience some degree of phlebitis. Garrelts et al (1994) in a study of 
patients receiving vancomycin calculated that the average cost of treating 
vancomycin induced phlebitis was $93.72 which in turn equated to an additional 
cost of $46.86 per patient receiving vancomycin.
The possibility of microbiologie contamination and pyrexia due to pyrogens is a 
serious concern in the use of intravenous administration.
Quercia et al (1986) cairied out a cost justification study for the use of what 
appealed to be expensive in-line filters. This group demonstrated that nosocomial 
bacteraemias in a smgical intensive caie unit increased hospital costs by 
approximately $168,000 amiually, based on the estimate that an average 
nosocomial infection cost $4,000. They ai’gued that the cost of placing in-line
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filters on all possible iv lines in their surgical ICU, estimated at $5,700 amiuaUy, 
would be more than offset by the savings made by reducing the incidence of 
nosocomial bacteraemia.
Final in-line filters do reduce micropai'ticulate and microbiologie contamination 
but can cause teclmical problems of their own, e.g. reduced air flow rates, air 
blockages, drug adsorption.
As discussed earlier Eisenberg et al (1987) measuied the economic impact of 
aminoglycoside-associated neplirotoxicity. The average additional cost per patient 
receiving aminoglycoside therapy at that time was $183.
Methods for improving quality control
US Hospitals have designated iv therapy (IVT) teams who aie responsible for iv 
catheter insertions and administration of iv di'ugs throughout the hospital. 
Implementation of this team approach to iv drug administration was advocated in 
the 1970's in an attempt to control infusion-associated septicaemia. It was found 
that asepsis of iv fluid systems was most efficiently and effectively implemented 
by IVT teams who rigorously followed established protocols for cannula 
insertions, drug preparation and administration, fr equent surveillance of infrisions 
and cannula sites and any otlier follow up care required. Published data concerning 
the costs of this service are sparse. A paper by Tomford et al (1984) demonstrated 
that the use of an IVT team resulted in decreased morbidity and therefore 
improved the quality of patient car e. The authors believed that the benefits accrued 
i.e. reduced phlebitis and bacteraemia, by employing an IVT team outweighed the 
opportunity cost of practising the mechanical task of iv catheter insertion. No 
attempt was made to actually quantify the costs of this service in dollar' terms. 
However a call was made for fru'ther research into the evaluation of the cost- 
effectiveness of the IVT team. An alternative scheme to an IVT team has been a 
'decentralized approach' suggested by Larson et al (1984). This study considered 
the integration of 'iv expert' nurses into the general nursing staff, i.e. selected 
nru'ses received additional education and training concerning venepimctme, 
catheter insertion and infusion therapy. These nurses contmued with normal duties 
but when venepuncture, catheter insertion or general care of an iv line was 
required on their ward, they were called upon to carry this task out. It was foimd
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that on those wards with an 'iv expert' on site there was a higher compliance with 
the iv guidelines and a lower risk of phlebitis. Equipment costs were foimd to 
decrease by 7.4%. Costs to start such a decentralized iv program on 10 clinical 
miits was calculated to be about $10,000. There is also a system of outpatient iv 
therapy in the States. A recent review by Balinsky et al concerning the cost 
effectiveness of outpatient parenteral antibiotics concluded that significant direct 
cost savings were made when inpatient therapy was replaced by outpatient 
therapy. Quantifying the benefits to the patient and including them in an analysis 
resulted in an increase in the overall cost-effectiveness of a home care based 
program. The authors make the point that costs were poorly defined in the studies 
evaluated. Both cost and charge data were utilised, making it difficult to 
determine the actual savings.
Table 4.5 summarises the cost factors associated with an average iv treatment with 
a gentamicin and ur eidopenicillin combination.
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Table 4.5 Cost factors associated with an average iv treatment with a 
gentamicin and ureidopenicillin combination.
£
Drag* 171.95
Consumables* 45.50
Persomiel time^ 45.65
Wastage (12%)! 20.63
Additional costs (assays)* 36.59 
Adverse events~ 107.02
(potential for neplnotoxicity)
Patient Discomfort intangible
Total 427.34
* taken from Malek et a / 1991
^ time taken from Malek et al 1991 i.e. 3 hours 54 minutes for prepaiation and 
administration of the drugs plus 1 horn 26 minutes for assay performance. A 
costing of £8.56 per hour was used based on smgical nursing costs for Scotland in 
the financial year ended in April 1990 (obtained fit'om David Clark, Unit 
Accountant, Dundee Acute Hospitals)
• taken from Davey et al 1990 
talcen from Eisenberg et al 1987, an exchange rate of $1.71 = £1 was applied.
4.4.1.4 Oral therapy as an alternative to iv therapy 
Oral therapy has several economic advantages
i) the initial puichase price is generally less expensive than the equivalent iv form 
of the drug. A comparison of iv and oral dosage forms of some commonly 
prescribed drugs can be seen in Table 4.6.
ii) Patient comfort is increased and the potential problem of phlebitis is removed. 
Moreover it is more likely that the patient can be discharged home on oral therapy. 
All of these factors improve quality of life.
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iii) A shorter hospital stay also results in a lower probability of contracting a 
nosocomial infection and a bed is released for further use. The only other way to 
achieve this is by setting up a home iv service, which is still likely to be 
considerably more expensive than oral therapy.
iv) Valuable medical and nui sing time is saved due to ease of administration.
v) The consimiables used during iv therapy ar e avoided.
vi) In hospital a patient has a reduced probability of missing a dose and an 
increased probability of receiving a dose on time as nurses administer oral 
medication under very regimented conditions.
vii) Adequate supervision of iv drug preparation and administration in hospital 
requires either a centralised intravenous additive service (CIVA) or a dedicated iv 
administration service, botli of which add further to the costs of iv therapy.
Table 4.6 Cost of one days recommended maximum adult dosage (from 
MIMS May 1991)
Drug Oral (£) IV(£)
Amoxycillin 1.05 5.24
Flucloxacillin 0.52 14.85
Erytliromycin 0.90 28.11
Ciprofloxacin 4.50 48.00
Cefruoxime 3.60 21.16
nb. these are not necessarily the doses regularly used, these doses were chosen to 
exemplify the differences in cost between iv and oral forms of the same dr ug.
Wliere it is totally imsuitable for a patient to be initially commenced on oral 
therapy, a shortened iv coiu'se with a change to oral therapy as soon as possible 
would also provide the economic benefits previously discussed. The economic 
implications of substituting parenteral therapy with oral antimicrobial therapy 
have been explored to some extent by others. Generally, the finding has been to 
support the use of oral antimicrobials in preference to parenteral therapy. 
Beneficial patient outcomes have been associated with substantial savings
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(Quintiliani et al 1987; Leigh 1988; Cooke et al 1991; Powers & Bingham 1990; 
Chan et al 1995).
Clinical evidence supporting the use of oral treatment has mainly come from 
observational studies. Mandell et al (1995) critically reviewed the ‘iv to oral 
switch’ literature. Most of the studies were small, were for a mixed bag of 
infections and focussed on the use of quinolones, although some did use B-lactam 
agents. Of the 32 studies reviewed only 13 were randomised, controlled trials. 
Despite these drawbacks Mandell and co-workers concluded that early 
substitution of oral agents for iv treatment did have a place in patient therapy. 
Fm'ther experimental evidence supporting the use of oral therapy has been 
provided by Chan et al (1995). These workers demonstrated in a randomised, 
controlled trial that oral co-amoxiclav was as efficacious as iv co-amoxiclav for 
the ti'eatment of commimity acquired lower respiratory tract infection.
Provided that equal patient outcome can be guaianteed with oral therapy it is 
difficult to imagine a scenario where use of the iv alternative would be more cost- 
effective. It is proposed therefore, that maximisation of valuable resoui'ces would 
be effected by tlie increased use of the oral route and that particular* attention is 
paid to the increased use of oral drugs in the management of serious infection. 
Wliat does remain a challenge is to change the intrinsic belief of doctors that iv 
antimicrobial therapy is preferentially better than oral tlrerapy. A recent study by 
Solomkin et al (1996) demonstrates how this worry about oral therapy affected the 
prescribing behavioiu* of American singeons. The study was designed to 
investigate tlie use of various antimicrobials in complicated infra-abdominal 
infections. One of the aims was to examine whether* bioequivalent doses of oral 
therapy would provide equivalent efficacy to contmued iv therapy for patients able 
to tolerate oral intalce in the early postoperative period. Patients were randomised 
in a double blmd fashion to one of tlir*ee categories shown in table 4.7. Physicians 
were encouraged to initiate oral (po) therapy for all tlu*ee treatment groups 
between 3 to 8 days after begimiing iv therapy. It was foimd that oral treatment 
was commenced for* those patients who became eligible for* po treatment which 
initially indicated considerable physician acceptance to this approach. 
Fiu'thermore, clinical success for* those patients who received active oral treatment
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was found to be equal to those patients who received only active iv treatment. 
Wliat was of interest was a subset of patients who were prescribed oral and were 
then changed back to iv because the physician thought that the treatment was 
failing the patient, even though the patients were already receiving active iv 
treatment, it was the oral component which was placebo. The physicians canying 
out the change from po to iv were imaware of this fact because of the double blind 
nature of the study. This would suggest that these physicians thought that it was 
the oral treatment that was failing the patients i.e. there is an intrinsic concern that 
oral therapy camiot be as effective as iv therapy. The results from this subset of 
patients being a measure of doctors behaviour rather than an assessment of a 
clinical endpoint.
Table 4.7 Antimicrobial randomisation categories of patients in Solomldn 
et al (1996) study.
Randomisation Initial treatment Day 3-8 Continued
treatment
Group 1
Ciprofloxacin iv + 
Metronidazole iv
Ciprofloxacin iv + 
Metronidazole iv
Continued iv 
or sequential po
Ciprofloxacin iv + 
Metronidazole iv
Ciprofloxacin iv + 
Metronidazole iv + 
Placebo po
Group 2
Ciprofloxacin iv + 
Metronidazole iv 
followed by 
Ciprofloxacin po
+
Metronidazole po
Ciprofloxacin iv + 
Metronidazole iv
Continued iv 
or sequential po
Ciprofloxacin iv + 
Metronidazole iv
Ciprofloxacin po + 
Metronidazole po + 
Placebo iv
Group 3
Irnipenern iv
Irnipenem iv Continued iv 
or sequential po
Imipenem iv
Imipenem iv + 
Placebo po
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4.5 Alternative locations for the administration of iv antibiotics -
Non-inpatient care vs Inpatient care
In North America a non-inpatient iv (NIPIV) service has been available since the 
1970's for a wide vaiiety of indications. One of the first indications NIPIV care 
was used for was chronic bronchopulmonaiy infection associated with cystic 
fibrosis (Rucker & Haiiison, 1974). These workers foimd that almost 70% of 
hospitalisations could be avoided and was associated with the benefits of fiscal 
savings in medical costs, lack of disruption of family routine and in some cases 
allowed continuation of schooling and employment. Soon after other workers 
(Stiver et al, 1978) reported the success of a pilot NIPIV caie prograimne which 
was used for a variety of infections including osteomyelitis, endocarditis and 
bacteraemia. It was stated that all patients in this programme preferred home 
treatment as it allowed a retuim to a more normal lifestyle. Treatment was reported 
to cost one third of that in the hospital. This pilot study formed the basis for a 
continuing NIPIV service (Stiver et al, 1982). After four years experience Stiver 
and colleagues (1982) remained enthusiastic about the service continuing to report 
patient satisfaction, cost savings and increased hospital efficiency due to the 
release of beds vacated by those patients entering the programme. For the 
programme to rim smoothly it was foimd that good communication chamiels 
between all team members was necessary. Other providers of NIPIV care support 
the fact that coherent teamwork is essential to the success of the programme 
(Relim & Weinstein, 1983, Kind, 1985, Sharp, 1986), as is patient selection 
(Stiver, 1982, Kind, 1985, Sharp, 1986). Amongst others, important criteria to be 
met are; the infection to be resolving, the patient and family to be motivated to 
participate in the programme and to be educationally aware and that home 
circumstances are suitable.
Since these initial reports several studies have demonstrated the efficacy, safety, 
reduction in cross-infection and cost savings associated witli this type of service 
(Chamberlain et al, 1988, Click, 1991, Wiernikowski, 1991, Bernstein, 1991, 
Scully, 1992, Thickson, 1993 Rubinstein, 1993). Poretz et al (1984) performed a 
cost benefit analysis of home iv therapy in which all quantifiable benefits e.g.
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increased productivity, return to work or school, etc. were measured. They 
determined a mean total benefit of $6,588 per patient, a mean total cost of $1,768 
per patient, and an overall benefit/cost ratio of approximately 5:1. The conclusion 
of the study being that "for all parties concerned, the benefits o f outpatient iv 
therapy versus hospital iv therapy far outweigh the costs".
There are now many different NIPIV programmes within North America which 
ai e organised in a variety of ways, some ai e hospital based, some aie organised by 
the family practitioner and some are run by independent companies (Poretz, 
1993). Regai'dless of how the programme is organised the service appears to be 
well accepted by patients and third party payors provided it is organised in an 
efficient mamier. However, worry and imcertainty can be an intangible cost to the 
patient and carers when a prograimne lacks organisation and a regular point of 
contact. This was amply demonstrated by Nolet (1989) who showed how lack of 
information and disorganisation of a NIPIV programme can lead to patient lack of 
confidence in the system and the subsequent desire to be treated in hospital. Table 
4.8 compares and contrasts the various costs of NIPIV care with inliospital care. 
Because NIPIV caie has now become such a large business in the USA, 
accreditation standards for providers have now been developed by the Joint 
Coimnission on Accreditation of Healthcare Organisations (JCAHO) (Malloy,
1990). The first home caie sui'veys were conducted in 1988, organisations which 
operate to the JCAHO's standaids and eains accreditation demonstrates to the 
consumer and the payor a commitment to providing the highest level of quality 
caie and service.
In the UK NIPIV care is generally not an alternative option to inliospital caie for 
the vast majority of patients, however, it is used for cystic fibrosis and oncology 
patients in some instances and it is becoming an option for AIDS patients. One of 
the largest differences between North America and the United Kingdom is that of 
culture and the belief in the UK that serious infection and subsequent intravenous 
therapy necessitates hospitalisation. To some extent this can be related to the way 
in which the financing of healthcare is organised in these two countries. North 
American patients aie primaiily responsible themselves for ensuring that their 
medical treatment is financed, in the UK cential government provides healthcare
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monies. One of the driving forces for the development of a NIPIV service for 
serions infection in North America has been a desire to reduce the costs of 
treatment (Rucker & Hanison, 1974, Stiver et al, 1982, Poretz et al, 1982, Relmi 
& Weinstein, 1983, Sharp, 1986, Chamberlain et al, 1988). Contraiy to this the 
driving force for the provision of NIPIV care for cystic fibrosis patients in the UK 
has been quality of life factors (Gilbert & Littlewood, 1988, BPA Working Party 
on Cystic Fibrosis, 1988).
Given the wide-ranging reports of cost-effectiveness of NIPIV care in North 
America its wider application in the UK deserves fiirtlier investigation. It is not 
possible to extrapolate the experience directly from the North Americans as they 
administer a greater proportion of antibiotics by the intravenous route compared to 
the UK, also the different healthcare financing system may affect the final cost- 
effectiveness of the programme.
Table 4.8 Comparison of the costs of NIPIV care
Hospital NIPIV
Direct Costs Hospitalisation -
Antibiotics Antibiotics
Consimiables Consumables
Staff time Patient/cai'cr time 
IV teclmique training
Indirect costs Loss of income Coimnuting costs for clinic
InteiTuption of education 
Family commuting costs
follow-up
Intangible costs Dependence 
Depression 
Confinement 
Sepai'ation fr om family
Worry and imcertainty
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4.6 Attempts to control the use and costs of antibiotics
Despite this, several methods have been used world-wide to control the use of 
antibiotics, these have included educational campaigns, restricted sensitivity 
reporting, limiting drug lists by requiring consultant approval, automatic stop 
dates, pecuniary measmes, generic substitution and last but not least local policy 
guidelines (Achong et al, 1977, Avorn et al, 1983, Manning et al, 1986, Hai'vey et 
al, 1986, Evans et al, 1986, Scher et al, 1986, Avorn et al, 1987, Sutters et al, 
1989, Friis et al, 1989, Dannenhofer et al, 1989, Wilson et al, 1991, Riley et al, 
1991, Mugford et al, 1991, Friis et al, 1991, Coleman et al, 1991, Cockburn et al, 
1992).
The introduction of an antibiotic policy in a gioup of hospitals in the UK was 
reported to have reduced antibiotic costs from 22% to 16% (Wolfson, 1980). 
However, as late as 1988 it was suggested that there was a general ignorance in 
the UK as to which methods of control are followed, whether they work to any 
degree and how to assess their true benefits (Gould, 1988). In response to tliis the 
British Society for Antimicrobial Chemotherapy (BSAC) set up a working party 
which would specifically look at these issues tlnoughout the UK. The findings of 
this pai'ty were reported in 1994 (BSAC Working Party Report, 1994). Health 
professionals (medical microbiologists and pharmacists) at 733 hospitals were 
initially approached to participate in the sui'vey. Responses which represented 427 
identifiable hospitals within the UK were obtained. It was fomid tliat control 
measures used tended to reflect the size of the hospital, with a greater proportion 
of lai'ger hospitals undertaldng educational campaigns, antibiotic studies and 
having policies for smgical prophylaxis in place. Small hospitals (less than 315 
beds) were only half as likely to have these as large hospitals (greater than 675 
beds). Audit was five times more common in lai'ge hospitals. It was felt that 
respondents in the study were more likely to mn control systems than non­
respondents therefore extrapolation of the findings to cover the non-responding 
hospitals would probably give an over-representation of control systems used. For 
all respondents the most common control measure used (79%) is the antibiotic 
formulaiy with prior consultant approval for certain restricted antibiotics. Very 
few microbiology laboratories routinely reported antibiotic sensitivities for
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antibiotics not included in their formularies. However, only 11% of respondents 
operated formal audit of antibiotic usage. Half of the respondents had a policy for 
smgical prophylaxis. Compliance with policies was monitored in 50% of 
responding hospitals with non-compliance being controlled by personal visits to 
the ward or by telephone contact with the non-complying prescriber. Ninety 
percent of respondents tliought policies beneficial but offered no evidence to 
substantiate this belief.
The overall conclusion of the BSAC working party was that although control 
measures for antibiotic usage are conmionplace their performance could be 
improved upon greatly. Education of prescribers was felt to be one way in which 
this may be achieved. As early as 1973, Kimin et al, discussed that this type of 
education needed to be continuous to have any lasting effect. The frndmgs of a 
prospective Drug Utilisation Evaluation (DUE) of ceftazidime supports this call 
(Okpara et al, 1994), as has the reports of others (Coleman et al, 1991). 
Prescribing practice was successfully altered in the Okpara et al (1994) study 
provided a pharmacist continually intercepted and acted upon those prescriptions 
deemed to be inappropriate. In a follow up study some six months later when 
continuous intervention had stopped, prescribing practice was demonstrated to 
have retmned to its previous poor standard, this was thought to be due to the 
constant tmiiover of staff. A study which demonstrated that a restrictive antibiotic 
policy can be used without a detrimental effect upon wound infection rates was 
carried out by Scher et al (1990). These workers reported a modest annual saving 
of approximately $32,000 associated with the introduction of a restrictive 
antibiotic prophylaxis policy, and although womid infection rates were reduced for 
both clean (Class I) and clean-contaminated (Class II) to 1.8% (24/1,298) from 2% 
(12/605) and 2.1% (17/801) ftom 4.9% (16/327) respectively, this did not reach 
statistical significance. The savings made related to reduced drug and 
administration costs, no accomit was made of the cost of the extra staff time 
involved in wound sm veillance procedures.
Multidisciplinary input has already been demonstrated to improve the quality of 
prescribing (Abramowitz, 1984, Fletcher et al, 1986, Briceland et al, 1988). All 
tluee of these studies combined the varying expertise of pharmacists and
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physicians to successfully modify prescribing behaviour. A coimnon theme 
between the three studies was the circulation of physician information sheets to 
prescribers composed by infectious disease specialists targeting specific 
antimicrobials, followed by personalised contact with a clinical pharmacist at 
ward level to review the content of the information sheets when prescribing did 
not meet information sheet criteria. Fletcher et al (1986) reported a net decrease in 
drug expenditiues of $161,396 and although a 0.5 full-time equivalent pharmacist 
was required for the program a return on investment for the service was greater 
than 10 to 1. Similaiiy, Briceland et al, 1988, reported projected annual drug cost 
savings of $33,000 with an additional saving of $7,000 in staff time.
Another recommendation of the BSAC report (1994) was Hf adequate control o f 
antibiotics is to be achieved, the microbiologist who is aware o f local sensitivity 
patterns, must work closely with the pharmacist who has Imowledge o f the day-to- 
day antibiotic prescribing patterns^ Tliis recommendation is almost identical to 
one made by Stobberingh et al (1993) which followed a similai* study carried out 
in the Netherlands. A disturbing finding of the Dutch study was that almost 20% 
of hospitals surveyed did not intend to set up antibiotic guidelines at all 
(Stobberingh et al, 1993).
Staff time has an associated cost, efficient use of staff time dictates that the gains 
of using this time should be maximised. Savings made by a control measure 
should be weighted by all the costs of implementing the measure which includes 
staff time. Furthermore a sensitivity analysis of the implementation costs should 
be carried out to determine the point at which it is no longer cost-effective to use a 
pai'ticular contiol measure. Most reports tend to concentrate on the savings 
achieved without actually considering implementation costs although some 
accounts do allude to this. Okpara et al (1994) in a DUE of ceftazidime with 
clinical pharmacist intervention reported a cost avoidance of over $9,500/month. 
The analysis of savings was based on the acquisition costs of ceftazidime and the 
acquisition costs of antimicrobial agents substituted for ceftazidime. Hidden costs 
of agents requiring monitoring, consmnables and staff time were not added in so 
this could well have changed the cost avoidance figme (Elnenkianz, 1989, 
Plumridge, 1990,). The authors still felt however, tliat the results of this study
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justified the cost of a full time clinical phaimacist to fimction as a quality 
assui'ance coordinator, the annual salary for this post was not given but it is likely 
that the salary is less than the annual savings of $114,000 (12 x $9,500).
Few studies have included the costs of implementing control measures but those 
that have consider implementation to be cost-effective. In Australia a connnercial 
advertising agency was used to change the prescribing of iv amoxycillin in 
primary pnemnonia to iv benzylpenicillin. A cour se of iv amoxycillin averaged 37 
Australian dollars compared with 7.30 Australian dollars for a course of iv 
benzylpenicillin. After the campaign 91% of patients were receiving 
benzylpenicillin as compared with 44% of patients before the campaign. However, 
the proportion had dropped to 68% 18 months after completion of the campaign. 
This figiue of 68% was still significantly higher than the proportion of patients 
who were treated with benzylpenicillin before tlie advertising campaign. The 
campaign costs of 10,000 Australian dollars were recouped within 12 months by 
savings on drug costs (Harvey et al 1986). One American hospital (Coleman et al
1991) foimd that limiting formularies, restricting the usage of new expensive 
antibiotics and promoting the use of selected antibiotics achieved only a limited 
success in controlling the costs of par enteral antibiotics. This Hospital introduced 
a scheme whereby the infectious disease service (IDS) team reviewed the need for 
restricted antibiotics prior to prescription, introduced broad based dosage 
restrictions, prospectively and continuously reviewed antibiotic usage with 
authority to discontinue selected antibiotics upon receipt of culture results, or on 
clinical evaluation of the patient. Fine detail costs are laboiu intensive to 
determine, so these workers used the crude measuie of average antibiotic cost per 
admission in order to assess the financial reductions achieved with the additional 
personal intervention teclmiques. The average monthly antibiotic costs diuing the 
26 month post policy period were $7,600 less than duiing the 16 month pre policy 
period resulting in an average yearly drug cost reduction of $91,200. A pharmacist 
was added as a permanent member of the IDS team by the medical centers 
administration after the realisation that the 23% reduction in drug acquisition costs 
diuing the first 4 months after policy initiation was twice the salary expense for 
the position.
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The costs of drug education can be justified by the savings that result fi'om 
improved drug use but this education must be of a continuous nature as shown by 
the Coleman study (1991), to maintain the change in prescribing habits effected. 
Removal of a restriction policy for antimicrobials has been shown by Himmelberg 
et al (1991) Xo result in an increase in the inappropriate use of these agents and 
total expenditure to increase by 103%.
4.7 Summary
The reasons why antimicrobials in the secondary care setting should be subject to 
economic evaluation are:-
9 Antibiotics ar e the lar gest smgle group of drugs used in hospitals in the UK.
® Inappropriate antibiotic usage centres around:
(i) increased antibiotic resistance with consequent loss of efficacy.
(ii) umiecessary exposure to toxic side-effects.
(iii) financial waste.
® Antibiotic cost-containment, within the confines of the overall drug budget can 
be acliieved by formularies and supplemental measur*es.
® Antibiotic cost-contaimnent measures used to date may be at the expense of 
patient outcome and may transfer costs elsewhere.
• Opportmiities exist to improve both resomce utilisation and outcome.
The economics of antibiotic utilisation is a complex interplay of many factors 
which include why the antibiotic is being used, which agent is selected, how it is 
being administered, what adverse effects the agent causes or can cause and what 
the final outcome of its use is. An important issue which deserves much closer 
scrutiny is the economic impact of bacterial resistance.
Many institutions, to varying degrees, have made an attempt to control 
antimicrobial use, primaiily in the form of formularies and policies. However, all 
too frequently, drug selection for formulary inclusion has tended to focus on 
acquisition cost alone, resulting in a cost-contaimnent exercise for the pharmacy 
budget. There have been reports of hidden costs, such as administration.
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monitoring and toxicity being taken into account dining the decision-making 
process but the wider issue of opportimity cost does not seem to have been 
weighted with any importance. For example, decreased frequency of 
administration of antibiotics (which by definition preselects certain antibiotics) on 
the neonatal unit wliich reported bacterial resistance problems due to work 
overload (Isaacs et al, 1988) may well have avoided the problem by allowing 
enough time for standaid infection control procedures to be observed.
Broad variation in cuiTent clinical practice is widely recognised (Davey et al,
1992). One reason put forwai’d for this is the weakness of the scientific evidence 
underlying medical practice, it has been estimated that only 15% of medical 
interventions are supported by solid scientific evidence (Smith, 1991). It is not 
unreasonable, therefore, to state that prevailing treatments as well as new 
ti'eatments, should be evaluated for cost-effectiveness. Without some form of 
structured approach in the selection and use of antibiotics, the financial penalties 
will, and have been shown to be exceedingly high.
Opportimities to improve both resouice utilisation and outcome have been 
identified. Evidence exists, for example, that the use of oral antibiotics in 
preference to their iv administration could be increased without compromising 
clinical outcome. In the UK the possibility that NIPIV caie may prove a cost- 
effective option for treatment of serious infection needs to be evaluated within the 
context of the NHS financing structui e.
The amount of pharmacoeconomic data on antibiotics generated thi'ough research 
is increasing but most is just drug cost containment. An issue which needs 
addressing because it has a direct impact on any antibiotic pharmacoeconomic 
evaluation is what form of outcome measurement should be used in an analysis as 
this can radically alter the conclusion drawn. A fiill discussion of the issues 
smToimding outcome measiuement and tlie impact it has on the 
pharmacoeconomic evaluation of antimicrobial use is given in the following 
chapter.
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Chapter 5
5. The economic issues of antibiotic use: part II - Outcome
Measurement
Without some form of systematic quantification the consequences and usefulness 
of an action camiot be assessed. Knowledge of the effects of caie on the health 
status of a patient therefore demands some form of outcome measure i.e. a health 
status index, that quantifies the impact of the treatment or intervention. Outcome 
measm*ement is inti'insic to economic appraisal of healthcaie prograimiies but is in 
itself a contentious topic as will be discussed fm'ther in this chapter.
One of the major issues with the economic literatme on antibiotic evaluation has 
been the focus on cost containment practices and to a much smaller extent, 
hospital length of stay. Assessment of antimicrobial treatment outcome, to date, 
has tended to focus on eradication of bacteria and the duration of treatment 
required to obtain eradication. Beyond this assessment little is known of what 
happens to a patient once dischar ged from the hospital. This deficit of Imowledge 
has been shown in other areas of medical care to lead to misjudgement of 
outcome. Lack of follow-up of surgical patients after discharge results in a 
substantial miderestimation of wound infection rate (Brown et al, 1987, 
Esuvaranathan et al, 1992, Bailey et al, 1992, Lynch et al, 1992). It is reasonable 
to assmne therefore that assessment of antibiotic treatment failure rate in hospital 
alone may represent the tip of an iceberg. Consequently, there is an mgent need to 
determine an adequate duration of post-discharge follow-up for patients who have 
received antimicrobial therapy so that tliis can be integrated into the overall 
evaluation of outcome. The practicalities of how this can be achieved also needs to 
be determined. An antibiotic economic appraisal which does not include some 
form of follow-up must be considered incomplete.
In the US measmes of outcome have been added to the standar ds set by the 
regulatory bodies that health care institutions must adhere to so that they can gain 
accreditation (O'Leary, 1987). However, because assessment of outcome is far* 
from simple a US initiative was lamiched to develop these measmes, by 1990 over 
$30 million was allocated for reseai'ch into this area (Epstein, 1990). The
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assumption was that analysis of routine observational data held in computer banks 
(Medicare, insmance companies, hospitals) could give information on what the 
best treatments were. By 1994, the conclusion reached was that this assumption 
was wi'ong, it was not possible to identify outcome measmes in this mamier that 
would assist in valuing different treatments and the initiative reseai'ch teams were 
disbanded (Sheldon, 1994).
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So what is needed from a quality outcome measure?
Basically, a quality outcome measme needs to be meaningful, relevant and fulfil 
the criteria given in table 5.1.
Table 5.1 Quality Determinants for Outcome Measures
Reliable: reproducible and consistent
Valid: accur ately measiues what it is intended to
measiue
Responsive: able to detect a clinically important
change
The varying characteristics of outcome measur ement and types of measure which 
have been used in antibiotic evaluation are now discussed.
5.1 Direct ys surrogate measures
An outcome measure can be classified as direct or surrogate. A direct outcome 
measure is one which measures an endpoint shown to have an effect on health 
related quality of life such as morbidity, disability or mortality. A surrogate 
outcome measure tends to monitor changes in physiological measines and 
assumes this affects health related quality of life, for example, laboratory values or 
functional tests (Editorial, 1990), however, this assmiiption may well be 
eiToneous. Direct measures have a greater validity than surrogate measures. In a 
review of proxy measures of artluitis Fries (1983) highlighted how poor surrogate 
measmes of actual disease status could be. Two frequently used siuTogate 
measures for progression of rheumatoid artluitis ar e erytluocyte sedimentation rate 
and DNA latex fixation titer yet neither correlate particularly well with ultimate 
outcome. In addition to tliis lack of validity and responsiveness. Fries (1983) 
showed these measures to be poorly reproducible. Conversely, Fries (1983) 
showed other smrogate measures (patient and physician global assessment) to 
have good con'elation to ultimate outcome and to be sensitive to change, 
reproducibility was not assessed so it is not possible to determine whether these
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aie reliable measures. Before a surrogate measiue is employed it is important to 
assess the quality of the measure for reliability, validity and responsiveness 
otherwise the relevance of the measur e chosen may well be nil.
To a large extent tlie type of measiue used is a function of the time available for 
assessment. Therapeutic outcome of antimicrobial therapy is soon laiown i.e. bad 
outcomes happen quite quickly, because of this it is possible to readily employ 
direct measures. Those used to date have traditionally been of a physiological and 
unidimensional nature (Coleman et al, 1991, O'Hariley et al, 1989, Siiwangool et 
al, 1991, Bates et al, 1995). Although therapeutic outcome is soon known it is 
important to determine when the episode is over as this can vary dependent on the 
tr eatment mider evaluation. For example, as discussed eaiiier, lack of follow-up of 
surgical patients into the community results in an underestimation of wound 
mfection rate.
Despite the amenability of antimicrobial evaluation to direct outcome 
measurement, assessment of therapy has largely focused on process outcome i.e. 
how the antibiotics are being used, for example, adherence of prescribing to 
antibiotic policies, frequency and timing of therapeutic monitoring of potentially 
toxic agents etc. Process outcome is important in its own right to ensure tliat 
antimicrobials are being correctly employed, but, process outcome results have 
frequently been extrapolated as a surrogate marker for patient outcome. This 
extrapolation may well be erroneous and lead to cost-containment practices which 
do not maximise beneficial patient outcome (Noel et al, 1978, Phelps et al, 1978, 
Hampson et al, 1988, Wyatt et al, 1992, Horn et al, 1992, Morgan et al, 1992). 
Table 5.2 lists examples of direct and surrogate outcome measures that have been 
used in antimicrobial treatment evaluation.
121
Table 5.2 Outcome measures used in antimicrobial evaluation
Direct Surrogate
Mortality Policy prescribing adherence
Morbidity Therapeutic drug monitoring
Timing of dr ug administration
ReciuTence of infection
Reduced complications
Side effects of therapy
Pathogen presence
5.2 Objective ys subjective measures
Outcome measures can also be classified as objective or subjective. Objectivity 
implies that a quantification process is reproducible and consistent by the natme of 
its impartiality, a patient is not seen as an individual but as part of an aggregated 
norm. Objective outcome measures used in health care assessment are intended to 
measure impairment i.e. abnormal anatomical, physiological or psychological 
structure or function e.g. FEVl, ESR etc. The measure of impairment is then 
intended to be used to indicate the level of disability or handicap brought to total 
body function by this impairment. Objective measures have the least meaning to 
patients. Conversely, subjective measines are not impartial in that they are a 
personal rating by an individual or group of individuals. An example of a 
subjective measure would be the amount of pain said to be experienced by a 
patient with a given clinical condition, obviously this will vary depending on the 
pain tlueshold of each individual. Subjective measiues are of most meaning to 
patients in that they can mdicate at a personal level the degree of handicap or 
disability brought to them by their impairment of normal body fimction.
Altliough there can be inherent problems with subjective measm*es in terms of 
reproducibility, they can provide an additional perspective which camiot be gained 
by an objective measure alone. Objective and subjective measiues are frequently 
used in the therapeutic assessment of patients witli infection, for example
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temperature measurement coupled to clinical impression is often used to ascertain 
whether an antibiotic regimen is effectively treating the illness. A published 
example of an objective measure being combined with patient subjective 
impression is a study by Hodson et al (1987). These authors compared the efficacy 
of conventional intravenous (iv) antibiotic therapy with oral ciprofloxacin in the 
treatment of acute exacerbations of pseudomonal chest infection in cystic fibrosis 
patients. Both groups of patients i.e. those treated intravenously and those treated 
orally showed equivalent improvement, however, the study also included a patient 
preference component in that the patients who received oral ciprofloxacin were 
asked whether they preferred oral treatment to iv treatment if they had received iv 
treatment in the past. Of the 20 patients, 17 said they preferred oral treatment to 
previous iv therapy (1 had no preference, 1 had not had previously received iv 
treatment, and 1 patient did not answer). It can be seen therefore that, all other 
things being equal, incorporation of patient preference data with efficacy outcome 
data in this instance would weight a decision to use oral ciprofloxacin rather than 
conventional iv treatment i.e. use of a subjective measure brought out something 
which otherwise would not have been observed with objective measures alone. To 
quote Fries (1983) 'outcome must reflect the values o f patients'.
Objective and subjective measures are suited to different research and practical 
applications and as such the purpose of an investigation has to be defined before 
the right outcome measure can be chosen, for example, an objective measure 
would be more suited to evaluating a treatment outcome for a given population 
whereas a subjective measure may be more helpful in helping set priorities for 
treatment.
5.3 Continuous ys discontinuous measures
Outcome measiues can also be categorised into continuous or discontinuous. A 
continuous or longitudinal outcome measure is sensitive to gradational changes 
and can be used, for example, to give an indication of severity of disease. A 
discontinuous measiue is of the yes/no type, for example, infection/no infection, it 
does not allow for any gradation. Traditional outcome measiues used in the 
assessment of antibiotic tr eatment have tended to be of a discontinuous natur e, for
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example, mortality, appropriate/inappropriate prescribing, success/failure of 
therapy. Although a discontinuous measure may adequately assess some aspects 
of antimicrobial treatment it may be too crude to adequately evaluate others. 
Mortality can be used to determine whether an agent prevents death and some 
measur e of cost-effectiveness can be interpreted from this but it is not as sensitive 
as the continuing measure, cost per life year saved (LYS), i.e. knowledge of the 
length of time that a par ticular" drug extends life allows a more sensitive evaluation 
of the cost-effectiveness of alternative agents. It would depend on what is being 
measured as to which measiue is the most appropriate i.e. although the cost per 
death prevented is quite crude it is a reasonable indicator to use for different 
ti'eatments within the same population, however it is not as good as cost per LYS 
when examining different treatments in different populations e.g. comparison of 
ti'eatments between 20 year" olds and 80 year" olds. The limitations of this measiue 
(LYS) is that no consideration is given to the quality of life within the extended 
life years saved. The sequential extension to the life year saved is the quality 
adjusted life year (QALY), it has to be noted though that methodological problems 
still exist with its application. Quality adjusted life expectancy is life expectancy 
combined with a measure of disability and distress. The changes in quality of life 
are calculated from the concept 'utility'. Utility is a value judgement which can 
vary widely depending on the individuals perspective. Even when a group of 
individuals who would be expected to have a similar perspective, for example, 
when a cohort of physicians trained in the same speciality, are canvassed on the 
utility they would assign to tire quality of life in a specific health state, wide 
variations are elicited. A study which highlights this problem was car'ried out by 
Weeks et al (1991). This study was examining the cost effectiveness of 
prophylactic intravenous immune globulin in chronic lymphocytic leulcaemia. The 
workers used decision analysis teclmiques to determine whether prophylactic 
intravenous inumme globulin was likely to result in an overall clinical benefit to 
patients receiving this treatment. Health outcomes were measured in terms of 
gains in quality-adjusted life expectancy, with 'utility' weights used to adjust life 
expectancy downward for decreases in the quality of life associated with a given 
clinical state. Utility estimates, used as weights in the calculation of quality
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adjusted life expectancy, were obtained from a sample of 10 practising oncologists 
experienced in the caie of patients with chronic lymphocytic leulcaemia. The 
estimates were based on the physicians assessments of the quality of life in 
various health states experienced by patients and were derived using tire reference 
gamble approach. In the reference gamble approach the respondent is asked to 
choose between life in a given clinical state and a gamble between death (assigned 
a value of 0) and perfect health (assigned a value of 1). The reference gamble 
elicits a measure of the respondent's assessment of the relative quality of life m 
that state, ranging from 0 to 1. The results from the 10 oncologists are shown in 
table 5.3.
Table 5.3 Utility estimates of 10 expert physicians of the quality of life in 
a given clinical state
Clinical state Low High Mean
CLL without infection 0.50 (1999 0.87
CLL with a trivial infection 0.50 0.999 0.86
CLL with a moderate infection 0.50 0.99 0.81
CLL with a major mfection 0.20 0.90 0.46
CLL = Clu'onic Lymphocytic Leukaemia
It can be seen fr om the range of values in the table just how much variation can be 
obtained even from experts within the same field and averaging the values can be 
almost meaningless as a wide variation can be hidden. This wide variation in 
clinical assessment of the same data set has been demonstrated by others (Chaput 
de Saintonge, 1988).
A moot point about the assigning of utility is who should be making the 
judgement. Given that outcome should be reflecting the values of patients and of 
society, using third parties, albeit experts within medical care, can lead to a 
situation whereby the values of patients are not adequately weighted. A study 
which highlights this was carried out by Chaput de Saintonge (1988), 48 
rheumatologists were asked to weight 10 conunonly measmed clinical variables 
and to then judge the change in disease activity for 30 patients using these 
variables. Their judgement policies were tlien modelled. It was found that
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although the expressed weighting given to patients global assessment was ranlced 
third, it only achieved a ranldng of 9 in the regression model, i.e. the weight the 
doctors believed they attached to this variable was not followed tlirough in their 
actions.
The purpose of an outcome measure such as the QALY is that comparisons can be 
made between interventions that may be widely dissimilar, yet the very fact that 
consensus is difficult to obtain withm a speciality questions the validity of using 
this for comparison between specialities at the present time. Even if the ideal 
situation existed whereby patients assigned utility values, consideration would 
have to be given to the effect that socio-economic, cultmal and etlmic background 
may cause on the assigning of values. Consensus problems in all clinical areas are 
well recognised (Smith, 1991), in a recent editorial (Mckee et al, 1994) it was 
stated that 'There is a strong case for clinicians to come together, locally or 
nationally, to develop and disseminate agreed definitions o f the most important 
diagnoses, procedures, and complications so that, when information is produced, 
everyone speaks the same language'. This is an apparently simple statement but it 
is not just the clinicians who need to come together it is the patients and other 
health care professionals also, such that the 'language' spoken includes everything 
that is important.
At present, the QALY does not appear to be an outcome measure that can be 
routinely applied to antimicrobial treatment. However, academic exercises using 
the QALY as an indicator of cost-effectiveness in antimicrobial treatment have 
been carried out. Tsevat et al (1989) used decision analysis and probability 
modelling to perform an economic analysis to evaluate whether patients with 
artificial joints should talce prophylaxis before dental procediues. Using sensitivity 
analyses to vary the assumptions within the overall analysis it was calculated that 
the marginal cost-effectiveness of erytlu'omycin prophylaxis compared to no 
prophylaxis ranged between $1,300 (probability of infection 25/100,000) and 
$393,600 (probability of infection 1/100,000) per QALY. The impact the utilities 
assigned have on the cost per resulting QALY can be dealt with by performing a 
sensitivity analysis, what does cause a problem is lack of scientific evidence for 
clinical assumptions. Central to the analysis by Tsevat et al (1989) was the
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assumption that a transient bacteraemia diuing a routine dental procedure can 
cause an infection of a prosthetic joint. At the moment no evidence exists one way 
or another as to whether a transient bacteraemia during a routine dental procedure 
can cause an infection of a prosthetic joint.
Two quite different studies which highlight the additional value of continuous 
outcome measiuement over discontinuous measinement in antibiotic treatment 
were carried out by Davey et al (1988) and Dimagan et al (1991). Davey et al 
(1988) evaluated antibiotic prophylaxis in both vaginal and abdominal 
hysterectomy. Using the traditional outcome measure of presence or absence of 
infection it was concluded that the prophylaxis was more effective in vaginal 
hysterectomy as pelvic infection was reduced from 20% to 2% whereas wound or 
pelvic infection after abdominal hysterectomy was only reduced from 18% to 
10%. However when an economic analysis was carried out using the smn cost of 
treatment and prophylaxis as the outcome measure in addition to a patient 
recovery score, the opposite conclusion was supported. Antibiotic prophylaxis for 
vaginal hysterectomy increased the overall antibiotic bill with minimal 
symptomatic benefit to the patients or conununity health services, conversely 
antibiotic prophylaxis for abdominal hysterectomy saved hospital and community 
resources, and resulted in measmable benefits to tlie patients. Two important 
points are illustrated in this study, firstly there is no real basis for equating pelvic 
infections after vaginal hysterectomy with wound or pelvic infections after 
abdominal hysterectomy. The definition of pelvic infection after vaginal 
hysterectomy included patients who had a piuulent vaginal discharge, but this 
event had no measurable effect on either their treatment or speed of recovery. In 
contrast, wound or pelvic infection after abdominal hysterectomy were associated 
with increased prescribing of antibiotics in hospital and after discharge from 
hospital, as well as measurably slower speed of recovery. The second point is that 
the use of continuous variables (costs of antibiotic treatment and recovery scores) 
are preferable for measmement of outcome rather than the discontinuous variable 
(infection/no infection) as this gives an indication of gradation of severity of 
infection.
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Another example of a discontinuous outcome measur e routinely used in antibiotic 
prescribing is that of 'appropriateness of prescribing'. Several papers (Achong et 
al, 1977, Jogerst et al, 1981, Swmdell et al, 1983, Jewesson et al, 1985, 
Suwangool et al, 1991) have reported results for full courses of treatment which 
have been graded as either appropriate or inappropriate, yet it is virtually 
impossible to validly grade an individual's overall treatment in this way (Davey et 
al, 1995). The argument against this 'yes/no' approach is that the amoimt of 
information available at any one time which assists in the rational choice of an 
antibiotic can change during the treatment period. An antibiotic prescribed on 
initial clinical presentation may no longer be considered to be appropriate when 
bacteriology results become Icnown. The appropriate/inappropriate approach does 
not allow for any grading "within the treatment period. Dunagan et al (1991) 
overcame this problem by grading each day of treatment as appropriate or 
inappropriate which reflected the informational soiu'ces available, as such a 
profile of the appropriateness of each antibiotic coui’se was established.
5.4 Unidimensional ys Multidimensional
An outcome measm*e can be imidimensional i.e. an isolated endpoint, or 
multidimensional i.e. composite. A composite measure provides a wider 
perspective as more than one endpoint is being considered. A study of competing 
astlmia treatments by Sculpher & Buxton (1993) depicts how using a composite 
measure, i.e. an episode free day (BFD), is more sensitive to changes in patients' 
health status than is the conventional imidimensional clinical parameter, FEVl, 
which is routinely used to assess the effectiveness of asthma therapies. The 
competing treatments were a short acting agent which needed to be administered 
four" times daily versus a long acting agent wliich only required to be administered 
twice daily. The composite measure was constructed from individual patients 
daily record of personal events including occiurence of any asthma attack, sleep 
disturbance, need for rescue therapy, adverse events and peak expiry flow rate 
data. An EFD was any day the patient was not subject to any of these events. Total 
daily cost was taken as mcluding the drug acquisition costs, rescue medication and 
the costs of treating adverse events. All costs were expressed in 1991 Canadian
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dollars ($Can). It was calculated that the incremental cost-effectiveness ratio was 
$Can7.29 per additional EFD for the longer acting agent. A weakness of this 
composite measure is the lack of sensitivity within the variables comprising the 
measiue because of the lack of gradational changes i.e. 1 asthma episode or 1 
adverse event diuing a given day results in the loss of 1 EFD regardless of the 
severity of the individual event. However, the measure still provides a valuable 
descriptive pictiue which is sensitive to changes in patients' health status that are 
not detected by the clinical single point measurement of FEVl.
Composite measures have also been shown to be of more use than unidimensional 
measures in the evaluation of antibiotic therapy (Davey et al 1988). Davey et al 
(1988) compared conventional outcome measurement with less traditional 
measiuernents in the evaluation of prophylaxis for vaginal and abdominal 
hysterectomy. These workers combined a patient perspective recovery score with 
the costs of prophylaxis and treatment of infection that occurred despite 
prophylaxis. In doing so it was demonstrated that prophylaxis is more cost- 
effective for abdominal hysterectomy than for vaginal hysterectomy. These 
findings are diametrically opposed to findings which use the conventional 
outcome measiue of reduction in infection rate alone.
Table 5.4 lists a few examples of imidimensional and composite outcome 
measiues.
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Table 5.4 Unidimensional & Multidimensional Outcome Measures
Unidimensional
Mortality
Recuirence of infection 
Side effects of therapy 
Patient mobility 
Symptomatic relief
Composite
Episode free day 
Quality adjusted life 
expectancy 
Repeat consultations
5.5 Specific measures vs generic measures
Outcome measures can also be described as specific or generic. A disease or 
treatment specific outcome measme is literally an outcome measure which is 
specific to one disease or treatment i.e. it has been designed to detect changes in 
that particular disease activity. A disease specific outcome measiue can only 
usefully be used to compare the outcome of treatments or interventions directed at 
that one disease or treatment unless the dimensions examined within the measure 
are of the same relevance to other diseases/treatments. The outcome measure 
instrument emphasises particular" parameters of significance to the disease under 
study, for example, the Arthritis Impact Measurement Scale (AIMS) or the Living 
with Astluna Questioruiaire (Hyland et al, 1991). A generic outcome measiue by 
comparison is designed to broadly apply across types and severities of diseases, 
across different medical interventions and to be applicable to a wide variety of 
patients or populations. It is intended to be used to compare treatments or 
interventions used in a wide spectrum of diseases and describes the impact of the 
treatment/intervention on the patient rather than provide a clinical assessment of 
disease status. These instruments can also be biased though depending on how 
they are constructed and which aspects of health assessment they explore.
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Examples of generic outcome instrmnents include the Nottingham Health Profile 
(NHP) and the Medical Outcomes Study Short Form (SF-36) (Ware et al, 1992). 
Although disease specific measures are initially designed for comparison of 
outcome within the disease they are addressing, they are considered to be more 
sensitive to changes in outcome for particular patient populations than are generic 
measures (Hyland, 1992). The reason for this is that general instruments may 
include items irrelevant to a specific disease and omit others that are relevant. For 
example, the SF36 includes items that measiue pam, which is not relevant to 
asthma, but does not include items that measure sleep, which is relevant to 
asthma. There is an issue of bias in both specific and generic measiues, ciurently 
the most that can probably be gathered from these instrmnents is that one persons 
quality of life is better than another persons. It will only be if bias can be 
eradicated fr om these instruments that the degree of how much better can be 
determined. The issue of bias however, will almost certainly never be resolved 
because of the incoiporation of value judgements. At the present time it would 
appear that both types of measme should be used in tandem so that relevant 
comparative data are available from both perspectives (Hyland, 1994).
The development of outcome measme instruments be they specific or generic, 
have lar gely focused and been devised around chronic long term illnesses. As such 
they are constructed to examine changes in health states over prolonged periods of 
time. Particularly in the area of disability, these measmes are relatively insensitive 
to short term change, but effectively measiue long term trends. The necessity for 
long term measmes is obvious since tliere are many clinical examples of short 
term tactics that are deleterious over a prolonged period. Fries (1983) used the 
indiscriminate use of corticosteroids in rhemnatoid artluitis (RA) as a prime 
example of this. In the short term, daily prednisone in RA is clinically and 
statistically superior to placebo in reducing synovitis, decreasing morning 
stiffness, increasing walking speed, decreasing the nmnber of tender joints and 
improving grip strength. However, in the long term, daily prednisone, as 
compared with non-steroid treatment, leads to increased mortality, increased rate 
of development of disability, increased symptoms due to long term side-effects, 
more hospitalisation, and increased direct and indirect costs of disease (Fries,
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1983). This example frirther illustrates how the use of short term siUTOgate 
measmes ar e not necessarily valid measures of final outcome.
The relevance and validity of existing outcome measure instrimients to acute 
conditions such as infectious diseases which require short term intervention has 
not been tested. This is a formidable area of research which would need to be 
cariied out before application of these instruments to acute conditions such as 
infectious diseases could be reliably employed.
5.6 Other aspects of outcome measurement
Having considered the various char acteristics that an outcome measur e can display 
there is another aspect that can alter the validity of a measure i.e. the setting in 
which the outcome is measiued. The environment in which the measur e is applied 
can artificially weight the results. For example, US Hospitals have learned that 
adequate assessment of the outcomes of inpatient car e also involves consideration 
of what happens to patients after they have left the hospital (Vladeck, 1988). A 
classic example of this is wound infection rate after surgery. It has been shown 
that failure to pursue surgical patients after discharge results in a substantial 
imderestimation of true womid infection rate. Law et al (1990) demonstrated the 
importance of commimity surveillance of postoperative womids. These authors 
found that of all patients whose woimds became infected, 41% of cases were 
diagnosed in hospital and 59% were diagnosed in the community. Others have 
reported similar- findings. Lynch et al (1992) in a trial of preoperative whole body 
disinfection in postoperative wound infection prophylaxis foimd that 61% of 
wound infections were diagnosed after hospital discharge. Esuvaranathan et al 
(1992) and Brown et al (1987) also foimd surgical wound infection rate to be 
double when patients were followed into the community. Bailey et al (1992) not 
only found gross underestimation of womid infections following hernia surgery 
when only hospital documented infections were used to determine wound 
infection rate but also the woimd complication rate was grossly luiderestimated. 
These authors found the wound infection rate recorded in hospital notes to be 3% 
compared with 9% when additional information was obtained from community 
sm'veillance. Womid complications were detected in 28% of patients by
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connminity surveillance compared with a complication rate of 7% in the case 
records for the same patients. Hardwick et al (1992) in the assessment of outcome 
data accuracy described similar findings for woimd infections post emergency 
apperidicectomy. Davey et al (1988) in a cost-benefrt analysis of antibiotic 
prophylaxis for abdominal and vaginal hysterectomy also found infection rate to 
be greater when commimity sui'veillance data were included.
5.7 Summary
In slumnary 'outcome' is a general term consisting of several separ ate dimensions. 
Outcome should collectively include all those variables, patient values included, 
which have an impact on the disease imder study, but as discussed, this is a very 
difficult area. It is an area where assmnptions caiuiot be made. The use of 
surrogate measures can only be considered valid where they have been 
demonstr ated to be a marker for outcome.
Wliat has been used m the evaluation of antibiotic treatment is a wide var iety of 
narrow spectrimi measures with a large emphasis on process outcome i.e. 
examination of the standard of delivery of care. Measures used have tended to 
evaluate only one dimension of outcome yet it is possible to have dimensions 
within one episode care that go in opposite directions, for example, it is possible 
to effect a clinical cure without eradicating bacteria. The level of complexity of 
outcome measiue used in an evaluation and the enviromnent in which it is made 
will radically alter the inferences and conclusions that can be drawn i.e. composite 
outcome indices and continuous variable indices will provide greater information 
than the traditional unidimensional measmes. What is ideally required is a single 
measiuement for overall outcome incorporating quality of life, which is 
responsive to how effective a treatment is i.e. a multidimensional global outcome 
measiue. For example, construction of a 'Pneumonia Outcome Scale' should be 
able to differentiate between the myriad of treatments available for this condition. 
Dimensions within the scale could include items such as resolution of primary 
infection, recurrent infection, occiurence of superinfection, otlier adverse 
outcomes etc. Each of these items are important but then the problem exists of 
how could they be weighted. Each individual piece of information would need to
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be assessed and then pulled together into 1 final measme so that comparison 
between treatments could be made. Much resear ch remains to be carried out in this 
area but what can we do at the present time? As demonstrated by Davey et al 
(1988) the use of multidimensional measm*es including monetary consimiption, 
although not aggregated into 1 final index, promises to be of greater use than 
traditional unidimensional measures, in determining the cost-effective allocation 
of resoiu'ces.
In the next two chapters, two aspects of antimicrobial treatment ar e evaluated in 
terms of multidimensional outcome, both traditional and continuous variable 
indices ar e used. The first study focuses on the use of the aminoglycosides but 
also examines the general antibiotic management of Gram-negative bacteraemia. 
This study uses observational data which has been collected in a systematic 
manner. It assesses appropriateness of practice and identifies outcome measures 
indicative of adverse outcome. Areas of resoiuce wastage are identified and 
clinical practice changes are suggested which may lead to more effective resource 
allocation. The second study focuses on the development and feasability of a 
novel (for the UK) health care delivery system for antibiotics i.e. non-inpatient 
intravenous car e. Costs and preferences for car e in a different setting were 
examined.
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Chapter 6
6. Drug utilisation study as a vehicle for economic analysis; What
are the opportunity costs? - Aminoglycoside/Bacteraemia study
6.1. Introduction - Aminoglycoside usage and Gram-negative
bacteraemia
Despite 40 years of clinical use and the advent of phaimacokinetic monitoring, 
major problems still exist with the prescribing of the aminoglycosides. These 
problems range from the intrinsic oto- and neplirotoxicity of these agents tlirough 
to the failure of therapy due to the fear- of inducing dose-dependent toxicity. Even 
so, aminoglycosides continue to be used on a daily basis for those patients either 
suspected or proven to have a Gram-negative infection because they are 
incorrectly perceived as effective, low treatment cost agents.
Gram-negative sepsis continues to have a high mortality rate. Survival in Gram- 
negative septicaemia is repoited to depend upon the extent of imderiying disease, 
neutrophil count and eai'ly use of appropriate antibiotics (Kreger et al, 1980). 
Using the aminoglycosides in the currently recommended dosage regimens leads 
to gross underdosmg (Zaske et al., 1980, Siumner et al., 1983, Li et al., 1989). 
Given that approximately half of all fatalities occm- during the first 24 horns it is 
not surprising that luiderdosing is associated with treatment failiue (Moore et al., 
1987). Therapeutic drug monitoring (TDM) is ostensibly used to maximise 
therapeutic aminoglycoside serum levels and to minimise toxic serum levels yet 
optimisation of levels is frequently elusive. Evidence in support of this statement 
are the results of a prospective audit of drug assay services and therapeutic drug 
use in a general hospital by Guest et al (1980). These workers found that only 
10% of gentamicin assays were within therapeutic range. Based on these results 
therapeutic monitoring services were introduced to educate and advise on the 
rational and appropriate prescribing of the aminoglycosides (Eckert et al, 1991). 
Despite these measmes an audit of aminoglycoside usage 9 years later did not find 
improved usage and that over 10% of measmed peak concentrations for 179 
patient courses were below 4mg/l (Li et al, 1989).
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Many studies have been canied out to determine the most effective method for 
influencing the clinical practice of drug prescribing (Wilson et al 1991, Evans et 
al 1986, Rubinstein et al, 1988, Coleman et al 1991, McDonald, 1976, Sutters, 
1989, Landgren et al 1988, Damienhoffer et al 1989, Mamiing et al, 1986, Riley et 
al, 1991, Friis et al, 1991, Eckert et al, 1991). Evidence suggests that no single 
intervention is wholly effective but rather that a combination of methods has the 
greatest impact for change. This is endorsed by Robertson et al (1996) who 
discussed further that selection of an effective strategy is dependent on knowing 
the obstacles which prevent change. These authors suggest a psychological 
framework which can be used to select an appropriate strategy when change has 
been resisted. MuirGray (1986) considered that tluee criteria should be fulfilled 
for an educational strategy to be effective in changing clinical behavioiu, these 
aie:-
(i) the education should be based on the doctors own work as well as on research 
findings
(ii) the doctor should be helped to assess his/her work and to compare it with that 
of others, and
(iii) that the whole team should be involved where teamwork is necessary for good 
quality care.
Not only does feedback of mformation about clinical practice have to be active 
and continuous to maintain change (Mugford et al 1991), the perceived position of 
the person providing the information is also important (Friis et al, 1991).
Several studies have documented Hie liidden costs of aminoglycoside therapy 
including costs of preparation, administration, monitoring and toxicity (Eisenberg 
et al, 1987, Davey et al, 1990, Plunuidge, 1990, Wright, 1991, Malek et al, 1992, 
Ken' et al, 1993) but there is a paucity of information about the consequences of 
failed treatment for the patient or the health services. The potential importance of 
this omission is illustrated by a trial comparing cefazolin with cefamandole as 
prophylaxis for cardiac siu'gery. The difference in drug acquisition cost ($82 per 
patient in favoiu of cefazolin) was more than offset by the cost of additional 
infections in the cefazolin group (average excess cost $401 per patient receiving
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cefazolin) (Roach et al, 1990). These excess costs were mainly attributable to 
réadmissions for sternal wound infection.
It is proposed that heightening clinicians awareness to the overall costs of 
aminoglycoside treatment in both monetary and outcome terms would lead to a 
more efficient allocation of resour ces. The objectives of this study were:- 
« To determine tlie general antibiotic therapy of Gram-negative bacteraemia and 
the indications which stimulate the initiation of aminoglycoside therapy.
9 To produce a costing analysis of aminoglycoside treatment in general and in 
reference to Gram-negative bacteraemia with a focus on patient outcome.
» To determine the opportunity costs of aminoglycoside h'eatment.
9 To identify measmes of outcome which can be used to value different 
antibiotic treatments, 
e To assess the predictive power of a previously published sepsis score to 
forecast potential cost and outcome.
9 To propose methods for improving aspects of antibiotic usage and to evaluate 
the effectiveness of written and personal contact for modifying prescribing 
practice.
The study was canied out in two phases, Phase I dealt with the identification and 
quantification of the problems associated with aminoglycoside usage and the 
treatment of gram-negative septicaemia. Phase II was an attempt to modify 
clinicians prescribing practice by feedback of data from Phase I. Evaluation of 
change effected was canied out by measming prescribing practice irmiiediately 
before and after feedback intervention. The time schedule of the various steps in 
each phase are sunmiarised below:-
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Summary of time schedule for Phases I & II
Phase 1
Aminoglycoside and septicaemia data 
collection
Data analysis
August 1990 - January 1991
January 1991
Phasell
Baseline prescribing practice data 
collection
Drug Information (DI) note produced 
Circulation of DI note to clinicians
Individualised seminar presentations
Prescribing practice data collection 
(post DI note and seminar 
presentations)
mid January 1991 - end February 1991 
(6 weeks in total)
February 1991
early March 1991 (one week prior to 
seminar presentations)
mid March 1991
End March 1991 - mid May 1991 (6 
weeks in total)
Study Funding and Medical Ethics Committee Approval
The funding of this study was provided by Bayer UK. Data collection and 
computer entry was subject to quality control by a member of Bayer UK staff. 
Approval for this was obtained from the Medical Ethics Committee of Dundee 
Acute Hospitals.
Within the sponsorship contract a clause existed stating that all data remained the 
academic property including publication rights, of those person(s) carrying out the 
study and that Bayer UK had no rights to veto data publication or presentation.
A full description of the execution , results and discussion of Phase I followed by 
the same for Phase II is presented below.
6.2 Phase I
A prospective utilisation audit of aminoglycoside prescribing and the general 
antibiotic management of Gram-negative septicaemia within Dundee Acute
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Hospitals (now Dundee Teaching Hospitals trust) was canied out during the time 
period August 1990 to January 1991. At the time of the study there were 1231 
acute beds on tlii'ee sites (Ninewells Hospital, Kings Cross Hospital and Dundee 
Royal Infirmary).
Methods
6.2.1 Study Population (Phase I)
The study population, 301 adult patient episodes in total, consisted of all those 
patients prescribed an aminoglycoside or who had a proven Gram-negative 
bacteraemia within the aforementioned time period. In 9 instances a patient 
entered the study more than once because of either a readmittance to hospital (8/9) 
during the data collection period or a recrurent septicaemia prior to discharge 
(1/9). Of the 8 patients who were readmitted, 7 were readmitted once and 1 was 
readmitted twice. Hence 9 patients accounted for 19 patient episodes.
The date of entry onto tlie study was talcen as the day the patient was prescribed a 
therapeutic course of an aminoglycoside for those patients in the aminoglycoside 
group, these patients may have previously received other antibiotics for the same 
infection.
For the bacteraemic patient episodes, the date of entry onto the study was taken as 
the first day they received any antibiotic for the presenting symptoms of the 
bacteraemia.
6.2.2 Data Collection (Phase I)
Prospective patient specific data were collected by a pharmacist by means of a 
standardised clinical record form (see appendix A) for each patient episode. 
Sources used for data assimilation were medical case notes, drug kardexes, TPR 
charts, biochemical reports, microbiological reports, personal interview of medical 
staff, fluid chai’ts, theatre sheets and musing notes.
6.2.3 Follow-Up (Phase I)
The hospital treatment of study subjects was monitored on a daily basis until the 
individual died or was discharged fiom the admitting hospital.
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All patients dischai'ged alive were subject to a three month follow up post 
discharge.
The General Practitioners of individual patients were contacted by mail (see 
appendix B for pro-forma) requesting details of any antibiotic prescription(s) 
supplied to the patient, with the reason for the prescription, within the three month 
period post discharge. If the GP had not replied within two weeks of pro-forma 
issue, a second request form was despatched.
Hospital re-adrnittance within the tluee month follow up period was determined 
from computerised records held by Tayside Health Board.
6.2.4 Data Analysis (Phase I)
The data from tins first phase of the study was analysed in terms of antibiotic 
combinations used, route and frequency of administration, reasons for change in 
antibiotic therapy, clinical indication initiating antibiotic prescription, result and 
outcome of therapeutic dmg monitoring, total costs of antibiotic treatment 
(inclusive of di'ug cost, consumables and staff time requfred for prépar ation and 
administration and any TDM undertalcen), ultimate patient episodes outcome and 
an assessment of any iatrogenic events. This analysed patient data was used in 
phase II of this study.
Fiuther analysis of this data was in terms of a previously published sepsis score 
(Cooke et al, 1993), patient follow up data was also used to determine whether 
fruther antibiotic treatment/hospital readmission suggested failiue of initial 
antibiotic treatment. These details were not used for presentation pmposes in 
phase II of tliis study.
Equipment and Database Packages (Phase I)
All data were stored and analysed in DBase IV (Ashton & Tate, Berks., UK) using 
a spreadsheet (Borland Quatti'oPro) and statistical sofrwaie (Minitab 8.0) on an 
Opus 386SX microcomputer.
Costs (Phase I)
Drug costs were talcen fr om Medical Index of Medical Specialities (MIMS) May 
1991.
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The cost of gentamicin assays was provided by the Department of Medical 
Microbiology, Ninewells hospital, Dundee.
Equipment costs are taken from Davey et al (1990) based on an average cost of 
£0.85 for a bolus injection and £2.23 for an infrision.
Staff costs are talcen from Davey et al (1990) based on £8.56 per hour, with the 
time of 5 minutes per IV 
Quality Control (Phase I)
Data collection was subject to quality control by a clinical research associate 
(CRA) from Bayer, UK.
Twenty medical case records were selected at random by the Bayer CRA and all 
aspects of data collection were cross checked with the exception of data obtained 
by personal interview with medical staff.
Computer data entry was also subject to quality contiol by a similar* method. The 
Bayer CRA selected at random twenty of the standardised clinical record forms 
and cross checked computer data entry of these records.
Clinical records for patients who died in hospital were reviewed jointly by an 
infectious disease consultant, clinical microbiologist and phai'macist to determine 
whether the treatment was appropriate. The assessment was based on the clinical 
condition of the patient and the spectrum of cover provided by the antibiotic(s) 
used. It did not take account of the antibiotic dosage.
Definitions:
Infections
The site of infection was established from the case records and by personal 
intei*view with the medical staff. Presenting complaints were divided into the 
infection categories of pulmonary, uiinaiy tract, abdominal, epididymo-orchitis, 
skin/soft tissue, blood and otlier as determined by individual patient's physicians. 
Patients with pyrexias of mibiown origin, postoperative pyrexias or general 
malaise without the clinical signs of septicaemia were categorised as blood 
infections.
Sepsis scores (see appendix C)
Patients with clinical or microbiological evidence of minary tract infection score 
one point unless the clinical event was postoperative (defined as occurring within
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481i of surgery) which scored foui* points. It was not possible to define upper 
urinai-y tiact infection fiom the information that was available, therefore this score 
was omitted. For respiratory infections patients were scored either two points 
(bronchitis or bronchiectasis) or foiu* points if there was radiological evidence of 
pneumonia. Additional points were not scored for 'hospital acquired pneumonia' 
because it was difficult to determine the true date of onset of pneumonia fi'om the 
clinical notes. Under 'septicaemia' patients were included if they had a confirmed 
bacteraemia or had clinically suspected septicaemia. For both groups patients 
scored one point unless the clinical event occurred witliin 48h of an invasive 
procedure (catheterisation, endoscopy etc.) or surgery, in which case the score was 
two or tluee points, respectively. Patients with confirmed bacteraemia who had a 
primary site of infection in the urinary or respiratory tr act were scored additionally 
for these sites.
Pre-existing diabetes was defined as any treatment for diabetes mellitus. Renal 
disease was defined as patients receiving cluonic dialysis. Hepatic disease was 
defined as biopsy proven cirrhosis and docmnented portal hypertension, episodes 
of past upper GI bleeding attributed to portal hypertension, or prior episodes of 
hepatic failme/encephalopathy/coma.
Outcome Measures (Phase I):
Inappropriate intravenous (iv) therapy/ Suitability for oral treatment 
Inappropriate iv days were defined as those days a patient was capable of talcing 
oral antibiotics i.e. they were receiving other oral medicines or were talcing food or 
on at least 25ml sips of water.
The criteria used in the assessment of patients suitable for treatment by the oral 
route but who were actually receiving iv therapy included:-
Temperatiue <37.5 and >36.5 
Pulse<100
MAP*^  >69 and <109
No operation within 48 hours
No specimen sent for C&S or a negative cultuie
142
* MAP - Mean ai’terial pressine is the product of systolic pressur e minus diastolic 
divided by tluee and added to diastolic pressure 
In addition to these criteria it was considered that:-
1) Intravenous (iv) therapy was appropriate for the first 24 hours postoperatively 
other than Urology patients who were frequently prescribed oral antibiotics 
postoperatively.
2) Those patients whose putative diagnosis was possible septicaemia were 
considered to be appropriately treated via the iv route for the first 24 hours.
3) All iv treatment of gut related problems (e.g. bowel obstruction, cholecystitis 
etc.) was considered appropriate.
4) Patients receiving concuiTent iv antibiotics inappropriately were evaluated as if 
only one antibiotic had been administered (e.g. if a patient received the 
combination of cefui'oxime, gentamicm and metronidazole inappropriately for one 
day then tliis was counted as 1 day of inappropriate treatment not as 3 antibiotic 
days).
Appropriate/Inappropriate antibiotic therapy
Assessment of whether a patient who died had received appropriate or 
inappropriate antibiotic therapy related to the spectnun of cover provided by the 
antibiotic selected for treatment and whether the clinical signs and symptoms 
necessitated antibiotic commencement. It did not relate to the actual dosage or 
fi equency of usage of the antibiotic.
Classification of the role of infection in réadmissions
Réadmissions were classified by inspection of the case notes. Patients with 
clinical evidence of infection at the time of readmission were fuither classified 
into those whom infection appeared to be the primary cause of readmission 
(readmission definitely infection related) and those in whom readmission may 
have been caused by some other aspect of the patient's condition (readmission 
possibly infection related).
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6.3. Results “ Phase I
The study population consisted of 301 patient episodes, 120 females (39.9%) and 
181 (60.1%) males.
Patient ages ranged from 15-92 years; the average age was 62 and the median age 
65.
Patients were located in various specialist units. The largest number of study 
patient episodes came from the Urology department (95 patient episodes, 31.6% 
of total), followed by 61 patient episodes (20.3% of total) fr'om Siugery. The 
medical department contributed 34 patient episodes (11.3%), the remainder were 
located in the following disciplines :- Intensive care. Respiratory medicine. 
Geriatric medicine. Haematology, Orthopaedics, Opthalmology.
The study group was divided into two main subpopulations, those who received an 
aminoglycoside (255 episodes in total) and those who had a documented gram- 
negative bacteraemia (86 episodes in total). There was some overlap between the 
two subgroups, in that 40 of the aminoglycoside patient episodes also had a grarn- 
negative bacteraemia. Of the remaining 46 gram-negative bacteraemic patients, 1 
patient did not receive any antimicrobial therapy and 45 received antibiotic(s) 
other than an aminoglycoside.
The number of patients who died whilst receiving antibiotic treatment was 36, 14 
of these patients had a documented gram-negative bacteraemia. Of this subgroup 7 
received an aminoglycoside containing regimen, the remainder received other 
antibiotic combinations. The remaming 21 deaths occuixed in patients who were 
receiving an aminoglycoside containing regimen for various infective foci other 
than gram-negative bacteraemia.
Of the total study population 28 patient episodes were granulocytopenic, this 
group merits fruther discussion as a prescribing policy was in force at the time of 
the study. The standard policy therapy for granulocytopenic patients on 
presentation of fever was a combination of gentamicin and piperacillin, if an 
adequate clinical response did not occiu within 48 hoius patients were changed 
onto second line antibiotics. However, the policy was not adhered to for 3
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granulocytopenic patients who were bacteraemic consequently they did not 
receive an aminoglycoside. These 3 patients were included in the bacteraemic 
group.
Phase I results are flirther discussed in the following individual sections 
Section 1 - Aminoglycoside data analysis 
Section 2 - Bacteraemia data analysis
Section 3 - Outcome of therapy including community smveillance 
Section 4 - Quality Control And Care Issues
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6.4. Section 1 - Aminoglycoside Data Analysis
Aminoglycoside therapy was commenced in over 50% of cases (132 of 255 
patient episodes) due to a suspected blood infection based on presenting signs 
suggestive of septicaemia. Typically these included rigors, alteration in 
consciousness, peripheral pallor or abnormal sweating. However, other patient 
episodes with suspected blood infection had pyrexias of unknown origm, general 
malaise or postoperative pyrexias witliout clinical signs of septicaemia. Only 40 of 
these patient episodes had a documented Gram-negative bacteraemia.
Other presenting complaints were divided into the infection categories of 
pulmonaiy, urmary tract, abdominal, epidiymo-orchitis, skin/soft tissue and other. 
Table 6.1/1 shows the number of patients for each category.
Of the 255 patient episodes who received an aminoglycoside, 231 received 
gentaniicin, 15 received netilmicin and 9 were initially coimnenced on gentamicin 
then transferred over to netilmicin because of increased age or decreased renal 
function.
Rarely was an aminoglycoside used alone (18 of 255 patient episodes, 7.1%) but 
rather in combination with one or more antibiotics. The most frequently used 
combination was that of gentamicin with augmentin (53 of 255 patient episodes, 
20.8%) followed by gentamicin, cefuroxime and metronidazole (44 of 255 patient 
episodes, 17.2%). Table 6.1/2 gives a full brealcdown of all the aminoglycoside 
antibiotic combinations used.
The Tayside antibiotic formular y in place at the time of this study recommended 
gentamicin or in certain circmnstances netilmicin in combination with another 
antibiotic for the following mdications only; cellulitis, post-operative woimd 
infections associated with gastro-intestinal surgery or sur gery of the female genital 
tract, septicaemia or suspected septicaemia and for specified types of surgical 
prophylaxis i.e. abdominal smgery or abdominal or vaginal hysterectomy.
At the time of the study only one clinical unit had its own individual antibiotic 
policy in place. The policy was for pyrexia of unknown origin in haematology- 
oricology patients and consisted of piperacillin and gentamicin as first-line 
therapy. Piperacillin was found to be combined with an aminoglycoside for 44 of
146
255 patient episodes (17.2%) over half (25 of 44; 56.8%) of these were 
haematology-oncology patients.
Aminoglycosides were rarely prescribed as part of an initial antibiotic regimen i.e. 
only 88 of 255 patient episodes (34.5%) were prescribed an aminoglycoside as 
first line tlierapy. The remaining 167 patient episodes had already received 
antibiotic treatment before an aminoglycoside was prescribed.
Duration of therapy with an aminoglycoside ranged from 1 to 33 days, with a 
mean of 5 days and a median of 2.5 days.
An intrinsic problem of aminoglycoside usage is that of neplrrotoxicity. Dose 
adjustment based on serum aminoglycoside levels limits dose-dependent damage 
and allows for therapeutic levels to be achieved. In this study only 187 patient 
episodes received therapeutic drug monitoring (TDM) with a range of 1-11 
assays/patient episode/comse (for a more detailed brealcdown of assay utilisation 
refer to Table 6.4/1 in section 4).
Witliin the study group 11 patients experienced a 50% increase in serum creatinine 
indicating a degree of neplnotoxicity. Five of these patients did not have elevated 
pre- or postdose levels and 6 did. Elevated serum levels refers to >2mg/l for a pre­
dose level and >10mg/l for a post-dose level for multiple daily aminoglycoside 
administration. One of the patients with a 50% increase in sermn creatinine had in 
fact been treated with grossly suboptimal aminoglycoside levels, post-dose=2.4 
mg/1, for the dur ation of treatment. Despite this the patient recovered fr om a gram- 
negative bacteraemia, the isolate of which was suggestive of bowel contamination. 
The antibiotics used m combination with the gentamicin were cefuroxime and 
metronidazole to which the isolate was sensitive.
Aminoglycoside therapy was initiated in 13 cases when the patients serum 
creatinine was above normal limits (150 micromoles/1) indicating a pre-existing 
impaired renal function. Use of the aminoglycosides in this type of patient may be 
pai'ticulaidy hazardous and brings into question the suitability of these patients for 
this type of treatment.
Almost 80% (203/255) of patient episodes prescribed an aminoglycoside were 
either taking oral medications or were able to do so, only 52/255 patient episodes 
(20.39%) were orally compromised at initiation of therapy i.e. were on nil by
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moutli orders, had had an operation within the preceding 24 hours, had significant 
ileus, had manifestations of gut ischaemia and/or gross electrolyte distur bances or 
were vomiting. All aminoglycoside courses were administered by the intravenous 
route with two notable exceptions, one patient was given a nebulised 
aminoglycoside for a chest infection and one patient received the aminoglycoside 
in the dialysate of a CAPD bag for acute CAPD related peritonitis.
Whilst in hospital the ultimate response to therapy for all diagnoses was success 
for 172/255 (67.5%) patient episodes and failure for 55/255 (21.6%), a further 
28/255 (11%) patient episodes were imassessable. Excluding gram-negative 
bacteraernias the success rate was 70% (151/215 patient episodes), the failure rate 
20% (43/215 patient episodes) with 10% (22/215 patient episodes) imassessable. 
The criteria used to define these outcomes are shown in Table 6.1/3 along with the 
number of patient episodes in each outcome category.
Only the direct costs have been measured in monetary terms in this study. The 
costs of using aminoglycoside treatment for proven bacteraemic episodes have 
been considered separately from aminoglycoside usage in other mdications so that 
this can be compared with the non-aminoglyoside treatment of proven 
bacteraemia. The costs of treating a neutropenic study patient episode with an 
aminoglycoside have also been considered separately from other aminoglycoside 
patient episodes as this group received an aminoglycoside as part of a written 
policy including other relatively expensive drugs such as piperacillin. In addition 
ICU patients receiving an aminoglycoside were examined separately as it was felt 
that these patients have a tendency to high resource usage because of their critical 
condition. Costs of anthnicrobial agents, assays, equipment and staff time were all 
found to be markedly higher m the neutropenic patients (median total treatment 
cost £599) and ICU patients (£471) when compared to other aminoglycoside 
patients. As a subgroup of the remaining aminoglycoside patients those with a 
bacteraemia were also found to have higher costs (£278) than those with another 
indication (£185). Table 6.1/4a gives the median and 95% confidence intervals 
(Cl) for the component costings of each of the subgroups considered.
Treatment costs were related to outcome. Compared with patients who had a 
successful outcome, treatment costs were an average of £357 per patient liigher in
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those who died (95% Cl £31-682) and an average of £418 higher in patients who 
failed to respond to initial therapy (95% Cl £89-747). Removal of patients with 
Gram-negative bacteraemia from the analysis had little impact on these results; 
treatment costs were £431 per patient higher in the non-bacteraemic patients who 
did not respond to initial treatment (95% Cl £61-802).
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6.5. Section 2 - Bacteraemia Data Analysis
During the six month study period there were 86 patient episodes with at least one 
positive blood culture for a Gram-negative organism. Although the age range for 
these patients was between 15 and 91 years the average age was 69 with a median 
age of 71.5 years.
The most common infecting organism was E.coli (45/86 cases, 52%) followed by 
Klebsiella species (10/86 cases, 11.6%), all infecting organisms are listed in Table 
6.2/ 1.
Of the 86 patient episodes 30 had another focus of infection. For 16 cases the 
organism isolated was the same as that causing the bacteraemia suggesting that 
this may have been the primary site of infection however further typing of the 
organisms was not carried out so it is not possible to make a categoric statement. 
Table 6.2/2 lists the other sites of infection and the time at which associated 
specimens were collected in relation to the blood cultur e specimen.
Although only 8/86 (9.4%) patient cases were initially orally compromised 
intravenous therapy was favoured at initiation of the treatment period for 72/86 
patient cases, 13/86 patient cases received oral therapy alone and 1 of the 86 
patient cases did not receive any antibiotic therapy. The purpose of this section of 
the study was to examine the antibiotic treatment of Gram-negative bacteraemia 
therefore the patient who did not receive antibiotic therapy is excluded from the 
following analysis, therefore only 85 patient cases are now examined.
There appeared to be little consensus of agreement about the initial tr eatment of a 
bacteraemia, the most frequently employed combination was gentamicin and 
augmentin but this only accomited for 16.5% (14/85) of cases. Gentamicin 
containing regimens accounted for 35.3% (30/85) of cases in total but there was a 
wide variation in the combination antibiotic(s) used. No patient received an 
aminoglycoside alone. An aminoglycoside was added into the antibiotic regimen 
for a further 10/85 patient episodes before the end of the treatment period. Table 
6.2/3 gives a detailed brealcdown of all antibiotic combinations at initiation of 
therapy.
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Wliilst in hospital the ultimate response to therapy for all bacteraemic patient 
episodes was success for 46/85, failine for 28/85 and 12/85 were unassessable. 
Table 6.2\4 shows the criteria used to define these outcomes and the number of 
patient episodes in each outcome category.
In total 40/85 bacteraemic patient episodes were treated with an aminoglycoside 
containing regimen, median direct costs £278 (95% Cl £191-507). The mortality 
in this subgroup was 17.5% (7/40 patients), death was thought to be directly 
related to the gram-negative bacteraemic episode for 5/40 of these patients (10%) 
and not directly related for 2/40 (one death was due to a rampant fungaemia 
secondary to granulocytopenia and the other was due to a gram-positive and 
Mvcoplasma pneumoniae bacteraemia secondary to granulocytopenia). The 
remaining 45/85 patient episodes were treated with a non-aminoglycoside 
containing antibiotic regimen, median direct costs £97 (95% Cl £ 69-143), Table 
6.1/4b shows the component costings for this group of patients, all of which were 
lower than those bacteraemic patients treated with an aminoglycoside containing 
regimen. The mortality of this subgroup was 15.6% (7/45 patients), death was 
thought to be directly related to the bacteraemic episode for 6/45 of the patients 
(13.3%) and not directly related for 1/45 (this patient died of pulmonary oedema 
and CCF).
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6.6, Section 3 - Outcome of therapy induding community surveillance:
6.6.1 Ultimate response to therapy in Hospital
The ultimate response to therapy whilst in hospital for the aminoglycoside 
subpopulation in terms of success, failure and unassessability and the criteria used 
to determine these are given in Table 6.1/3. The ultimate response to therapy 
whilst in hospital for the bacteraemic subpopulation again in terms of success, 
failure and unassessability and the criteria used to determine these are given in 
Table 6.2\4 section 2.
Calculated sepsis scores and their relation to the above hospital outcome measures 
and median treatment costs are given separately in Table 6.3/1 for the non- 
bacteraemic aminoglycoside patients, the bacteraemic aminoglycoside patients 
and the non-aminoglycoside bacteraemic patients. From this table it can be seen 
that the distribution of sepsis scores are very smiilar- in the bacteraemic patients 
who did or did not receive an aminoglycoside. Sepsis scores were higher in the 
bacteraemic patients; greater than 70% had a sepsis score 5 and above compared 
to only 43% of the non-bacteraemic patients (see Figure 6.2a). In the bacteraemic 
patients there was also a marked increase in mortality with ascending sepsis score 
(Figure 6.2b), in survivors there was also a relationship between sepsis score and 
initial treatment failure (figure 6.2c). The median sepsis scores were 10 for 
patients who died in hospital, 6.5 for patients with treatment failure and 5 for 
survivors with full response to treatment. In the aminoglycoside group mortality 
was 10/40 (25%) and 7/30 (23%) had an adverse outcome. In the non­
aminoglycoside group mortality was 7/45 (16%) and 7/38 (18%) had an adverse 
outcome. The relationship between sepsis scores and outcome was not so clear in 
the non-bacteraemic patients (see figines 6.2b & 6.2c). Median sepsis scores were 
4 in survivors, 5 in patients who died in hospital and 6 in patients with initial 
treatment failure.
For all subgroups as tire sepsis score increased so did the median cost of treatment. 
Although the distribution of sepsis scores were very shnilar* between the 
bacteraemic patients who received an aminoglycoside and those that did not, the
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median treatment costs were quite dis-similar* (Table 6.3/1). The median treatment 
cost of a bacteraemic patient treated with an aminoglycoside containing regimen 
was at least double that of a bacteraemic patient treated with a non­
aminoglycoside containing regimen.
Witliin the aminoglycoside group i.e. both bacteraemic and non-bacteraemic 
patients, treatment costs were related to outcome. Compared with patients who 
had a successfiil outcome, treatment costs were an average of £357 per patient 
higher in those who died (95% Cl £31-682) and an average of £418 higher in 
patients who failed to respond to initial therapy (95% Cl 89-747). Removal of 
patients with Gram-negative bacteraemia from the analysis had little impact on 
these results; treatment costs were £431 per patient higher in the non-bacteraemic 
patients who did not respond to initial treatment (95%CI £61-802).
Of the 215 non-bacteraemic aminoglycoside patients, 20 (9.3%) had zero sepsis 
scores indicating little clinical evidence of infection. None of these patients died 
yet median treatment costs were £123 per patient (range £14-701, avg £209 per 
patient). The diagnostic group with the lowest sepsis score was epididymo-orchitis 
(median 0; range 0-5). There were no deaths in this group yet the median 
treatment cost was £112 per patient (range £51-651; avg £150). Analysis of 
variance showed a weak relationship between sepsis scores and treatment cost in 
the aminoglycoside group, so that sepsis score only accounted for a maximum of 
2.6% of the variance in treatment costs.
6.6.2 Further antibiotic treatment in the community
Tlnee month follow up questionnaires were circulated to GPs for 245 patients. 
Although 266 patients were discharged alive, 21 patients were known to have died 
or been readmitted to hospital at the time the questiomiaires were sent out. 
Questioimaires were returned for 225 (92%) of the 245 patients. In addition to 
completing the questionnaire, two GPs noted that the hospital discharge letter had 
not mentioned that their patient had received aminoglycoside therapy. Of 84 
patients who were dischar ged home to continue on oral antibiotic treatment, this 
was not continued by the GP on eight occasions. A further 63 patients received 
new antibiotic prescriptions witliin two months of dischar ge for fiuther symptoms
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of infection which may have been related to the original infection. Of this 63, 
seven had also received a second therapeutic course whilst remaining in hospital 
and prior to discharge.
6.6.3 Readmission to hospital
It was determined from the health boar d computer that 69 patients were readmitted 
within tlrree months of discharge. These records were accessed to determine 
whether thefr readmission was related to their previous infective episode. It was 
possible to access 64 case notes but 5 were untr aceable.
From the information available in the case notes it was considered that 26 patients 
were readmitted due to infections related to their primary infective episode 
whereas 38 cases were either, emergency admissions, elective admissions or out­
patient appomtments not related to the primary infective episode. Table 6.3\2 A 
gives detailed information about the 38 patients readmitted for reasons other than 
recurrence of their infective episode. Table 6.3\2B shows the number of patients 
from each original infection category readmitted with signs suggestive of 
reciuTence of infection.
6.6.4 Death and appropriateness of therapy
Of the 301 study patient episodes, 36 patients died whilst receiving their initial 
antibiotic treatment. A further 29 died after completing antibiotic treatment but 
during the tlrree month follow up period. Table 6.3/3 summarises the 
appropriateness of therapy and whether the patient had underlying pathology. 
Appropriateness was based on whether the clinical signs and symptoms 
necessitated antibiotic commencement and if so, the spectriim of antimicrobial 
cover provided by the initial antibiotic. Seven patients (19.4% of all deaths) were 
considered to have received inappropriate treatment and did not have underlying 
pathology which could have contributed to their death as determined fr'om the 
medical case notes. However, a note of caution is that the Post Mortem (PM) 
report fr om one of tlie patients who appeared to have no underlying pathology 
according to the medical case notes was found to have widespread métastasés due 
to an unlmown primary at necropsy. This highlights that data on the majority of
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patients, who did not have a PM, must be regarded as incomplete when 
considering underlying pathology.
Of the 14 patients with bacteraemia who died, death was considered to be dhectly 
related to the initial septic episode for 11 and not directly related for 3. Two of the 
tlnee patients had rapidly fatal imderlying pathology (one death due to a rampant 
fungaemia secondary to granulocytopenia and the other due to a gram-positive and 
Mvcoplasma pneumoniae bacteraemia secondary to granulocytopenia), the third 
patient died of pulmonary oedema and CCF.
Of the 71 bacteraemic patients who survived the initial treatment period 4 died 
whilst still in hospital but for reasons not directly related to the septic episode. Of 
the 68 discharged alive a further 7 died in the tlnee month follow up period.
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6.7 Section 4 - Quality Control And Care Issues
6.7.1 Therapeutic Drug Monitoring (TDM)
At the time of this study in Dundee acute units, the aminoglycosides were almost 
without exception administered as an iv bolus. Reconnnendations were in place 
stating that therapeutic drug monitoring of paired blood samples be taken (i.e. to 
measure trough and peak levels) for patients in receipt of aminoglycoside 
treatment. The recommendations stated that trough levels be talcen immediately 
before administration of an aminoglycoside and peak serum levels be measur ed 30 
minutes after administration unless indicated otherwise, dosage adjustments being 
based on this premise.
Of the 255 patient cases who received an aminoglycoside dur ing the study period 
only 187 (73.3%) received any form of therapeutic drug monitoring (TDM). For 
these patients the range of assays/patient episode/corrrse varied from 1 to 11. 
However only sufficient data were available to interpret assays for 173 patient 
cases. Table 6.4/1 summarises the assay results. Only 15% (48/321) of 
interpretable assays had a trough and conesponding peak level within the 
recommended therapeutic range. Underdosing (70%, 224/321) was more common 
than overdosing (23%, 74/321). However, overdosing was more frequently 
corrected by dose adjustment: 49/74 (66%; 95% Cl 55-77%) v.y 95/224 (42%; 95% 
Cl 36-49%).
6.7.1.1 TDM and mortality outcome in hospital
Of the sixteen patients who died (Table 6.3/3) whilst receiving 'appropriate' 
aminoglycoside therapy, 3 (18.7%) did not receive any TDM. For the 13 patients 
who did receive TDM, initial aminoglycoside levels were above the recommended 
range for 1 patient, subtherapeutic for 8 (61.5%) and iminterpretable for 2 
(12.5%).
6.7.1.2 Relationship of drug monitoring costs to overall treatment costs
As a proportion of overall treatment cost TDM contributed an average of 12.5% 
(median 9.9%). To some extent the proportional contribution made by TDM was
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dependent on the combination antibiotics used with the aminoglycoside. However, 
the shorter the course of antibiotic treatment, the more sensitive the total treatment 
cost was to the monitoring costs (Table 6.4/2). Drug monitoring costs accounted 
for greater than 20% of the total tieatment costs in 17% of patients receiving 
TDM.
6.7.2 Management errors
In addition to the 68 patient cases who did not receive any TDM a set of recurring 
management eiTors came to light which included:- 
11 Failure to adjust doses for baseline serum creatinine 
(13 instances)
Case example:- A 77 year old, 60kg woman with a serum creatinine of 
247imiols/l (calculated creatinine clear ance 16ml/min) was commenced on 
Gentamicin lOOmg thi'ee times daily.
A more appropriate dose would have been 120mg every 48 hours assuming stable 
renal function.
21 Inappropriate administration times i.e. unto 4 hours 
late (10 instances)
Case example:- The highest trough occurred in Case 1 above. The 2pm dose was 
missed and administered at 6pm, the next dose was then given at 10pm. Serum 
levels the following day revealed a trough level of 6,3mg/1 and a peak of 11.4mg/l. 
The effects of the inappropriate dosing times were almost certainly compounded 
by the failure to adjust the dose for the baseline serum creatinine.
31 Administration of additional doses due to non-recording of the first 
administered dose 
(9 instances)
Case example:- A patient prepared for tlieatre was given the prescribed 
prophylactic 140rng gentamicin bolus, however the dose was not recorded on the 
kardex. On receiving the patient in theatre the anaesthetist noticed the omission on 
the kardex and administered a fuither 140mg gentamicin to the patient. The 
double dosing was not discovered until some hours later when tire anaesthetist
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requested that the house officer ensui'e all patients receive prescribed prophylactic 
antibiotics.
41 Failure to use assav results (38 instancesl
Case example;- A 70 year' old woman with a klebsiella bacteraemia was treated 
from Days 1-3 with gentamicin 120mg bd. As her pyrexia persisted the 
gentamicin dose was increased empirically to 160mg bd for Days 4-9. Serum 
levels on Day 5 revealed a trough of 0.8mg/l and a pealc of 4.5mg/l despite this the 
dosage was not increased further.
Case example:- An 83 year old woman was treated initially with cefuroxime for a 
suspected chest infection, it was then determined that she had a positive gram- 
negative blood culture. Gentamicin 40mg tid was then commenced in addition to 
the cefuroxime for seven days despite serum levels on day 3 showing a trough of 
1.4mg/l and a pealc of 2.4rng/l.
51 Ad hoc dosage reductions bv inexperienced house 
officers leading to suboptimal treatment (3 instances)
Case example:- a 77 year' old woman had a gentamicin dosage adjusted on the 
basis of serum levels to 160rng bd. The on-duty house officer covering this ward 
for the weekend had not observed this dosage before and so decided it was 
incorrect, the house officer proceeded to change the dose back to 80mg tid for the 
duration of the weekend period because 'that was the dosage stated in the data 
sheet'.
6.7.3 Missed doses
The number of patient cases who had at least one missed or non-recorded dose 
during therapy was 134. The total nmiiber of missed/non-recorded doses was 620, 
with a range of 1-35 per treatment course. The reasons for these missed/non 
recorded doses and the number of doses in each category are given in Table 6.4/3. 
It can be seen that for almost 65% (402 instances) of the non recorded doses it was 
not possible to elucidate whether the dose had been administered. Figure 6.1 
shows the percentage of missed/non-recorded doses per treatment per patient.
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Twenty five patients 'missed' more than 10% of their prescribed treatment and 1 
patient 'missed' almost 92% of the prescribed therapy.
6.7.4 Lack of documented information
For the purposes of audit medical staff were interviewed to determine the reasons 
for change in antibiotic agent, dose, frequency or route of administration. For 301 
study patient episodes, 49 had at least one change in therapy for which no clear* 
reason could be defined, i.e. the medical staff present did not know the reason for 
change and there was no documentation in the medical notes explaining the reason 
for change. A further 10 patients had a change in therapy by mistalce.
6.7.5 Inappropriate intravenous (iv) treatment
As only 52 of 255 (20.4%) patient cases receiving an aminoglycoside were orally 
compromised it was considered that there must have been a proportion of patients 
mmecessarily treated by the iv route. Application of objective pre-defrned criteria 
to the study population (301 patient cases) selected out 26 patients who appeared 
to be have been ideally suited to receive oral treatment. Review of these patients' 
case notes showed that 23 patients had received iv therapy unnecessarily, 3 of 
these patients had not required any form of antibiotic treatment and the remaining 
20 patients would definitely have been suitable for treatment by the oral route. 
Half of these patients had a diagnosis of epididymo-orchitis. The remaining 3 
patients however, had a serious clinical condition which necessitated treatment by 
the iv route. Using the set criteria alone to determine which route a patient should 
be treated by would have allowed these patients to fall tlnough the 'catch net'. The 
clinical diagnoses of those patients selected by the objective criteria as having 
received mmecessaiy iv treatment and verification of this by the medical case 
notes ar e given in Table 6.4/4.
6.7.6 Antibiotic Failure Rate
In this study 19 patients of 265 survivor episodes (36 patients died) required 
further antibiotic treatment whilst in hospital, 15/19 of these cases were for the 
same indication as the initial antibiotic course. This gives a treatment failure rate 
of 5.7% (15/265) for surviving patient cases.
159
At 3 month follow up with the patients GP, 63 had been prescribed an antibiotic 
whilst in the community (this does not include continuation antibiotics from the 
hospital).
Twenty six patients were re-admitted to hospital witli signs and symptoms 
suggestive of recurrence of infection, 6/26 (23%) were readmitted within 7 days of 
discharge.
Recalculation of the antibiotic treatment failure rate using information from 
community surveillance shows how the rate more than doubles fr'om 5.7% to 
15.5% (15/265 + 26/265) by incorporating only those cases readmitted to hospital. 
If all patients who received an antibiotic from the GP (63/265) are also included in 
the calculation the failure rate rises to 35.5% (15/265 + 26/265 + 53/265'"') *(of the 
63 patients receiving antibiotics from the GP 10 were readmitted).
During the study 36 deaths occiuTed whilst patients were receiving antibiotic 
therapy. For 32 the deaths were considered to be directly related to the initial 
infective episode. If these deaths are incorporated into the estimation of antibiotic 
treatment failure calculated for surviving patients (range 5.6% - 35.5%), the 
overall treatment failme rate for the whole study population ranges from 15.6% to 
38.5% (15+32/301 - 15+16+53+32/301) depending on whether community 
surveillance is included.
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6.8 Discussion - Phase I
In a cost compai'ison of inti'avenous antibiotic administration based on direct costs 
alone, Plumridge (1990) demonstrated that the acquisition cost of an antibiotic is a 
poor predictor of total daily treatment cost pailiculaiiy for those antibiotics with a 
relatively low acquisition cost. A group of antibiotics which have generally been 
perceived to be very effective and inexpensive to use because of their low 
acquisition cost are the aminoglycosides. This observational clinical practice study 
provides strong evidence, in the form of overall direct treatment costs and 
outcome data, to challenge this perception. In this study, utilisation of the 
aminoglycosides were found to be fraught with management problems, treatment 
failure was not an uncommon occurrence, ti*eatnient costs escalated with adverse 
outcome and the costs of treating a gram-negative bacteraemia were high when 
compared to alternative therapies. Tlnee readily measurable indicators of outcome 
were identified which can be used to value different antibiotic treatments. Further 
discussion of these findings follows.
In Dundee Acute Units the aminoglycosides were found to be used for a wide 
range of indications (table 6.1/1). The predominant indication being suspected or 
proven bacteraemia. Selection of use was primarily as a second line agent i.e. 65% 
of the 255 study patients had already received another antibiotic before the 
aminoglycoside was prescribed. This may well have been a reflection of concern 
about then* dose related toxicity. In addition to the aminoglycoside, 93% of 
patients were receiving concurrent antimicrobials with a similar* spectra of 
activity. Both of these factors make it difficult to assess the precise role of 
aminoglycoside treatment in the final outcome, however the study findings will be 
compared and discussed in relation to previously published standards. Almost 
equal numbers of proven gram-negative bacteraemias were treated with 
aminoglycoside (n=40) and non-aminoglycoside (n=45) containing treatment 
regimens.
Whilst in hospital antibiotic treatment failure rate was 5.7% for* smvivors, 
incorporation of those patients whose death was considered to be directly related 
to the infective episode and therefore to treatment failure increased this rate to 
15.6%. This was further increased to 38.5% when community sm*veillance i.e.
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additional antibiotics prescribed by the GP and readmission to hospital with signs 
and symptoms suggestive of recurrence of infection, were included. There appear 
to be no published data on long-term follow up of patients in the community who 
have received therapeutic courses of antibiotics in hospital. Davey et al {199\) in a 
discussion of the human and non-frnancial costs of hospital-acquired infection 
stated that a full assessment of morbidity can only be accomplished by home 
follow up. Recent studies have shown that failure to pursue surgical patients after 
discharge results in a substantial underestimation of true wound infection rate 
(Reirner et al, 1987, Davey et al, 1988, Law et al, 1990, Lynch et al, 1992, 
Esuvaranathan et al, 1992, Bailey et al 1992). This study suggests that there is a 
high probability that the detectable failure rate in hospital of antibiotic treatment is 
an underestimation of the true failure rate. Obviously these data ar e flawed in that 
all subsequent infections cannot definitely be related to the initial infective 
episode without fiill typing of bacterial isolates and this information was not 
available. However, the point is made that the treatment failure rate of 5.7% for 
surviving patients, determined by need for further antibiotic therapy whilst in 
hospital, has a high probability of being an underestimate of the true failure rate 
which may be as high as 38.5%.
Community surveillance of antibiotic treatment rarely addresses antibiotic 
toxicity. The bilateral vestibular* damage caused by aminoglycosides may not 
become manifest until a patient is discharged home. This type of damage is 
distressing to the patient causing a peculiar* form of dysequilibrimn associated 
with a hallucination of vertical movement of the surroundings. The damage is 
irreversible and has been termed 'bobbing oscillopsia'. Cases of 'bobbing 
oscillopsia' caused by aminoglycoside toxicity continue to be reported in the 
medical literature (Rarnsden et al, 1982, Braliams, 1986, Duncan et al, 1987). Two 
GP's indicated on the cormnunity surveillance proforma's that they had been 
unaware from their patient's hospital discharge letter of the aminoglycoside 
treatment. This has ramifications in that should a patient present to the GP with 
signs and symptoms of aminoglycoside toxicity the physician does not have the 
background information on which to base a diagnosis.
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Long term connmmity smveillance is time consuming and demanding of 
resomces but total lack of smveillance appear s to lead to a gross underestimation 
of treatment failure. A two week period of observation would have picked up 
almost 50% (11/26) of réadmissions in this study which were primarily due to 
infection and would also have minimised the number of réadmissions which were 
due to other reasons. However, even within this two week period there were 5 
réadmissions which were not due to infection, so that tracldng réadmissions from 
computerised data (Chambers et al, 1990, Milne et al, 1990, Colledge et al, 1994) 
may give a falsely liigh estimate of adverse outcomes miless individual patient 
records are checked. Unfortunately, case note review may not always be ideal 
because of lack of documentation. Taylor et al (1990) in a study to determine the 
impact of smgeon's diagnosis on surgical wound infection rates foimd that the 
reason for the postoperative prescription of antibiotics was often missing from 
clinical case records. Bailey et al (1992) found in their study of commimity 
smveillance of complications after hernia smgery, that many womid complications 
were not recorded in the hospital records and therefore could not be audited by 
case note review. In the present study 49 patient cases had at least one change in 
therapy for which no clear reason could be defined, i.e. docmnentation in the 
medical case notes explaining the reason for change was absent.
In terms of process outcome it was foiuid that there was frequent miderdosing of 
the aminoglycosides, lack of adequate dosage adjustment, overuse of the 
inti'avenous route, other adverse events due to hmnan error and a recmring lack of 
documentation. In the review of individual patient records it was virtually 
impossible to grade overall treatment as appropriate or inappropriate because of 
the multiplicity of changes that were made within any one treatment period. This 
problem has been recognised in another audit of aminoglycoside treatment and 
management of bacteraemia (Dmiagan et al, 1989) which concluded that it was 
only possible to grade each day of treatment as appropriate or inappropriate. 
However, one of the reasons for treatment failure in the present study could be 
miderdosing. The recommended dosage of 2-5mg/kg/day of an aminoglycoside 
agent (gentamicin, netilmicin, tobramycin) is frequently associated with 
subtherapeutic serum levels. Flint et al (1985) in their study of 68 critically ill
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patients with nosocomial pneumonia, reported that only 19% of patients treated 
with an aminoglycoside were considered to have therapeutic levels (peak serum 
level of 8-lOmg/l) from the outset, compared with 58% of patients who were 
considered to be subtherapeutic. These findings of subtherapeutic aminoglycoside 
levels are similar to others (Anderson et al, 1976, Guest et al, 1980, 1980, 
Summer et al, 1983, Sculier et al, 1984, Li et al, 1989, Hickling et al, 1989, 
Zeitany et al, 1990). The pharmacokinetics of aminoglycosides in critically ill 
patients are extremely variable, and dosage requirements vary widely even in 
patients with normal renal frmction. In one large study (Zaske et al) the half-life of 
gentamicin varied from 0.4-7.6 hours in those with a normal estimated creatinine 
clearance, the daily dose requirement ranged from 0.7-25,8mg/kg/day. Moore et al 
(1984), by multivariate analysis, fomid the most important factor in the treatment 
of Gram-negative pneumonia with aminoglycosides to be adequate peak 
concentrations and further demonstrated (1987) that a determinant of the clinical 
therapeutic response to aminoglycoside treatment is the peak concentration 
achieved i.e. the greater the maximum pealc to MIC ratio, the greater the clinical 
response rate. It can be seen therefore, tliat the dosage of aminoglycoside selected 
for treatment is critical. Failure to achieve adequate peak aminoglycoside 
concentrations eariy in the cour se of treatment must contr ibute to an increased 
morbidity and mortality.
A large proportion of patients in the present study receiving aminoglycoside 
therapy were grossly underdosed and a significant proportion, (26.7%), did not 
receive any therapeutic drug monitoring, (TDM). Cumulative assay results (see 
Table 6.4/1) demonstrated the need for serum assaying early in the treatment 
course to provide information for dosage adjustment. Unfortimately, intervention 
aimed at optimisation of the antibiotic dosage was required but not executed in all 
cases. Although miderdosing was tliree times more frequent than overdosing, it 
was overdosing which was more frequently corrected. This may well have been a 
reflection of concerns about dose-related toxicity which has been described by 
others (Noone et al, 1974). Sixteen patients died who were considered to have no 
underlying pathology and to have received appropriate aminoglycoside therapy 
(table 6.3/3), 8 of these patients were known to have subtherapeutic levels, it could
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be ai'gued therefore that the suboptimal drug levels contributed in part to their 
mortality. As discussed extensively by Parker et al (1993) a method to overcome 
underdosing is aminoglycoside administration once daily. The practical 
advantages of this being; a straightforward dosage calculation, a guaranteed peak 
serum concentration in the therapeutic range, a potential reduction in treatment 
period, easier quality control of preparation and administration, a decrease in 
persomiel time, fewer assays are required and consumable costs are lower.
A set of recur ring management eri'ors described by many other workers (Davey et 
al, 1983, Clark et al, 1986, Cousins et al, 1989, Li et al, 1989, Davey et al, 1990, 
Lesar' et al, 1990, Dimagan et al, 1991, Leape et al, 1991) were observed in this 
study. These included failure to adjust doses for baseline serum creatinine, 
inappropriate administration times i.e. up to 4 hours late, administration of 
additional doses due to non-recording of the first administered dose, transcription 
errors between kardexes, failure to use assay results, ad hoc dosage reductions and 
missed doses. Any or all of these en*ors may have contributed in part to an adverse 
patient outcome.
Almost 80% of study patients receiving intravenous (iv) antibiotics were found to 
be capable of taking oral medication, indicating an overusage of the intravenous 
route of administration. Using highly selective criteria (see 6.7 section 4), 26 
patients were considered to have been suitable for oral treatment from the outset. 
Case note review confirmed that the vast majority of these patients had received iv 
therapy unnecessarily. However, 3 patients of the original 26 were in a serious 
clinical condition requiring intravenous treatment. Using the objective selection 
criteria alone to determine which route a patient should be treated by would have 
allowed these patients to fall tlnough the 'catch nef and mideiiines the necessity 
for 'clinical judgement' to be exercised when using guidelines of this natine. In a 
discussion of the phaimacoeconomics of iv drug administration Parker et al 
(1992) concluded that the disadvantages of the iv route far outweighed the 
advantages and where feasible should be avoided. These authors frnther stated that 
maximisation of valuable resources would be achieved by the increased use of the 
oral route. The economic advantage of expediting antibiotic therapy from the iv 
route to the oral route was first discussed by Quintilliani et al (1987). These
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workers as late as 1987 pointed out that although a number of antibiotics with 
pharmacokinetic and microbiologie activity suitable for treating serious infections 
existed, clinical experience was limited. Since then, several programs (Grasela et 
al, 1991, Allen et al, 1992, Frighetto et al, 1992, Solomkin et al, 1996) have 
demonstrated that it is possible to substitute oral therapy for iv therapy without 
compromising outcome but in order to maintain change intervention needs to be 
prospective. As already discussed in Chapter 4, it will be necessary to remove the 
‘worry’ from doctors that oral is not quite as good as iv therapy before oral 
therapy in serious infection is fully accepted. Seto et al (1996) has reported 
minimum net montlily savmgs of HK$26,000 from an ongoing iv to oral switch 
campaign. Unfortunately, this campaign has focused on process outcome alone 
and has not included any form of patient outcome. Another similar study (O'Brien 
et al, 1996) carried out in the UK. estimated savings of £1,000 over a four week 
period if patients inappropriately treated by the iv route were changed to oral 
therapy. Allen et al (1992) identified that there are no agreed guidelines for the 
appropriate time to change from iv to oral therapy, however the criteria used by 
these workers to determine when a patient was suitable for oral therapy were 
similar' to those used in this cuiTent study.
Drug cost accounted for the majority of the total treatment cost for all patients 
(tables 6.1/4 a&b). Not surprisingly drug costs were proportionally higher for the 
neutropenic patients who received an increased number of expensive concurrent 
'policy' antibiotics. For the aminoglycoside patients, proportional drug monitoring 
costs (average 12.5%, median 9.9%) were lower tlian reported by others 
(Plumridge, 1990, Malek, 1992). This study was purely observational in approach 
and reflects the 'real' costs of treating a population with aminoglycosides and not 
the idealised 'controlled study' situation whereby all patients who should receive 
therapeutic drug monitoring (TDM) in fact do. Only 73% of the study population 
were subject to monitoring, consequently the proportional costs of serum assaying 
for the aminoglycoside population as a whole ar'e lower than the proportional costs 
would be for any individual patient who did receive TDM. However, it was shown 
tliat the shorter the course of antibiotic treatment, the more sensitive total
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treatment cost was to monitoring cost (table 6.4/2). Total monitoring costs for 187 
patients were £6,264.
Aminoglycoside treatment costs were related to outcome, being substantially 
higher m those who died and who failed to respond to initial therapy irrespective 
of their presenting diagnosis. Only initial treatment costs were evaluated in this 
study, costs in the commimity and from readmission were not included in the total 
treatment cost because it was not always transpai’ent that the two episodes were 
directly related. However, one clear example in which readmission was, without 
dispute, related to the initial infective episode illustrates the potential magnitude 
of the costs of inadequate antibiotic treatment. Total treatment cost for the first 
admission was £186. The patient was readmitted two days after discharge with 
gross suppmation of the wound and the total tieatment cost for the second 
admission was £1757 (antibiotics, equipment, staff time).
Overall treatment costs varied markedly between the two groups of bacteraemic 
patients, witli those having received an aminoglycoside being substantially higher, 
median overall treatment cost £278, than those not receiving an aminoglycoside 
containing regimen, median overall treatment cost £97. It could be argued that the 
difference in treatment cost was related to seriousness of infection but calculated 
sepsis score and hospital outcome was very similar between the two groups (table 
6.3/1).
The opportunity costs associated with aminoglycoside therapy revolve ai'ound the 
monitoring, toxicity and failure of these agents. In this study the costs of 
monitoring were £6,264 for 187 patients and the associated staff time involved in 
sample talcing. Had alternative agents been used then this money and staff time 
would have been released for use elsewhere. There has been no attempt in this 
study to attach a monetaiy value to any toxicity resulting from the use of the 
aminoglycosides. However, Eisenberg et al (1987) found that 7.3% of patients 
treated witli an aminoglycoside at 6 Pliiladelphia aiea hospitals developed 
aminoglycoside-associated neplnotoxicity. The additional cost per case of 
neplnotoxicity was $US446 for ancillary seivices, $US825 for additional routine 
days and $US1152 for intensive care days. Additional consultations were $US78 
per patient. Therefore the mean total additional cost was $US2501. The
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occm’rence of tliis toxicity is not certain for any particular patient but is a 
probability. Therefore tlie cost of treating this toxicity has to be divided between 
all patients receiving aminoglycoside treatment. Eisenberg calculated that the 
average additional cost per patient receiving aminoglycoside therapy was $US183,
i.e. this is the 'risk' cost of developing renal toxicity. This is an opportunity cost to 
the institution in that should an alternative agent to the aminoglycosides be used 
the cost of toxicity would not have to be met.
The opportunity costs of antibiotic failure are the resources consumed in 
retreatment which could be used in some other programme. The bearer of the 
opportunity costs of antibiotic failure is dependent on when and where treatment 
failure is manifest. Obviously it is the hospital if the treatment failure occurs prior 
to patient discharge but if treatment failure occurs after discharge either all of 
these costs or a proportion of these costs are transferred out to the community. If 
the infection is not serious enough to warrant re-admission to hospital then all of 
the costs are borne by the community, for example, GP time, antibiotic costs, 
consumable costs (wound dressings etc.), cormnunity nmsing time. In the present 
study 63 patients received further antibiotics from their GP within two months of 
hospital discharge. If the infection is serious enough to require re-admission to 
hospital then a proportion of the costs are still borne by the community in that the 
GP is involved in the re-admission procedme which is demanding of their time 
and also perhaps in initially attempting to treat the infection. In the present study 
26 patients were readmitted with infections considered to be related to their 
primary mfective episode. Once re-admitted the hospital is then responsible for 
frnther costs inciuTed by the infection which includes bed residency in addition to 
the direct costs of retreatment. No attempt was made in this study to evaluate in 
total monetary terms the opportunity cost of failed aminoglycoside treatment for 
the study population, however, a case example which shows how costs can 
escalate is the patient who consumed a frirther £1757 in direct retreatment costs 
after readmission following failed aminoglycoside therapy.
Even if clinicians remain unconvinced that aminoglycosides should be used rar ely, 
it is still possible to minimise the opportunity costs of treatment by changing fr om 
multiple daily administration to single daily administration (Parker et al, 1995).
168
One of the aims of tliis study was to evaluate the predictive power of a sepsis 
score (Cooke et al, 1993) to forecast potential cost and outcome of treatment. The 
scoring system had evolved from earlier scores targeted at patients with surgical 
sepsis with the intention that it should be based on information readily available in 
any hospital unit. Although the investigations required to complete the score are 
simple in comparison with the APACHE score, these simple investigations were 
performed inconsistently in practice and even the clinical information required to 
complete the score was often not in the patient records. Most of the deficiencies 
could be addressed prospectively but would cause a problem for application of the 
score retrospectively. In addition to this problem of availability of data for the 
sepsis score there were some problems with definition. The recently published 
definitions for hospital-acquired infection (Ayliffe et al, 1993) will help to achieve 
consistency and could reasonably be used as the standards for the sepsis score. 
The terms 'post-procedural' and 'post-operative' require better definition, both in 
terms of the procedur es to be included and the interval before scoring which is 
considered relevant. The sepsis score mcludes three points for 'septicaemia' which 
is postoperative. In this observational study the majority of the patients in the 
postoperative category (operation within 48 hours) had transient pyrexia without 
other signs of sepsis yet four' of 11 patients who had been operated on within the 
previous week died and all 11 patients had a hypotensive episode. This indicates 
that it would be preferable to distinguish between suspected infection and 
suspected sepsis, defined by evidence of infection plus physiological criteria of 
inflammatory response, additionally, the period of time defined by 'post-operative' 
needs to be clarified. Despite these problems there appeared to be a relationship 
between ascending sepsis score and increased morbidity and mortality for 
bacteraemic patients, the relationship was somewhat equivocal for non- 
bacteraemic patients. As the sepsis score increased so did the cost of treatment, the 
score therefore appears to be a potentially useful method not only for objective 
assessment of disease severity but also as a predictor of potential cost. Such a 
measure would help to identify patients with low scores who may be suitable for 
less aggressive treatment, as well as alerting clinicians to patients who may 
require more intensive care. The majority of patients were capable of talcing oral
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treatment, yet even patients with zero sepsis scores continued to receive expensive 
iv therapy. A recent UK audit used the sepsis score to match pairs and compare 
outcome of patients who received oral versus paienteral treatment, this showed 
similar- outcomes even though the patients who received oral treatment had sepsis 
scores ranging from 1 to 13 (Cooke et al, 1993).
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6.9 Phase II
Analysis of the data fi'om Phase I showed that the indications for initiation of 
aminoglycoside tr eatment, the suitability of par ticular patients for this form of 
therapy, the dosages used and all aspects of therapeutic drug monitoring utilisation 
were quite poor. Additionally when all direct treatment costs (drug, equipment, 
staff, monitoring) were talcen into account aminoglycoside usage was foimd to be 
an expensive form of therapy that was not always associated with a successful 
outcome. In addition an overall reciu'ring problem was that of over-reliance on the 
iv route for antibiotic admhiistration.
By feeding this data back to clinicians and therefore heightening awareness to 
these problems of use and the costs associated with aminoglycoside usage, an 
attempt was made to modify prescribing practice. Data feedback was achieved by 
written (Drug Information note) and oral presentation.
Methods
6.9.1 Study population (Phase II)
The clinician groups selected for data feedback were urological, surgical and 
medical (clinical pharmacologists) staffs. These clinicians were responsible for the 
car e of 63% of patients who constituted the study population in Phase I. The 
remaining patients in Phase I were car ed for by a diverse group of clinicians 
ranging from Intensive Care tlnough to Opthalmology. Within tlie time limitation 
of the study it was not logistically possible to target tliis diverse group of 
clinicians for data feedback.
6.9.2 Baseline prescribing practice data collection (Phase II - part 1, mid- 
January 1991 to end February 1991)
For each of the clinician groups constituting the study population, baseline 
antibiotic prescribing habit data were collected fr om the war ds serviced by these 
clinicians for six weeks using an abbreviated form of the clinical record form used 
in Phase I (see appendix F). This data included the number of patients receiving 
antibiotics, indication for antibiotic, type of antibiotic used, route of 
administration, length of treatment, change of treatment etc. A quick analysis of
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this data to identify any other antibiotic prescribing problems peculiar to 
individual clinician groups was used to supplement data from Phase 1 of the study 
which was destined for feedback to these clinicians.
6.9.3 Drug Information (DI) Note production and circulation (Phase II, 
Februaiy 1991)
Data from Phase I of the study (mismanagement of aminoglycoside usage, 
treatment costs, inappropriate usage of the iv route etc.) were used to produce a 
drug information note entitled 'Rational Antibiotic Prescribing: The Relative Role 
of Intravenous and Oral Therapy' (see Appendix D).
The drug information note was circulated to the study population one week prior 
to their oral data presentations.
6.9.4 Individualised seminar presentations (Phase II - mid March 1991)
Seminars were held with each of the study population clinician groups to present
data fr om Phase I of the study augmented with baseline antibiotic prescribing data 
collected in Phase II, parti.
6.9.4.1 Data presentation to Clinical Pharmacologists
It was necessary to analyse baseline prescribing data for presentation as the data 
was being collected, therefore not all data were included. In this preliminary 
analysis 50 baseline patient records of the final 71 were used. The additional data 
used to supplement the general findings of phase 1 ar e shown in Table 6.5/1. Case 
examples of the patients treated by the iv route were used to highlight how costs 
ar e escalated not only by use of the iv route instead of the oral route but also by 
such things as incorrect fr equency of dosing and prolongation of use of the iv 
route.
6 9.4.2 Data presentation to Surgeons
As with the medical unit it was necessary to analyse baseline prescribing data for 
presentation as the data were being collected, therefore not all data were included. 
In this preliminary analysis 54 records of the final 57 were used.
A recurring problem was related to the licensed indications for usage of drug 
prescribed. Of 25 patients who had received iv cefuroxime 10 had been changed to 
oral cephalexin, this change was inappropriate in 7 instances. The 7 cases of
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inappropriate usage was because this group had an intra-abdominal related 
infection, cephalexin does not have a Product Licence for this type of infection. 
The point was made that in addition to expediting the change from the iv route of 
administration to the oral route attention to the Product Licence of the oral 
antibiotic selected also has to be given. Prophylactic antibiotics prescribed at die 
time of operation were also foiuid to be continued for no appaient reason in a 
number of patients.
6.9.4.3 Data presentation to Urologists
Data from Phase 1 of the study highlighted a subpopulation of patients with 
epididymo-orchitis whose treatment schedule was less than optimal. Table 6.5/2 
smnmarises this data. The seminar- presentation to the Urologists focused on the 
treatment of this infection in addition to the general study findings.
The infecting organisms associated with epididymo-orchitis are usually chlamydia 
or gram-negative bacilli, a differential determination of the infecting organism can 
only be carried out by obtaining a sample for culture by prostatic massage. There 
were no prostatic massage samples collected for any of the Phase I patients so 
lorowledge of the infecting pathogen(s) was milaiown . Based on this and the 
laiowledge that the aminoglycosides penetrate prostatic tissue poorly an 
alternative treatment strategy was proposed. This consisted of a two week course 
of oral ciprofloxacin 500mg twice daily to cover potential infection with gram- 
negative organisms, moderate coverage being given to chlamydia. Because 
chlamydia are slow growing organisms it was considered that the ciprofloxacin 
alone would not provide adequate coverage to a chlamydial infection so at the end 
of the ciprofloxacin treatment it was suggested that a two week course of once 
daily doxycycline at a dose of 200mg (tetracycline is the drug of choice for 
chlamydial infections) should then be employed to complete the treatment course. 
This treatment protocol would therefore provide coverage to both groups of 
frequent pathogens responsible for epididymo-orchitis. The perceived benefits of 
this strategy were reduced costs, £55.05 (MIMS, Feb. 1992) for one months oral 
treatment, and unproved outcome as compared with an average iv treatment cost 
of £150 shown to have been associated with treatment failure. In addition it was
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thought that these patients would have an eaiiier discharge because oral therapy 
can be taken at home.
At the end of each presentation, physicians were requested to complete a 
questiomiaire (see Appendix E) which had been 'tailored' to their particular- 
seminar.
6.9.5 Prescribing practice data collection, post seminar presentations (Phase 
II - part 2, end March 1991 - mid May 1991)
Following the seminar* presentations, six weeks of antibiotic prescribing data were 
collected in the same marmer as was used for the baseline antibiotic prescribing 
data (Phase II - parti).
6.9.6 Data Analysis (Phase II)
Comparison of the two sets of prescribing practice data collected in parts 1 and 2 
were intended to allow an evaluation of any prescribing behaviour modification 
brought about by the information feedback sessions.
Equipment and Database Packages (Phase II)
All data were stored and analysed in DBase IV (Ashton & Tate, Berks., UK) using 
spreadsheet (Borland QuattroPro) and statistical software (Minitab 8.0) on an 
Opus 386SX microcomputer.
Costs (Phasell)
Drug costs for Phase II were taken fr om MIMS February 1992.
Tests of Significance
The tests of significance applied to changes in prescribing behaviour between 
parts 1 and 2 of Phase II were the Chisquare test of significance with Yates 
correction for small numbers and determination of confidence inter-vals using the 
method for proportions.
Outcome Measures (Phase II);
Inappropriate intravenous (iv) therapy/ Suitability for oral treatment
Inappropriate iv days were defined as those days a patient was capable of talcing 
oral antibiotics i.e. they were receiving other oral medicines or were taking food or 
on at least 25ml sips of water.
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The criteria used in the assessment of patients suitable for treatment by the oral 
route but who were actually receiving iv therapy included:-
Temperatuie <37.5 and >36.5 
Pulse<100
MAP* >69and<109
No operation within 48 hour s
No specimen sent for C&S or a negative cultiue
* MAP - Mean arterial pressure is the product of systolic pressure minus diastolic 
divided by tlnee and added to diastolic pressme 
In addition to these criteria it was considered that:-
1) Intravenous (iv) therapy was appropriate for the first 24 horns postoperatively 
other than Urology patients who were frequently prescribed oral antibiotics 
postoperatively.
2) Those patients whose putative diagnosis was possible septicaemia were 
considered to be appropriately treated via the iv route for the first 24 horns.
3) All iv treatment of gut related problems (e.g. bowel obstruction, cholecystitis 
etc.) was considered appropriate.
4) Patients receiving concurrent iv antibiotics inappropriately were evaluated as if 
only one antibiotic had been administered (e.g. if a patient received the 
combination of cefrnoxirne, gentamicin and metronidazole inappropriately for one 
day then this was comited as 1 day of inappropriate treatment not as 3 antibiotic 
days).
6.9.7 Results Phase II
General demographic details of patients recruited in both parts of Phase II are 
shown in Table 6.5/3. It can be seen that there were substantially fewer patients 
receiving antibiotics in the second part of Phase II i.e. 140 vs 218. The actual case 
mix appears to be different between the two parts of Phase II. In part 1 27% of 
antibiotic prescriptions were for either a suspected or proven chest infection
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compared to only 17% in part 2. This may have been due to some extent to 
seasonal variation as part 1 was imdeitalcen diuing tire winter whereas part 2 was 
caiTied out during the spring.
Over 50% of patients prescribed antibiotics both in parts 1 and 2 of Phase II 
received them via the oral route. The proportion of patients receiving a cour se of 
antibiotics initially by the intravenous (iv) route followed by oral administration 
was relatively constant between the two parts also, 18% in part 1 and 20% in part
2. However the time to change (measiued in days) from iv to oral appeared to 
decrease in part 2 i.e. only 49% of patients were changed fr om iv to oral within 2 
days in part 1 as opposed to 65% who were changed to the oral route within 2 
days in part 2. This difference is not statistically significant. Wliat appears to be 
statistically significant is the change in number of inappropriate iv days. Over 
tliree quarters of total iv days were considered to be inappropriate in part 1 
whereas less than 50% were considered so in part 2. Table 6.5/4 provides a 
breakdown of the niunber of inappropriate iv days and the statistical significance 
between parts 1 and 2 for observed differences overall and also by speciality. 
During the presentations to the various speciality groups it was suggested that oral 
ciprofloxacin would be a suitable substitute for an aminoglycoside. The proportion 
of patients prescribed ciprofloxacin increased from 10% in part 1 to 27% in part 2. 
From the questiomiaires (see appendix E) circulated to the physician groups the 
speciality specific data and cost data generated the most interest. Without 
exception all physicians felt that tliis type of audit should be repeated on a regular* 
basis. Table 6.5/5 summarises the responses received from the questionnaires.
6.9.8 Changes in prescribing behaviour by speciality 
Clinical Pharmacology
The largest change in prescribing habit was apparently seen with this group. The 
proportion of inappropriate iv days in part 1 was 80%, reduced to just over 24% in 
part 2 with a P value <0.001.
From the questionnaires issued at the end of the seminar* 8 of 11 physicians had 
answered that they thought their prescribing practice would be changed as a result 
of the information supplied to them (see table 6.5/5).
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Surgery
Five of seven surgeons thought their prescribing practice would change as a result 
of the seminar (see table 6.5/5). This translated to an apparent change of 
inappropriate iv days of 68.2% in part 1 to just over 47% in part 2, statistical 
significance P<0.01.
Urology
All of tire ur ologists present (8) thought their prescribing practice would change 
(see table 6.5/5). Yet an analysis of tire overall prescribing of iv antibiotic therapy 
did not show statistically significant changes, tire proportion of inappropriate iv 
days in part 1 was 85.4% arrd 74.5% irr part 2. However, wlreir tire antibiotic 
treatirrerrt of those patieirts with epididymo-orclritis adrrritted after the seminar* 
preserrtation was examined, almost all (11 of 13) were prescribed the treatmerrt 
protocol suggested, although one of these patients also received tlnee days of iv 
gerrtarnicin concurrerrtly with the oral ciprofloxacin for* reasorrs mrknowrr. One 
patierrt received oral ciprofloxacin irr cornbirratiorr with metronidazole prior* to an 
orchidectomy arrd the diagrrosis of epididyrrro-orchitis was unsme irr the thirteenth 
patierrt arrd was poteirtially coirsidered to be a cellulitis of the scrotmrr, tlris patient 
was prescribed 2 days of gentarrricin in corrrbinatiorr with 2 days of iv augmerrtirr 
arrd the course of treatmerrt completed with oral augnrentin. There was a 
fourteenth patierrt who received the rrew treatmerrt protocol for epididymo-orchitis 
but this patient was located on a sur gical ward in Nirrewells hospital. The registrar 
treating this patierrt had previously beerr employed in the mology department and 
had become aware of the reconmrerrdatiorrs for* treatmerrt of epididyrrro-orchitis.
To deternrirre whether the rrew treatmerrt protocol suggested at semiirar* prevented 
recurrerrt irrfectiorr, all patierrts adrrritted irr the post-serrrirrar data collection period 
with a diagrrosis of epididymo-orchitis were followed for tlnee months after* their* 
hospital discharge (see Table 6.5/6). For* these patierrts the rrew treatirrerrt protocol 
appeared to be associated with a high degree of success and an average direct 
nrar girral cost saving of £95 per patierrt.
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6.10 Discussion - Phase II
Feedback of study findings fulfilled the thiee criteria MuirGray (1986) considered 
important for an educational sti*ategy to be effective in modifying clinical 
behaviour. Subjectively, clinicians appeared to have a high degree of interest in 
the findings and in particular were sensitive to cost data (table 6.5/5). A large 
proportion considered that their prescribing practice would be modified by the 
informational feedback. However, as demonstrated by Chaput de Saintonge et al 
(1988), what doctors thinlc they do and what they do in practice can be quite 
diverse events. In the first instance for the study population as a whole, it appeared 
that prescribing practice was modified with a statistically significant decreased 
usage of the iv route, inappropriate iv antibiotic days decreased from 75.9% to 
46.3% (P<0.001), (table 6.5/4). As a group the Clinical Phaiinacologists appeared 
to show the greatest change overall from 80% down to 24.3% (P<0.001), however, 
the Urologists showed little statistical change in general iv antibiotic usage (85.4% 
to 74.5%, P>0.10).
In retrospect, however, the methodology for this phase of the study was less than 
robust. Although it appeared that a statistically significant change in prescribing 
practice for iv antibiotics occuiTcd, it was not possible to attribute the change to 
the intervention for more than one reason. Firstly, an oversight occurred relating to 
the timing of data collection. The intention of this phase of the study was to 
compare prescribing practice behaviour, pre and post intervention for a static 
study population. The collection of the baseline prescribing data i.e. pre­
intervention, commenced in mid-January and continued for the following 6 weeks. 
Unfortunately there was a changeover in jimior house staff at the beginning of 
February. The ramification of this being that the study population pre-intervention 
was somewhat different to that post-intervention. Given that the junior house staff 
cany out the lai'gest proportion of prescribing albeit imder the auspices of their 
seniors, an uncontiolled variable had been introduced into the data collected. 
Secondly, only half of the staff fr om the surgical group attended their intervention 
seminar. Consequently the non-attenders would only have have received the 
printed information (DI note) as feedback.
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Thirdly, it is highly probable that the case-mix of patients for whom antibiotics 
were prescribed, changed between the pre-intervention and post-intervention data 
collection periods. It can be seen from table 6.5/3 that there was a higher 
proportion of patients in the pre-intervention period with a chest infection i.e. 27% 
vs 17%. It is highly possible that the patients in the post-intervention period were 
not as ill as those in the pre-intervention period and tlierefore were not perceived 
to need iv antibiotics for as prolonged a time span as those in the pre-intervention 
period.
These tlnee vaiiables alone, dynamic study population, incomplete delivery of 
feedback and change in case-mix, considerably weakens the inference that the 
intervention used was the cause of an observed reduction of iv antibiotic 
prescribing. In addition to these variables there may well have been other 
unloiown variables which may have explained the change seen. It is for these 
types of reasons that Brennan et al (1994) ai'gue strongly that tests of statistical 
significance should not be used as evidence for the validity of observational 
results.
Although the methodology used in this phase of the study was flawed and overall 
it was not possible to determine whether the informational feedback did have any 
effect on prescribers behaviom*, a dedicated change in the treatment of epididymo- 
orchitis did take place after the inteiwention, i.e. a clinically significant change 
occinred (O'Brien et al, 1994). It can be mgued that this pai'ticulai* change in 
prescribing behaviour was as a direct result of the informational feedback because 
the treatment protocol proposed at feedback was both more effective and less 
expensive than that used historically. Consequently it would have been very 
difficult for the Urologists to justify the continuation of historical prescribing 
behaviour in this instance.
6.11 Summary Discussion for Phases I and II
In conclusion, imlike the failed US patient outcome reseaich initiative (Sheldon, 
1994) which used computerised non-systematic observational data, the first part of 
this study has shown that observational data collected with a systematic approach 
can be used to identify meaningfiil outcome measines. By focusing on both
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process and patient outcome, this current study has demonstrated that although 
aminoglycosides aie ubiquitous in use, their management is poor and they aie not 
low tieatment cost agents. In fact, the aminoglycosides aie associated with several 
opportmiity costs; monitoring, toxicity and heatment failure. In addition to death 
in hospital, thi’ee readily measurable indicators of adverse outcome of hospital 
antibiotic therapy associated with mai'ked increases in hospital treatment costs 
were identified. These were:- change to an alternative iv dmg regimen; 
retreatment with antibiotics in hospital; and readmission with infection. A fuither 
element of resource wastage was also identified in that a high proportion of 
patients capable of receiving oral therapy were being treated with mtravenous 
antibiotics.
The study also tested the predictive power of a sepsis score (Cooke et al, 1993) to 
forecast potential cost and outcome of treatment. Evidence to support the score as 
a method of stratifying bacteraemic patients for risk was produced provided the 
data for the score was collected prospectively. As the sepsis score increased so did 
the cost of treatment, the score therefore appeal's to be a potentially useflil method 
not only for objective assessment of disease severity but also as a predictor of 
potential cost. Such a measine would help to identify patients with low scores who 
may be suitable for less aggressive treatment, as well as alerting clinicians to 
patients who may require more intensive caie. Evidence to support the predictive 
power of the score for non-bacteraemic patients was lacking.
The intention of Phase II was to measure the effect that feedback of cost and 
antibiotic management data from Phase I had on clinicians antibiotic prescribing 
behavioin. Unfortunately, tlie methodology used in the second phase of the study 
was foimd to be poor in design. The prescribing behavioin data collected, both 
before and after feedback, were found to possess more than one known 
confoimding vaiiable, dynamic study population, incomplete delivery of feedback 
and a change in case-mix. The lack of a contiol group frnther exacerbated these 
problems. Although a statistically significant difference in prescribing behaviom 
was observed between the two data collection periods, the presence of these 
confoimding vaiiables invalidated the statistical analysis. As a consequence it was 
not possible to determine whether informational feedback had altered general
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antibiotic prescribing practice. The presence of these confounding variables serve 
to liighlight the important issue discussed by Brennan et al (1994) that extreme 
caution is required when applying statistical tests to observational data.
Despite the lack of evidence to suggest that feedback had had any effect on 
general antibiotic prescribing, the treatment of epididymo-orchitis did appear to 
have been influenced in a positive manner. A dedicated change in the treatment of 
epididymo-orchitis did talce place after the intervention, i.e. a clinically significant 
change occuired (O'Brien et al, 1994). It can be ai'gued that this particular change 
in prescribing behavioin was as a direct result of the informational feedback 
because the treatment protocol proposed at feedback was both more effective and 
less expensive than that used liistorically. Consequently it would have been very 
difficult for the Urologists to justify the continuation of historical prescribing 
behaviour in this instance.
How has this study affected current practice?
The findings of this study have led to several local initiatives which have 
minimised the opportmiity costs identified. Local initiatives include;
« The development of a policy for once daily administration of aminoglycosides 
published in the antibiotic formulaiy of Dundee Teaching Hospitals NHS Trust. 
• Publication and dissemination of treatment guidelines for suspected sepsis and 
consultant review of patients with bacteraemia in the Directorates of Medicine 
and Smgery. Early in 1993 a sepsis protocol to be used by junior doctors in the 
empirical management of sepsis was established after consultation of a 
multidisciplinary group. The protocol was produced on a single sheet and was 
also made available in poster form on all relevant waids. It was aimed at best 
guess therapy pending the results of cultme and other investigation. In addition, 
an misolicited bed side consultation has been made by an Infectious Diseases 
(ID) consultant to all patients with a docimiented bacteraemia in the above 
Directorates. Diagnosis and suggested changes to therapy are made by the 
consultant to the patient’s clmician. It has been estimated that the total cost of 
rmming this service, including full audit and feedback of results, is about 
£6,500 per year (Nathwani et al, 1996). Although tlie cost is not fully offset by
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savings in antibiotic costs, it is felt that the quality of caie given to patients is 
much higher and therefore tlie service continues to operate.
® Strategic changes in the location of patients with epididymo-orchitis from an 
acute siu'gical bed in the Urology unit to an acute medical care bed in the 
Infectious Diseases miit (following the results of the study routine treatment of 
these patients is now by the oral route), 
e Implementation of guidelines and standards for the use of paienteral and oral 
antibiotics in the Directorate of Medicine. A further frill scale audit has shown 
compliance with standards for initiation of parenteral treatment to be 99% and a 
lower compliance of 82% with tlie timing of switch from parenteral to oral 
treatment. A process of continuing education and training for all staff involved 
in prescribing, administering and monitoring antimicrobial therapy is ongoing.
Implications for practice and for future research
This study has shown that cuirent clinical practice is not always ideal and can be 
associated with many opportunity costs. Although time and effort is involved in 
determining simple and meaningfi.il patient outcome measuies, this investment 
will need to be continued if we are to move away fr om narrow cost-containment 
practices which may be increasing resource use elsewhere. Heightening clinicians 
awareness to tlie costs of treatment coupled to measmes of outcome can be 
successfiil in modifying clinical behavioui' to more efficient practices (re: 
epididymo-orchitis). However, as highlighted by the deficiencies of this study, if 
changes in clinical behavioin aie to be measuied in a significant maimer the 
mechanism used will require cai'eful design. Docmnentation needs to be improved 
otherwise any form of meaningful retiospective evaluation will be difficult to 
undertalce. Post-dischaige follow-up must be included in patient outcome in future 
studies of antibiotic therapy. Even if the follow-up period is limited to the first two 
weeks post-dischaige, with an acknowledgement that some failures will still be 
missed, it will at least give an indicator of failuie rate without which no reasonable 
estimate can be made.
With paificulai* reference to aminoglycoside usage, it is believed that the work and 
findings of this study have contributed to the ongoing debate about once daily
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aminoglycoside dosing (Paiicer et al ,1993, O’Shaiighnessy et al, 1994, Pai'ker et 
al ,1994, Parker et al ,1995, Freeman et al, 1997).
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Figures and tables for Chapter 6
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Figure 6.2a Distribution of sepsis scores for ail bacteraemic patients (n=85)
and non-bacteraemic aminoglycoside (n=215)
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Figure 6.2b Mortality by sepsis score in all bacteraemic patients (n=85) and 
non-bacteraemic (n=215) patients
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Figure 6.2c Rate of treatment failure for all surviving bacteraemic patients (n=68) and
for surviving, non-bacteraemic, aminoglycoside (n=194) patients
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Table 6.1/1 Presenting Complaint For Intiation Of AminoglycosideTherapy
Infection Patient % ofCategoiy Episodes Total
Blood 132 51.8
Pulmonaiy 20 7.8
Urinary 22 8.6Tract
Abdominal 30 11.8
Epididymo- 14 5.5
orchitis
Skin/Soft 12 4.7Tissue
Other 25 9.8
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Table 6.1/2 Antibiotic Combinations On Initiation Of Aminoglycoside Therapy.
Combination Patient Episodes % Of Total
Gentamicinalone 18 7.1
Gentamicin + 53 20.8Augmentin
Gentamicin +
Augmentin + 28 11.0Metronidazole
Gentamicin +Cefuroxime + 44 17.2Metronidazole
Gentamicin + 30 11.8Piperacillin
Gentamicin +Piperacillin + 6 2.4Metronidazole
Gentamicin +Metronidazole 19 7.4
Other combinations 57 22.3(<5 patient episodes each)
(including netilmicin,amoxycillin,
penicillin,ampicillin,ceftazidime,ftisidic acid,
flucloxacillin,vancomycin,ciprofloxacin,erytliromycin,cephalexin,trimethoprim,ceftuoxime,piperacillin)
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Table 6,1/3 Ultimate Response To Therapy For The Aminoglycoside Group In Hospital*
i) For all diagnoses 
Success
Resolved on original treatment
Resolved on iv therapy followed by 
po ti'eatment
Resolved but therapy stopped due 
to Adverse Drug Reaction
Failure 
Died #
Changed to alternative iv antibiotic 
with subsequent resolution
Patient episodes
53
118
1
Total 172
28
18
Antibiotic recommenced for same
indication because of recur rent symptoms 9
Total 55
20.8
46.3
>0.5
67.5
11
7.1
3.5 
21.6
Unassessable
iv therapy changed to po treatment then 
back to iv therapy
Further antibiotics for another mfection
Other 16
Total 28 
Overall Total 255
2.7
2.0
6.3
11.0
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cont Table 6.1/3 Ultimate Response To Therapy For The Aminoglycoside 
Group In Hospital*
ii) For all diagnoses minus proven gram-negative bacteraemics 
Success Patient episodes
Resolved on original treatment 47
Resolved on iv therapy followed by 
po treatment 104
Total 151
21.9
48.4
70.0
Failure
Died
Changed to alternative iv antibiotic 
with subsequent resolution
22
15
Antibiotic recommenced for same
indication because of recuirent symptoms 6
Total 43
10.2
7.0
2.8
20.0
Unassessable
iv therapy changed to po treatment then 
back to iv therapy
Frnther antibiotics for another infection
Other 12
Total 22 
Overall Total 215
2.8
1.9
5.6
Some people were readmitted to hospital witliin a short time period following discharge with a recmrence of their original infection.
 ^died thr ee weeks after discontinuation of antibiotics
Dehisced wound, died after discharge to another hospital, longterm antibiotics for miknown septic focus, for leg amputation, for organ transplantation, self discharge, self discontinuation etc.
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Table 6.1/4b Component costings (drug, equipment and staff time) for 
bacteraemic patients treated with a non-aminoglycoside antibiotic regimen 
(n=45)
Median 95% Cl
Drug £68 £48-96
Equipment £17 £9-24
Staff Time £9 £6-12
Total cost £97 £69-143
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Table 6.2/1 Frequency Of Infecting Organism Causing Bacteraemia
( Ix  E.COÜ+KlebsiellaH-Strep.spp,Ix E.coli+Proteus,
Ix  E.COÜ+Klebsiella+ Strep.faecalis+ Clostridia spp., IxPseudomonas spp + Staph.epidermidis,Ix Haem.influenzae+ Staph.epidermidis)
Organism PatientEnisodes (%)
E.coli 45 52,3
Klebsiella 10 11.6
Pseudomonas spp 6 7.0
Salmonella 4 4.7
Proteus 4 4.7
Enterobacter 4 4.7
B.fragilis 3 3.5
N.meningitidis 2 2.3
Acinetobacter 1 1.2
conforms 2 2.3
Mixed 5 5.8
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Table 6.2/2 Type And Time Of Specimen In Relation To The Initial Blood Culture Specimen For Those Bacteraemic Patient Episodes With Another Focus Of Infection
Focus of infection and No of episodes with No of episodes with
specimen same organism different organism
Urinaiw tract
Urine same day 6 1
1-7 days earlier 1
16 days earlier 1
1-7 days later 1 2
Dipslide same day 4 1
1-7 days earlier 2
subtotal 13 6
Abdominal
Womidswab 1-7 days earlier 1
1-7 days later 2
subtotal 1 2
Pulmonary
ET Aspirate same day 1
1-10 days earlier 1 1
Sputum 1 day later 1
subtotal 1 3
Other
Mouth swab 1
Faeces 1 1
Skin swab 1
subtotal 1 3
Overall total 16 14
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Table 6.2\3 Initial antibiotic treatment of Bacteraemic patients
Antibiotic No patient episodes % of total
14Gentamicin + Aiigmentin
Cefuroxime + Metronidazole
Augmentin
Ciprofloxacin
Amoxycillin
Cefuroxime
Gentamicin + Piperacillin
Gentamicin + Cefuroxime + 
Metronidazole
Gentamicin + Metionidazole
Ciprofloxacin + Metronidazole
Penicillin
Penicillin + Chloramphenicol
Cephalexin
Flucloxacillin
Co-trimoxazole
Amoxycillin + Ciprofloxacin
Vancomycin
Amoxycillin + Ceftazidime 
Gentamicin + Cefuroxime 
Trimethoprim
Gentamicin + Cefuroxime + 
Flucloxacillin
Total
16.5
10.6 
10.6
9.4 
8.2 
8.1
7.1
3.5
2.4
2.4
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2 
1.2
85'
* nb 1 patient with bacteraemia did not receive any antibiotic therapy
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Table 6.2\4 Ultimate response to therapy for bacteraemic patient episodes
No. patient % of total 
episodes
Success
Resolved on original treatment 19 22.1
Resolved on iv therapy followed by po therapy 26 30.2
Resolved but therapy stopped due to adverse
drug reaction 1 1.1
Subtotal 46 53.5
Failure
Died 14 16.3
Changed to alternative iv antibiotic and resolved 5 5.8
Antibiotics recommenced for same indication
because of recurrent symptoms 9 10,5
Subtotal 28 32.6
Unassessable
IV therapy changed to po therapy then back to
iv therapy 1 1.1
Fui'ther antibiotics for anotlier indication 4 4.7
Other* 6 8.1
Subtotal 11 14
Overall total 85
* self discharge, po treatment to iv then back to po, died after transfer to another 
hospital, query need for antibiotics as query significance of bacteraemia, long term 
antibiotics for imloiown septic foci etc.
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Table 6.3/2 Patients readmitted to hospital within three months of hospital discharge n=69
Notes untraceable n=5
A) Readmitted but reason not related to original infection n=38
Reason for readmittance No of patients
Arranged admission for investigative procedure eg. 5cystoscopy, colonoscopy
Outpatient clinic review 8
Admission for unrelated problem eg. pain 15management, convalescence, haematemesis, radiotherapy etc.
Arranged admission for elective surgery 10
B) Readmission considered to be related to original infection n=26
Initial foci of infection and time to readmittance No of patients
from original discharge
Blood: 1-7 days 3
15-21 days 5
22-28 days 2
>28 days 2
Respiratoiy; 1-7 days 2
8-14 days 1
>28 days 1
Urinary: 8-14 days 2
22-28 days 2
>28 days 1
Epididymo-orchitis : 1-7 days 1
>28 days 1
Other 8-14 days 2
>28 days 1
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Table 6.3/3 Death whilst receiving initial treatment, underlying pathology andappropriateness of therapy
No of deathsNon-bacteraemic receiving aminoglvcoside therapvAppropriate treatment + nnderlying pathology 4Appropriate treatment + no underlying pathology 12Inappropriate treatment + no underlying pathology 6
Bacteraemic receiving aminoglvcoside therapvAppropriate treatment + nnderlying pathology 3Appropriate treatment + no underlying pathology 4
Bacteraemic not receiving aminoglvcoside therapvAppropriate treatment + nnderlying pathology 3Appropriate treatment + no underlying pathology 3Inappropriate treatment + no underlying pathology 1
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Table 6.4/1 Aminoglycoside assay results for patients receiving Therapeutic Drug Monitoring
No of Assays (No of patients)
Uninterpretable assays (Lack of data on 50 (42)sampling times)
Interpretable assays 321 (173)
Assays within recommended range 48 (33)
Overdosepostdose>10mg/l 27 (26)postdose <10mg/l but trough 47 (36)>2mg/l 74 (62)total overdose Underdose 224 (139)
postdose <8mg/l
Dose adjustmentdecreased dose due to high serumconcentrations 49/74 (66%) (62)increased dose due to low serumconcentrations 95/224 (42%) (139)
At the time of tliis study the Tayside recommended therapeutic ranges for gentamicin and netilmicin were predose level <2mg/l
postdose level > or = 8mg/l but < or = lOmg/1.
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Table 6.4/3 Reasons for missed antibiotic doses
Reason for non-administered or non recordeddose No. of doses
Not recorded on Kardex therefore no evidence of 402 
administration
Not recorded on Kardex but on fluid chart 90
Nil by Mouth orders 37
Reasoned missed dose *
Nil in Stock 16
Dose changed due to misunderstanding 8
Misunderstanding between med. & nur sing staff 7
Venflon tissued or no iv access 7
Patient absent 7
Patient non compliance 2
Other 15
* Examples of reasons include
1) preceding dose given late therefore prescribed dose not given
2) in transit to ICU3) at theatre4) problems with givmg set5) imable to swallow, vomiting
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Table 6.4/4 Clinical condition of patients deemed to have received iv treatment 
unecessarily by pre-defined selection criteria and verification by case-note review 
n=26
Necessity of iv treatment determined 
by case note examination
No therapy required
Suitable for oral therapy
Intravenous tr eatment necessary
Clinical diagnosis (No. patients)
Ureteric colic (1)
Cerebrovascular accident (1)
Clrronic obstructive aiways disease with 
no indication of infection (1)
Epididymo-orchitis (10)
Chest infection (4)
Urinary tract infection (3)
Cellulitis (1)
Renal colic (1)
Swinging pyrexia (1)
Subacute bacterial endocarditis (1) 
Clir'onic obstructive aiways disease with 
infection (1)
Osteomyelitis (1)
205
Table 6.5/1 Additional baseline data used to supplement findings from Phase I 
presented to Clinical Pharmacologists
Baseline audit of all patients receiving 
antibiotic therapy (13/1/92-25/2/92) on two 
medical wards
No of patients 
n=50
Indication for antibiotic treatment
Proven or suspected chest infection 33
Urinary tract infection 8
Assorted other infections 9
Unable to take oral medication 2
Treated by the oral route only 42
Total direct costs of treatment £415
Treated by the intravenous route 8
Total direct costs of treatment £921
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Table 6.5/2 Epididymo-orchitis patient data from Phase I presented to 
Urologists
Patients with epididymo-orchitis No of patients
Treated with an aminoglycoside containing 
regimen 16
Unable to take oral therapy 0
Suitable for oral therapy at initiation of 
treatment determined by selection criteria and 
case-note review
10
Total direct cost of these cases £2517
Average cost per patient £150
Median cost per patient £112
Underwent Therapeutic Drug Monitoring 7
Subtherapeutic 6
Overdose 1
GP antibiotic prescription for recurrent
infection 4
Hospital readmission due to recurrent 
infection
2
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Table 6.5/4 Inappropriate iv days
AU Phase II results, parts 1 & 2 
Part 1 Part 2
Patients (no) 215^ 132*
Total days 1704 1350
(Oral and intravenous)
Intravenous (iv) days 261 214% of total days 15.3% 15,9%
Inappropriate iv days 198 99
(% of iv days) 75.9% 46.3%
95% Cl 70.7-81.1 39.6-52.9Difference 29.6%
95%CIofdiff 21.1-38.1Chisquaie with
Yates correction 42.71 with Id.f P<0.001
By speciality 
Urology
Patients (no) 89 62
Total days 738 739(Oral and iv)
No.iv days 82 55% of total (oral & iv) 11.1% 7.5%
Inappropriate
iv days 70 41(% of iv days) 85.4% 74.5%
95%CI 77.7-93.0 63.0-86.1Difference 10.8%95%CI of diff -3.0-24.6Chisquare with
Yates correction 1.85 with Id.f. 0.50>P>0.10
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cont Table 6.5/4 Inappropriate iv days
Clinical PharmacologyPart 1 Fart2
Patients (no) 69 38
Total days (Oral and iv)
554 371
No.iv days 50 
% of total (oral & iv) 9.1% 7419.9%
Inappropriate 
iv days (% of iv days)
40
80%
18
24.3%
95% Cl 68.9-91.1Difference 55.7% 95%CI of diff 40.9-70.5 Chisquare with
Yates correction 34.94 with ld.f. P<0.001
14.5-34.1
Surgery
Patients (no) 57 32
Total days (Oral and iv) 412 240
No.iv days 
% of total (oral & iv) 12931.3% 8535.4
Inappropriate iv days 
(% of iv days)
88
68.2%
40
47.1%
95% Cl 60.2-76.3 36.4-57.7Difference 21.2%95%CI of diff 7.8-34.5Chisquare withYates conection 7.51 with Id.f. 0.01>P>0.001
^ The population of patients in this pai*t was 218, however 3 patients were unevaluable 
for inappropriate iv days, 1 patient was on longterm antibiotic therapy for osteomyelitis and bacterial endocarditis with many confounding factors such as changes in therapy due to deterioating renal frmction, 3 patients case notes were untr aceable and it was not possible to determine length of tr eatment.
* The population of patients in this part was 140, however 8 patients were imevaluable 
for inappropriate iv days, 1 patient was on longterm antibiotic therapy for osteomyelitis and bacterial endocarditis with many confoimding factors such as changes m therapy due to deterioating reanal function, 7 patients case notes were untraceable and it was not possible to determine length of treatment.
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Table 6.5/6 Community surveillance of patients admitted with epidiymo 
orchitis in the post-seminar data collection period (31/3/92-14/5/92)
Three month follow-up No of patients Comment
No further antibiotics 7
Change of antibiotic at 1 Vomiting due to
discharge doxycycline
Died 1 Due to ischaemic heart 
disease, not related to 
epidiymo-orchitis episode
Further antibiotics 2 Haematuria following 
catheter change (1)
Only received 1 day of 28 
days initial treatment (1)
Surgical removal of testis 1
No response from GP 2
213
Chapter 7
7, Feasability of assessing the costs and benefits of a novel healthcare
programme within a UK hospital.
7.1. Introduction - Non-inpatient intravenous (NIPIV) antibiotic care
versus Inpatient intravenous antibiotic care
As discussed previously in chapter 5 (The economic issues of antibiotic use) a NIPIV 
service for the administration of antibiotics has been widely available to North 
American patients since the 1970's. Within the UK, provision of this type of service 
has been on an ad hoc basis and limited to a select population of hospital patients, 
primarily those suffering from cystic fibrosis with recuiTent mfection (Gilbeit et al, 
1988). Given that this type of service is considered cost-effective in the US setting for 
a myriad of conditions, a feasibility study designed to examine the logistics, costs and 
benefits of such a service for patients with acute infection was undertaken in the 
Infectious Diseases Unit (IDU) of Dundee Acute Hospitals NHS Trust, Tayside. 
Within the study, tlu'ee perspectives were considered, that of the patients, the initial 
secondary care provider and that of other health care professionals who could possibly 
become involved in the provision of a NIPIV service.
The objectives of this study were:-
e To determine which patients are suitable for home or outpatient intravenous (iv) 
antibiotic care.
« To determine how practical provision of a home/outpatient iv antibiotic service is 
within Tayside.
® To quantify the costs and benefits of non-inpatient iv treatment versus outpatient 
iv treatment.
® To evaluate the perceptions of both study patients and Tayside General 
Practitioners (GPs) of this type of service.
® To assist in the production of a business plan for a NIPIV seiwice.
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7.1.1. Patients and Methods
From January 1994 through to November 1994 all patients admitted to the IDU of 
Dimdee Acute Hospitals were considered for non-inpatient care. The miit is the 
regional unit for treating adults with infection and serves a population of 
approximately 400,000. The unit is comprised of 54 beds, 28 of these are devoted to 
orthopaedic patients who have an infective complication with the remainder devoted 
to patients with any other infection. The majority of admissions to the unit are direct 
referrals from GPs in the conununity but a significant number are referrals from other 
units within the Trust.
On admission, patient assessment was undertalcen by a junior house officer and senior 
house officer/registr'ar, difficult cases being assessed by the on-call infectious diseases 
(ID) consultant. If antibiotics were considered appropriate, patients were cormnenced 
on a standard regimen identified by a imit protocol. The route of administration being 
determined by clinical need at the point of prescription. Patients receiving iv 
antibiotics for 24 hour s were ftuther evaluated by a senior member of the study team 
to determine whether a need existed to continue with the iv route and if so, whether 
the patient was a prospective candidate for the NIPIV progranmie. This required that 
the patient was medically stable, was expected to require the iv route of administration 
for at least 5 days and had an infection amenable to either ceftriaxone or teicoplaninh 
If these criteria were met the patient was socially assessed tluough a personal, 
interactive, semi-structured interview. Encouragement was given to the patient to have 
a family member or friend present at the interview. Several horns prior to interview an 
information sheet (see appendix G), which explained the background and reasons to 
the study, was given to each of the patients such that they could discuss it with their 
family/friends if they so desired, it also gave them the opportimity to fonnulate any 
questions. At interview all aspects of the study were explained to the patient and the 
opportimity was given for the patient to ask as many questions as they wanted. Each 
interview took approximately 30 minutes to cairy out. The social assessment included 
fully informing the patient of all aspects of the study,
^These antibiotics were chosen because they only required administration once daily and therefore, 
from a patients perspective, preparation and administration requirements were relatively simple.
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determining that the patient was motivated and willing to paiticipate and that home 
circimistances were supportive for this form of therapy, for example, easy access to a 
telephone, suitable drug storage facilities etc. (full details of the social assessment 
screening questionnaire are given in the appendix G). On admission to the study each 
patient signed a consent form.
The study included an outpatient ami and a home caie aim. Outpatient treatment 
necessitated attendance at the wai'd once a day for antibiotic admmistration and iv 
access assessment. Home treatment necessitated that the patient or a relative/carer be 
trained to prepare and administer the prescribed antibiotic at home. The patient was 
required to attend the ward twice weekly for iv access assessment. On entering a 
patient to the study a plamied discharge to the home enviromnent was caiiied out. 
This included the insertion of an appropriate iv line, and where necessary, instmction 
in aseptic teclmique and cai*e of the iv line (see appendix G for patient guidelines and 
information pack). The two types of iv access used were a 21G venflon catheter or a 
peripherally inserted 'midline' (PIC line) catheter. Instruction in aseptic teclmique and 
iv access care continued until the patient felt comfortable and competent and the 
instmctor equally considered the patient competent in their teclmique. At this point 
transport aiTangements and review dates and times for return to the hospital were 
confirmed. Transport arrangements included a private facility (taxi) or reimbursement 
of travel costs, whichever the patient prefeiTed. Additionally, the time aiTanged for 
attendance at the hospital was that which was convenient to the patient. This allowed 
tliose patients returning to work to attend either before or after the working day. Prior 
to discharge each patient was asked what they perceived the benefits and drawbacks of 
such a service to be, they were interviewed again at the end of their treatment to 
determine if their opinion had changed.
On dischai'ge to the home environment each patient was supplied with all items they 
would require (drugs and all consmnables they would require for preparation and 
administration and for caie of their iv access), in addition a cascade 24 horn* contact 
list (see appendix G) was supplied. Each patient had a final appointment with one of 
the infectious disease consultants to assess their response to treatment and whether 
any fui'ther therapy or investigation was required.
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Even though clinical responsibility was maintained by the hospital for the patient 
during the study period, each patient's GP was contacted on the day of discharge to 
their home to give notification that the patient would be in the community with an iv 
access in situ. The GPs and members of the community musing team were not asked 
to be directly involved in the study. Fmlhermore, no hospital based member of the 
team visited the patient at home although advice and support was available at all 
times.
Detailed financial accomiting of all drugs and consumables used was recorded for 
each patient, this included those consumables used in providing an iv access. Note 
was also talcen of the amount of staff time taken in patient continuing caie. Total 
transportation costs or distance travelled, were recorded for each patient. In order to 
create a comparable costing for hospital based treatments two ID consultants 
independently made an estimate, based on the clinical history, of what therapy these 
patients would have reasonably received had they remained in hospital. Treatment was 
defined according to the written guidelines in the IDU. These guidelines specify the 
drug, dose, route of administration and duration of treatment. For example, guidelines 
for the management of cellulitis recommend iv treatment with flucloxacillin, Igm, 
foiu times daily, m addition to benzylpenicillin, 1.2gms, four times daily, both for 48 
hours, followed by a further 7 days of oral flucloxacillin, 0.5gm, four times daily. The 
consultants also estimated the length of patient stay. This allowed all direct costs 
(drugs, consmnables, staff time) of study treatment to be compared and contrasted 
with the standai'd direct inpatient treatment costs had the patient remained as an 
inpatient.
A telephone sm vey of all Tayside GP teams was canied out to determine their attitude 
to the provision of a NIPIV service. This was achieved by initially contacting each 
practice by letter briefly explaming Üie reasons for and the pmpose of a NIPIV service 
and providing a copy of the questions to be explored at interview (see appendix G). 
Contact was then made by telephone to arrange a suitable time to carry out the 
interview. Although only one partner per practice was interviewed, it was assimied (as 
requested) that the views expressed were a consensus of all the partners in the 
practice.
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A focus group of study patients participated in a roundtable discussion with non- 
clinical marketing experts to further establish their views on the NIPIV scheme. 
Medical etliics committee approval was sought and obtained for tliis study.
7.1.2. Equipment and Database Packages
All data were stored and analysed using spreadsheet (Borland QuattroPro) software on 
a Toshiba 486 microcomputer.
7.1.3. Source of costs
All antibiotic drug costs were taken fr om MIMS July 1994.
Staff time was talcen as the average cost of one hour's musing time (£10/lioiu) in 1994 
(Davey, 1996).
Consmnable costs (syringes, needles, giving sets, sterets, vecafrx, tegaderm etc.) were 
provided by central supplies dept, Dmidee Acute Hospitals Unit, 1994.
Vygon Nutriline 'PIC 300mm midline catheter kit - purchase cost from Vygon (UK) 
Ltd. 1994- £25/kit (each kit included all consimiables required for aseptic insertion 
e.g. swabs, guide needle, syringe etc.).
Chest X-ray charge - £22 (calculated by Business Manager, Radiography dept., Kings 
Cross Hospital, 1994).
In the calculation of staff time for hypothetical inpatient costs, the prepar ation and 
administration of a bolus mjection was talcen as 10 minutes (Cousins et al, 1989).
7.1.4 Calculation of treatment costs
For those patients in the home iv arm the cost of treatment was inclusive of staff time 
taken to coimsel and assess the patient, staff time taken to provide the iv access (i.e. 
insertion time etc.), cost of x-rays to determine appropriate location of access staff 
time taken for aseptic preparation and administration training, drugs and consmnables 
used and the staff time taken for evaluation of the iv access site and of any remedial 
action required (e.g. replacement of access etc.).
The cost of treatment for patients in the outpatient arm included staff time taken to 
coimsel and assess the patient, staff time talcen to provide the iv access (i.e. insertion
^Only those patients with a PIC line inserted required a chest x-ray.
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time), cost of x-rays to determine appropriate location of access drugs and 
consmnables used and staff time talcen for preparation and administration of antibiotic 
and evaluation and care of the iv access site.
7.1.5 Transportation costs
Patients own travel was offered to be reimbmsed at 26p/niile (this figure was 
calculated by the RAC, 1994, to cover car-, average wear, tear* and fuel costs - personal 
commmiication).
Taxi transportation charges as per contractor (approx. 75p/mile).
7.1.6 Study Funding
Monies were not readily available from within the NHS service to cany out this study 
therefore equal sponsorship was sought from the manufactmers of the antibiotics 
(ceftriaxone and teicoplanin) chosen for use, namely Roche and Marion Merrell Dow. 
Antibiotic selection preceded study funding.
Within the sponsorship contract entered into with each company a clause existed 
stating that all data remained the academic property including publication rights, of 
those person(s) canying out the study and that neither company had the right to veto 
data publication or presentation.
7.2. Results
7.2.1 Study population characteristics
Dming an 11 month period, 1,057 patients were admitted to the IDU. Less than 60% 
(559) were receiving antibiotics. More than 50% of these patients (304/559) received 
antibiotics by the oral route, leaving a subgroup of 255 (24% of original admission 
population) patients from which to recruit. From tliis subgroup 24 patients met the 
initial criteria and were socially suitable for entry into the study. Table 7.1 shows the 
reasons for non-recruitment of the other 231 patients, the main reasons were short 
term need of parenteral antibiotics and medical instability. However, social 
circumstances were a factor in 25 patients that may have been smmomitable with
^Only those patients with a PIC Ime inserted required a chest x-ray.
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greater comiminity support. A Anther 2 patients were recruited to the study horn the 
ID outpatients clinic and another 3 were referred to the study Aom other units in the 
hospital giving a final total of 29 study patients. The reasons for iv treatment of the 
study patients in preference to oral therapy are given in Table 7.2.
Recruited patient age ranged fiom 17-75 years and the length of treatment ranged 
fi'om 1-88 days. The longest length of treatment for the home arm was 69 days and 88 
days for the outpatient arm. Figure 7.1 shows the distribution of length of treatment. 
Table 7.3 shows the indication, location of treatment and antibiotic used. The major 
indication for NIPIV treatment was skin and soft tissue infection accounting for over 
50% of patients, with the remainder of patients having a mixed bag of infections. A 
larger proportion of patients were treated as outpatients, 19, versus 10 patients in the 
home ar m.
7.2.2 The costs of treatment
The component costs of treating a patient on the NIPIV programme are given in table 
7.4a. The consumable costs associated with the preparation and administration of the 
study drugs have been separated fiom the consumable costs associated with 
establishing and caring for the iv access. The rationale being that with any iv 
treatment, access is necessary, and will therefore be the same for all treatments and as 
such can be disregarded in comparisons between treatments. Consequently the 
following comparisons of study treatment costs with hypothetical inpatient costs 
exclude Hie iv access costs. Conversely, the consumables associated with drug 
preparation and administration will vary with the frequency and type of drug used. 
The iv access costs have been shown in table 7.4a for the sake of completeness, it can 
be seen from this table that on average, iv access costs account for less than 3% of the 
total treatment cost.
NIPIV study treatment costs (drug acquisition, consumables used, staff time) are 
compared and contrasted with the hypothetical direct inpatient treatment costs (as 
determined by ID consultant consensus) in table 7.4b. Hypothetical direct consirmable 
and time costs are not given for patients 4 and 17 because it was decided (by the two 
ID consultants) that had they stayed in hospital it would have been possible to treat 
them orally because total compliance would be achieved which could not have been
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guaranteed in the community, this being the rationale for iv treatment in the 
cornmimity. Both patients had osteomyelitis.
The average cost per NIPIV study patient was £665 compared with the average cost of 
£427 for inpatient treatment. This indicates average additional costs of £261 per 
patient for NIPIV therapy, however if orthopaedic cases are excluded (patients 4, 6, 
16,17 and 24), the additional cost of NIPIV treatment per patient reduces to £62 (see 
table 7.5a). Orthopaedic infections are associated with particularly high treatment 
costs because of their clrronicity and therefore duration of treatment required. From 
table 7.5b it can be seen that the average cost of treating an orthopaedic patient was 
£2548 in the NIPIV programme compared to £1523 had the patient been treated as an 
inpatient, giving an additional cost of £1025 for the NIPIV programme.
Overall NIPIV costs for the 29 study patients exceeded the hypothetical inpatient 
treatment costs by just over £6,600. This was primarily brought about by the 
difference in drug acquisition costs. The acquisition costs of the drugs used in the 
study exceeded those that would have been used in the hospital by 70% (£17,219 cf 
£10,030), to a small extent this was offset by the NIPIV consumable costs being lower 
than those for inpatient treatment (£464 cf £1369).
The daily acquisition cost of teicoplanin was much greater than that of the daily 
acquisition cost of ceftriaxone (£52.10/400mg teicoplanin vs £11.46/1 gm ceftriaxone). 
To observe how total treatment costs were affected by drug acquisition costs, a 
comparison has been made between actual NIPIV study ti'eatment costs and what the 
costs would have been, calculated on the basis that patients were treated with 
ceftriaxone where possible. The vast majority of patients would have been suitable for 
ceftriaxone treatment with the exception of two mdividuals. One of whom had a 
macrolide/lincomycin/streptogramin resistant Staphylococcus epidermidis infection 
(patient 24) and another who had a Staphylococcus evidermidis infection (patient 17) 
resistant to both cefuroxime and augmentin. It can be seen from table 7.6 that 
preferential use of ceftriaxone rather than teicoplanin in the 13 patients identified as 
suitable, would have reduced their average treatment cost fiom £509 to £133 giving a 
cost difference of £376 per patient, in favour' of ceftriaxone. Putting these treatment 
costs back into the NIPIV study population as a whole and comparing with the 
proposed hospital inpatient costs it can be seen (table 7.7) that the average NIPIV
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treatment cost would be reduced to £486 with a cost difference of £59 per patient in 
excess of hospital inpatient treatment, this is however, without excluding the high cost 
orthopaedic infection patients. Examining the effect that the orthopaedic patients have 
in this scenario is shown in tables 7,8a and b. Excluding the orthopaedic patients, and 
using ceftriaxone where possible for the NIPIV patients, the average cost of treatment 
would have been reduced to £132 compared to £199 for hospital inpatient treatment 
giving a cost difference of £67, this time in favour of NIPIV treatment (see table 7.8a). 
However, the average cost of treating an orthopaedic infection patient still remained 
higher in the NIPIV setting (£2190) than in the hospital setting (£1522) (see table 
7.8b) primarily because it was not possible to use ceftriaxone for two of the patients 
(17 & 24) for the reasons already discussed. In addition, another substantial 
component in the cost difference in this instance is that oral therapy could be used in 
the hospital as compliance would be guaranteed which it could not be in the 
commimity. Wliat has to be remembered though is that these costs relate to the 
preparation and administration of drug alone and does not talce into consideration the 
bed day costs of an orthopaedic patient which was on average 63 days. Table 7.9 
siunnwises the various costing scenarios described above.
7.2.3 Impact of the NIPIV programme on utilisation of hospital bed days 
The total number of bed days saved by the 29 patients on the NIPIV programme 
totalled 532, representing an average of 18 bed days per patient. However this figure 
is skewed by the five orthopaedic patients who accounted for almost 60% (316) of 
these bed days. The average nimiber of bed days saved per non-orthopaedic patient 
was 9 days with a median of 5.5 days which is in stark comparison to tire average of 
63 days and median of 62 days for an orthopaedic patient.
It can be seen from table 7.10 that the total bed day capacity of the ID unit was 19,710 
and as a proportion the 532 days saved by those patients on the NIPIV programme 
represented only 2.7%. Capacity utilisation for the ID unit was assumed to be arormd 
45% based on the preceding 3 years average, as such the 532 bed days saved still only 
represented 4% of 1994 expected actual bed day consumption.
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At the time of this feasability study the ‘hotel cost’ per bed day in the ID Unit was 
calculated to be £313 (Scottish Health Service Costs, 1994). It could be argued 
therefore that £166,516 (532x£313) had been saved, however unless the savings could 
be made tangible by reducing fixed costs this argument would be flawed.
Considerable rationalisation of the ID service has talcen place and in 1996 the number 
of inpatient beds has been reduced to 35, 22 on the Kings Cross site and 12 in a new 
Orthopaedic Infection Unit at Dundee Royal Infirmary. Nonetheless, at the level of 29 
patients per year', NIPIV therapy would still have a minimal effect, even on this 
reduced bed capacity.
7.2.4 Transportation costs
Of the 29 patients, 14 requested or required the taxi transpor'tation proffered, the 
remainder (15) chose to use their own transport. Although the patients using their own 
transport had the opportunity for travel reimbur sement to the hospital not one patient 
decided to take advantage of this. Table 7.11 shows the individual mileage covered by 
patients and the costs of taxi transportation. Wliere taxi transportation was provided 
the average cost was £114 per patient. However, 4 of the patients were orthopaedic 
patients who received transportation for 28 days or longer, their average cost was 
£266 per patient, giving an average cost of £53 per patient for the remaining group.
7.2.5 Patients perspective of NIPIV treatment who received this form of 
treatment
As part of the initial screening process, patients were asked what their perceived 
benefits of home/outpatient iv treatment might be, these benefits fell into 1 of 5 
categories and are simmiarised in table 7.12, it can be seen that the most frequently 
cited advantage is the freedom afforded of being at home. During the screening 
process patients were also asked whether they or their relatives had concerns of any 
nature regarding NIPIV treatment. Of the 29 patients, 26 had no personal concerns 
whatsoever, 3 had concerns which were of a low level nature in that the concerns did 
not deter the patient from participating in the programme. Sixteen patients had chosen 
to discuss entry into the programme with a close relative or friend and 13 had not. Of 
the 16 patients who did discuss the NIPIV programme with a relative or friend,
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concerns were expressed by 4 relatives. The nature of the concerns expressed both by 
patients and relatives are given in table 7.13.
Of the 29 study patients, 26 completed the 'end of study' questionnaires, 1 patient did 
not return the questionnaire, 1 patient died and the remaining patient was removed 
from the study after their initial diagnosis was changed after 1 day on the NIPIV 
programme. The results from the questiormaire are smnmarised in tables 7.14 & 15. 
Of the 26 patients, 8 (33%) reported a problem but 75% (6) of these were of a quite 
minor nature (fr'om a medical viewpoint that is, rather from the patients perspective) 
and were related to either the speed of injection or to the discomfort caused by the iv 
access. Two patients (7.7%), however, were considered to have experienced a problem 
of an important nature and were related to hypersensitivity type reactions. The 
experience of these two patients and the ramifications for a NIPIV service are 
discussed fuither in section 7.2.7 Safety of NIPIV car e. The vast majority of patients, 
92% (24), said tliey would repeat this form of therapy again, the reasons given by the 
two patients (8%) who said they wouldn't, considered that they would have had more 
rest had they remained in hospital. Five patients (19%) thought that NIPIV had caused 
them 'out of pocket' expenses but qualified this by stating that this was of their own 
choice. The perceived advantages of the patients prior to participating in the study 
were corroborated by the actual advantages experienced (table 7.15).
Nine of the patients who had been tr eated between January and August 1994 on the 
NIPIV programme were interviewed in a focus group discussion. The meeting was 
facilitated by Professor Stephen Parkinson and Daragh O'Reilly of Bradford 
Management Centre. A summary of the key points fiom this discussion are given in 
table 7.16. All patients participating in the discussion group stated they would repeat 
this form of therapy and felt the treatment at home improved their quality of life.
7.2.6 GP perspective of NIPIV treatment
A response to tlie summary letter circulated to 61 GP practices representing 295 
individual GPs was obtained from 41 practices (representing 125 GPs). Not all 
practices responded to all questions.
Of the 41 practices surveyed, 22 estimated from previous experience that they would 
refer between 1-10 patients with infection to the IDU per aimmn, 10 thought they
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referred between 11-20 patients annually and the remainder felt they couldn't give a 
realistic estimate. Of the practices who were able to give a rough refeiTal estimate, the 
majority considered their referrals to be due to skin and soft tissue infections or chest 
infections.
Wlien asked about the advantages/disadvantages of a NIPIV service to both 
themselves and to their patients, a large proportion (71%) saw no advantage to 
themselves and a substantial disadvantage (46%) in the form of an increased 
workload. When considering the patients potential benefits of a NIPIV service, the 
majority of GPs thought that the patients would gain from getting home quicker and 
being in their own environment. The disadvantages to the patients discussed by the 
GPs varied widely but all centred aiound the lack of experience of this type of 
therapy. All advantages and disadvantages discussed by the GPs are shown in table 
7.17.
Wlien the GPs were asked whether they would favour the availability of a NIPIV 
service, a larger proportion (24/39) said they would favour one than wouldn't (4/39). 
A further 11 practices felt that they would need more information before they could 
answer. The options presented to the GPs for how a NIPIV service could be organised 
and the GP responses to these options are given in table 7.18. It can be seen tliat 
majority support only remained for a NIPIV service when both funding and 
responsibility remamed within the secondaiy cai*e sector.
7.2.7 Safety of NIPIV care
Eight patients (27.6% of study population) reported a medical related problem 
associated with their NIPIV care. The type of problem expressed by six patients was 
considered to be of a quite minor nature (fr om a medical viewpoint that is, rather from 
the patients perspective) and was related to either the speed of mjection or to the 
discomfort (phlebitis) caused by the iv access. The problem experienced by the 
remainmg two patients (6.9% of study population) was of a more serious nature. Both 
these patients displayed a hypersensitivity type reaction whilst receiving antibiotic 
treatment as outpatients. The first reaction followed administration of a second dose of 
teicoplanin which was being used to treat a right leg cellulitis. The antibiotic had been 
administered within the hospital with the patient then retuining home. The onset of
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symptoms (rigours, global piloerection, dry mouth, chest tightness and shortness of 
breath) occuired some 60 minutes post dose, the episode being of approximately 20 
minutes duiation. The patient contacted the hospital during the episode and although 
advised to return to the ward the patient declined but returned the following day. 
Treatment was changed to ceftriaxone, the patient continued on the programme and 
the infection was successfully treated. The second reaction was experienced by a 
patient being treated with ceftriaxone for osteomyelitis of die right temporal bone. The 
reaction was first experienced some 30 days after initial antibiotic commencement and 
took the form of a tr ansient flushing sensation in the face and neck hnmediately 
following antibiotic administration. From this point forward the patient reported an 
increasing degree of transient flushing sensation on administr ation of ceftriaxone. An 
antihistamine (terfenadine, 60mg twice daily) was administered to try to ameliorate 
the problem but with little success. Antibiotic administration was stopped 26 days 
after the first report of ‘flushing’. On follow-up the patient reported that the reaction 
had abated. During the antibiotic treatment, this patient was also talcing medication 
(isosorbide mononitrate, glyceryl trinitrate, fi'usemide, aspirin, amlodipine, lisinopril) 
for imderiying pathology of ischaemic heart and peripheral vascular disease. However, 
given the chcumstantial evidence it was felt that the ‘flushing’ reaction was in fact 
due to the ceftriaxone rather than die other clnoriic medication.
7.3. Discussion
The stimulus for this feasability study was the consistent reports from the US on the 
cost effectiveness and patient popularity of NIPIV services. The experience 
encountered in this study reflects both similarities and dissimilarities with the US 
reports. The similar ities centred around the workability and patient preference for such 
a service, the dissimilarities were of a fiscal nature and the reserved attitude of 
primary care physicians to their involvement in die provision of this type of service.
As in the US, the study used a multidisciplinary health care team and successfully 
demonstrated that it is logistically feasible to select and treat patients with varied acute 
infection in the non-inpatient setting. However, the number of patients selected over 
the 11 month period was relatively small, this was due in the main to the selection
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procédur e which required that patients were perceived to require antibiotics for 5 or 
more days. Seventy three percent (186/255) of patients in the IDU receiving iv 
antibiotics did so for less than 5 days. Therefore tire procedural criteria accounted for 
the low recruitment rate rather than medical instability which may have been expected 
to be more problematic i.e. less than 10% of patients (20/255) were unsuitable for 
reasons of medical instability. It is entirely possible, therefore, that the recruitment 
rate could have been substantially higher.
A surprising aspect from the patient social assessment interviews was that although 
NIPIV therapy was an entirely new concept, very few patients or relatives had 
concerns about participating in the programme. In fact at the end of treatment, patients 
expressed a consistent, distinct preference for this form of therapy when compar ed to 
the alternative of hospital inpatient car e and this was independent of the length of time 
a patient spent in the programme. Most problems experienced by patients were of a 
minor nature and neither deterred the patient from continuing on the programme or 
from expressing thefr intention that they would readily participate again. Poretz
(1993) reported that adverse drug reactions occur no more often in the NIPIV setting 
than in the hospital setting and that the incidence of plilebitis is actually lower than in 
the hospital. However, the issue of safety of NIPIV care was raised in tliis feasability 
study by two patients (6.9%) experiencing an adverse event which was of a serious 
nature. The issue being that if an adverse event occurs within the confines of a 
hospital there ar e trained personnel on hand to deal with the problem. This catch net 
does not exist for patients in the home setting.
Given that NIPIV car'e originated in the US and the predisposition that Norlh 
Americans have for litigation it would be reasonable to assume that a vast literature 
concerning safety and legal issues alone would exist, this doesn’t appear* to be so. 
Safety aspects are referred to in the literature but it is somewhat piecemeal. An 
explanation for this may lie with the way NIPIV car*e developed around the purpose of 
reducing the costs of treatment to patients. It would seem that North American 
patients have implicitly accepted the risk of an adverse event occuning at home for 
the benefits of convenience and lower care costs. From the information that is 
available it certainly appears that adverse reactions are no more frequent than those 
occurring in hospital, it is not unreasonable therefore, to assimie that this has come to
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be considered ‘acceptable risk’. In one of the first reports of NIPIV care in 62 patients 
with cystic fibrosis, Rucker et al (1974) stated that no major complications were noted 
although mild phlebitis necessitating changing tlie iv line site was required after 7-8 
days in some patients. The initial experience of Stiver et al (1978) with the NIPIV 
care of 23 patients concluded that side effects were no different from those in-hospital 
treated patients and that there was actually a decreased prevalence of phlebitis in 
patients treated at home. Foui' years and another 102 patient treatments later, these 
workers (Stiver et al, 1982) reported tlie continued acceptance of NIPIV care in that 
no side effects were experienced that necessitated discontinuation of home treatment 
or readmission to hospital. Others have also reported the safety of NIPIV care, Kind et 
al (1985) treated 315 patients over a 10 year period with no problems relating to the 
outpatient use of antibiotics. In a review of North American NIPIV literature Balinsky 
et al(\9%9) concluded 'there currently exists sufficient data to support both the safety 
and clinical effectiveness o f outpatient parenteral antibiotic therapy\ This conclusion 
has continued to be endorsed by others (Bernstein, 1991, Grizzard, 1991, Graham, 
1991, Williams, 1993). However, the quantification of ‘acceptable risk’ from the 
existing literature is somewhat nebulous. The Manitoba home iv antibiotic program 
was reviewed after 12 years of operation (Cote et al, 1989), there had been 748 
admissions to the program equating to 15,366 patient days. During this time phlebitis 
was occuning at a rate of 14.7% and there had been 7 penicillin induced allergic 
reactions, 1 reaction was severe leading to respiratory failure requiring resusitation. 
Despite tliis the overall conclusion of the review was that the home iv program was 
safe and effective. Implicit in this conclusion tlierefore is that phlebitis occurring at 
14.7% and 1 respiratoiy failme for 748 admissions constitutes ‘acceptable risk’ to tliis 
particular healthcare provider. In a different study (New et al, 1991) the complications 
observed and considered ‘acceptable’ were phlebitis occurring at a rate of 11.3% and 
aminoglycoside associated problems occurring at a rate of 2%. Adverse event rates 
vary between individual drugs and tlierefore, so will the ‘acceptable’ risk, for 
example, Tice (1991) considers ceftriaxone to have a ‘good’ safety profile for use in 
the outpatient setting with a 4% incidence of adverse effects, whereas Morales et al
(1994) consider cefotaxime to be acceptable in a similar setting with an adverse event 
rate of 40%. The severity of an adverse event is obviously important in determining
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‘acceptability’, those experienced by Morales et al (1994) with cefotaxime were 
lar gely considered mild.
Several models of home iv care now exist within North America (Tice, 1993) and it 
has been estimated that some 250,000 patients are treated annually (Rubinstein, 1993), 
consequently, basic safety standards have evolved that a service must meet in order to 
earn accreditation by the Joint Commission on Accreditation of Healthcare 
Organisations (Malloy, 1990). These include administration of the first dose and 
observation by a trained professional, adequate training and education of 
patients/carers in preparation and administration teclmiques, the ability of 
patients/carers to identify adverse events and the issue of anaphylaxis kits. In addition, 
patients should have access to a trained professional on a 24 hour basis.
If NIPIV car e is to become as widely acceptable in the UK as it has in North America, 
tlien it will have to be considered safe by those using it. To this end two aspects will 
need to be made explicit. Firstly it will be important for a consensus to be reached 
between those receiving and providing the care as to what constitutes ‘acceptable’ risk 
and secondly, measur es will need to be in place which minimize the risk of an adverse 
event occuning and ameliorate the situation should an adverse event occur.
There was a high correlation between perceived and actual advantages of NIPIV care 
expressed by the patients in tlris feasability study. The most frequently cited benefit 
was that of having the freedom of being at home followed by the opportunity to return 
to work or deal with personal matters. This desire to return to a more normal lifestyle 
reflects the benefits expressed by patients in the US, Furthermore, to talce advantage 
of an ear lier discharge to the home environment, study patients were prepar ed to incur 
costs to themselves by providing their own transport. Patients' perspective should be 
considered in any service development as they are the end user. The type of 
qualitative interview approach used in this study, to elicit patients' perspective, has 
been found useful by others in the UK (Harries & Hill, 1994).
As previously mentioned, reports fiom tlie US consistently report cost savings 
associated with NIPIV services. The fiscal findings in this study were not as clear* cut 
as the US r*epor*ts, this is possibly due to two major* differences that exist between the 
UK and US. Firstly, the reports fiom the US ar*e from well established infiastructures 
designed to specifically provide a NIPIV service. This feasability study did not have
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an established infrastructme and sought to incorporate this type of service into an 
existing secondaiy caie setting. Secondly, US patients and third party payers 
immediately realise cost savings from entiy into a NIPIV programme as they no 
longer have to pay hospital 'hotel' costs. The payment for secondaiy caie treatment is 
organised in an entirely different manner in the UK and cannot be directly compaied 
with that of the US. The demand for the NIPIV programme generated by the 
feasability study reduced bed day consumption by a negligible 4%. It is highly 
unlikely therefore that fixed costs (staffing levels, other overheads etc.) would be 
decreased because of this reduction, consequently the potential ‘hotel cost savings’ of 
£166,516 (see section 7.2.3) are illusory. Decreasing fixed costs appears to be quite a 
complex issue as highlighted by others (Stern et al, 1995). One study (Stern et al, 
1995) demonstrated that although a 30% reduction in the average length-of-stay for 
laiee aifliroplasty patients could be achieved, the associated decrease in fixed costs 
was a more modest 13%. The examination of financial costs in this NIPIV feasability 
study has therefore, focused on the direct, variable treatment costs, as these can be 
readily identified and valid comparisons made between alternative forms of treatment. 
An initial inspection of treatment costs in the feasability study and assuming a payer 
perspective alone i.e. the hospital, could lead to the conclusion that provision of a 
NIPIV service is economically unattractive. Comparison of the direct, variable 
treatment costs between the study NIPIV care and hypothetical inpatient hospital care 
showed the average cost difference per patient (£228) to favoiu* inpatient care. 
However, closer examination of these costs revealed more than one identifiable 
influence within the study which caused this preference, these were the existence of a 
high treatment cost subpopulation i.e. orthopaedic patients with an increased average 
cost of treatment of £1,025 for NIPIV care, and the unforced use of the high 
acquisition cost antibiotic, teicoplanin. This unforced use of teicoplanin reflects an 
important limitation of the study which was brought about by the sponsorship. The 
sponsors, Roche & Marion Merrell Dow, insisted that equal numbers of patients were 
treated with ceftriaxone or teicoplanin. Removal of these biases reversed the average 
cost difference per patient to £67 in favour of NIPIV care (see table 7.9).
Other costs to consider associated with this study of NIPIV provision, ar e tliose of 
transportation for those patients who were unable to provide their own. The average
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cost in the study per orthopaedic patient was £266 and £53 per non-orthopaedic 
patient. From this closer examination of costs it appear* that treatment of an 
orthopaedic patient on this type of NIPIV programme remains imattractive, however, 
this is not the case for* the short duration treatment of non-orthopaedic patients, even 
when the costs of transportation (£53) ar*e offset against the treatment cost gain of 
NIPIV (£67) therapy. The economic case disfavouring orthopaedic patients however, 
is not quite as clear* cut as it would appear. The var iation of clinical treatment for* this 
group of patients is wide and although some ar e presently considered suitable for oral 
treatment in Dundee Teaching Hospitals Trust (DTHT), standard therapy in the US is 
iv treatment for six weeks as it is by others in the UK (Kalley et al, 1996). Should a 
change in treatment policy occur* in DTHT then the curTent economic evaluation may 
well change.
Unlike their US counterparts, the GPs' approached in this study were somewhat 
reluctant to participate in the care of a patient in receipt of NIPIV therapy and were 
equally reluctant to fund this form of therapy. The consensus was that tlris type of 
service would involve an increase in workload with little benefit to the GPs'. Since the 
time of the GP survey, the govermnent has issued a directive (NHSME EL(95)5) 
which is prescriptive about the way in which packages of care to patients at home 
initiated in the secondary care sector should be funded. Essentially, it can no longer be 
the responsibility of the GP to prescribe drugs etc. for specific 'packages of care' (e.g. 
NIPIV therapy) to patients at home. It is now the District Health Authorities (DHAs) 
(or* their reorganisational successor (see chapter* 2)) who have been charged with 
making financial arrangements for* this type of patient. The DHA has to make the 
appropriate logistic arrangements and contract negotiation with whoever* they deem fit 
to provide the 'package of care' service to the 'at home' patients. The service can be 
provided by contract with a Trust or directly with an NHS or* commercial supplier*. 
The directive, NHSME EL(95)5, has effectively excluded GPs from fiirfher 
participation in the supply of NIPIV car e, so to some extent the negative perspective 
adopted by the GPs can be disregarded in fiitur e considerations of whether* the further 
development of a NIPIV programme should be taken forward. However, fundholding 
GPs could possibly become purchasers of NIPIV care in a similar* manner to the 
DHAs. The perspective fundholders may then adopt, could in all likelihood, be
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different from tliose GPs primaiily concerned about personal workload implications 
i.e. the cost-effectiveness of a NIPIV service would become an important issue for the 
fundliolding budget.
In suimnaiy, the study objectives were achieved, NIPIV caie is feasible. Appropriate 
selection criteria for patient recruitment to a NIPIV programme were developed, 
provision of a quality service was shown to be practical and examination of the costs 
and benefits highlighted segments of the market (within the parameters of the study) 
for which this type of service initially appears to be cost effective and not so cost- 
effective. Study patients expressed a high degree of preference for NIPIV care and 
were supportive for the continuation of this alternative form of Üierapy even though 
some costs were identifiably transferred to themselves, conversely the majority of 
GPs' were only supportive of the idea of such a service provided there were no 
financial or increased workload implications. The issue of ‘safety’ was raised by this 
feasability study, as a result, the notion of ‘acceptable risk’ deserves exploration in the 
frirther development of NIPIV care.
The production of a business plan for a NIPIV service using the findings from this 
study is cuirently imderway. In addition, suitable orthopaedic patients are currently 
being treated in this non-inpatient mamier even tliough at a financial level it has 
initially appeared more costly. The driving force for this being the patient non- 
financial benefits accrued by avoiding long-term hospitalisation.
This study has also highlighted an important issue which needs to be borne in mind 
when interpreting results from this type of feasability programme, that is, bias 
introduced by a conflict of interest. Resour ces were not available fr om public funds to 
carry out this study. It was only possible to readily, secure funding from 
pharmaceutical sponsors, consequently certain parameters had to be adhered to within 
the study i.e. funding was dependent on equal numbers of patients being treated with 
ceftriaxone and teicoplanin. Consequently a source of bias was introduced in the form 
of drug acquisition cost. It should become a prerequisite that the results fr om futur*e 
studies are examined for sour'ces of bias similar to that just described.
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Implications of this study for future research
It is to be hoped that facilitation of frirther service development will be aided by the 
publication of NHSME EL(95)5, as a source of funding for specific packages of care 
at home, has now been identified. The NIPIV programme just described was a 
feasability study, however, the programme has provided a base on which further 
developments could expand. For example, demand for the serwice could be increased 
by including those patients who require less than 5 days iv antibiotic treatment and by 
incorporating other conditions amenable to NIPIV therapy, such as congestive cardiac 
failure, peripheral vascular disease and some long term AIDS care.
In 1995, a multidisciplinary, expert workshop was convened to set out and discuss 
current views in the UK, on the pros and cons of non-inpatient par*enteral antibiotic 
therapy (Non-inpatient use of parenteral antibiotics, 1995). This expert panel raised 
and ranlced 16 issues which needed to be acted upon to ensur*e appropriate non­
inpatient use of parenteral antibiotics. The Dimdee feasability study has addressed 7 of 
these issues comprehensively and a further 3 in part (see below), those issues which 
have only been addressed in part and the remaming 6 which have not been addressed 
at all will require future clarification if a NIPIV programme is to be established as a 
stand alone combined primary/secondary car e service.
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#
Figure 7.1 Distribution of length of treatment for patients on NIPIV program
8-14 15-21 22-28 >28
No of days treatment
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Table 7.1 Reasons for non-recruitment of patients receiving iv antibiotics 
onto the NIPIV study
Reasons for non-recruitment No of patients
Short term iv antibiotics (<5 days) 186
Medically unstable 20
Socially not suitable (e.g. histoiy of depression, too infirm, 
etc.)
19
Other (e.g. too far to travel, study antibiotic unsuitable) 6
Table 7.2 Reasons for iv route of administration vs oral route
• Failure of oral therapy 
» Immunocompromised
® Serious infection- need to ensure high serum levels 
® Underlying pathology e.g. diabetes 
e Ramadan
Table 7.3 Indications and antibiotic used for treatment in study population
Indication (% of study population) Teicoplanin 
(no of patients)
Ceftriaxone 
(no of patients)
Cellulitis (51.7) 9 6
Osteomyelitis (10.3) 2 1
Other orthopaedic infection (6.9) 1 1
Line sepsis (6.9) 2 -
Pneumonia (10.3) - 3
Lung abscess (3.4) - 1
PUO (6.9) - 2
?Tonsilitis (3.4) 1 -
Location of treatment
Outpatient clinic 9 4
Home 6 10
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Table 7.7: NIPIV study costs calculated on the basis that patients were treated where possible 
with ceftriaxone and compared with hypothetical hospital inpatient costs.
Patient
ID Allstudycosts(ceftrlax) ÂltTherAilCosts Diff(Study-AlîTher)
1 148 169.36 -21.36
2 197.21 83.3 113.91
3 78.64 232.87 -154.23
4 2754.45 523.45 2231
5 86.55 254.68 -168.13
6 549.92 2674.35 -2124.43
7 62.19 83.3 -21.11
8 135.15 430.1 -294.95
9 72.15 83.3 -11.15
10 310.91 1120.86 -809.95
11 442.07 394.42 47.65
12 184.36 83.3 101.06
13 284.78 212.8 71.98
14 21.95 83.3 -61.35
15 55.63 83.3 -27.67
16 703.46 1106 -402.54
17* 3655.69 462.84 3192.85
18 394.03 312.48 81.55
19 72.5 83.3 -10.8
20 55.38 83.3 -27.92
21 72.47 83.3 -10.83
22 45.14 83.3 -38.16
23 17.64 22.68 -5.04
24* 3287.44 2847.6 439.84
25 88.39 83.3 5.09
26 106.18 258.36 -152.18
27 39.04 83.3 -44.26
28 72.54 79 -6.46
29 123.22 287 -163.78
total
average
14117.08
486.80
12388.45
427.19
1728.63
59.61
suitable only for treatment with teicoplanin
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Table 7.8a: NIPIV study costs calculated on the basis that patients were treated where possible 
with ceftriaxone and compared with hypothetical hospital inpatient costs but excluding all 
orthopaedic infection patients
Patient
ID Allstudycosts(ceftriaxone) AlteniativeTlierapyAIICosts Diff(Study-AlîTher)
1 148 169.36 -21.36
2 197.21 83.3 113.91
3 78.64 232.87 -154.23
5 86.55 254.68 -168.13
7 62.19 83.3 -21.11
8 135.15 430.1 -294.95
9 72.15 83.3 -11.15
10 310.91 1120.86 -809.95
11 442.07 394.42 47.65
12 184.36 83.3 101.06
13 284.78 212.8 71.98
14 21.95 83.3 -61.35
15 55.63 83.3 -27.67
18 394.03 312.48 81.55
19 72.5 83.3 -10.8
20 55.38 83.3 -27.92
21 72.47 83.3 -10.83
22 45.14 83.3 -38.16
23 17.64 22.68 -5.04
25 88.39 83.3 5.09
26 106.18 258.36 -152.18
27 39.04 83.3 -44.26
28 72.54 79 -6.46
29 123.22 287 -163.78
total 3166.12 4774.21 -1608.09
average 131.92 198.93 -67.00
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Table 7.9 Summaiy and comparison of the average direct treatment costs 
associated with NIPIV treatment and hospital inpatient treatment under 
different conditions.
Condition 1 Average direct Average direct Cost differencetreatment cost of NIPIV treatment cost of
treatment hypothetical hospital
inpatient treatment £228
n=29 n=29 (favours hospital
treatment)
£655 £427
Condition 2 Average direct Average direct
treatment cost of NIPIV treatment cost of
treatment minus hypothetical hospital
# orthopaedic patients inpatient treatment
minus orthopaedic
patients
n=24 n=24 £62
(favours hospital
£261 £199 treatment)
Condition 3 Average direct Average direct
treatment cost of NIPIV treatment cost of
treatment for hypothetical hospital
orthopaedic patients inpatient treatment
for orthopaedic
patients
n=S n=5 £1,025# (favours hospital
£2,548 £1,523 treatment)
Condition 4 Average direct Average direct
treatment cost of NIPIV treatment cost of
treatment using hypothetical hospital
ceftriaxone where inpatient treatment
possible
n=29 n=29 £60
(favours hospital
£486 £427 treatment)
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cont Table 7.9
Summary and comparison of the average direct treatment costs associated with 
NIPIV treatment and hospital inpatient treatment under different conditions.
Condition 5
Condition 6
Average direct
treatment cost of NIPIV 
treatment using
ceftriaxone where
possible minus
orthopaedic patients
n=24
£132
Average direct
treatment cost of NIPIV 
treatment using
ceftriaxone where
possible for orthopaedic 
patients
n=5
£2,190
Average direct
treatment cost of 
hypothetical hospital 
inpatient treatment 
minus orthopaedic 
patients
n=24
£199
Average direct
treatment cost of 
hypothetical hospital 
inpatient treatment
n=5
£1,523
Cost difference
£67
(favours NIPIV 
treatment)
£667 
(favours hospital 
treatment)
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Table 7.10 Bed day capacity of IDU 1994
No of beds Bed days*
Ward 1 10 3,650
Ward 9E 22 8,030
Ward 9W 22 8,030
Total 54 19,710
* Bed days = No of beds x 365
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Table 7.11: Transportation mileage and costs
Patient
ID Total mileage - own transport Reimbursement cost {£) Total taxi cost (£)
1 34 5.44
2 120 19.2
3 14 2.24 366.33
4
5 14 2.24
6 126
7 60 9.6
8 12 1.92
9 24 3.84
10 84 13.44
11 56 8.96
12 52.4
13 60.7
14 4 0.64
15 54
16 60 9.6
17 510
18 102.5
19 12
20 13.8
21 19.8
22 25.2
23 4 0.64
24 63
25 150 24
26 105
27 8 1.28
28 16 2.56
29 88
total 660 105.6 1598.73
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Table 7.12 Patient perceived benefits of NIPIV treatment 
n-29, 60 responses
Perceived benefit % expression
Freedom of being at home e.g. cook, shopping, 79
sleep in own bed, etc.
Less stressful 38
Can return to worli/deal with personal 31
matters
Less family disruption 31
Increase social contact 21
Table 7.13 Concerns about NIPIV treatment expressed by patients and 
relatives
Nature of patient expressed concern 
» Feels safer in hospital but self
rationalised that this is because 
this form of treatment is a new 
idea
® Could envisage difficulties
arranging for children to be cared 
for
Didn’t like the idea of having an iv o 
access in situ at home
Nature of relative expressed concern 
© Mother (x2) concerned about the 
level of care given on the NIPIV 
programme might not be the same 
in hospital
Wife thought that better treatment 
would be given in hospital
Wife needed reassurance that it 
was OK for her husband to go 
home with an infection
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Table 7.14 Results of ’End of NIPIV Study’ questionnaire n=26
Question Replied Yes
Did you encounter any problem? 8 (33)
Would you repeat this form of therapy? 24 (92)
Did this form of therapy improve your quality of life? 24 (92)
Did this form of therapy allow you more control of 18 (69)
your treatment?
Did this form of therapy cause you any ’out of pocket’ 5 (19%)
expenses?
Table 7.15 Summary of results from question 4 from ’End of NIPIV Study’ 
questionnaire, ’Could you give examples of the sort of things you were able to do 
which you would not have been able to do had you stayed in hospital? n=26, 60 
responses
Example % expression
Freedom of being at home e.g. cook, shopping, 85
sleep in own bed, etc.
Less stressful 19
Can return to worlc/deal with personal 62
matters
Less family disruption 38
Increase social contact 27
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Table 7.16 Summaiy of key points from patient focus discussion group (n-9) 
of NIPIV therapy provided by experts from Bradford Management Centre.
Reaction to the NIPIV sei*vice was favourable, the principal benefits being the 
ability to recuperate at home and to go back to work if so desired.
The orientation about the service was effective.
The seiwice was perceived positively by all respondents.
CPs had limited awareness and Imowledge of the service.
No-one said that the family/carers had expressed a concern about the 
treatment.
Several ways were suggested to make the seiwice even better, these included: 
a specific location for the service 
appointments
a single named contact person 
creating greater awareness amongst CPs.
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Chapter 8
8. Summary and Conclusions
The work in this thesis sets out to examine whether economic evaluation of selected 
antimicrobial usage in the secondary caie sector can influence decision maldng and 
lead to more efficient resomce allocation.
Chapter 2 looked at the methods used by different govermnents to control national 
drug expenditme as a whole. Although a highly visible component of healthcare 
spends, the drug budget only represents some 10-12% of the total. The methods 
directed at controlling drug expenditure are reflective of the system of healthcare 
financing in different coiuitries. UK government controls have been of a cost- 
contaimnent nature primarily directed at the primary care sector even though drug 
usage in the secondary car e sector can have a substantial impact on the primary sector. 
The goverrunent has vired responsibility for the control of their own drug costs to the 
secondary care sector. An issue raised is that although the Goverrmient recognises that 
economic evaluation has a role to play in ensuring cost-effective healtlicare resource 
allocation, there is a lack of an infra-structure to support such evaluation.
Chapter 3 looked at the methods used to control drug expenditure in the secondary 
care setting. The drug budget has, traditionally, been viewed in isolation fiorn other 
cost centres within the sector. Formularies have been an important cornerstone in 
containing costs but the marmer in wliich they have been constr ucted may well impact 
on other healthcare utilisation. It is important therefore that caution is exercised in the 
limitation of formularies in order that the quality of healthcare is maintained and 
patient outcome is not compromised.
To guarantee that cost-effective drugs are chosen for use there is a need to integrate 
knowledge of patient outcome into the drug selection procedme i.e. a need exists for 
pharmacoeconornic evaluation. The lai’gest, single, therapeutic group of drugs 
responsible for up to 30% of a hospitaTs drug budget is the antimicrobials. It should 
be important therefore, to those responsible for resource allocation, that these drugs 
are used in the most cost-effective manner.
Chapter 4 clarifies the issues why the selection and use of antibiotics are in need of 
fiirther evaluation and how this can be talcen forward.
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Chapter 5 examines the various qualities and characteristics an outcome measur e can 
possess and how they may be used in the comparative economic assessment of 
antimicrobial treatment.
Conventional evaluation of antimicrobial therapy has relied on a wide variety of 
narrow spectrimi, unidimensional, patient and process outcome rneasmes and most 
financial appraisal has tended to focus on drug acquisition costs rather than taking a 
holistic view of all treatment costs. Consequently, the value of various therapies in 
relation to each other remains lar'gely unlcnown. Wliat is needed is some form of easily 
applied rneasmernent which responds to treatment effect. As discussed in chapter 5 
the ideal measure would be a single index drawn together from those dimensions 
which affect all the costs and benefits of a therapy. Much research remains to be 
carried out before this ideal is reached.
The two studies undertalcen for this thesis have attempted to demonstrate how the 
combination of the costs of treatment with clinical and process measm es of outcome 
can be used to avoid resource wastage.
Chapter 6 reports and discusses the first study, which was an audit of aminoglycoside 
utilisation and the general antibiotic management of gram-negative bacteraemia. The 
first part of tliis study involved the systematic collection of clinical practice data, 
which were then analysed for appropriateness of caie. This was carried out by 
comparing the observed practice with published evidence based cai'e. Analysis 
showed the aminoglycosides to be poorly managed and associated with several 
opportunity costs. Tluee readily measurable indicators of adverse outcome of hospital 
antibiotic therapy associated with marked increases in hospital tieatment costs were 
characterised. These were: - 
® Change to an alternative iv drug regimen,
® Retreatment with antibiotics in hospital,
9 Readmission with infection.
In addition, another area of wastage was the excessive use of the iv route for antibiotic 
administration.
The second phase of this study was a detailed feedback of these findings to selected 
clinicians. In addition to heightening clinicians awareness to the management 
problems and associated cost of the aminoglycosides, this informational feedback was
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also an attempt to persuade prescribers to reduce the overall use of iv antibiotics by 
talcing advantage of oral administiation thereby limiting resource wastage. Data were 
collected pre- and post informational feedback to determine what impact, if any, the 
intervention had on prescribing behavioui*. Statistical analysis appealed to show a 
significant reduction in the usage of the iv route, however, the method for this phase 
of the study was seriously flawed due to the presence of several confounding variables 
and the lack of a control group (frilly discussed in Chapter 6). Consequently, it was 
not possible to imdisputedly infer that the informational feedback was responsible for 
the decreased fiequency of use of the iv route. However, for one paiticulai* disease 
state, epididymo-orchitis, a dedicated change in treatment did immediately follow the 
intervention. It can be ai'gued that this paiticular change in prescribing behavioiu was 
as a direct result of the informational feedback because the treatment protocol 
proposed at feedback was both more effective and less expensive than that used 
historically.
Despite the presence of methodological flaws in the second phase of this study the 
overall findings have led to several local initiatives which minimised the opportunity 
costs identified. These initiatives include;
® The development of a policy for once daily administration of aminoglycosides.
® Publication and dissemination of treatment guidelines for suspected sepsis and 
consultant review of patients with bacteraemia in the Directorates of Medicine and 
Surgery.
® Sti'ategic changes in the location of patients with epididymo-orchitis fi'om acute 
surgical beds in the Urology unit to acute medical care beds in the Infectious 
Diseases unit (following the results of the study routine treatment of these patients 
is now by the oral route).
® Implementation of guidelines and standards for the use of paienteral and oral 
antibiotics in the Directorate of Medicine.
The presence of confoimding variables (botli laiown and luilaiown) is a major problem 
with studies which are of an observational nature and which do not have a control 
group. A published study which serves to highlight tliis particular problem is one by 
Horn et al (1996). This observational study of cost contaimnent strategies examined
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drug usage for five disease states in six HMO’s scattered across the US. The results 
led workers to conclude In the case o f limited formularies, w>e found the unintended 
consequence o f increased utilisation o f healthcare resources \ The inference being 
that the formularies scrutinised were performing in a paradoxical mamier, i.e. as drug 
formulary restiiction increased so did other healthcare resource utilisation. However, 
this study was methodologically flawed by its luicontrolled, obseiwational nature. The 
heterogeneity of HMO’s and the type of patient directed to them are well recognised 
and as such it is difficult to control for these differences, as a result unidentified 
confomiding variables may exist witliin the populations observed. Other criticisms 
(Ross-Degnan et al, 1996) levelled at this work include the use of only one 
observation time period and the fact that clinical practice varies so widely tluoughout 
the US. It is possible therefore that there may be one or more other explanations for 
the increase in healthcare resource utilisation observed in this study other than the 
presence of a restrictive formulary. In a rejoinder to the criticisms levelled at then 
work, Horn (1996) agreed that the data generated did only justify cautious inference 
that the presence of a restr ictive formulary in an HMO may lead to an increase in 
other healthcare resources.
If the arninoglycoside/bacteraernia study reported in Chapter 6 were to be repeated it 
would benefit from several modifications to the design, primarily in Phase II.
Although the prospective clinical data collected in the first phase of the study could be 
limited to that which was required to answer questions set a priori. A  mistake that was 
made in the phase I data collection set was the tendency to over collect data 'because 
it may come in useful or prove interesting". An example of this was the collection of 
daily TPR measurements for each patient in the study when it was only necessary to 
have measurements for the first and last day the patient was on the study.
Phase II was methodologically flawed because of the presence of several confomiding 
variables. These variables could be controlled for in the following rnarmer:-
1) The timing of prescribing data collection pre- and post intervention should be 
carefully planned to avoid any change in medical staff dming this time period 
i.e. a static study population is necessary.
2) Ensure that all aspects of informational feedback reach all members of medical 
staff who have input to the prescribing process.
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3) Control for patient case-mix pre- and post informational feedback.
4) Include a matched control group for the study population (i.e. the prescribers 
targeted for informational feedback), this would involve measuring the 
prescribmg habits of clinicians not given informational feedback, on similai' 
war ds with a similar case-mix of patients. Ideally the matched control group 
would be in another hospital, if the control group were within the same unit or 
hospital as the study population it is possible that the study population could 
speak to the controls post informational feedback thereby introducing a bias.
Sponsorship for this study came fiorn the connnercial sector. In an effort to avoid the 
problem of bias fiorn this source, mechanisms appropriate to the study proposed by 
Hillman et al{\99\) were put in place prior to conmiencernerit. These workers 
(Hillman et al, 1991) discussed the reasons, how and why, bias occurs. In this paper 
they make 8 recommendations to limit bias introduced by commercial sponsorship. 
The recommendations relate specifically to economic evaluation type studies, in 
surmnary these are;
First, written agreement between the sponsor and investigator(s) should be in 
the form of a research grant and should stipulate that the researchers publish 
findings regardless of their nature.
Second, the selection of alternatives to be compared in an economic analysis 
should be based on their clinical relevance and at a minimum meet FDA 
requirements for comparators in controlled trials.
Third, if a study is designed by the sponsor, the investigator should be allowed 
to include additional costs, economic perspectives and comparator drugs as 
they deem necessary. If the funding group constrains the investigator this 
should be made explicit in the reporting of results.
Fourth, if a project is fimded by instalment, results should be withheld fiom 
the sponsor until publication of results are guaranteed and fimded.
Fifth, investigators should ensur e that results of an economic analysis ar e not 
influenced in the favour of the sponsoring company. Results should be 
supported by sensitivity analyses.
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Sixth, investigators should publish valid results regar dless of their promotional 
value to the sponsoring company.
Seventh, resear chers who receive a grant should not act as consultants on 
projects related to the study medication dming the active period of the grant. 
Finally, researchers should talce all reasonable steps to ensme that the level of 
fiinding permits methodologically somid, clinically relevant results witli 
enough statistical power to detect important differences among the alternatives 
compared.
The implementation of these mechanisms would appear* to have been successM as no 
appar ent bias was detected. To a lar ge extent this lack of bias related to the nature of 
the study i.e. specific drugs were not being compared against each other.
The second study imdertalcen for this thesis is reported and discussed in chapter 7. 
This study examined the feasibility of treating patients with intravenous antibiotics on 
an ambulatory basis and also compared the costs and benefits of such a programme 
with traditional, hospital inpatient treatment. The perspective of both patient and 
provider were factored into the study. A not dissimilar* study has recently been 
repor ted by Kayley et al (1996), although, two important differences exist between the 
two studies. Kayley et al (1996) specifically targeted patients with AIDS who required 
antibiotic treatment greater than two weeks, and secondly, no assessment of treatment 
costs were made. The feasability study reported in this thesis, a) did not target any 
specific patient group, essentially patients (meeting emolment criteria) with or* without 
pre-existing disease were emolled onto the study with any infection expected to 
require more than 5 days treatment, and b) the economic viability of non-inpatient 
intravenous treatment (NIPIV) was explored.
Both this study and the Kayley et al (1996) study concluded that NIPIV care is 
feasible and prefened to in-hospital treatment by patients. Kayley et al (1996) 
reported no serious complications, however, the issue of safety was raised in the 
feasability stirdy reported in this thesis by two patients experiencing a serious adverse 
event. As a result the notion of what constitutes ‘acceptable risk’ deserves exploration 
in the fruther* development of NIPIV car e. Another* contrast between the two studies is 
brought about by economic evaluation. Kayley et al (1996) concluded, witliout any 
hard evidence, that this form of therapy would probably benefit NHS budgets. The
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study in this thesis, which incorporated a comparison of direct, variable costs, 
demonstrated that this assumption could well be ill-founded. Initial inspection of the 
direct, variable NIPIV treatment costs appeared higher than the comparative treatment 
costs in hospital, therefore making NIPIV care appear economically imattractive. 
Despite this, cost-effective aspects of NIPIV treatment were identified by carrying out 
a sensitivity analysis. NIPIV care was fomid to be cost-effective provided high 
acquisition cost drugs were not used and treatment of long duration infection was 
excluded. During the NIPIV feasability study it was calculated that bed day 
consrunption was reduced by 4% which equated to ‘hotel cost savings’ of £166,516. 
However, the point has been made (Chapter 7) that unless fixed costs were decreased, 
which is milikely with a negligible bed day consrunption of 4%, the ‘hotel cost 
savings’ would be illusory.
As stated in the discussion of chapter 7, further development of a quality NIPIV 
service would require establislmient of an infrastructure for support and provision. 
However, barriers to the implementation of NIPIV therapy in the acute care sector, 
crurently exist at resource management level. In the US there is a financial incentive 
to the Hospital to get people home quicker. This incentive does not exist in the NHS 
as explained by Lowson (1993). Crurently, patient stay in hospital is calculated on 
average cost/day (i.e. total cost of treatment (most of wliich occrus in the first few 
days of hospitalisation) divided by nrunber of days in hospital) rather than on 
cost/successfrrl outcome. This is an inadequate way of evaluating the cost of treatment 
as it doesn’t relate to efficiency. If length of stay is reduced, although there is a lower 
cost/successfril outcome the average cost/day is increased. In the pursuance of 
efficiency a move away from using the term average cost/day to cost/successful 
outcome is needed, it is only then that incentives will exist to explore other non­
inpatient modalities such as NIPIV caie.
One of the major drawbacks of this feasability study was the small number of patients 
recruited. If the study were repeated it would benefit by expanding the demand for the 
service. A greater database would provide fiuther information concerning safety, 
patient preference, patient outcome etc. This could be moved fbiwaid by changing the 
patient selection criteria to include those patients who require less than 5 days 
antibiotic treatment, recruiting patients who require antibiotics from other units within
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the hospital and/or incoiporating other conditions amenable to NIPIV therapy, such as 
congestive cardiac failme, peripheral vascular disease and some long term AIDS care. 
Another drawback to this feasability study was the bias introduced by the commercial 
sponsorship despite preventative mechanisms suggested by Hillman et al (1991) being 
put in place. Although the antibiotics chosen for use in the study would have remained 
the same, regardless of the source of frmding (selection was based on their 
antimicrobial spectra and their once daily dosmg requirement), a sponsorship 
agreement predetermined that both antibiotics be employed equally. A sensitivity 
analysis was conducted to examine the impact of this bias, which has been reported 
frilly in Chapter 7. An hnprovement to this study therefore would be non-cornrnercial 
sponsorship such that antibiotic utilisation could be left enthely to the discretion of 
the prescriber.
An ideal feasability study for NIPIV care would therefore be one which:
a) had a large patient population,
b) was randomised between NIPIV care and in-hospital car e,
c) was controlled,
d) compar ed a wide variety of antibiotics, and
e) was non-cormnercially fimded.
In summary, the work rmdertalcen for this thesis has provided a small degree of 
evidence that basic economic evaluation can be used to inform decision rnaldng and 
indicate where efficient resource allocation lies, however, as discussed, there are many 
improvements which could be made to the design of both studies should they be 
repeated. Both studies were sponsored by the commercial sector and although no 
apparent bias due to this source occmTed in the first study, some bias was introduced 
into the feasability study of NIPIV care. This serves to highlight a major problem that 
can occur* with commercial sponsorship. The ideal situation would be if this type of 
Health Services Research could be fimded fiorn non-commercial sources.
Published evidence of hospitals using economic evaluation is thin on the gromid. One 
hospital (Delaney, 1996), however, has recently repor*ted their use of 
pharmacoeconornic evaluation to justify the use of an expensive acquisition cost drug 
(enoxaprin). Without the pharmacoeconornic evaluation the drug would almost
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certainly have been excluded from use within tlie hospital as it was estimated that raw 
drug cost alone per amium would have increased the ding budget by almost 5% 
(IR£21,500). Nevertheless, because enoxaprin reduces the incidence of post-operative 
deep vein tlirombosis from 20% to 6%, annual tieatment costs of IR£96,350 for this 
adverse event can be averted, as a result tliis cost avoidance more than offsets the 
increase in drug budget.
Ciurently, many dings, antibiotics included, aie used without Imowledge of how they 
impact on the utilisation of other healthcare resources, as a consequence this indicates 
that there is a place for the use of economic evaluation in the decision making process 
of resource allocation. The proportion of any national healthcare spend accoimted for 
by antibiotics is relatively small, in 1996 this was in tlie region of 6-7% for England 
and Scotland. It would be unrealistic therefore to imagine that the economic 
evaluation of antimicrobial use would become a specific taiget within a national 
strategy to evaluate healthcai e. It will remain therefore, in the interests of those parties 
that antimicrobial use has the greatest impact on, to ensure they are used in the most 
efficient mamier.
Purchasers of healthcare ’need' (in the economic sense of 'capacity to benefit') 
economic mformation on clhiical practice such that resouices can be allocated in the 
most efficient manner. Unfortimately a two fold problem exists; firstly the information 
needs to be in existence and secondly, the information needs to be readily accessible. 
A solution to tliis problem lies with govermiient sponsored clinical audit and the 
National Register of Resear ch recently commissioned by the NHS Executive. Clinical 
audit provides a formn for gathering economic information, the results of which 
should be stored on the aforementioned Register. It is estimated that the NHS 
Executive will have spent £834niillion by the end of the century (Anon., 1996b) on 
clinical audit project's yet finds it difficult to assess the benefit of spending tliis 
money. If a condition for fimding of firtme clinical audit project's be that some form 
of economic assessment is incorporated into the project, service provision cost and 
benefit data, could be assembled. Information of this natme could then be used to 
assist in the efficient allocation of resomces.
Although the National Register of Resear ch is intended to compile a complete picture 
of all applied health research it only incorporates reseai’ch projects funded by the
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NHS, major charities and the MRC. It does not encompass that research imdertalcen 
fimded by other means, for example, the commercial sector. Unless this is addressed 
in some manner a complete picture cannot be achieved and useful information may 
not be made nationally available.
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Appendix A
Septicaemia/Aminoglycoside Study
Clinical Record Form
Patient ID No:..............
Patient Name:
Unit No:
Date of admission: 
Consultant:
Weight:
Presenting complaint: 
Diagnosis:
Ward:
Dob:
Date of dischar ge:
Page 1 
Sex: M/F
Absorption
Abnormal GI state:
Other:
Administration
Compromised oral route: 
Compromised other routes: 
Comprehension/compliance :
Missed doses
Date Drug Time Reason
Page 2
Chronic Health Evaluation
Indicate whether any of the following chr onic conditions were evident prior to this 
hospital admission:
Liver Disease
Biopsy proven cirrhosis and documented portal hypertension Yes/No 
Episodes of past upper GI bleeding attributed to prtal hypertension Yes/No 
Prior episodes of heptaic failur e/encephalopathy/coma Yes/No
Cardiovascular disease
Angina or symptoms at rest or minimal exertion eg getting dresses Yes/No
Respiratory disease
Chr onic restrictive, obstructive or vascular' disease resulting in 
severe exercise restriction i.e. imable to climb stairs or perform 
household duties Yes/No
Documented clrronic hypoxia, hypercapnia, secondary 
polycythaemia, severe pulmonary hypertension (>40nmiHg) 
or respiratory dependency Yes/No
e
Immuno compromised state
Indicate if, prior to hospital admission, the patient had:
a) Any therapy that suppresses resistance to infection e.g. 
inmiuno-suppression, chemotherapy, radiation, long term low 
dose steroids during 30 days prior to admission to hospital or 
recent high dose steroids (>15mg/kg for 5 days or more)
b) Evidence of a disease that is sufficiently advanced to 
suppress resistance to infection e.g. leulcaemia, lymphoma, 
AIDS, documented diffose metastatic cancer
Yes/No
Yes/No
Page 3
Site of Infection
Sample Date taken Result and sensitivities
Operation within 481ir? Yes/No
Specify operation:
Invasive procedure within 481rr? Yes/No
Urinaiy catheterisation Yes/No
Intravenous cannula Yes/No
Long iv line Yes/No
Cardiac pacemaker Yes/No
Swan Ganz/other ail catheter Yes/No
Peritoneal dialysis Yes/No
Other (specify) Yes/No
No detectable primai y site of infection Yes/No
Physiological points
Temperatoe:
MAP:
Resp rate:
Serum sodium: 
Serum potassium: 
Sermn creatinine: 
Serum bicarbonate: 
PCV:
WCC:
Hb:
Platelet count: 
Plasma albumin; 
Plasma bilirubin: 
Urea:
Glucose:
Glasgow coma score:
On entiy to study
Page 4 
On completion of study
Symptoms and signs of septicaemia
Rigors Yes/No
Alteration in consciousness Yes/No
Peripheral pallor Yes/No
Abnormal sweating Yes/No
Gentamicin levels
Date Predose (mg/1) Postdose (mg/1) Other (mg/1) Serum creatinine (umol)
# Page 5Antibiotics
e
Date
commence
d
Drug Dose Route
admin
Method
Bolus/inf
Date of 
change or 
stop date
Reason
Other drugs (only if ADR):
Clinical progress and treatment changes
Page 6
Date:
Day of week:
Day of treatment:
Clinical Progress
Temp (liighest): 
Frequency of observation:
Pulse (highest):
Frequency of observation:
MAP (lowest):
Frequency of observation:
Systolic bp:
Changes in treatment
Drug:
By whom?:
Reason;
Drug:
By whom?:
Reason:
Drug:
By whom?:
Reason:
Drug:
By whom?:
Reason:
Drug:
By whom?:
Reason:
Appendix B 
GP Letter and Proforma
Deal' Dr
Re: Aminoglycoside/Septicaemia study 1990-1992
We are caii'ying out a study involving those patients within Dundee Hospitals who 
have:
a) Been prescribed an aminoglycoside, or
b) Have been septicaemic.
Yoiu' patient (patient name and DoB) has been entered into this study, we would 
be grateful if you could supply us with information regai'ding all antibiotic 
prescriptions (if any) that (patient name) has had in the thiee month period post 
disclu'ge (discharge date specified).
A pro-forma is enclosed with a self addressed envelope for retuin.
Many thanks,
Yours sincerely
Sharon E Parker 
Reseai'ch Phaimacist
pp Dr PG Davey
Infectious Diseases Consultant
Aminoglycoside/Septicaemia study 
Three month follow-up Proforma
Patient name:....................................................
Patient ID No:.... ...................
Date of discharge from  ...............Hospital:.
Date of Bnth:
Date Antibiotic Dose and fr equency Length of treatment Indication
Other information if appropriate:
Please specify if no antibiotics prescribed within this period
Patient has died Yes/No If yes, Date of death.
Signatur e of General Practitioner
Appendix C
Calculation of sepsis scores
Physiological assessment Score
Maximum daily temperature (®C) 137.5-38.4
38.5-39 2
>39 3
<36 3
Haematology
haemaglobin (g/L)
70-100 1
<70 2
white blood cells (x 10^/L) 110-30
>30 2
<3 3
platelets (x lO^/L) 
100-150 
<100
Biochemistry
plasma albumm (g/L)
1
2
<25 2
plasma bilirubin (umol/L)
>25 2
glucose (mmol/L)
<10 2
creatinine (umol/L)
<20 2
>140 3
Underlying condition
diabetes 2
hepatic disease 3
renal disease 3
Site of infection
urinary tiact
lower 1
upper 2
postoperative add 4
respiratory tiact
oropharyngeal 1
bronchitis/bronchiectasis 2
pneumonia 4
hospital-acquired add 3
septicaemia
pyrexia of unlaiown origin 1
postprocedural 2
postoperative 3
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N in e w e lls  H osp ita l and M edical S ch o o l .  D undee 6 0 1 1 1  Ext. 2 3 5 1
RA TIONAL ANTIBIO TIC PRESCRIBING: THE RELA TIVE 
ROLE OF INTRAVENOUS AND ORAL THERAPY
An audit o f antibiotic prescribing in Tayside Hospitals between September 1990 and January 1991 revealed that, in a number of cases, intravenous therapy was administered to patients in whom the oral route was not compromised and in situations where a suitable oral agent was indicated. This Note examines the reasons for overuse of intravenous antibiotics, the advantages and disadvantages of this route and argues that, in many instances, ora! therapy is often appropriate from the outset, or at least soon after i. v. therapy is initiated.
The A n tib io tic  A u d it - Sum m ary o f  Conclusions:
(I) The intravenous route is frequently used in cases where oral 
antibiotic therapy is appropriate.
(ii) Early transfer from i.v. to oral antibiotic therapy is often possible in 
cases where the oral route is initially compromised.
(iii) Failure to adequately assess the likely cause of infection leads to 
over-reliance on broad spectrum drugs, despite their disadvantages.
R e co m m en d a tio n s  w h en  initiating an tib io tic  therapy:
(i) Consider the likely infecting pathogen(s>.
(ii) Select an antibiotic regimen accordingly.
(iii) Choose the route of administration, remembering 
that oral therapy is frequently appropriate.
(iv) Monitor the patient’s response and consider 
changing from i.v. therapy (if used initially) to 
oral therapy when possible.
Intravenous antibiotic therapy
In traven ou s administration d e livers  a drug directly to the sy s te m ic  
circulation and th erefore  g u a r a n te e s  1 0 0 %  bioavailability. It is rea son ab le  
to s e l e c t  this route routinely in an in tens ive  care  sett ing  and for initial 
t rea tm en t  o f  l ife-threatening in fec t io n s .
However intravenous drug therapy has certain disadvantages.
Intra ven ou s  a c c e s s  is a s s o c ia te d  w ith  a risk o f  local infection and th e  
possib il ity  th erefore  o f  se p t ic a e m ia .
M any in tra ven o u s  antib iotics  p r o d u c e  irritation and throm bophlebitis  at the  
injection s i te  or t i s s u e  n e c r o s is  during ex travasation .  The final 
#  c o n c e n tr a t io n  and rate o f  adm inistration  m ay be critical and require careful
m anipulation .
Finally, in tra ven o u s  antibiotic th era p y  is invariably more ex p e n s iv e  than  
eq u iv a le n t  oral th erap y  (e .g .  1 0  t im es  more in the  c a s e  of c iprofloxacin, s e e  
t ex t ) ,  and o v e r u s e  o f  th e  i.v . rou te  can  add significantly to the  drug b u d get .
In addition to  th e  drug itself,  th e  c o s t  o f personnel time involved in its 
preparation and adm inistration, th e  u s e  o f  co n su m a b le s  (giving s e t s ,  
sy r in g e s ,  e tc . )  and p o ss ib ly  p la sm a  monitoring to o  (e .g .  gentam icin) m ust  be  
ta k en  into a c c o u n t .  For e x a m p le  th e  audit revealed that the “totai cost" of antibiotic regimen which inciuded an aminogiycoside (these drugs are rarely given alone) was increased by 50%  by th e s e  "hidden” c o s t s ,  d e sp i te  the  
fa c t  that g en ta m ic in  is a relatively in ex p en s iv e  drug.
A further co n s id era t io n ,  in th e  c a s e  o f  the  a m in o g lyco s id es ,  is th e  difficulty  
in ca lcu la ting  th e  real c o s t  o f  t r ea tm e n t  in the  ev e n t  o f  toxicity. From the  
audit ,  a f e w  p atien ts  w h o  d e v e lo p e d  a c u te  renal failure incurred th e ,  not  
in co n s id era b le ,  additional e x p e n s e  o f  h aem odia lys is  as a result.
In summary, the advantages o f  i.v. antibiotics are recognised in "intensive care” and acute severe infections where the oral route m ay be compromised. However, it m ust be stressed  0  that, in many cases, oral therapy is possible from the outset or,if  not, soon after i. v. therapy is started.
Oral antibiotic therapy
S ev era l  s tu d ie s  h a v e  s h o w n  that oral antibiotics can be substitu ted  for i.v. 
th erap y , or in d eed  u se d  in p lace  o f  i.v . therapy, w ith ou t loss  o f  therapeutic  
e f f ic a c y .  M any oral antib iotics  are rapidly and exten s iv e ly  ab sorb ed  w ith o u t  
rem oval during first p a s s  (i .e. th e re  is little or no presystem ic  elimination).  
T h e a d v a n ta g e s  in term s o f  c o n v e n ie n c e  to both  patients and personn el ,  
w ith o u t  th e  inherent risks a s s o c ia t e d  with i.v . a c c e s s  and the (usual)  
co n s id er a b le  in c r e a se  in c o s t  o f  i .v .  therapy are ob v ious .
This is particularly true in th e  c a s e  o f  ciprofloxacin, metronidazole and  Augmentin (co -a m o x ic la v ) ,  s e e  o ver .
Ciprofloxacin
BloavailabiHty is a p p rox im a te ly  7 0 % .  H o w ev er ,  food delays the rate, but 
n ot  e x te n t ,  o f  a b so rp t io n  w h ic h  is a lso  reduced  by concurrent u se  of 
a n tac id s .
P lasm a c o n c e n tr a t io n s  are similar fo l low in g  a single  oral d o se  o f  5 0 0 m g  
and  a 3 0  minute i .v .  Infusion o f  2 0 0 m g .
Dally c o s t  o f  i .v .  a n d  oral th erap y  is £ 4 8 . 0 0  and £ 3 . 0 0  respectively.
Me tronidazole
T h e oral bioavaiiability is high. P eak  plasm a con centrat ions  are similar for 
a o n e  hour i.v . in fu s io n  and  an eq u iv a len t  oral d o se .
Daily c o s t  o f  i.v . a n d  oral th erap y  Is £ 1 4 . 3 4  and 7 0 p  respective ly .
Auamentin fco-amoxlclav)
Unlike ampicillln, t h e  bioavaiiability o f  amoxycillin is high (approximately  
8 5 % ) .  T h e  drug is minimally a f f e c te d  by first p a ss  m etabolism .
T h e  usual d o s e  is  5 0 0 m g / 1 0 0 m g  c la vu ia n ate  , 8-hourly but up to 
1 g / 2 0 0 m g  c la v u ia n a te ,  6-hourly  m a y  be administered.
T h e  addition o f  c la v u ia n a te  d o e s  n o t  alter bioavaiiability and clavuianate  
i t se lf  is w ell  a b s o r b e d ,  a ch iev in g  p e a k  p lasm a con centrat ions  within 4 0 -  
6 0  m in u te s .  / ;
Daily c o s t  o f  i .v . (.1. 2 g  8-hourly) an d  oral therapy is £ 8 . 1 0  and £ 2 . 1 0  
resp ec t iv e ly .
Therefore when antibiotic therapy is indicated, consider the 
following:
1. W h at  is th e  likely in fecting  p a th o gen (s)?  G u idance is available in the  
Antibiotic Policy or, if not,  s e e k  further advice .
2 .  Is oral therapy p o ss ib le  and ca n  the  drug se le c te d  be adm inistered  by  
th is  route?
3 .  if the  oral route is initially c o m p ro m ised ,  rem em ber to  transfer as s o o n  
a s  p oss ib le  from th e  i.v . route to  th e  oral route w h e r e  su itable  oral therapy  
e x is t s .
Various criteria ca n  be u sed  to  a s s e s s  w h e th er  or not oral 
therapy is su itable;
(i) an ora! drug is available,
(ii) the oral route is no longer compromised,
(iii) clinical improvement in the patient's condition is apparent,
(iv) the patient's temperature is reducing,
(v) their is no dear evidence of septic shock.
4 .  U se  the Data S h e e t  a s  a gu ide to  d o s a g e  and route o f  administration.
This reflects  the  P rod u ct L icence but note  that d if feren ces  in drug d o s a g e  
b e t w e e n  th e  i.v. and oral routes m a y  be apparent s in c e  d o s a g e  forms o f  a 
g iv en  drug m ay  b e  se p a r a te ly  l ic en sed .
This is particularly true in th e  c a s e  o f  the  beta - lactam  antib iotics  w h ich  h ave  
relatively poor bioavaiiability . For ex a m p le ,  cefuroxime sodium  injection and  
oral cefuroxime axetii ta b le ts  do  n o t  h av e  identical l icen sed  indications and 
are n o t  n ecessa r i ly  in terch an g eab le .
Therefore when transferring from i.v. to oral antibiotic therapy (i) confirm that the oral form is licensed for the purpose intended and (ii) prescribe drugs using upper dose ranges as a guide.
S o m e  e x a m p le s  o f  an t ib io t ic s  w h ich  m ay be considered  by the  i.v. and oral 
ro utes  and their l i c e n se d  d o s e  ra n g es  are included, b e lo w .
Drug i.v.dose upper range oral dose
Augmentin 1 .2 g 2 tab le ts(co-amoxiclav) ( i g (SOOmgamoxycill in) amoxycillin)
8-hourly 8-hourly
Ciprofloxacin 2 0 0 - 4 0 0 m g 5 0 0 - 7 5 0 m g
1 2-hourly 1 2-hourly
Metronidazole BOOmg 4 0 0 m g
8-hourly (or 1g  rectally) 
8-hourly
Does an alternative ora! agent apply in the event that an antibiotic given  initially b y  the i. v. route is unavailable in oral form or the Product Licence does not recognise the oral route for the given indication?
It m ay  indeed  b e  p o s s ib le  to  su b st itu te  oral therapy under th e s e  
c ir c u m s ta n c e s .  O n c e  aga in  h o w e v e r ,  the need to rev iew  the infecting  
p a th o g e n (s )  and s e l e c t  a drug rationally using the  Data S h e e t  a s  a gu id e  to  
indication and  d o s a g e  is s t r e s s e d .
E xam ples  in w h ic h  an oral antibiotic m ay be considered  a s  a rep lace m en t  for  
initial i.v . th erapy  include:
Ciprofloxacin 7 5 0 m g  p .o .  
p s e u d o m o n a s  in fe c t io n s .
1 2-hourly for gentamicin or ceftazidime in
Augmentin (Co-amoxiclav) 2 tab le ts  p .o .  8-hourly for cefuroxime sodium  
w h e r e  cefuroxime axetii does  not h a ve  a l icensed  indication e .g .  intra­
abdom inal s e p s i s ,  b o n e  and joint infection.
Choice of antibiotic
T he T a y s id e  audit a lso  found In c o n s is t e n c y  in the  se lection  o f  an antibiotic  
or antibiotic  com b in a t io n  for a g iv en  clinical situation . For this reason  there  
w a s  a t e n d e n c y  to  u s e  multiple drug reg im en  unn ecessar ily  and broad  
sp e c tr u m  antib iotics  inappropriately.
M any in fec t io n s  w h ich  are freq u en tly  en co u n ter ed  can be readily linked with  
o n e  or o th er  c o m m o n  p a th o g e n s  w h e n  antibiotic therapy, e v e n  empirically,  
m a y b e  suitably  refined. It is o f t e n  m istak en ly  a ssu m ed  h o w e v e r  that  
"broad spectrum " e q u a te s  w ith  " e n h a n c e d  antibiotic potency"  w h e n  in fact  
s u c h  a g e n t s  are more likely to  be  a s s o c ia t e d  with the  e m e r g e n c e  o f  multiple  
re s i s ta n c e  and su p er in fect ion .
Further advice may be available in the Antibiotic Policy or from other local guidelines. If not, contact Medical Microbiology or the Drug Information Service.
Appendix E 
Seminar Questionnaire 
Surgical 
Rational Antibiotic Presribing
Name......................................................... Wai'd.....
Please circle position held
JHO SHO Reg Sm’ Ref Consultant
1. Did you have the opportunity to read the Drug Information Note ‘Rational 
Antibiotic Prescribing: The relative role of iv and oral therapy? Yes/No
2. Wliich of the following aspects of the presentation did you find of most
interest, please choose one or more if you wish:-
a) Aminoglycoside audit findings
b) General antibiotic usage NW 9&10 audit data
c) Other, please specify
3. Having listened to this presentation do you tliink your prescribing practice 
will be affected 
Yes/No 
If Yes, which aspect (s)?
4. Do you thiiilc this type of audit should be repeated on a regular' basis
Yes/No
If Yes, how frequently?
If No, why not?
Seminar Questionnaire 
Medical 
Rational Antibiotic Presribing
Name....................................... Wai'd.......................
Please circle position held
JHO SHO Reg Siir Ref Consultant
1. Did you have the opportunity to read the Drug Information Note ‘Rational
Antibiotic Prescribing: The relative role of iv and oral therapy? Yes/No
2. Wliich of the following aspects of the presentation did you find of most 
interest, please choose one or more if you wish:-
a) All Tayside audit findings
b) NW 5&6 audit data
c) Costs of iv therapy
d) Other, please specify
3. Having listened to this presentation do you thhik your prescribing practice 
will be affected 
Yes/No 
If Yes, which aspect (s)?
4. Do you think this type of audit should be repeated on a regular* basis
Yes/No
If Yes, how frequently?
If No, why not?
Seminar Questionnaire 
Urology 
Rational Antibiotic Presribing
Name......................................  Ward.......................
Please circle position held
JHO SHO Reg Sm* Ref Consultant
1. Did you have the opportunity to read the Drug Information Note ‘Rational
Antibiotic Prescribing: The relative role of iv and oral therapy? Yes/No
2. Wliich of the following aspects of the presentation did you find of most 
interest, please choose one or more if you wish:-
a) General aminoglycoside audit findings
b) Epididymo-orchitis information
c) Cost data
d) Other, please specify
3. Having listened to this presentation do you think youi* prescribing practice 
will be affected 
Yes/No 
If Yes, which aspect (s)?
4. Do you think tliis type of audit should be repeated on a regular basis
Yes/No
If Yes, how fr equently?
If No, why not?
Appendix F
Patient ID No:
Phase II
Septicaemia/Aminoglycoside Study 
Clinical Record Form
Patient Name:
Unit No:
Date of admission: 
Consultant:
Weight:
Presenting complaint: 
Diagnosis:
Ward:
Dob:
Date of discharge:
Page 1 
Sex: M/F
Absorption
Abnormal GI state:
Other:
Administration
Compromised oral route: 
Compromised other routes: 
Comprehension/compliance :
Missed doses
Date Drug Time Reason
Page 2
Site of Infection
Sample Date taken Result and sensitivities
Operation within 48hi? Yes/No
Specify operation:
Invasive procedure within 48hi*? Yes/No
Urinaiy catheterisation Yes/No
Intravenous cannula Yes/No
Long iv line Yes/No
Car diac pacemaker Yes/No
Swan Ganz/other art catheter Yes/No
Peritoneal dialysis Yes/No
Other (specify) Yes/No
No detectable primaiy site of infection Yes/No
Physiological points
Temperatui’e:
MAP:
Resp rate:
Serum sodium: 
Serum potassium: 
Sei'um creatinine: 
Serum bicarbonate: 
PCV:
WCC:
Hb:
Platelet count: 
Plasma albumin: 
Plasma bilirubin: 
Urea:
Glucose:
Glasgow coma score:
On entry to study
Page 3 
On completion of study
Symptoms and signs of septicaemia
Rigors Yes/No
Alteration in consciousness Yes/No
Peripheral pallor Yes/No
Abnormal sweating Yes/No
Gentamicin levels
Date Predose (mg/1) Postdose (mg/1) Other (mg/1) Serum creatinine (umol)
Page 4
Antibiotics
Date
commence
d
Drug Dose Route
admin
Method
Bolus/inf
Date of 
change or 
stop date
Reason
Other drugs (only if ADR):
^  Appendix G
INFORMATION SHEET FOR PATIENTS ABOUT THE STUDY  
OF HOM E ANTIBIOTIC THERAPY,
What is this study?
We are investigating the use of two antibiotics which have been successfully used to treat 
many types of infections worldwide. They are not new or experimental drugs. For nearly 
10 years people with different infections in many parts of the world, especially the USA, 
have been treated successfully with these antibiotics at home. We want to repeat this 
experience in the UK.
Why should I take part?
The infection that has led you to be admitted into hospital requires you to receive a course of 
intravenous (injectable) antibiotics given through a small plastic Une (venflon) that lies in 
one of the veins in your arm.' You would normally receive this type of treatment in hospital 
for a period of a few days or longer depending on your condition. Giving these antibiotics 
a t home would allow you to get home more quickly.
Are the antibiotics safe?
These antibiotics are safe (millions of patients have received them worldwide) and if you 
agree to take part, you will already have received at least one dose before you go home. The 
other advantage of these antibiotics is that they are easy to make up and are only given once 
daily.
For how long will I receive these antibiotics?
Your course of antibiotics will last fors:, weeks.
What does saying yes involve?
As these antibiotics are given by an injection you will have a venflon put into your arm while, 
you are receiving the treatment. Your nurse and doctor will explain to you how they work 
and there will always be someone to contact if you experience any difficulties with either the 
venflon or the antibiotics.
If you agree to have home treatment you will return to the ward each day to receive your
injection and to see one of the medical staff.
Will my medical care be different if Ï take part?
Your overall care will not be affected by your participation in this study. We may
reassure you that you will not be asked to participate in this study if we did not think that 
your medical condition was suitable. You may withdraw at any time without affecting 
your medical care. We will require your signed consent if you are willing to participate.
You will be closely supervised by the doctors at King's Cross Hospital throughout your 
treatment. You will be covered by the usual insurance against medical negligence from the 
Dundee Teaching Hospitals Trust.
NON-INPATIENT IV CARE STUDY
INITIAL SCREENING - HOME TV THERAPY
Patient label
Study No.
Antibiotic.
1, Do you live alone or *with a relative?
If relative specify
2, Do you possess a phone?
Phone no. 
If no, do you have access to a phone?
Please specify
3, Have you ever had iv therapy before?
4, Manual dexterity
If compromised specify......................................
Alone/Relative
Yes/No
Yes/No
Yes/No
Full/Compromised
5. What benefits do you think being treated as an outpatient gives you?
6. Do you have any concerns regarding iv therapy at home? 
If yes, specify.................................................................................
Yes/No
7. Have you discussed your form of treatment with other family members? Yes/No
If Yes what relationship?  ............ .................................... ........
Was their response positive? Yes/No
If No Why not?...............................................  ;....... .
8. W hich area/space do you plan to use for carrying out the
injections?............................................................................................................................
9. W ho will administer the antibiotic? Self/Relative
If relative specify.........................................................................................................
10. Will you be able to return for a review visit every 3-4 days Yes/No
11. W ould you like transport arranging for you Yes/No
GP contacted date phone call...................... date letter sent.........................
NON-INPATIENT IV CARE STUDY
INITIAL SCREENING
Patient label
Study No.. 
Antibiotic.
1. Do you live alone or with a relative?
If relative specify
2. Do you possess a phone?
Phone no. 
If no, do you have access to a phone?
Please specify
3. Have you ever had iv therapy before?
4. Physical mobility
If compromised specify..................................... .
Alone/Relative
Yes/No
Yes/No
Yes/No
FuIl/C omp remised
S. What benefits do you think being treated as an outpatient gives you?
6. Do you have any concerns being treated as an outpatient? 
If yes, specify...,...............................................................................
Yes/No
7. Have you discussed your form of treatment with other family members?.,.,.Yes/No 
If yes was there response positive? Yes/No
If Yes what relationship?................................................................
If No Why not?
CONSENT FORM
( f u l l  Q&ise aod address). ;
iremlf aad T o l u a t s r l l /  c o n s e n t  to  take  p a r t  l a  & e l i a i c a l  r e s e a r c h  s tu d y  obc.
which  3 0  f a r  aa Is kaowa s h o u ld  mot carry may u n u s u a l  risk .
I have  r e a d  the accompanying i n f o r m a t i o n  s h e e t .  The n a t u r e  and purpose
of t h e  s tu d y  has been  e x p l a i n e d  t o  me by D r    ______   ,
I have  had the o p p o r t u n i t y  t o  ask  any q u e s t i o n s  and I u n d e r s t a n d  f u l l y  
what  i s  p ro p o se d ,
Î r e c o g n i s e  that I say  r e c e i v e  no b e n e f i t  p e r s o n a l l y  f r o s  t h e  s tudy .
I a c c e p t  t h a t  t h e r e  say  be o t h e r ’ r i s k s  a s s o c i a t e d  w i t h  the  p r oce du re s  
which a r e  no t  d i r e c t l y  a t t r i b u t a b l e  t o  n e g l i g e n c e  on t h e  p a r t  of those  
u n d e r t a j ç i n g  the p r o c e d u r e s ,
X u n d e r s t a n d  t h a t  Î an f r e e  t o  w i thd ra w  ay c o n s e n t  a t  any t i n e  wi thou t  
p r e j u d i c e  to  me o r  my m e d ic a l  c a r e .  I have been a s s u r e d  t h a t  any 
i n f o r m a t i o n  o b t a i n e d  from me w i l l  n o t  be d i s c l o s e d  to  any o t h e r  p a r t y  
i s  a manner which w i l l  r e v e a l  my i d e n t i t y .
S i g n a t u r e  ____________________________________  D a t e ...........................  ... .................
X c o n f i r a  t h a t  ï / ü r .   __________   h a v e / h a s  e x p l a i n e d  the n a tu r e
and p u r p o s e  o f  t h e  c l i n i c a l  r e s e a r c h  s tu d y  .and the  p r o c e d u r e  in 
r e s p e c t  o f  which c o n s e n t  has been  g i v e n  by t h e  above named.
S i g n a t u r e _________________________________  Date............ ...................... .....
NON-INPATIENT IV CARE STUDY 
PATIENT INFORMATION - HOME IV THERAPY
Patient Name.
You have been prescribed an antibiotic called Teicoplanin (TARGOCID^) at a dose of 
mg once a day.
Although you will have been trained to prepare and self-administer this antibiotic whilst in 
hospital, here are a set of instructions to help refresh your memory if you are unsure of 
what to do next. In addition other useful information is included such as general guidelines 
and contact telephone numbers etc.
Contents Page number
Supplies 2
General points 2
Quick reference guide to preparing 
and administering your antibiotic 3
Full preparation and administration 
instructions for your antibiotic 4-5
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SUPPLIES
You will be provided with:- doses of antibiotic and water
ampoule breaker 
syringes 
needles 
alcohol swabs 
Hepsal
Gauze dressings and adhesive tape 
disposable paper towels 
cardboard trays 
'Sharps' bin
When you have finished treatment please return any remaining items to the hospital - the 
Sharps bin must be returned for destruction. This can be done at your follow-up visit.
GENERAL POINTS
1. Try to establish a routine and use the same area each time. Somewhere you can keep as 
clean as possible, for example, kitchen surface, trolley or tray. Wash area thoroughly with 
a detergent solution before and after use. Dry area completely. Use disposable towels for 
washing and drying the area of choice.
2. Only allow people in the room with you who are helping.
3. Avoid distractions, for example, unplug the telephone for a short time if necessary and 
don't have small children or pets in the room.
4. When you have assembled your equipment and antibiotic it is always good practice to 
check the name, strength and expiry date of the antibiotic before preparation and 
administration. You will be shown where to locate this information on the antibiotic vial.
QUICK REFERENCE GUIDE TO PREPARING 
AND ADMINISTERING YOUR ANTIBIOTIC
Step 1 Wash and dry hands
Tr
Step 2 Assemble equipment and antibiotic
&
Step 3 Wash and dry hands
 ^ Step 4 Prepare syringes and needles
Step 5 & 6 Prepare antibiotic
Step 7 Prepare hepsal
Step 8 Wash and dry hands
&
Step 9 Check iv line
I ^
Step 10 Flush line with hepsal
Step 11 Administer antibiotic
then
Flush line with hepsal 
Step 12 Apply dressing
Step 13 Tidy up waste
FULL INSTRUCTIONS 
PREPARATION AND ADMINISTRATION OF YOUR ANTIBIOTIC
Step 1
Wash your hands thoroughly and dry with a disposable paper towel - this is one of the 
most important means of preventing infection.
Step 2
Assemble all equipment and drugs before starting the procedure. On a cardboard tray you 
will need Antibiotic powder ampoule plus the water ampoule for reconstitution 
Hepsal ampoule 
Ampoule breaker 
Syringes 
Needles 
Alcohol swabs
Fresh gauze dressing and adhesive tape 
Also another cardboard tray will be required for the prepared antibiotic injection and 
hepsal injection.
nb Do not use any items that are damaged.
Step 3
Wash and dry hands as before.
Step 4
Open a syringe and needle pack onto a clean surface and attach the needle to the syringe 
leaving the cover over the needle. Prepare a second syringe and needle, one is for the 
antibiotic and one for the hepsal.
Step 5
Using an alcohol swab clean the neck of the antibiotic ampoule and water for 
reconstitution ampoule. Allow to dry.
Step 6
Break the ampoule tops of the antibiotic and water, remove the cover from one needle and 
syringe and draw up the entire contents of the water ampoule. Add this slowly to the 
powdered antibiotic and roll the ampoule gently until the powder is completely dissolved, 
taking care to avoid formation of foam. If the solution does become foamy then allow to 
stand for about 15 minutes for the foam to subside. Draw up the entire contents of the 
dissolved antibiotic ampoule with the needle and syringe, expel any trapped air bubbles by 
holding the syringe upright and tapping the syringe with a fingernail before pressing the 
plunger. Ensure that there are no visible particles m the antibiotic solution, this is a highly
unlikely event but if so discard and prepare another. Place the needle and syringe on the 
new cardboard tray.
Step 7
Using an alcohol swab clean the neck of a hepsal ampoule and allow to dry. Remove the 
cover from the second needle and syringe and draw up the entire contents of the ampoule, 
expel any trapped air. Place the needle and syringe on the new cardboard tray.
Step 8
Wash and dry hands as before.
Step 9
Remove dressing from over the iv line and check that it is still in position in the vein. 
Briefly examine surrounding area for signs of redness, swelling, pain or discomfort 
Should any of these signs be apparent contact the hospital before proceeding, however if 
everything appears to be in order proceed as follows.
Step 10
Carefully unclip the green cover of the iv line. Remove the needle from the hepsal syringe, 
taking care not to touch the hub of the syringe attach it to the iv line. Slowly inject about 
2mls into the line, remove the syringe and place back on the cardboard tray taking care not 
to touch the hub of the syringe.
Step 11
Remove the needle from the antibiotic syringe taking care not to touch the hub of the 
syringe, attach the syringe to the iv line. Slowly inject the entire contents into the iv hue 
over a 3 to 4 minute time period. Remove the syringe and replace with the remaining 
hepsal syringe. Slowly inject the remaining contents of the hepsal syringe into the iv line. 
Remove and replace the green cover.
Step 12
Place a clean, dry gauze dressing over the iv line.
Step 13
With the exception of the paper covering the needles and syringes, paper towels and the 
cardboard trays, all other waste, broken ampoules, needles, syringes, swabs, used dressing 
etc. must be placed in the 'Sharps' disposal bin and not with household rubbish.
POSSIBLE COMPLICATIONS
Although infrequent, there are a few mild complications that can occur, these include:-
Blocked iv line - i.e. it becomes impossible to push the contents of the syringe into the iv 
line, although this shouldn't happen if the line is always flushed through both before and 
after the antibiotic has been administered it does occasionally occur. DO NOT FORCE 
THE PLUNGER OF THE SYRINGE. Contact the hospital
Dislodged iv line - although extremely unusual, if an event occurs which causes the line to 
become dislodged for example by catching the line on something during your daily 
activities contact the hospital as it will probably need to be replaced.
Redness, discomfort or pain of exit site of iv line - this may be a local infection or an 
indication that the line may need changing. Contact the hospital.
If there are any other events which give cause for concern please do not hesitate to 
contact the hospital.
CONTACT TELEPHONE NUMBERS
Ninewells Hospital 0382 60111 (This switchboard answers for Kings
Cross Hospital)
Ward 1 extn 6951
Ward 9 East extn 6959
Ward 9 West extn 6999
or ask the hospital telephonist to bleep the doctor on call for Infectious Diseases for 
Kings Cross Hospital Wards 9
Research Pharmacist-Sharon Parker extn 6946 or ask switchboard to radiopage (Mon-
Fri 9-5 only)
OUTPATIENT INFORMATION 
POSSIBLE COMPLICATIONS
Although infrequent, there are a few mild complications that can occur, these include
Dislodged iv line - although extremely unusual, if an event occurs which causes the line to 
become dislodged for example by catching the line on something during your daily 
activities contact the hospital as it will probably need to be replaced.
Redness, discomfort or pain of exit site of iv line - this may be a local infection or an 
indication that the line may need changing. Contact the hospital.
If there are any other events which give cause for concern please do not hesitate to 
contact the hospital.
CONTACT TELEPHONE NUMBERS
Ninewells Hospital 0382 60I I 1 (This switchboard answers for Kings
Cross Hospital)
Ward 1 extn 6951
Ward 9 East " extn 6959
Ward 9 West extn 6999
or ask the hospital telephonist to bleep the doctor on call for Infectious Diseases for 
Kings Cross Hospital Wards 9
Research Pharmacist-Sharon Parker extn 6946 or ask switchboard to radiopage (Mon-
Fri 9-5 only)
NON-INPATIENT IV CARE STUDY 
END OF STUDY PATIENT QUESTIONNAIRE
For completion by the patient and/or carer.
Patient label
Study No  ..................
1. Did you experience any problems with this therapy? Yes/No
If Yes please specify?..,.................................................. ......................................................
2. Would you repeat this form of therapy again? Yes/No
If No Why not?  .................................................................................................................
3. Did this form of therapy improve any of the following areas:
a) 'Quality of life’ Yes/No
b) Allow more control of your therapy > Yes/No
c) Other please specify.......................................................
4. Could you please give examples of the sort of things you were able to do which 
you would not have been able to do had you stayed in 
hospital.................................................................................................................................. ......
5. Do you think this form of therapy caused you any out-of-pocket expenses? 
Yes/No
If Yes please specify................................................................................................... .............
Dear Dr
Re: Non-Inpatient IV Antibiotic Care
Non-Inpatient IV Care has been provided as a routine service in the USA for the last 
decade.
Since January 1994 we have been conducting a feasability study of Non-Inpatient IV 
Care for suitable patients within Tayside. We approach this in one of two ways. A 
patient either attends the hospital once daily as an outpatient to have their antibiotic 
administered and their iv access and progress evaluated or, the patient/relative/carer is 
taught how to prepare and administer the once daily prescribed antibiotic at home but 
the patient attends the hospital twice weekly to have their iv access and general 
progress evaluated. Patients requiring less than seven days treatment usually attend 
daily as an out-patient and those requiring greater than seven days usually prefer to be 
taught for self-administration, but the options are flexible. The type of patients selected 
for this type of care are medically stable, are prepared to go home and are resident as 
an in-patient only because of their iv therapy. To date we have met with great 
enthusiasm from the patients offered this service and we feel it is a success.
We would like to introduce this form of care as an ongoing service. However before 
doing so we need to know what the referral pattern of individual Tayside GP practices 
are for patients requiring iv therapy and what the GPs feel about such a service.
A member of our team will contact your practice in the next few days to arrange a 
suitable time to canvas your response by telephone. Could we ask you to discuss and 
complete the short enclosed questionnaire with your partners so that we take as little of 
your time as possible.
We would be extremely grateful for your co-operation with this matter 
yours sincerely
Sharon E Parker Dr D Nathwani Dr P G Davey
Senior Research Pharmacist Consultant Consultant
Infectious Disease Infectious Disease
GP Survey of Non-Inpatient IV Antibiotic Care 
GP practice: - Date:
No. Partners in practice:
1) Could you estimate approximately how many patients in your practice were sent 
to hospital for management of infection since January 1994? Don't know
1-10
11-20
21-30
2) What conditions did they have? (Unprompted) (Prompted)
Skin & soft tissue 
Osteomyelitis 
Pneumonia 
Severe UTI
3) What do you /your partners feel would be the main advantages and 
disadvantages of this type of service to yourself?
Advantages Disadvantages
4) What do you /your partners feel would be the main advantages and 
disadvantages of this type of service to your patients?
Advantages Disadvantages
5) How would you (your partners) respond to the availability of such a service?
In favour Not in favour Need more information
